0.9816284607	muscular dystrophy
0.9791746178	cardiopulmonary resuscitation
0.9777287401	locus coeruleus
0.9775106215	spinal cord
0.9766699783	diabetes mellitus
0.9747750477	computed tomography
0.9735154992	lupus erythematosus
0.9735112517	chest radiography
0.9734832586	action potentials
0.9734288065	cardiogenic shock
0.9734198210	intensive care unit
0.9729456058	myasthenia gravis
0.9720287925	excimer laser
0.9717061514	ascending aorta
0.9712306711	positron emission tomography
0.9711885480	substantia nigra
0.9708440489	myotonic dystrophy
0.9707221492	staphylococcus aureus
0.9704534984	ion channels
0.9698218813	situs inversus
0.9692417425	ebstein's anomaly
0.9690613473	angina pectoris
0.9687796984	ionizing radiation
0.9679491910	takotsubo syndrome
0.9678289391	united kingdom
0.9677424033	obstructive sleep apnea
0.9670761143	ventricular septal defect
0.9669768306	carotid endarterectomy
0.9669134983	skeletal muscle
0.9669122225	sinus venosus
0.9660964784	chronotropic incompetence
0.9660926555	myocardial infarction
0.9660590361	ventral tegmental area
0.9657144651	gap junctions
0.9656342844	olfactory bulb
0.9656210247	percutaneous coronary intervention
0.9655403107	smooth muscle
0.9655228319	hypertrophic cardiomyopathy
0.9651896782	atrial flutter
0.9651619376	pulmonary embolism
0.9650275763	latin american
0.9648416569	endoplasmic reticulum
0.9647789386	body mass index
0.9647375525	paravalvular leakage
0.9646535457	pericardial effusion
0.9643625279	electromagnetic interference
0.9643410621	machine learning
0.9643023077	chronic kidney disease
0.9641368046	pleural effusion
0.9640918692	conscious sedation
0.9639611214	magnetic fields
0.9639251702	drosophila melanogaster
0.9638664265	patent foramen ovale
0.9636876856	deep vein thrombosis
0.9635644961	coronary artery bypass grafting
0.9634637223	nitric oxide
0.9634162407	kansas city cardiomyopathy questionnaire
0.9633202603	systolic anterior motion
0.9631241319	arteriovenous fistula
0.9630315532	magnetic resonance imaging
0.9628850455	phrenic nerve
0.9624709122	hypertrophic obstructive cardiomyopathy
0.9622810078	minimally invasive
0.9619362497	gap junction
0.9618426789	lymph node
0.9616152320	infective endocarditis
0.9615628861	dilated cardiomyopathy
0.9613576533	lyme carditis
0.9612710842	congestive heart failure
0.9611116973	western blot
0.9610667172	cochrane library
0.9608710936	alcohol septal ablation
0.9608416569	rheumatoid arthritis
0.9607817071	sleep apnea
0.9606926708	autosomal dominant
0.9606507507	conduction disturbances
0.9606036210	blood transfusion
0.9605608198	septal myectomy
0.9604649122	transthoracic echocardiography
0.9600878126	unique identifier
0.9600305089	logistic euroscore
0.9600033150	oxygen saturation
0.9598743290	north america
0.9598289391	wiley periodicals
0.9598068950	fulminant myocarditis
0.9597649593	life expectancy
0.9593423884	mayo clinic
0.9591209745	sinoatrial node
0.9590114021	ureteropelvic junction
0.9589622622	sick sinus syndrome
0.9589279721	pr interval
0.9588595259	chronic obstructive pulmonary disease
0.9587552009	brugada syndrome
0.9586935677	twiddler's syndrome
0.9585743901	sinus pauses
0.9585351868	vagus nerve
0.9584571522	latin america
0.9581270192	energy harvesting
0.9579939075	magnetic resonance
0.9579704516	junctional ectopic tachycardia
0.9578915833	loop recorder
0.9578819637	conduction abnormalities
0.9575123798	fatty acid
0.9570601240	upper extremity
0.9570087494	endomyocardial biopsy
0.9568218351	mitral regurgitation
0.9567431082	diabetic ketoacidosis
0.9566904864	takotsubo cardiomyopathy
0.9564141620	emergency department
0.9563963060	polymerase chain reaction
0.9562120805	suprachiasmatic nucleus
0.9559393027	general anesthesia
0.9558907377	ion channel
0.9558084963	extracorporeal membrane oxygenation
0.9556075488	chest pain
0.9554757146	electroanatomic mapping
0.9552023127	paravalvular leak
0.9550968252	cardiopulmonary bypass
0.9545015509	manual traction
0.9544997138	systemic lupus erythematosus
0.9544205633	remote monitoring
0.9541121960	mechanical ventilation
0.9540816467	outflow tract
0.9540357980	capsurefix novus
0.9539738981	family members
0.9539210536	guinea pig
0.9535259369	transesophageal echocardiography
0.9534191576	acurate neo
0.9534175883	cleveland clinic
0.9534163951	vasoactive intestinal peptide
0.9531790257	superior vena cava
0.9531763471	magnetic field
0.9531186631	blood pressure
0.9530660162	monte carlo
0.9529383216	real world
0.9529118714	ictal asystole
0.9527950859	acute kidney injury
0.9527915609	axillary vein
0.9526125792	protein losing enteropathy
0.9524320228	parkinson's disease
0.9521911902	supraventricular tachycardia
0.9518547019	hazard ratios
0.9518284816	cephalic vein
0.9517233753	transient ischemic attack
0.9514233221	cardiac resynchronisation therapy
0.9513921301	paravalvular regurgitation
0.9512799093	electromagnetic fields
0.9511924064	neonatal lupus
0.9511710461	heart transplantation
0.9511048725	antiarrhythmic drugs
0.9510614780	bifascicular block
0.9510512169	aortic root
0.9509066607	circumflex artery
0.9505764309	cor triatriatum
0.9505476453	global longitudinal strain
0.9502799212	left ventricle
0.9502549238	united states
0.9502038550	boston scientific
0.9501901860	transcription factor
0.9501892409	constant darkness
0.9500874211	late gadolinium enhancement
0.9499436791	operating room
0.9498457747	paravalvular leaks
0.9498175696	fluorinated steroids
0.9497971599	exercise capacity
0.9496806941	mesenchymal stem cells
0.9496279500	vasc score
0.9495047007	amino acid
0.9493948314	septic shock
0.9493256264	newer generation
0.9492843841	vasovagal syncope
0.9491736415	vasoactive intestinal polypeptide
0.9490626572	action potential
0.9490078687	pulmonary artery
0.9489927962	povidone iodine
0.9488982462	sleep deprivation
0.9488302498	transthoracic echocardiogram
0.9487534718	edwards lifesciences
0.9487407604	cardiac arrest
0.9485719866	internal mammary artery
0.9485146644	respiratory disturbance index
0.9484123520	western blotting
0.9483029788	exome sequencing
0.9482723105	coronary artery
0.9475465295	bundle branch block
0.9475316280	interquartile range
0.9474042254	sarcoplasmic reticulum
0.9473488667	cesarean section
0.9473308669	resource utilization
0.9472390271	feedback loops
0.9471064019	energy harvester
0.9468543010	nyha class
0.9465448032	inferior vena cava
0.9465381599	orthotopic heart transplantation
0.9465168374	risk stratification
0.9465112102	receiver operating characteristic
0.9464058754	creatine kinase
0.9461006064	patch clamp
0.9459677506	sudden death
0.9459239005	kearns sayre syndrome
0.9458689727	internal jugular vein
0.9458573807	young adults
0.9457929483	sj√∂gren's syndrome
0.9457613747	metal artifact reduction
0.9457373299	poorly understood
0.9453962718	glucose tolerance
0.9453807700	exclusion criteria
0.9451429544	battery depletion
0.9451140693	pace maker
0.9450062845	fabry disease
0.9448245982	sudden cardiac death
0.9443543056	oxidative stress
0.9440783015	incompletely understood
0.9439971260	informed consent
0.9438194599	propensity matching
0.9437979554	orthostatic hypotension
0.9436756571	hazard ratio
0.9435827402	balloon aortic valvuloplasty
0.9434652431	ejection fraction
0.9433786734	cavotricuspid isthmus
0.9433643373	pulmonary vein isolation
0.9432737777	speckle tracking
0.9431542713	tricuspid regurgitation
0.9431336910	gi motility
0.9429816490	clinicaltrials.gov identifier
0.9429063458	air embolism
0.9427074091	north american
0.9424217384	antibacterial envelope
0.9422174649	sinus node dysfunction
0.9422137700	intrinsically photosensitive retinal ganglion cells
0.9420694041	qrs duration
0.9419941806	statistical significance
0.9419148440	saphenous vein
0.9418724069	reveal linq
0.9418424532	rna sequencing
0.9417573827	mechanically expandable
0.9414075254	congenital heart disease
0.9414061243	jet lag
0.9413745051	stem cells
0.9412972008	beta blockers
0.9412807224	temporary epicardial pacing wires
0.9412592761	post mortem
0.9412341638	ionic currents
0.9409506086	situs inversus totalis
0.9406948753	sinus bradycardia
0.9406665368	deep brain stimulation
0.9406538208	septal perforator
0.9406003688	pocket hematoma
0.9404344227	palliative care
0.9403844150	freely moving
0.9403189160	logistic regression
0.9402702979	staphylococcus epidermidis
0.9402108820	subclavian vein
0.9402080630	junctional rhythm
0.9399618503	effective orifice area
0.9398940083	jugular vein
0.9397938404	congenital heart defects
0.9396851586	coronary artery disease
0.9396333844	vital signs
0.9395943640	arginine vasopressin
0.9395229750	oral anticoagulation
0.9395228764	cerebrovascular accident
0.9393953408	mm hg
0.9393488372	secondary endpoints
0.9391995081	blood cultures
0.9390158499	coronary angiography
0.9389339493	progenitor cells
0.9388903055	circadian rhythms
0.9388775877	pulse oximetry
0.9386791743	fisher's exact test
0.9384926344	glossopharyngeal neuralgia
0.9382229065	google scholar
0.9382096767	hyperpolarization activated cyclic nucleotide gated
0.9381816266	beta blocker
0.9380951701	aortic insufficiency
0.9380899715	left atrial appendage
0.9380815163	sinus rhythm
0.9379789410	protein kinase
0.9379184482	chest radiograph
0.9378501959	investigational device exemption
0.9378442002	tricuspid annuloplasty
0.9375967516	adverse event
0.9375134467	randomized controlled trials
0.9374986900	lyme disease
0.9374637286	heart transplant
0.9373974032	renal failure
0.9372942046	pocket irrigation
0.9372450566	intuity elite
0.9372354532	mad honey
0.9371865893	balloon expandable
0.9367837063	cross sectional
0.9366381548	secondary prevention
0.9365319278	induced pluripotent stem cell derived cardiomyocytes
0.9364591951	angiotensin converting enzyme
0.9364230575	renal pelvis
0.9363822374	pg ml
0.9362324379	long qt syndrome
0.9361813444	innominate vein
0.9361660578	quality assurance
0.9361492682	odds ratio
0.9359883344	leadless pacemakers
0.9358281090	oral anticoagulants
0.9357597980	structural valve deterioration
0.9353153373	reel syndrome
0.9352128980	circadian clocks
0.9351355339	case summary
0.9350325348	transvenous lead extraction
0.9349071322	gene expression
0.9346565237	aortic stenosis
0.9346062275	atrioventricular block
0.9344900968	log rank
0.9343827058	fatty acids
0.9343001076	cardiac tamponade
0.9340289641	african american
0.9338889901	radiation exposure
0.9338613431	jude medical
0.9336234325	congenital central hypoventilation syndrome
0.9335118234	axillary artery
0.9333412334	persistent left superior vena cava
0.9331585453	trifascicular block
0.9331462380	accessory pathway
0.9330318428	adenylyl cyclase
0.9328657116	coronary sinus
0.9328360647	nutritional status
0.9328293888	seckel syndrome
0.9327104629	propensity score matching
0.9325345058	beh√ßet's disease
0.9323522750	peripheral vascular disease
0.9322503698	infra hisian
0.9320334748	transvalvular gradients
0.9319521428	steroid eluting
0.9319148135	conduction defects
0.9318923521	rotational atherectomy
0.9318252833	atrioventricular canal
0.9318228374	reticular telangiectatic erythema
0.9317389276	microelectrode array
0.9317257060	oral anticoagulant
0.9316176459	multiple myeloma
0.9315102375	ssa ro
0.9314831688	hospital stay
0.9314703067	mitral valve
0.9312863630	myocardial scar
0.9311716789	cox proportional hazard
0.9311545358	bicuspid aortic valve
0.9311108746	adverse events
0.9307991877	left bundle branch block
0.9307814927	master clock
0.9305259543	glomerular filtration rate
0.9304707904	aortic arch
0.9300284452	propensity matched
0.9299558204	tightrail ‚Ñ¢
0.9299426233	peripheral clocks
0.9298344804	circadian misalignment
0.9298139161	open label
0.9297961429	learning curve
0.9296665373	inclusion criteria
0.9295905360	optical mapping
0.9293535771	acute coronary syndrome
0.9293301388	adipose tissue
0.9291179245	left sided
0.9290062747	interatrial septum
0.9289051327	syncopal episodes
0.9288414228	capture thresholds
0.9288154097	axillary vein puncture
0.9286556608	cardiovascular implantable electronic devices
0.9285201705	voltage clamp
0.9284531800	feedback loop
0.9284345142	lateral tunnel
0.9284255629	sinus node
0.9283145907	image quality
0.9282879714	pulse generator
0.9282830161	renal insufficiency
0.9281843927	ventricular tachycardia
0.9280800951	narrow qrs
0.9279158337	mobile phone
0.9278843486	cardiac resynchronization therapy
0.9278486085	sinus arrest
0.9278019309	meta analysis
0.9277290995	mg dl
0.9276650660	venous thromboembolism
0.9275524279	decision making
0.9274710307	radiation oncology
0.9273157706	cyclic nucleotide
0.9272997135	danish nationwide
0.9272299873	south asians
0.9272233059	heparin bridging
0.9270906140	polymorphic ventricular tachycardia
0.9269651097	interatrial block
0.9269009196	estimated glomerular filtration rate
0.9268929005	charlson comorbidity index
0.9268396813	isis crprx
0.9266676776	coronary artery bypass graft
0.9265795918	connective tissue
0.9264460907	sapien xt
0.9263618436	chagas disease
0.9263557518	coagulase negative staphylococci
0.9263175007	shift workers
0.9262987032	ninth revision
0.9261713324	passive fixation
0.9261567749	atrial fibrillation
0.9261367592	case reports
0.9260676841	mechanical circulatory support
0.9260575024	sleep disordered breathing
0.9259322894	pregnant woman
0.9259019734	cerebral infarction
0.9258222017	hypoplastic left heart syndrome
0.9257896830	pulse width
0.9257355973	supra annular
0.9256415651	murine small intestine
0.9255922110	cerebrovascular events
0.9255720251	conduction disturbance
0.9253281238	guinea pigs
0.9251661721	tricuspid valve
0.9251591370	multivariate analysis
0.9249602100	dispersive electrode
0.9249139472	abdominal pain
0.9247827284	minute ventilation
0.9246466318	renal denervation
0.9244212993	implantable loop recorders
0.9243919652	stem cell
0.9241316043	implantable cardioverter defibrillator
0.9240336517	mitral annular calcification
0.9239593313	left anterior oblique
0.9238669740	forced desynchrony
0.9238654918	cox regression
0.9238531851	sts prom
0.9238434056	electroanatomical mapping
0.9238046703	heart failure
0.9237797346	insertable cardiac monitor
0.9237242199	randomly assigned
0.9236466754	transient receptor potential
0.9235747715	kaplan meier
0.9234089466	spatio temporal
0.9230553647	cox maze iii
0.9230273438	dorsal raphe
0.9229823661	chordae tendineae
0.9229016116	atrial standstill
0.9228436800	left ventricular
0.9227489118	sleep restriction
0.9225701570	weight loss
0.9224814395	expert consensus statement
0.9220632651	‚àó cm
0.9220464342	immune checkpoint
0.9220148538	tyrosine kinase
0.9218837864	spinal cord injury
0.9217486458	sleep wake
0.9215881045	inappropriate sinus tachycardia
0.9215265290	rapid deployment
0.9214891167	risk factors
0.9214759480	qt interval
0.9214220362	phase shifts
0.9210997161	class iii iv
0.9209505133	acute rheumatic fever
0.9209122157	fontan palliation
0.9204942783	implantation depth
0.9203053758	peer reviewed
0.9202795569	end stage renal disease
0.9200948025	orbital atherectomy
0.9200862847	gastrointestinal motility
0.9199847238	intraventricular conduction
0.9199152174	left ventricular assist device
0.9196494249	implantable loop recorder
0.9196295524	ng ml
0.9194382448	incidental finding
0.9193069260	antibiotic prophylaxis
0.9190846241	‚ÄØ ¬± ‚ÄØ
0.9190375272	edwards sapien
0.9186253116	active fixation
0.9184764193	para hisian
0.9184217734	ectopic beats
0.9181726936	stun gun
0.9179442761	alzheimer's disease
0.9178781583	linear regression
0.9178237885	multivariate logistic regression
0.9176384967	beats min
0.9175628523	longitudinal strain
0.9175224975	75th percentile
0.9174686248	bicuspid aortic valves
0.9174227252	burst firing
0.9173300979	pallid breath holding spells
0.9169665981	carotid sinus
0.9166922021	white blood cell
0.9166713285	trial registration
0.9166312848	transesophageal echocardiogram
0.9165734738	mir 263b
0.9165630042	platypnea orthodeoxia syndrome
0.9164622213	slow wave
0.9163787971	cardiovascular implantable electronic device
0.9162973273	ischemic heart disease
0.9162438145	arterial switch
0.9160265856	conduction abnormality
0.9160082044	air kerma
0.9159279881	skilled nursing
0.9158539212	wnt signaling
0.9158175622	aortic regurgitation
0.9157906914	anzacs qi
0.9157834138	pocket haematoma
0.9157502911	life threatening
0.9157143623	syrian hamsters
0.9156434981	brachiocephalic vein
0.9154700252	matched pairs
0.9153654868	anzhen hospital
0.9152258264	nonischemic cardiomyopathy
0.9152023727	paraventricular nucleus
0.9151074071	nonsustained ventricular tachycardia
0.9149817892	bruise control
0.9147827787	energy expenditure
0.9147513591	sodium bicarbonate
0.9147288162	temporal lobe epilepsy
0.9147204458	evolut pro
0.9146546480	single ventricle
0.9146156528	twiddler syndrome
0.9145866769	left ventricular outflow tract
0.9145724739	cycle length
0.9145660631	carotid artery stenting
0.9145113544	perimembranous ventricular septal defect
0.9144119459	short term
0.9143934280	ventricular fibrillation
0.9140916185	foreign body
0.9140900514	multivariable logistic regression
0.9139706856	broad spectrum
0.9139156818	vena cava
0.9138964336	weight gain
0.9135938423	continuous positive airway pressure
0.9134339713	african americans
0.9134078349	epileptic seizures
0.9133709700	systolic blood pressure
0.9133263990	extracellular matrix
0.9132044929	conduction disorders
0.9131121107	intensive care
0.9130389101	edwards sapien xt
0.9130322517	wild type
0.9129352948	ryanodine receptor
0.9127687655	diffuse large b cell lymphoma
0.9125435052	closed loop
0.9123152298	femoral artery
0.9119687053	end points
0.9116348108	fatty acid composition
0.9116267161	tricuspid annular plane systolic excursion
0.9115222399	died suddenly
0.9114470546	slow wavesicc
0.9114339990	coronary artery bypass surgery
0.9113682138	cdc ir
0.9112655601	free running
0.9112370232	mouse embryonic stem
0.9111670260	complete atrioventricular block
0.9110693292	ifn Œ≥
0.9110545736	soft tissue
0.9107904068	cation channel
0.9107881980	obstructive hypertrophic cardiomyopathy
0.9107558418	medium term
0.9106666535	clinically relevant
0.9106643400	remained unchanged
0.9106503737	cox proportional hazards
0.9104311130	anti ro
0.9103726548	mr conditional
0.9100264512	contrast venography
0.9099186110	locking stylet
0.9098888815	rev erbŒ±
0.9098658341	lyso gb3
0.9098196460	qtc interval
0.9097422064	thoracic aorta
0.9096793036	follow ups
0.9096257847	receptor antagonist
0.9095745300	genetically encoded
0.9095183431	confocal microscopy
0.9093458472	balloon venoplasty
0.9091619194	paravalvular aortic regurgitation
0.9089140358	chart review
0.9088423007	computed tomographic
0.9087176048	mental health
0.9086899260	brain natriuretic peptide
0.9086644955	retrospectively reviewed
0.9086442149	pulmonary vein
0.9085030593	arrhythmic events
0.9080490650	american heart association
0.9077660667	procedural success
0.9076584584	sts score
0.9076316074	mobitz type
0.9075914034	spontaneously beating
0.9075160072	euroscore ii
0.9072618625	implantable cardioverter defibrillators
0.9072146980	radiation doses
0.9067321874	sgarbossa criteria
0.9067255353	pressure gradient
0.9065765356	inappropriate shocks
0.9064827006	bipolar disorder
0.9063696531	enterococcus faecalis
0.9063676972	homeodomain transcription
0.9061054814	cardiac implantable electronic devices
0.9057619073	central venous catheter
0.9054813813	rem sleep
0.9054492867	atrial septal defect
0.9053981671	autologous pericardium
0.9053174602	foreign bodies
0.9052688423	extracardiac conduit
0.9050380376	noncoronary cusp
0.9049556055	cerebrovascular accidents
0.9048208417	bright light
0.9047906914	xen d0103
0.9046542943	obstructive hcm
0.9045601499	balloon valvuloplasty
0.9045333662	case presentation
0.9039995110	thromboembolic events
0.9035511376	roc curve
0.9034910426	snc da neurons
0.9034573657	peripheral artery disease
0.9032880325	qrs complexes
0.9032200697	diastolic depolarization
0.9030941282	locomotor rhythms
0.9024621782	body temperature
0.9024495823	mml:mrow mml:mo
0.9022489359	national inpatient sample
0.9020538729	complete heart block
0.9020169498	3rd degree
0.9018628717	fontan circulation
0.9017487874	sa node
0.9015986906	university hospital
0.9015657205	ischemic cardiomyopathy
0.9015377093	baffle leaks
0.9015201278	radiation dose
0.9011391806	venous access
0.9010001270	gram negative
0.9008580375	physical restraint
0.9007979150	remains unclear
0.9007474692	electron microscopy
0.9005868951	wheel running
0.9005250823	electric fish
0.9004479070	transcatheter heart valves
0.9004370698	subaortic stenosis
0.9003407223	capture threshold
0.9003036990	nt probnp
0.9002047000	wistar rats
0.9001806923	major vascular complication
0.9001581829	potassium channels
0.9001558100	transient ischaemic attack
0.9000197099	breast cancer
0.9000052395	left bundle branch area pacing
0.8997098096	international normalized ratio
0.8995867247	cardiac implantable electronic device
0.8995396526	carotid sinus massage
0.8995336082	cardioverter defibrillator
0.8995017368	atrio ventricular
0.8993790511	left ventricular outflow tract obstruction
0.8992457578	light dark cycles
0.8991753895	left anterior fascicular block
0.8989671366	molecular clocks
0.8989667266	autonomic dysregulation
0.8986185244	discharged home
0.8985562632	perimembranous ventricular septal defects
0.8983266963	skin disinfection
0.8980579981	melatonin secretion
0.8980302308	gait speed
0.8979875238	primary prevention
0.8978285605	contrast medium
0.8978244921	cardiopulmonary exercise
0.8978078872	signaling pathways
0.8977102477	circadian disruption
0.8976278290	medicare beneficiaries
0.8975226556	coagulase negative
0.8974034473	peripheral tissues
0.8972745831	pluripotent stem cells
0.8972687678	public health
0.8972593493	unexplained syncope
0.8971966893	radiofrequency ablation
0.8970016055	saline solution
0.8969268129	tertiary center
0.8968579824	axillary venipuncture
0.8966655948	cost effectiveness
0.8966000459	annuloplasty ring
0.8964901588	st paul
0.8964233040	wall thickness
0.8964105991	free wall
0.8964063244	health care
0.8962522018	balloon inflation
0.8961910390	children weighing
0.8961350646	bundle pacing
0.8960779203	tilt table testing
0.8959628201	vsd closure
0.8957575655	human induced pluripotent stem cells
0.8957372197	mobitz ii
0.8956146575	inferior vena cava filter
0.8954492877	ventricular standstill
0.8953709304	annular rupture
0.8953149181	heart rate
0.8953110147	paced qrs duration
0.8952290583	delayed rectifier
0.8951607175	mm ¬† hg
0.8950915924	hirschsprung's disease
0.8950202503	aortic annuli
0.8949803386	left atrium
0.8949591202	general anaesthesia
0.8949423161	coronary angiogram
0.8949386476	inotropic support
0.8949140487	perimount magna
0.8948329244	interventricular septum
0.8948184226	receptor encephalitis
0.8947889542	nationwide readmission database
0.8947811776	coronary arteries
0.8947243590	transcatheter heart valve
0.8946817150	gram positive
0.8946076632	valve academic research consortium
0.8944962009	mid term
0.8944957596	prosthesis patient mismatch
0.8944294874	chest tube
0.8944193586	pulmonary hypertension
0.8943231277	open heart surgery
0.8943086910	ring annuloplasty
0.8943003175	european countries
0.8939350112	nyha functional class
0.8938038082	battery longevity
0.8937566571	slow waves
0.8935840538	mg kg
0.8933716544	fluorodeoxyglucose positron emission tomography
0.8933577487	transoesophageal echocardiogram
0.8931980163	long term
0.8931337826	landing zone calcification
0.8930724005	antibiotic envelope
0.8929843402	premature ventricular contractions
0.8929670413	cultured iccs
0.8927664260	qrs width
0.8926934407	su avr
0.8926894134	case series
0.8925979752	patient prosthesis mismatch
0.8925603735	membrane potential
0.8925057902	oxygen consumption
0.8924931735	small intestine
0.8924662872	prosthetic valve
0.8923792235	electronic apex locators
0.8922192631	nop lbbb
0.8921767414	flecainide toxicity
0.8921664441	sigmoid septum
0.8919418377	adverse effects
0.8919388748	locomotor activity
0.8919182039	functional capacity
0.8917880251	transoesophageal echocardiography
0.8916945413	standard deviation
0.8914962002	cancer borealis
0.8913662860	clk cyc
0.8912516372	single chamber
0.8910402454	modified single patch
0.8909231871	ct scan
0.8908866779	power transfer
0.8907490570	major bleeding
0.8907139390	genome wide
0.8904211482	pre existing
0.8902136980	electromagnetic field
0.8900358327	mml:mrow mml:mo ‚Äñ mml:mo mml:mo ‚Äñ
0.8899785648	atrial high rate episodes
0.8898895852	uterine contractions
0.8898778281	root abscess
0.8896109353	dual chamber
0.8895689959	‚Äñ mml:mo mml:mo ‚Äñ mml:mo mml:mrow
0.8895575606	glial cells
0.8891350204	hospital stays
0.8891135654	cardioinhibitory vasovagal syncope
0.8890361748	body weight
0.8890345252	atrioventricular nodal
0.8890040558	tvt registry
0.8889997845	genetically modified
0.8888411145	circadian clock
0.8887455166	valvular heart disease
0.8886852644	positron emission
0.8886084935	physical activity
0.8884290421	heart rate variability
0.8883136550	electrical cardioversion
0.8882413735	cardiac catheterization
0.8881892704	cox maze iv
0.8880157383	sn da
0.8878436364	cell types
0.8876410339	st segment elevation myocardial infarction
0.8876217267	purkinje fibers
0.8876155217	motor vehicle crashes
0.8873630582	core clock genes
0.8873189806	national health insurance
0.8872705938	intercostal space
0.8872571284	carotid artery
0.8872346281	femoral vein
0.8871981335	transprosthetic gradient
0.8871971058	electrode array
0.8869895668	lymph nodes
0.8869755975	randomised controlled trial
0.8868786951	acc aha hrs
0.8867594340	seat belt
0.8867297068	disabling stroke
0.8866969247	spontaneous beating
0.8865990849	mg bid
0.8865709376	outpatient clinic
0.8865582604	fdg uptake
0.8865020937	clinical trials
0.8864957125	electric field
0.8864522874	hv interval
0.8860600192	european lead extraction controlled
0.8859578254	gastric emptying
0.8856831432	voltage gated
0.8856349018	angiotensin ii
0.8856131831	multivariable analysis
0.8853193356	people's hospital
0.8851798571	ventricular septal defects
0.8851726186	redo avi
0.8850277018	video assisted
0.8849878239	left bundle branch
0.8849853660	dopaminergic neurons
0.8848812545	sutureless aortic valve replacement
0.8848702754	laser sheath
0.8848635600	teaching hospital
0.8848506220	corrected qt
0.8845187468	apache ii
0.8844521099	prohibitive surgical risk
0.8843710904	fuwai hospital
0.8841629884	repositionable lotus valve
0.8840789228	pet ct
0.8840082292	emergency physician
0.8839511082	heart block
0.8837217784	univariate analysis
0.8837139510	observational studies
0.8836181407	posttraumatic stress
0.8834793925	hemodynamic instability
0.8833082020	cardiac sarcoidosis
0.8831868475	transcatheter aortic valve replacement
0.8830278513	lung cancer
0.8827974584	embryonic stem cells
0.8827889413	dental equipment
0.8827689920	technically challenging
0.8827610297	atrioventricular node
0.8825947927	power supply
0.8825867168	hyperpolarization activated
0.8823074556	hcn channel
0.8820717559	pericardial sac
0.8819394021	hips cms
0.8819053329	food intake
0.8818769112	carpal tunnel
0.8818604985	dim light
0.8818032650	inter electrode distance
0.8817821426	urinary bladder
0.8817095437	conduction delay
0.8814425198	absent right superior vena cava
0.8813652765	mml:mn mml:mo
0.8813173444	emergency room
0.8813003406	life saving
0.8811435697	myenteric plexus
0.8810886528	brain slices
0.8809778781	cyclic nucleotide gated
0.8807185596	dynamic clamp
0.8806528454	mri scans
0.8806515123	st segment elevation
0.8806268464	bold oscillations
0.8806163067	Œ≤ blocker
0.8805731190	hipsc cms
0.8804211200	power consumption
0.8800756818	coronary cusp
0.8800533202	mini thoracotomy
0.8800522667	cha2ds2 vasc
0.8799961425	aortic valve
0.8799840066	symptomatic bradycardia
0.8798847033	org 1998 math mathml
0.8797538135	pigment dispersing
0.8796396713	gastrointestinal tract
0.8796073176	icu stay
0.8795767148	european heart rhythm association
0.8795316873	internal jugular
0.8795046296	confidence interval
0.8794934134	american heart association task force
0.8793873332	video eeg
0.8793430576	sino atrial node
0.8792461230	adversely affect
0.8791434178	cochrane central
0.8790774339	spike initiation
0.8790029528	constant dark
0.8790017195	fontan conversion
0.8789067941	surd avr
0.8788505303	mental status
0.8787858021	rna seq
0.8787763532	intensive care unit stay
0.8785958492	epithelial cells
0.8785733899	inflammatory cytokines
0.8785522645	tachycardia bradycardia syndrome
0.8784527988	end diastolic volume
0.8782805617	vagal reflex
0.8780715831	aortic valve replacement
0.8780170135	nurse led
0.8779364434	sympathetic nerve
0.8778000550	mode switch
0.8777608892	composite end point
0.8777402772	transcatheter aortic valve implantation
0.8776891989	muscarinic m3
0.8776059709	health care utilization
0.8774928406	micra tps
0.8771302775	light dark
0.8771156154	mml:mo mml:mi t mml:mi mml:mrow mml:math
0.8768569003	surgical aortic valve replacement
0.8767594709	community dwelling
0.8767385626	adverse clinical events
0.8766684896	venous occlusion
0.8764431221	quality adjusted life years
0.8764376457	qt prolongation
0.8764229871	activated cl
0.8764043128	electra registry
0.8763024410	immunofluorescence staining
0.8762798698	partial anomalous pulmonary venous connection
0.8762414988	cardiac contractility modulation
0.8761178560	catheter ablation
0.8759962478	mir 133a 3p
0.8757646244	loop recorders
0.8757617311	vascular access
0.8757462985	methicillin resistant
0.8756207693	transcription factors
0.8751336905	working memory
0.8751195489	subclavian artery
0.8748924365	diastolic dysfunction
0.8747988194	ischemic stroke
0.8746205278	low birth weight
0.8745548711	steady state
0.8744606511	class iii
0.8744060974	systolic function
0.8744007062	severely calcified
0.8743435782	body surface area
0.8742100209	neuronal excitability
0.8741553165	usual care
0.8741201865	liver transplantation
0.8739856802	trial registration number
0.8739573207	chi square
0.8738086460	peri procedural
0.8736981691	pineal gland
0.8736682728	atrioventricular septal defect
0.8736463576	ipsc cms
0.8736161620	micra ‚Ñ¢
0.8735833181	adenosine monophosphate
0.8734934159	upper limb
0.8734412739	pericardial tamponade
0.8733794952	tyrx ‚Ñ¢
0.8733101160	systematic review
0.8731706501	muscle weakness
0.8730670477	fluoroscopic guidance
0.8730661171	wearable cardioverter defibrillator
0.8730391157	perivalvular abscess
0.8727129785	mesc cms
0.8727119308	baseline characteristics
0.8726634084	vagal nerve
0.8725588923	lesion set
0.8725155064	paroxysmal atrial fibrillation
0.8724028442	motor vehicle
0.8723558443	spanish pacemaker registry
0.8722630426	laser sheaths
0.8720445072	inverse probability
0.8719963382	interventional cardiology
0.8719133326	freedom solo
0.8718666649	antithrombotic therapy
0.8718375684	suprachiasmatic nuclei
0.8717277742	guideline recommendations
0.8716885908	prosthetic valves
0.8716784512	coupled oscillators
0.8716551618	radiofrequency catheter ablation
0.8715644080	implantable electric devices
0.8714920594	transthyretin cardiac amyloidosis
0.8712814032	technically feasible
0.8712569939	restricted feeding
0.8712211675	paroxysmal supraventricular tachycardia
0.8710383995	deep learning
0.8710300063	dormant sanc
0.8709682567	post market
0.8709524408	cha2ds2 vasc score
0.8709114790	systolic pressure
0.8707884558	ventral lateral neurons
0.8706812211	pure aortic regurgitation
0.8705703792	remains controversial
0.8705464726	circadian photoentrainment
0.8705089261	odds ratios
0.8702811336	stand alone cox maze iv
0.8701359529	hcn channels
0.8698285614	mitral valve replacement
0.8697324682	pacemaker mediated tachycardia
0.8694844847	literature search
0.8693741144	light dark cycle
0.8692695630	chest wall
0.8692457867	left ventricular ejection fraction
0.8692192834	blood samples
0.8691512205	cc tga
0.8690922283	terminal pro b type natriuretic peptide
0.8690335810	double blind
0.8690258901	knockout mice
0.8689378770	structurally normal
0.8689267642	teaching centers
0.8689212457	lead extraction
0.8689030423	meta analyses
0.8687350126	night shifts
0.8687048259	deglutition syncope
0.8686536005	blood culture
0.8686160982	protein expression
0.8686133844	tricuspid valve repair
0.8685680178	retrospectively analyzed
0.8685611862	multislice computed tomography
0.8684843658	multiorgan failure
0.8684200527	crt survey ii
0.8682373397	cardioverter defibrillators
0.8681326212	battery life
0.8681279810	uneventful recovery
0.8680471075	pa pf
0.8680205740	atrial tachyarrhythmia
0.8679899432	pulseless electrical
0.8678363962	intermediate surgical risk
0.8677542034	anti ro ssa
0.8674602395	binding sites
0.8673988530	urgent emergent
0.8673815873	local anaesthesia
0.8673567969	mutation carriers
0.8672702344	tilt table test
0.8671788000	venous pole
0.8671277793	randomized trials
0.8669579908	st jude
0.8667341911	pigment dispersing factor
0.8667282755	tissue engineering
0.8666888519	field strength
0.8666373631	wave inversions
0.8663913994	total cavopulmonary connection
0.8662744945	sinus pause
0.8661845231	pip aad
0.8659511674	spinal cord stimulator
0.8659051804	leadless pacemaker
0.8658145163	tertiary referral
0.8656593790	major vascular complications
0.8653752643	ro ssa
0.8653351950	minnesota living with heart failure
0.8652248370	dual antiplatelet therapy
0.8651740600	paced qrs
0.8651575390	brain stem
0.8650482337	close proximity
0.8648283816	hemodynamically unstable
0.8646637099	mediastinal radiation
0.8645874954	venous obstruction
0.8645014743	extracorporeal circulation
0.8643954371	randomized controlled trial
0.8643483973	evolution rl
0.8643358401	computational modeling
0.8643123249	core laboratory
0.8641026256	blood transfusions
0.8639992830	oxygen uptake
0.8638896936	holter monitoring
0.8638494216	interatrial conduction
0.8638352563	emergency medicine
0.8636916307	ml kg min
0.8636753591	bicuspid aortic stenosis
0.8636240745	cardiopulmonary arrest
0.8635226983	propensity score matched
0.8633953174	anatomic repair
0.8633909883	angiotensin receptor
0.8633302764	safety profile
0.8633165577	small bowel
0.8629960547	antiarrhythmic drug
0.8629271616	left ventricular hypertrophy
0.8629230524	surgical site infections
0.8629217702	sapien s3
0.8628362574	potassium currents
0.8627407169	vagally mediated
0.8627321765	membranous septum
0.8627159025	chagas cardiomyopathy
0.8627104744	systemic embolism
0.8627038674	wall motion
0.8627028914	newly diagnosed
0.8626978292	controlled trials
0.8626880909	mechanical dilator sheath
0.8625888331	ap firing rate
0.8624353996	remain unclear
0.8624208668	relative contraindication
0.8624025406	comparative effectiveness
0.8624013587	tissue doppler
0.8623645483	radiation therapy
0.8621296816	guideline directed
0.8621253811	ivc filter
0.8621011096	rv fw ls
0.8618913924	hisbp versus rvp
0.8618645245	lead extractions
0.8618256485	animal models
0.8618115409	physical examination
0.8615569283	hek293 cells
0.8614587314	propensity score
0.8614364149	carotid sinus syndrome
0.8612655399	clinic visits
0.8612586654	myocardial perfusion
0.8611518179	fontan completion
0.8611471351	congenital heart block
0.8611221772	channel blocker
0.8611091070	molecular clockwork
0.8610937476	high degree atrioventricular block
0.8608496876	heart rhythm society
0.8608477524	intravenous drug abuse
0.8607743558	reverse remodeling
0.8606080153	redo savr
0.8605864022	donor hearts
0.8605618389	conduction recovery
0.8603906203	sutureless avr
0.8603215079	red blood cell
0.8603105241	gastrointestinal stromal
0.8602798387	bariatric surgery
0.8602769757	evolution sheath
0.8601201331	structural heart disease
0.8597524922	device interrogation
0.8595213468	local anesthesia
0.8594078203	ultrasound guided
0.8592412834	lesion sets
0.8591760270	fibrous tissue
0.8590854866	single photon emission
0.8590363864	radial strain
0.8590288616	pocket infections
0.8589403852	mathematical modeling
0.8589203887	apnea hypopnea index
0.8588821540	lower extremity
0.8588359357	qrs morphology
0.8588233019	brain regions
0.8586284869	guide wire
0.8585548957	abandoned leads
0.8584335125	clinical practice
0.8584298920	laser assisted
0.8582931231	meta regression
0.8582666308	international classification of diseases
0.8581062230	poor prognosis
0.8578344991	case report
0.8575050520	av block
0.8574865216	papillary muscle
0.8572829396	end point
0.8572576565	food and drug administration
0.8572295532	complication rates
0.8570910080	clinically meaningful
0.8568865386	comorbidity burden
0.8568767754	2nd degree
0.8568274716	bovine pericardial
0.8566645321	lead dislodgement
0.8560455022	neurological deficit
0.8559328653	iliac vein
0.8558747488	st elevation myocardial infarction
0.8557556341	stored electrograms
0.8557126316	sympathetic nervous
0.8556801796	left anterior descending coronary artery
0.8555821636	‚ÄØ gy
0.8555630139	circadian rhythm
0.8554955585	anterior leaflet
0.8554767646	functional class
0.8554627978	cardiology department
0.8554530211	transfemoral access
0.8553781733	cardiovascular diseases
0.8553208859	syncopal episode
0.8551684944	medical records
0.8550598884	chest radiographs
0.8549925302	numerical simulations
0.8548732580	mri surescan
0.8548547130	sudden unexpected death in epilepsy
0.8547582757	diagnostic yield
0.8545972610	rotational sheaths
0.8544816284	remote transmissions
0.8544107782	radiofrequency energy
0.8540093160	subjective night
0.8539547561	axis deviation
0.8538625002	blood flow
0.8536180277	gap junctional
0.8534567856	drug refractory
0.8533614548	outpatient visits
0.8533315941	st jude medical
0.8532306457	prognostic implications
0.8532058601	temporal lobe
0.8531440643	left internal mammary
0.8530579127	energy harvesters
0.8523182790	synaptic transmission
0.8522968819	light chain
0.8520452363	atrioventricular conduction
0.8520278588	robotic assisted
0.8519281792	myocardial infarctions
0.8518116814	technical challenges
0.8516381351	premature ventricular contraction
0.8515525596	bidirectional glenn
0.8515343624	venous thrombosis
0.8515096090	reflex syncope
0.8513485156	literature review
0.8512366020	access route
0.8510899028	urinary tract
0.8509646373	stented bioprostheses
0.8506315223	magnetic resonance conditional
0.8505569325	nationwide readmissions
0.8504776561	safety endpoint
0.8498904566	fdg pet
0.8497546948	intrinsically photosensitive
0.8496552472	inferior wall
0.8495058601	acute cholecystitis
0.8494429769	transcriptional regulation
0.8494022091	maze procedure
0.8493988641	minimal invasive
0.8493813749	posterior leaflet
0.8493124238	remains uncertain
0.8489955585	case description
0.8488702312	rt pcr
0.8488084543	superior vena cava syndrome
0.8487359930	transthoracic impedance
0.8487049780	diastolic filling
0.8486732471	categorical variables
0.8486669192	kccq os
0.8486124278	st elevation
0.8486038254	st segment
0.8485870584	¬† ¬± ¬†
0.8485564347	edwards intuity
0.8484697882	wolff parkinson
0.8483208067	high degree av block
0.8482060685	oral cavity
0.8481667708	av nodal
0.8481168910	transvalvular gradient
0.8481094063	fdg pet ct
0.8480551775	renal dysfunction
0.8479645666	venous stenosis
0.8478080387	local anesthetic
0.8476522127	ion currents
0.8476056127	camp pka
0.8472685135	potassium channel
0.8471925979	implantable devices
0.8470696006	thrombus formation
0.8469934772	exercise intolerance
0.8469658208	pivotal role
0.8469285353	foramen ovale
0.8468781933	mitral valve repair
0.8467430428	common carotid artery
0.8466177726	potentially lethal
0.8465734570	cardioinhibitory response
0.8464513317	fast track
0.8464485751	renal function
0.8462622018	implantable defibrillator
0.8462577373	abdominal wall
0.8459088464	laser lead extraction
0.8458685885	cycle lengths
0.8457686976	exercise training
0.8457409954	interstitial cells of cajal
0.8457137963	mobitz type ii
0.8456034648	success rates
0.8455312521	Œ≤ adrenergic
0.8453134898	cavoatrial junction
0.8452531445	position paper
0.8449726556	mode switching
0.8448575496	electronic medical record
0.8448430163	society of thoracic surgeons
0.8447768836	sutureless valves
0.8446822972	pulmonary artery pressure
0.8446007505	neuropeptide pigment dispersing factor
0.8445715691	temperature rise
0.8444964256	success rate
0.8442042764	syncopal recurrences
0.8439949047	permanent pacemaker
0.8439101761	direct current cardioversion
0.8437149470	bypass grafting
0.8435279206	antibiotic therapy
0.8433333475	clinical suspicion
0.8432150376	biatrial anastomosis
0.8431782581	cardiac operative risk evaluation
0.8430822629	medical history
0.8429049325	perceval sutureless
0.8427007248	competing risk
0.8426798017	qrs axis
0.8426229763	coronary atherosclerosis
0.8425647466	statistically significant
0.8425641652	biventricular pacing
0.8423826592	secondary end points
0.8422975525	neural circuits
0.8422604094	chest radiation
0.8422549037	lymphatic vessels
0.8420057671	gene transfer
0.8417246706	mood disorders
0.8415558293	avj ablation
0.8414980986	venous anomalies
0.8414725357	antiplatelet therapy
0.8414245809	infarct size
0.8413765883	mid septum
0.8413144997	fascicular block
0.8412121774	mri conditional
0.8411727553	pa vsd
0.8411570828	resting membrane potential
0.8411486951	room temperature
0.8410653000	quartile iii
0.8406025726	np lbbb
0.8405745629	observational study
0.8405567732	¬† Œºv
0.8405101147	neurally mediated syncope
0.8404441652	neurally mediated
0.8403786713	swab cultures
0.8403433357	sk channels
0.8402755783	serum creatinine
0.8402183979	left bundle branch pacing
0.8401960786	positive airway pressure
0.8401156880	pocket infection
0.8400654874	cephalic vein access
0.8400104173	healthcare providers
0.8399972430	pacing induced cardiomyopathy
0.8398915415	motor patterns
0.8398254121	spontaneous firing
0.8397920619	lotus edge
0.8396935465	glucose metabolism
0.8394698670	highly prevalent
0.8392574119	hs ctni
0.8392279201	specific absorption rate
0.8391985484	nanostim lp
0.8391231095	factors influencing
0.8390425322	holter monitor
0.8390017477	atrial tachyarrhythmias
0.8389221336	derived stem cells
0.8388982335	breath holding spells
0.8386551422	left ventricular assist devices
0.8386077743	adjusted odds ratio
0.8385324482	venous spasm
0.8385280777	late onset
0.8384567982	cryptogenic stroke
0.8383844421	phase shifting
0.8383504650	green light
0.8382370192	phasic contractions
0.8380696793	post operative
0.8380611912	implantable cardiac defibrillators
0.8379025731	long standing
0.8377593030	university hospitals
0.8376697641	femoral approach
0.8375142623	primary endpoint
0.8373030709	generator replacement
0.8372923908	night shift
0.8372792934	online survey
0.8372538221	temporary pacing
0.8372372422	high resolution
0.8372278498	congenital anomaly
0.8366077743	adjusted hazard ratio
0.8365213135	cognitive impairment
0.8365197472	premature beats
0.8361301614	sudden deaths
0.8361207001	medtronic corevalve
0.8361043917	remains elusive
0.8360024502	bacterial colonization
0.8356404727	ryanodine receptors
0.8356334876	multivariable cox regression
0.8356253035	epicardial pacing wires
0.8355297782	cell autonomous
0.8354353952	operative mortality
0.8352571926	select secure
0.8351287666	cardiovascular magnetic resonance
0.8350140276	pocket hematomas
0.8347733035	catheterization laboratory
0.8345635168	atrioventricular nodal reentrant tachycardia
0.8344342616	overexpressing mesc cms
0.8343896372	infectious endocarditis
0.8343461614	ld cycles
0.8343126071	participating centers
0.8341716944	temporary epicardial pacing wire
0.8341674023	clamp configuration
0.8340876613	american college of cardiology
0.8340478817	multivariate cox
0.8339830830	cardiac implantable electrical devices
0.8339294294	mrna expression
0.8338237746	transcriptional translational
0.8337607111	tachy brady
0.8336526850	permanent pacemaker implantation
0.8335657649	clinicaltrials.gov number
0.8335420754	congenital heart diseases
0.8334952270	myocardial injury
0.8334276951	left anterior descending artery
0.8334241907	renal impairment
0.8332981908	lotus valve
0.8332887973	electrically coupled
0.8331480797	mass spectrometry
0.8331310612	conduction disorder
0.8330338099	asynchronous mode
0.8329049952	arteriovenous access
0.8328468856	femoral access
0.8327790799	adrenergic receptor
0.8326945473	wide qrs
0.8326440177	direct visualization
0.8324827971	genes encoding
0.8324564228	hemodynamically stable
0.8322123261	Œ≤ blockers
0.8321660083	key points
0.8318432371	nanostim leadless
0.8318166645	memory formation
0.8316787861	implantable cardiac devices
0.8315421953	qrs prolongation
0.8314006623	systolic dysfunction
0.8313372084	congenitally corrected transposition
0.8312256470	pregnant women
0.8311222459	left ventricular systolic dysfunction
0.8310685824	mild pvl
0.8310504063	intra operative
0.8309707210	evolution ¬Æ
0.8309402029	left atrial
0.8306209687	atrial tachycardia
0.8305715513	edge to edge
0.8305472059	slow pathway
0.8302957452	pacemaker insertion
0.8302557203	pulmonary veins
0.8301528664	va conduction
0.8300921899	anterior wall
0.8300863813	symptomatic relief
0.8298538696	post hoc
0.8298191160	electrical impulses
0.8297418175	factors affecting
0.8297180682	young man
0.8296676114	ventricular arrhythmias
0.8295927699	biatrial maze
0.8294080285	largely unknown
0.8293709529	vagal tone
0.8292398076	havb chb
0.8290004020	worse prognosis
0.8288399932	genetic variants
0.8287920790	real life
0.8287564937	symetis acurate
0.8283102146	circadian alignment
0.8283005724	ras inhibitors
0.8282490988	lead tip position
0.8280255670	cardiothoracic surgery
0.8280203815	ventricular tachyarrhythmias
0.8279763894	light exposure
0.8279211983	arrhythmogenic right ventricular cardiomyopathy
0.8278668239	tilt testing
0.8276739576	glenn shunt
0.8276009198	cross clamping
0.8275972145	anti platelet therapy
0.8275138145	reverse transcription
0.8272217520	acurate ta
0.8270964364	atrioventricular valve regurgitation
0.8270716192	randomized clinical trials
0.8270092335	unknown aetiology
0.8270061879	extremely rare
0.8268243036	aortic annulus
0.8266691803	septal hypertrophy
0.8265734682	pluripotent stem cell
0.8264143623	potential confounders
0.8262779171	placebo controlled
0.8262274767	circular muscle
0.8261841126	special attention
0.8259933432	years ago
0.8259859117	plane systolic excursion
0.8259790715	swallow syncope
0.8258217276	remain elusive
0.8256768034	stem cell derived cardiomyocytes
0.8255502659	cox regression analysis
0.8255198969	incremental cost effectiveness
0.8255127053	aortic bioprostheses
0.8253295963	bidirectional rotational
0.8252844416	delay optimization
0.8250846772	blanking period
0.8249168566	patient specific computer simulation
0.8247119430	hcn isoforms
0.8246956631	excessive sleepiness
0.8246867716	remotely monitored
0.8246254631	gait variability
0.8245946801	sars cov
0.8245877629	esc ehra
0.8244676398	lead perforation
0.8244326717	membranous septum length
0.8243631931	female gender
0.8242613788	deleterious effects
0.8239797355	transcatheter valve therapy registry
0.8239536617	device success
0.8239284918	hemodynamic performance
0.8238623739	electronic medical records
0.8237229825	latest generation
0.8236739990	giant cell
0.8236642915	implantable cardiac defibrillator
0.8236041819	generator change
0.8235881984	pq interval
0.8235656189	dimensional echocardiography
0.8235619035	searched pubmed
0.8234581086	risk assessment
0.8231325111	risk score
0.8231291619	replacement notification
0.8230211405	pr intervals
0.8229906542	torsade de pointes
0.8228777361	preventive measures
0.8228553266	la dimension
0.8228536386	technical difficulties
0.8228394569	major adverse cardiovascular events
0.8228371639	receiver operating characteristic curve
0.8227381681	coronary obstruction
0.8227119060	composite endpoint
0.8225910496	intestinal transit
0.8225680139	inflammatory markers
0.8225548515	wolff parkinson white syndrome
0.8225058071	potentially fatal
0.8224011389	133a 3p
0.8222027478	cook medical
0.8221959375	chronically implanted
0.8221141217	binding protein
0.8218947868	great arteries
0.8218869891	permanent pacemakers
0.8217700421	lead fracture
0.8214782939	avoid unnecessary
0.8214474351	stroke tia
0.8214129297	causative organism
0.8211632477	mitral annular
0.8211061454	torsades de pointes
0.8210122235	al amyloidosis
0.8209531224	suture line
0.8208723219	updated valve academic research consortium
0.8208504028	expert consensus
0.8208397407	post operatively
0.8207408064	axillary vein access
0.8206294861	therapeutic hypothermia
0.8206035879	high grade atrioventricular block
0.8205350542	cox proportional hazards regression
0.8205340721	clinically significant
0.8204714603	indexed effective orifice area
0.8204289821	locomotor behavior
0.8203464627	prosthetic valve endocarditis
0.8200724696	transgenic mice
0.8199215133	silent af
0.8198636599	procedural details
0.8198175492	post transplant
0.8197926104	behavioral rhythms
0.8197792539	small intestines
0.8197716446	decision making capacity
0.8192540097	balloon expandable valves
0.8192509711	intracellular calcium
0.8192332455	high risk
0.8191823645	cardiac resynchronization
0.8191166135	derived cardiomyocytes
0.8190629896	respiratory failure
0.8190267460	pacemaker dependency
0.8189859117	estimated glomerular filtration
0.8184411763	sleep apnoea
0.8184085162	purkinje cell
0.8183544565	subgroup analysis
0.8181742364	lighting conditions
0.8179622106	dose area product
0.8178890285	sutureless aortic valves
0.8178668310	double patch
0.8178154351	transcatheter versus surgical aortic valve replacement
0.8177848216	pacemaker implantation
0.8176277316	class iv
0.8175874901	gamma oscillations
0.8174605169	lateral wall
0.8173251905	composite endpoints
0.8172698443	past medical history
0.8171821382	diagnostic accuracy
0.8170813215	ischemia reperfusion
0.8169662232	private hospitals
0.8168277222	lvot obstruction
0.8168232238	closed loop stimulation
0.8168154929	actuarial survival
0.8166555634	tricuspid valve replacement
0.8165509217	acute myocardial infarction
0.8164471027	burst generation
0.8164027190	relative risk
0.8163602261	observational cohort study
0.8161562041	staphylococcus aureus bacteremia
0.8161419373	permanent pacemaker insertion
0.8161052144	drug resistant
0.8159149751	cardiovascular disease
0.8158569964	neonatal rat
0.8157008423	bloodstream infection
0.8155419119	master circadian pacemaker
0.8152973811	limited data exist
0.8152463211	patient selection
0.8152383168	expandable transcatheter heart valves
0.8150379024	sudden cardiac arrest
0.8150191141	pacemaker potentials
0.8146800463	av canal
0.8146629770	dp dt
0.8143865858	escape rhythm
0.8143190304	appropriately selected
0.8142681203	prospectively collected
0.8139824387	sutureless and rapid deployment
0.8139788953	pre excitation
0.8138834980	congenitally corrected
0.8137514955	tachycardia induced cardiomyopathy
0.8137222373	medically refractory
0.8136984542	medical center
0.8136668433	subclavian vein puncture
0.8136234628	temporary pacing wires
0.8134114279	circadian dspd
0.8133253467	apex locators
0.8130821957	arterial hypertension
0.8130237413	health status
0.8129682305	restrictive cardiomyopathy
0.8126560990	predisposing factors
0.8125420719	intermediate term
0.8125148753	chronotropic response
0.8124743453	super responders
0.8124144897	circadian phase
0.8123504436	clock genes
0.8122898515	vascular complications
0.8122541510	girk channels
0.8121733698	sayre syndrome
0.8120950124	intra aortic balloon
0.8120791544	cm ¬≤
0.8116959833	tertiary care center
0.8116520942	anti inflammatory
0.8115997091	sinus tachycardia
0.8115799192	micra leadless pacemaker
0.8114944760	peripheral oscillators
0.8111027175	cumulative dose
0.8110260062	hematoma formation
0.8109155645	tertiary hospitals
0.8107824783	phase resetting
0.8106644602	guidelines recommend
0.8106109087	cardiac surgery
0.8104549685	multidetector computed tomography
0.8102040976	fluoroscopy guided
0.8101406059	quality improvement
0.8100876269	temporal trends
0.8100360354	preserved ejection fraction
0.8100145006	pre dilatation
0.8099016231	risk adjustment
0.8097568008	enteric neurons
0.8097506593	cut and sew
0.8096560677	primary endpoints
0.8094778785	eam guided
0.8094750582	multidisciplinary team
0.8093369512	dependent manner
0.8092749150	acute coronary syndromes
0.8092002664	consensus document
0.8090613151	intracellular ca
0.8089971337	ventilatory support
0.8089813121	conservative management
0.8089733116	genetically confirmed
0.8089360018	central venous pressure
0.8088279421	protective effect
0.8087236868	transcatheter aortic valve
0.8084618103	secondary end point
0.8084433120	longer term
0.8084179987	prospectively enrolled
0.8083840910	anticipatory activity
0.8083361792	dddrp + mvp
0.8082963254	funny current
0.8081954843	hipsc derived
0.8080295849	totally endoscopic
0.8079799743	molecular clock
0.8079769354	dilator sheath
0.8079718777	direct oral anticoagulants
0.8075737090	main outcome measures
0.8073628681	negative chronotropic
0.8073043638	cardiac arrhythmias
0.8072736410	moderate certainty
0.8071633757	plasma membrane
0.8071239639	central venous
0.8070383151	natriuretic peptide
0.8069501876	intraventricular conduction abnormalities
0.8067176579	working myocardium
0.8064770249	physician led
0.8064658429	health care costs
0.8064072872	receptor agonist
0.8062870458	synaptic inputs
0.8062519669	¬† √ó ¬†
0.8061218882	retinal ganglion cells
0.8059679082	dose dependently
0.8057950853	heart disease
0.8056567808	chronic shift workers
0.8054512964	proportional hazards models
0.8054249848	mml:mo mml:mo
0.8053993220	response curve
0.8053094156	treatment options
0.8052315728	gold standard
0.8051554106	size selection
0.8050925053	perceived duration
0.8050553915	extraction tools
0.8050338328	leadless cardiac pacemakers
0.8049372363	biatrial ablation
0.8048967860	thoracic surgeons american
0.8048643241	cost utility analysis
0.8047847127	upper gastrointestinal
0.8047566400	cell cycle
0.8047494418	gastric motility
0.8047434969	wake promoting
0.8046511158	reentrant tachycardia
0.8043899481	consecutively enrolled
0.8039273867	regional wall motion
0.8038895349	mml:mi mml:mrow mml:math
0.8038084962	nationwide inpatient sample
0.8037228389	sv glenn
0.8034990390	left anterior descending
0.8033713704	medicare fee for service
0.8031095962	beats per minute
0.8026678004	severe aortic stenosis
0.8025873170	central pattern generator
0.8023051822	prognostic factors
0.8022419283	numerically lower
0.8022399746	diabetic rats
0.8021865338	neural networks
0.8020357673	venous anomaly
0.8018511295	mitral valve surgery
0.8011149400	phase delays
0.8010621029	bypass graft
0.8009580751	voltage dependence
0.8007761874	adult congenital heart disease
0.8007062435	acc aha
0.8003495248	health insurance
0.8002747277	annulus diameter
0.8002257452	healthy controls
0.8001469846	lymph heart
0.8000430502	speckle tracking echocardiography
0.7999690986	primary efficacy end point
0.7999452314	atrio ventricular block
0.7998989575	heart rhythm disorders
0.7997819376	chest ct
0.7995796034	phrenic nerve stimulation
0.7995724111	multidisciplinary heart team
0.7994374752	1st degree av block
0.7994107509	exercise testing
0.7993413333	transcatheter aortic valves
0.7991073090	aortic bioprosthesis
0.7989989765	ct scans
0.7989477956	embolic events
0.7989151450	strongest predictors
0.7988955941	major adverse events
0.7988468731	demographic characteristics
0.7987114249	theta oscillations
0.7983356845	rhythm disorder
0.7983221299	fontan operation
0.7982879384	significantly reduced
0.7981087124	met inclusion criteria
0.7979693728	positively correlated
0.7978880524	multi institutional
0.7978540681	complete av block
0.7978066798	early discharge
0.7977548243	randomized clinical trial
0.7976621503	log rank test
0.7976148481	ventricular pacing
0.7975968119	academic research consortium
0.7973839166	cardiac implantable electrical device
0.7973682870	rapid deployment valves
0.7973417847	pressure gradients
0.7972438797	post hoc analysis
0.7971085173	electric shock
0.7970610161	cardiac strangulation
0.7968602194	computed tomography angiography
0.7968304803	outflow obstruction
0.7968269011	risk factor
0.7965838157	constant light
0.7965436356	clinical presentation
0.7965204190	ddd cls
0.7965127813	subclinical af
0.7965009089	main outcomes and measures
0.7964449194	inverse probability of treatment weighting
0.7963426957	viv tavi
0.7962639729	av node
0.7962354427	sars cov 2
0.7961257285	important roles
0.7961039551	intermediate risk
0.7957380674	intravenous antibiotics
0.7957122309	ca ¬≤ ‚Å∫
0.7954643107	surgical intervention
0.7953941038	ultrasound guided axillary
0.7953673252	store operated ca
0.7953641091	hemodynamically significant
0.7950155244	length of hospital stay
0.7950098949	proportional hazards model
0.7944174442	post procedural
0.7942730674	long standing persistent
0.7941345904	prognostic significance
0.7941270730	40 hz light flicker
0.7941225407	superfluous leads
0.7940940014	clinical outcomes
0.7939260187	venous puncture
0.7935347775	access site
0.7935233329	prolonged asystole
0.7933920520	random effect
0.7932460570	cardiac perforation
0.7931907103	cox proportional hazards models
0.7930131292	decompensated heart failure
0.7929545110	ms length
0.7929347032	beats minute
0.7927194889	beam energy
0.7924188374	home monitoring
0.7923925518	economic burden
0.7923809094	Œ≤ adrenergic stimulation
0.7922826278	registration number
0.7922510770	double outlet right ventricle
0.7920671532	deep venous thrombosis
0.7918661618	learning points
0.7918031405	blood loss
0.7917762284	af burden
0.7916880679	sinus node disease
0.7916018765	narrower qrs
0.7914623519	diagnostic tool
0.7911997016	major complications
0.7911389440	human induced pluripotent stem cell
0.7910529855	septal thickness
0.7910005863	international guidelines
0.7908858419	tilt test
0.7908730830	requiring transfusion
0.7907408507	inappropriate shock
0.7906801628	electrical impulse
0.7901160485	tetralogy of fallot
0.7901152286	bioprosthetic valves
0.7900793365	valve sparing root
0.7900088287	fibrotic tissue
0.7897439477	central venous stenosis
0.7896775911	german aortic valve registry
0.7895562008	false positive
0.7895121240	rapidly progressive
0.7892556394	data collection
0.7891814692	lead placement
0.7891042224	fixation beats
0.7889902116	adverse outcomes
0.7889355015	median sternotomy
0.7889273499	delivery sheath
0.7889242373	minute walk
0.7887956341	rheumatic heart disease
0.7886819020	interquartile range iqr
0.7886452620	qrs complex
0.7885092595	aortic cross clamping
0.7884503444	female sex
0.7883598549	electronic databases
0.7882738543	tv repair
0.7880596033	older adults
0.7879805899	doppler echocardiography
0.7878633441	remained stable
0.7877113203	investigational device exemption trial
0.7877061636	high dft
0.7874741333	severe tricuspid regurgitation
0.7874455544	lead removal
0.7874372138	lbb capture
0.7874340291	mid septal
0.7874300150	sodium channels
0.7873988509	primary end point
0.7873507100	remains unknown
0.7871203671	echo guided
0.7869445270	primary outcome
0.7867471822	clinical trial
0.7867289356	anti ssa
0.7866853333	multivariable regression
0.7865800517	motility disorder
0.7865563212	step by step
0.7864609796	asynchronous pacing
0.7863856781	paced qrsd
0.7860695631	central veins
0.7857675814	annular plane
0.7857599884	intra aortic balloon pump
0.7856016901	mode selection
0.7855496494	phase shift
0.7855255339	transplant free survival
0.7854486912	tr progression
0.7852923098	chest x ray
0.7852070889	rhythm disturbances
0.7851909840	genetic testing
0.7849669100	phase angle
0.7849348730	renal replacement therapy
0.7848870834	double outlet
0.7847859923	mri compatible
0.7847642476	young adult
0.7846497012	clinical trial registration
0.7846396141	tricuspid annulus
0.7844754624	tricuspid valve regurgitation
0.7844369387	transvenous lead extractions
0.7844147647	drug abuse
0.7843666925	large intestine
0.7843578322	early recognition
0.7842100862	adjusted odds
0.7839154629	pacemaker placement
0.7837404721	viv tavr
0.7834408790	single cell
0.7834302977	propensity scores
0.7833546467	neural network
0.7833387753	electrical stimulation
0.7832724697	va ecmo
0.7832717054	functional status
0.7832561902	high frequency
0.7832232749	telemetry monitoring
0.7831407279	recently introduced
0.7830623508	sleep wake cycles
0.7828928339	c reactive protein
0.7828191322	receptor antagonists
0.7827110533	tricuspid annular
0.7826981868	retrospective observational study
0.7825031398	supraventricular arrhythmias
0.7822146229	standardized protocol
0.7820629033	adenosine stress
0.7819598181	motor pattern
0.7818320918	pacing threshold
0.7818061548	nodal reentrant tachycardia
0.7817410276	shortness of breath
0.7817365823	mouse small intestine
0.7817041461	rvot septal pacing
0.7815136421	micra transcatheter pacing study
0.7813272860	rate responsive
0.7803755902	middle aged
0.7803476245	procedural characteristics
0.7801212481	exercise stress test
0.7801065407	beating rate
0.7800371817	ko san
0.7790349128	tachy brady syndrome
0.7789992286	intraventricular conduction delay
0.7787405152	postoperative delirium
0.7786622819	sympathetic and parasympathetic
0.7783032450	subclinical cardiac perforation
0.7781290741	endocardial leads
0.7780050784	icc ss
0.7779208328	aortic aneurysm
0.7777945281	pre existing rbbb
0.7775234290	conduction defect
0.7774999775	learning objective
0.7773207313	rapid deployment aortic valve replacement
0.7773012447	electrical activity
0.7772296084	coronary revascularization
0.7771843831	collaborating centers
0.7766453789	pacing thresholds
0.7766079634	animal model
0.7763936839	left ventricular function
0.7761971354	morning and evening
0.7758638614	precordial leads
0.7757477758	transcatheter mitral valve repair
0.7756459320	anti nmda
0.7754197170	circadian behavior
0.7752016656	multivariate regression analysis
0.7751495796	kaplan meier curves
0.7751069642	femoral venous access
0.7748072400	tav in sav
0.7747289765	traditional chinese
0.7746222584	lv dp dt
0.7744970909	potential role
0.7744617830	peri operative
0.7744422595	junctional escape
0.7741559376	antimicrobial therapy
0.7741048159	short form
0.7740914375	risk profile
0.7740512047	aortic valve stenosis
0.7739637075	ml min 1.73
0.7739293186	junctional escape rhythm
0.7737419515	vagus nerve stimulation
0.7736658761	leadless cardiac pacemaker
0.7735362583	fix hf
0.7735025964	projection neurons
0.7734674644	haemodynamic performance
0.7733022004	cross clamp and cardiopulmonary bypass
0.7732300431	therapeutic option
0.7730218957	chi square test
0.7729158627	clinical characteristics
0.7728791835	av conduction
0.7725308430	recurrent syncope
0.7724986706	antitachycardia pacing
0.7724298786	health related quality of life
0.7722013921	tertiary centers
0.7721756681	high surgical risk
0.7721686365	clock gene expression
0.7720399824	anomalous pulmonary venous connection
0.7719901347	su savr
0.7718110493	major adverse cardiac events
0.7717872368	medical record
0.7717690223	frequently encountered
0.7717447849	retrograde conduction
0.7715648861	nt pro
0.7715378597	post approval registry
0.7714482122	apnea hypopnea
0.7713940191	cardiovascular events
0.7713122105	efficacy endpoint
0.7713052248	wolff parkinson white
0.7712735967	long axis
0.7711730326	sleep promoting
0.7711587398	large vegetations
0.7710909934	imaging modality
0.7709391225	pre procedural
0.7709293223	significantly higher
0.7706206691	smooth muscle cells
0.7705307338	human embryonic
0.7704665229	fluorescent protein
0.7703911407	aortic root replacement
0.7703004871	voltage sensor
0.7700555545	recalled leads
0.7700332044	pre operative
0.7700275051	fully understood
0.7697719071	slice computed tomography
0.7697149476	bav and tav
0.7694656990	web of science
0.7691442986	bivp or hisbp
0.7689443042	post translational
0.7687094848	single center experience
0.7685951219	sutureless bioprosthesis
0.7684905080	embryonic stem cell
0.7683054149	cied infections
0.7681427147	rescue thv in thv
0.7680619069	ventricular repolarization
0.7678264928	measurements and main results
0.7677213008	congenital complete heart block
0.7676878696	chinese population
0.7676772607	new york heart association class
0.7676676605	lmna mutation
0.7676538268	sudden onset
0.7675955143	aortic valve area
0.7673772820	avt pacing
0.7668178740	structural remodeling
0.7667870918	mechanisms underlying
0.7667184306	subclavian vein occlusion
0.7666201636	human induced pluripotent stem
0.7664907513	switch operation
0.7663573622	anxiety and depression
0.7662810706	svc obstruction
0.7662480074	post dilatation
0.7660919245	root replacement
0.7659477975	left innominate vein
0.7658678974	sodium calcium
0.7658646886	clock gene
0.7656660394	steroid therapy
0.7655379791	ap firing
0.7653248102	non small cell lung cancer
0.7653219797	sinoatrial node myocytes
0.7651444178	ano1 channels
0.7651183186	cardiopulmonary bypass and cross clamp
0.7650263998	icc dmp
0.7648798263	interventricular septal
0.7648214371	sutureless valve
0.7647174931	persistent af
0.7646851436	transapical aortic valve implantation
0.7646593127	permanent pacemaker placement
0.7645921244	complete procedural success
0.7643484340	medical therapy
0.7642580043	membrane potentials
0.7641595261	lv ejection fraction
0.7640468278	severe sa
0.7639217571	silent atrial fibrillation
0.7638259442	dual antiplatelet
0.7638167734	long lasting
0.7637803303	clamp recordings
0.7637319971	referral center
0.7636583510	sodium current
0.7636414186	logistic regression analysis
0.7636224887	male gender
0.7634746346	aortic valve calcification
0.7634275590	preexisting lbbb
0.7634200234	retrospectively analysed
0.7632343795	myocardial ischemia
0.7631468142	aortic dissection
0.7630716618	tertiary hospital
0.7630477795	double chamber
0.7628960263	vein cannulation
0.7627899706	significantly lower
0.7625910370	atrial septal defects
0.7625741497	electrical coupling
0.7625061089	high degree avb
0.7624753381	video assisted thoracoscopic surgery
0.7623094095	heart rhythm
0.7622208284	thromboembolic risk
0.7621615996	scn slices
0.7619388012	statistical differences
0.7618131681	myocardial fibrosis
0.7615974636	lc neurons
0.7615855388	atrioventricular dissociation
0.7615850770	minimal contrast
0.7614081075	case control study
0.7613345515	right anterior mini thoracotomy
0.7613149262	cardiac amyloidosis
0.7613137489	heart team
0.7612820512	transvenous leads
0.7608128411	channel blockers
0.7606314109	sick sinus
0.7603401478	consecutive patients undergoing
0.7601960855	permanent hbp
0.7600192647	right bundle branch block
0.7596688579	left atrial volume index
0.7596538123	lower limb
0.7593260410	new york heart association
0.7590733365	acute myocarditis
0.7589446849	activated protein kinase
0.7589069239	balloon dilatation
0.7587390936	sinoatrial nodal cells
0.7584803057	subcutaneous implantable cardioverter defibrillator
0.7584077150	conduction velocity
0.7582296789	children's hospital
0.7581740085	secondary outcomes
0.7581118200	family history
0.7580016629	conduction block
0.7579026770	atrioventricular node ablation
0.7578447795	congenital heart surgery
0.7578427477	lead displacement
0.7577859423	motility disorders
0.7576940205	prolonged pr interval
0.7576224760	transapical approach
0.7573925606	diagnostic challenge
0.7571910715	beating heart
0.7571117173	valve replacement
0.7571080417	degree avb
0.7570817376	consensus statement
0.7569348511	wise crt
0.7565822446	independently predicted
0.7565467645	tricuspid stenosis
0.7565278336	spinal cord stimulation
0.7564656923	nerve stimulation
0.7564129996	per2 expression
0.7562550901	pro bnp
0.7561141752	frailty syndrome
0.7561130876	previous studies
0.7559571320	cardiac output
0.7558697735	device landing zone
0.7558169745	sex differences
0.7553898096	rate adaptive
0.7553533895	cardiac involvement
0.7553047480	lvot gradient
0.7552590523	surgical site infection
0.7552200091	sodium channel
0.7550749969	perceval prosthesis
0.7550012191	contrast volume
0.7549851989	delivery catheter
0.7549424797	end stage
0.7547902609	ventricular capture
0.7547861830	attr ca
0.7544287965	ventricular dyssynchrony
0.7543788104	atrioventricular blocks
0.7539784700	patient satisfaction
0.7537274634	newly implanted
0.7537148388	landing zone
0.7537014804	atrial myopathy
0.7536732939	management strategies
0.7535925851	maze iii procedure
0.7534821959	racial disparities
0.7534569760	nationwide cohort study
0.7534518114	contrast enhanced
0.7534339235	ventricular tachyarrhythmia
0.7532590179	pacemaker potentials in cultured iccs
0.7532426962	prediction model
0.7531352564	t wave inversions
0.7530358416	posterior wall
0.7527228987	incremental cost
0.7526152971	remain poorly understood
0.7524363418	mri examinations
0.7523942313	stent placement
0.7523507632	referral centre
0.7523383837	permanent pacing
0.7520300566	icc networks
0.7519954177	sustained ventricular tachycardia
0.7518149596	pilot study
0.7517502410	active fixation leads
0.7517129747	based lvh
0.7515642459	new york heart association functional class
0.7512698166	proximal and distal
0.7511136689	transfemoral aortic valve implantation
0.7510415420	retrospective study
0.7509539386	1st degree
0.7509380153	safety concerns
0.7509377609	mri scan
0.7508502196	circadian rhythmicity
0.7507864103	international registry
0.7507299398	left atrial diameter
0.7505614921	newly detected
0.7504583063	sample size
0.7504452537	beat to beat
0.7504130099	multicenter study
0.7503452619	persistent atrial standstill
0.7503280062	bioprosthetic valve
0.7503072457	pacemaker implantations
0.7502791669	iii iv
0.7502037979	electrophysiological study
0.7498334086	fully repositionable and retrievable
0.7498177337	carotid stenosis
0.7497656858	tricuspid valve surgery
0.7497278492	membrane hyperpolarization
0.7495850776	basal septum
0.7492909824	phase advance
0.7491184909	degenerative mitral
0.7487324472	proof of concept
0.7486452592	modified duke criteria
0.7485464780	bnp levels
0.7485112901	bicuspid aortic valve stenosis
0.7484902924	bundle branch blocks
0.7483598011	wall motion abnormalities
0.7483009022	cross clamp
0.7482911053	symptomatic severe aortic stenosis
0.7482501698	systematic review and meta analysis
0.7482068921	mathematical model
0.7481640022	significantly longer
0.7479523829	covid 19 outbreak
0.7478878321	highly correlated
0.7477715115	cardiac rhythm management
0.7476050498	nkx2 5
0.7474797078	multicenter registry
0.7473308378	intrinsic rhythm
0.7473299164	daily activities
0.7469607524	vvi mode
0.7469380030	united network for organ sharing
0.7469014635	cied infection
0.7468792568	ppm implantation
0.7466874741	related complications
0.7465893055	receptor blockers
0.7465758145	breath holding
0.7465648109	retrievable lotus
0.7464873150	arrhythmic burden
0.7464104182	intuity valve
0.7462151127	current drain
0.7461012091	significantly decreased
0.7460909261	statistical analysis
0.7460758459	acute kidney injury requiring dialysis
0.7458881516	electrophysiological properties
0.7458349169	patch repair
0.7457386045	molecular basis
0.7457216916	safety end point
0.7454358659	store operated
0.7452014253	sleep related bradyarrhythmia
0.7450538953	coronavirus disease 2019
0.7450427303	multivariable analyses
0.7450226322	mml:mo mml:mi t mml:mi
0.7449892001	jarvik 2000
0.7448556362	loss of consciousness
0.7447623846	single arm
0.7447116110	gene mutations
0.7443401079	single center
0.7441913159	icm detected
0.7441344910	anesthetic management
0.7437688658	lasting ‚â•
0.7436987313	cell count
0.7436045806	anti arrhythmic drugs
0.7435831348	leadless intracardiac
0.7435771478	rhythm disturbance
0.7434933327	device related infection
0.7433869519	mitral stenosis
0.7433655230	complication rate
0.7433175864	safely and effectively
0.7431926294	transfer function
0.7431750107	atrial arrhythmias
0.7431703701	multicenter experience
0.7430324007	current guidelines recommend
0.7427857980	closely related
0.7427354423	procedural complications
0.7427196730	active implantable medical devices
0.7425800805	moderate pvl
0.7425446847	¬† gy
0.7425179584	task force
0.7423398703	mouse embryonic
0.7422458940	clinical implications
0.7420859100	da neurons
0.7420641854	multivariable adjusted
0.7419913102	minor complications
0.7419819807	aortic ¬† valve
0.7419330920	primary end points
0.7417850477	subcutaneous icd
0.7415296645	lead dislodgment
0.7413258348	long term survival
0.7412176642	signaling pathway
0.7410997915	differential diagnosis
0.7409964226	tendril leads
0.7409568583	multivariable cox
0.7409512636	kidney disease
0.7409066173	cost effective
0.7404839250	wave amplitude
0.7404283786	insertable cardiac
0.7403727269	statistical difference
0.7403142002	‚ÄØ = ‚ÄØ
0.7403007210	preserved lvef
0.7399936586	exercise stress
0.7398967036	tertiary care
0.7395698624	multivariate cox regression analysis
0.7395480396	matched cohorts
0.7394769740	icc mp
0.7393771941	post dilation
0.7392651758	epicardial leads
0.7388657603	partial anomalous pulmonary venous
0.7388395517	high grade av block
0.7386024748	circadian behaviors
0.7385469107	community based
0.7383141508	retrospectively evaluated
0.7381532613	beneficial effects
0.7379083217	small intestinal
0.7377119677	midterm outcomes
0.7375197570	clock neurons
0.7374435503	valve surgery
0.7372191469	differed significantly
0.7369795422	‚àÜ hr
0.7369027463	significantly increased
0.7366188300	leadless vvi
0.7365664127	physiology and behavior
0.7364996361	surgical ablation
0.7362474746	end systolic
0.7360297434	wave propagation
0.7360100031	life threatening bleeding
0.7359416517	ddd mode
0.7357108813	single ventricle physiology
0.7356307440	data set
0.7354185505	alternative access
0.7349810719	rapid ventricular pacing
0.7349655203	positive correlation
0.7348603577	rv apical pacing
0.7345650967	implantable electronic devices
0.7345303162	av node ablation
0.7344990931	renal artery
0.7343094924	metabolic syndrome
0.7342619237	vagal stimulation
0.7341373913	retrospective chart review
0.7341283110	circadian locomotor
0.7340897766	thromboembolic complications
0.7340817992	av synchrony
0.7340067923	temporary pacemaker
0.7339067438	severe bradycardia
0.7337912987	right anterior minithoracotomy
0.7337377679	multivariate cox regression
0.7334787726	functional tricuspid regurgitation
0.7334326308	central venous access
0.7331769029	conclusions and relevance
0.7331428912	current clamp mode
0.7330402988	refractory period
0.7330362576	incidence and risk factors
0.7329425461	indexed effective orifice
0.7327431622	device malfunction
0.7325258998	selection criteria
0.7324857804	cardiovascular mortality
0.7321895960	level of difficulty
0.7321849045	significantly improved
0.7321745155	f fluorodeoxyglucose positron emission tomography
0.7321568747	prolonged ventilation
0.7319349070	non vitamin k antagonist oral
0.7318835308	propagation patterns
0.7317746436	¬† mm ¬† hg
0.7317417125	spontaneous sanc
0.7315435320	leadless pacemaker and subcutaneous
0.7314032244	case report and literature review
0.7312193517	previously published
0.7312033747	nucleotide gated
0.7309911957	pallid breath holding
0.7308496916	motor activity
0.7308358824	univentricular heart
0.7307496583	cox models
0.7307329085	major or life threatening bleeding
0.7306717466	pre discharge
0.7306551638	introduction and objectives
0.7305722747	post tavr
0.7305168449	recent studies
0.7304839947	area product
0.7302719051	potassium current
0.7302067924	nt probnp levels
0.7298941049	medline and embase
0.7294861439	european society of cardiology
0.7294804071	syncopal events
0.7292044234	x ray
0.7291748969	mir 124
0.7291018265	surgical bioprostheses
0.7289920067	mri scanning
0.7289475687	transfemoral tavi
0.7289033092	materials and methods
0.7288441478	high grade
0.7285964181	af recurrence
0.7285595840	light pulses
0.7285364850	cognitive function
0.7285336549	igf 1
0.7284915738	computed tomography scan
0.7283585774	placement of aortic transcatheter
0.7283268658	surgical correction
0.7281739272	rv pacing
0.7279565338	randomized trial
0.7279388965	clinical relevance
0.7278639724	d dimer
0.7277998950	ppm dependency
0.7277215534	univariate and multivariate
0.7275720282	valve hemodynamics
0.7275521152	transfemoral transcatheter aortic valve replacement
0.7273460002	left ventricular dysfunction
0.7271235004	septal pacing
0.7270667106	lead fragments
0.7269041911	hospital admissions
0.7265441308	‚â• moderate
0.7265374810	elderly population
0.7264448774	ischemic chb
0.7263803623	high volume
0.7261986803	lead revision
0.7259240040	conditional pacemaker systems
0.7258723189	retrospective review
0.7258608993	eq 5d
0.7257930121	studies reporting
0.7248906318	coronary artery bypass graft surgery
0.7246670971	western blot analysis
0.7246152644	primary care
0.7244919912	mml:math xmlns:mml =
0.7244740374	patient characteristics
0.7244578968	normal sinus rhythm
0.7243422489	surface ecg
0.7241632513	studies comparing
0.7241612664	hazard ratio hr
0.7241526821	myocardial perforation
0.7241175691	hb capture
0.7241033189	charlson comorbidity
0.7240699275	transient ischemic
0.7240112933	chronotropic effects
0.7239368868	root mean square
0.7236882028	risk ratios
0.7235597052	managed ventricular pacing
0.7233230174	ct angiography
0.7231985954	serum troponin
0.7230356763	pacemaker potential depolarization
0.7227635185	patch clamp recordings
0.7225921541	residual aortic regurgitation
0.7225631331	pm dependency
0.7225313811	prosthesis depth
0.7224614917	behavioral and physiological
0.7223971247	activated cyclic nucleotide
0.7222473087	operator experience
0.7222030032	population based cohort study
0.7220293293	indonesian version of
0.7218676376	clinical manifestations
0.7217475475	event free survival
0.7216709501	post procedure
0.7216140730	dual chamber pacemakers
0.7215961175	endogenous circadian
0.7214582551	outcome measures
0.7213713155	strong evidence
0.7212473969	mutant mice
0.7212270566	cardiac implanted electronic devices
0.7209664466	pacemakers and implantable cardioverter defibrillators
0.7209361090	pacemaker malfunction
0.7208951485	f fdg pet ct
0.7205661675	pediatric heart transplant
0.7205163357	avp neurons
0.7201364249	wide qrs complex
0.7199760183	implantable medical devices
0.7198971510	resting heart rate
0.7198426456	holter ecg
0.7196781631	device infection
0.7195916763	consecutive patients
0.7195214993	multivariate regression
0.7195073600	initial presentation
0.7194044211	united network
0.7192266109	myotonic dystrophy type
0.7189635928	inhibitory effect
0.7188309990	sinoatrial nodal
0.7186856970	numerical model
0.7185849552	mirna 155
0.7184810291	cohort study
0.7184465654	rapid ventricular response
0.7184460269	real time polymerase chain reaction
0.7184020613	median age
0.7182328551	multivariate logistic regression analysis
0.7180380320	the hypothalamic suprachiasmatic nucleus
0.7180045748	implantable cardioverter
0.7178623934	persistent atrial fibrillation
0.7177184579	resynchronization therapy
0.7174951576	axillary approach
0.7174798266	antibiotic treatment
0.7173607864	kaplan meier analysis
0.7172023892	technical success
0.7171586034	cox maze
0.7171542343	paroxysmal af
0.7168746512	inflammatory response
0.7164983508	end diastolic diameter
0.7164625169	significantly shorter
0.7163600721	head up tilt
0.7163210201	congenital complete atrioventricular block
0.7163056187	birth weight
0.7162663159	suture technique
0.7159659473	svc syndrome
0.7159490572	complete avb
0.7159208206	risk ratio
0.7158717532	end systolic volume
0.7157264325	quadripolar leads
0.7157259514	cajal cells
0.7156817202	vitro studies
0.7155963801	ta tavi
0.7153588240	device implantation
0.7153242270	nyha class iii
0.7152910813	food and drug administration approved
0.7152707124	sinus of valsalva
0.7150194800	circadian oscillators
0.7150110590	myotonic dystrophy type 1
0.7149917729	anoctamin 1
0.7149660539	lead position
0.7146562176	gene regulation
0.7145515627	noncardiac surgery
0.7145220784	evolut r pro
0.7144575604	echocardiographic parameters
0.7144571139	clinical picture
0.7142904454	risk adjusted
0.7142753721	left ventricular end diastolic diameter
0.7142203972	autonomic dysfunction
0.7141549347	biological clock
0.7139583581	overexpressing mesc
0.7134874911	implantable defibrillators
0.7134471794	eye movement
0.7132126175	critical role
0.7130430667	tr grade
0.7129486541	randomised controlled
0.7128412960	atrial switch
0.7128100637	aureus bacteremia
0.7127994349	thoracoscopic ablation
0.7126001147	older age
0.7125495226	leadless transcatheter pacemaker
0.7124998928	trans catheter
0.7124430330	vegetation size
0.7123408924	serum levels
0.7122738923	lv gls
0.7121489702	background and purpose
0.7120903488	smooth muscle contraction
0.7118654657	high throughput
0.7118263113	heart institute
0.7117377787	spontaneous activity
0.7116171969	tf tavr
0.7115052914	left ventricular dyssynchrony
0.7114357828	endocardial pacing
0.7114266666	prospective study
0.7113928056	covid 19
0.7113498351	highly variable
0.7113326964	isolated plsvc
0.7113103245	long pauses
0.7110406625	france tavi
0.7109778749	micra transcatheter pacing system
0.7107030862	pluripotent stem cell derived
0.7106713848	background and objectives
0.7104718408	negative predictive value
0.7103211854	clinical scenarios
0.7102267685	laser extraction
0.7100209708	chronic lung disease
0.7099646611	generate rhythmic
0.7097727715	deficient mice
0.7091581822	de novo
0.7089137010	low dose
0.7087342797	worse survival
0.7085634314	central pacemaker neurons
0.7085197477	action potential firing
0.7084096944	venous stenosis or occlusion
0.7083633756	intra atrial
0.7083046185	low risk
0.7082924188	dual chamber pacemaker
0.7080933219	video assisted thoracoscopic
0.7080858545	random effects meta
0.7080237973	septal defects
0.7077356955	av delay
0.7077319193	medical technologies
0.7077221612	icu admission
0.7076909055	hospital readmission
0.7074701109	atrial enlargement
0.7073623267	thoracic surgeons predicted risk of mortality
0.7072567766	xt thv
0.7071869355	random effects
0.7070024480	critical care
0.7069739441	pacemaker and implantable defibrillator
0.7067224068	permanent pacemaker implantations
0.7066446127	syncope collapse
0.7066321373	published literature
0.7065395352	behavior and physiology
0.7063922531	systolic and diastolic
0.7062370581	avn ablation
0.7062152081	dual coil
0.7062144964	right ventricular outflow tract
0.7062025375	patient demographics
0.7061635211	matched cohort
0.7060877515	interval timing
0.7060672123	avnrt ablation
0.7060026388	cardiovascular death
0.7059017048	ex vivo
0.7057290839	dopamine neurons
0.7056762094	young children
0.7056393347	early and mid term
0.7054627775	stress testing
0.7054191904	initial experience
0.7051274408	diastolic function
0.7050132292	previously reported
0.7047254125	persistent bacteremia
0.7046961212	valvular disease
0.7046677249	head and neck
0.7042045498	multivariate model
0.7039158908	observation period
0.7039047936	pacemaker cells
0.7038012853	methods and results
0.7034848715	edwards intuity valve
0.7034054019	median weight
0.7030642223	prolonged qt interval
0.7030039534	short and long term
0.7028829497	multi center
0.7025588645	contraction frequency
0.7024325509	fw ls
0.7023338937	whole cell patch clamp
0.7022757338	inverse probability of treatment
0.7021618427	lead perforations
0.7019955237	incidence rate ratio
0.7018927603	surgical avr
0.7018643320	subclavian approach
0.7017175323	¬† ms
0.7017159710	lead failure
0.7015198746	leadless pacemaker implantation
0.7014889809	spontaneous contractions
0.7012605800	regression analysis
0.7011466704	statistically significant differences
0.7009791651	length of stay
0.7009366500	patients and methods
0.7009362263	enteric nervous system
0.7009085338	early postnatal
0.7008582772	negative feedback
0.7008230068	cardiac pacemakers
0.7007641887	rv lead positioning
0.7007396416	significantly fewer
0.7007319638	sts acc
0.7006103353	relative risk rr
0.7004901220	mechanical dilator
0.7004535215	japanese population
0.7003440995	complete atrioventricular septal defect
0.7002983532	third degree av block
0.7001919862	pm implantation
0.7001497670	future research
0.7001172154	physiological and behavioral
0.7000299600	rhythmic behavior
0.7000225990	elective replacement
0.6999727236	mechanical dyssynchrony
0.6999673554	tavr or savr
0.6998859211	myocardial damage
0.6998269162	ventricular myocytes
0.6997843508	death or transplantation
0.6997708189	material and methods
0.6997244837	b type natriuretic peptide
0.6996863049	next generation sequencing
0.6994170917	temporary pacemakers
0.6993396341	lead tip
0.6993222048	cox proportional
0.6991347037	s3 thv
0.6988334872	physiological processes
0.6986487485	clinical modification
0.6984842944	atrioventricular junction
0.6983214497	undergoing tmvr
0.6982027956	case highlights
0.6981013653	validation cohort
0.6980711835	tf tavi
0.6979197573	left ventricular outflow tract gradient
0.6978573004	san cells
0.6978011248	c kit
0.6976682405	membrane depolarization
0.6975576051	repaired tetralogy of fallot
0.6975185237	permanent pacemaker requirement
0.6972950087	epicardial pacing
0.6972945245	embolic stroke
0.6972783250	proportional hazards regression
0.6971285967	rapid atrial pacing
0.6970714743	organ sharing
0.6969945504	left ventricular systolic function
0.6969465843	safety endpoints
0.6969393215	early and late
0.6968468297	vascular injury
0.6967994330	atrioventricular synchronous pacing
0.6967971439	analyzed retrospectively
0.6967172384	neuronal firing
0.6965874263	mice lacking
0.6965407507	bioprosthetic tricuspid valve
0.6964397558	corevalve prosthesis
0.6962406588	drug administration
0.6960564213	transvenous lead removal
0.6960456018	class iii or iv
0.6960376794	short axis
0.6957390446	third degree atrioventricular block
0.6955040593	multivariable logistic
0.6952245604	long term outcome
0.6951111001	terminal pro
0.6948684421	circadian timing
0.6946779175	bradycardia or asystole
0.6945353338	background and aim
0.6943340508	underlying mechanisms
0.6939653723	valve size
0.6938018620	Œ≤ ar
0.6937762634	ii iii
0.6935894581	long qt
0.6933474898	neuronal activity
0.6933438602	clinical outcome
0.6933185193	liver disease
0.6931680026	balloon pump
0.6929935492	tavi or savr
0.6929369502	electrical performance
0.6928615988	adverse cardiovascular events
0.6927666841	slow ventricular response
0.6926936795	pacemaker and implantable cardioverter defibrillator
0.6925427133	mr imaging
0.6925347094	patients undergoing
0.6925002785	temporary transvenous pacing
0.6922673085	firing rates
0.6921932453	percutaneous closure
0.6921837969	mrna and protein
0.6920730502	redo surgical aortic valve replacement
0.6918274954	ventricular assist device
0.6917504534	diagnostic and therapeutic
0.6914866268	firing patterns
0.6914331632	cardiac devices
0.6913061949	pre transplant
0.6912335348	n methyl d aspartate
0.6911720540	onset persistent left bundle branch block
0.6911719058	findings suggest
0.6910127936	hyperpolarization activated cyclic nucleotide
0.6910050738	inward rectifier
0.6909771263	ventricular septum
0.6909469236	electrocardiographic monitoring
0.6908535213	percutaneous lead extraction
0.6907484014	ventricular paced rhythm
0.6904859204	accelerometer based
0.6903954192	sur 8
0.6903860155	early and midterm
0.6903321215	multi centre
0.6901943016	sf 36
0.6901714029	confidence intervals
0.6901466746	readmission rates
0.6901399324	fee for service
0.6898655680	hospital discharge
0.6897682417	predicted risk of mortality
0.6896924257	cardiac function
0.6896284785	biological processes
0.6892396299	major adverse cardiac and cerebrovascular events
0.6891477294	neonates and infants
0.6889188691	inferior myocardial infarction
0.6888316781	rv apex
0.6887505341	atrial sensing
0.6887213004	minimally invasive aortic valve replacement
0.6886377480	vitamin k antagonist
0.6885793346	ventral lateral
0.6884079606	electrophysiology laboratory
0.6884073413	kinase inhibitor
0.6883281381	anti arrhythmic
0.6882403400	tricuspid valve annulus
0.6881537810	head to head
0.6881496550	quality of life
0.6876883487	highly expressed
0.6876847693	median age of treated patients
0.6876411020	venous anatomy
0.6875477161	c fos
0.6875196914	women and men
0.6875078325	core clock
0.6874875066	respiratory rhythm
0.6874722763	aortic valves
0.6874029024	sustained vt
0.6873687869	continued access
0.6873671085	implantable cardiac monitor
0.6872402109	postoperative complications
0.6872369751	bundle capture
0.6871302707	right ventricular apical pacing
0.6871161659	multivariable logistic regression analysis
0.6871145871	atrioventricular junction ablation
0.6870143466	valve academic research consortium 2 criteria
0.6869919664	ta tavr
0.6869305234	guideline based
0.6867898133	rdi pm
0.6865754890	elevated thresholds
0.6865478392	axillary access
0.6864807046	males and females
0.6864214709	adverse cardiovascular
0.6864109886	sudden unexpected death
0.6863337069	peripheral blood
0.6862538810	cardiac implantable electronic device infections
0.6862452030	¬† mm
0.6862212431	conduction disease
0.6861872174	circadian pacemaker neurons
0.6860130060	slightly higher
0.6859108333	post tavi
0.6858802504	readmission database
0.6855726378	anterior mitral
0.6853645776	iphone 12
0.6852752670	cross clamp times
0.6851654183	ilr monitoring
0.6850857463	survival benefit
0.6849974752	lv systolic function
0.6848375988	ventricular arrhythmia
0.6847625310	bleeding complications
0.6845711656	retrospective cohort study
0.6845028324	predictive power
0.6844658357	event rate
0.6842482338	subclinical atrial fibrillation
0.6839865024	vip neurons
0.6838978686	diagnostic and prognostic
0.6838958882	stimulus size
0.6838949852	circadian oscillations
0.6837429519	december 31
0.6836000068	prospective observational study
0.6835226134	bursting activity
0.6834977459	younger age
0.6833739370	venous drainage
0.6833562853	paroxysmal atrioventricular block
0.6832952848	ct images
0.6832299516	ventricular septal defect closure
0.6830228219	calcium volume
0.6830160336	stress echocardiography
0.6828030610	self expanding
0.6824776896	passive fixation leads
0.6824270602	national database
0.6823746680	negative correlation
0.6823667815	phase iii
0.6823178901	scn neurons
0.6822826955	coupled clock
0.6821024940	kidney failure
0.6818398623	tavr and savr
0.6818214627	sts prom score
0.6816999792	single blinded
0.6815863740	endocardial lead
0.6815556685	high degree
0.6815198346	internal clock
0.6815048988	et al
0.6814658286	ionic mechanisms
0.6814598634	random effects models
0.6814068502	peak gradient
0.6813394019	an independent clinical events committee
0.6811016107	intracardiac echocardiography
0.6810331478	neurological events
0.6809844390	outflow tract obstruction
0.6809844226	right anterior oblique
0.6806450258	biological pacemakers
0.6804761745	december 2012
0.6803370419	risk benefit
0.6803051401	men and women
0.6801531702	morbidity and mortality
0.6800919089	pacemaker and defibrillator
0.6799364395	type 2 diabetes
0.6796198162	aimed to investigate
0.6795561329	primary percutaneous coronary intervention
0.6795405337	anti tachycardia pacing
0.6795246584	implant depth
0.6794962036	intra procedural
0.6792581210	january 2005
0.6792409766	periprocedural complications
0.6791589347	lv end diastolic
0.6788272202	muscle contraction
0.6785386945	rr intervals
0.6785043997	aortic cross clamp
0.6784176555	transcatheter valve
0.6783787611	computational model
0.6783054961	operative risk
0.6780753726	co morbidities
0.6780361828	study design
0.6779799439	rate response
0.6778210981	natural history
0.6777483985	decision making process
0.6776445406	valve migration
0.6776006449	major and minor
0.6775160527	new zealand
0.6774746593	femoral extraction
0.6774604567	temperature cycles
0.6773338677	pacing modes
0.6771295844	walk test
0.6770248352	cardiac resynchronization therapy defibrillator
0.6769997927	class ii
0.6769218545	ascending aortic
0.6768917779	tbx18 gene
0.6767537142	congenital atrioventricular block
0.6767112042	coronary artery obstruction
0.6765951866	transplant recipients
0.6760965041	cumulative incidence
0.6760286914	retrospective single center study
0.6759299520	acute rheumatic
0.6758875193	lead failures
0.6758853868	baseline demographics
0.6758001264	tavr versus savr
0.6757622797	moderate or greater
0.6757023765	structure and function
0.6756937545	annular size
0.6755398675	ventricular hypertrophy
0.6753947441	mammalian heart
0.6753474843	firing rate
0.6749031776	single centre
0.6747009734	tavi and savr
0.6745939953	amplitude and frequency
0.6744750045	cardiac transplantation
0.6744022225	night cycle
0.6743715768	intensive care unit admission
0.6741282332	mouse hearts
0.6741273289	se valves
0.6740534548	rhythm control
0.6738443642	remote monitoring of cardiac implantable electronic
0.6737003858	significantly greater
0.6736872002	met criteria
0.6736041923	hypopnea index
0.6734108396	cardiac pacing
0.6733966584	close monitoring
0.6733049456	obstructive pulmonary disease
0.6732255638	atrial pacing
0.6732142043	evolut r 34 mm
0.6731570698	generation balloon expandable
0.6731205998	major adverse cardiovascular
0.6729782024	small ventral lateral
0.6729115455	target dose
0.6727249823	pacemaker activity
0.6726659651	anticoagulant therapy
0.6724714491	dual chamber pacing
0.6723767038	infectious disease
0.6723361962	neural activity
0.6722517933	oxygen therapy
0.6722517392	central and peripheral
0.6722247110	clinical events committee
0.6718409610	pr and qrs
0.6717873640	rhythm disorders
0.6716741911	dose reduction
0.6716464087	hospital records
0.6716117280	6 mwt
0.6715330456	coronary heart disease
0.6714439642	quality control
0.6713264504	fold increase
0.6712860386	clinical features
0.6708258207	electrophysiological parameters
0.6708165137	pacemakers and icds
0.6707636499	heart valves
0.6707324812	male sex
0.6706691069	molecular rhythms
0.6706237871	clinical and echocardiographic
0.6706003959	sought to determine
0.6704658122	gene mutation
0.6703611285	output power
0.6702076717	collected retrospectively
0.6701261307	initially presented
0.6699616591	procedural outcomes
0.6699536078	adult fontan patients
0.6698354289	safety and efficacy
0.6697828634	‚ÄØ mm
0.6697289992	multidisciplinary approach
0.6696293517	healthy subjects
0.6695447616	pm and icd
0.6694863840	catheter based
0.6694215609	de vega
0.6694093776	new onset persistent left bundle branch
0.6692783995	bradycardia and asystole
0.6691941206	patient's condition
0.6688487500	orthotopic heart
0.6687087103	ppm requirement
0.6685482986	central hypoventilation syndrome
0.6685055538	generator pocket
0.6684737661	children and adolescents
0.6684524503	pulmonary venous
0.6683854533	echocardiographic findings
0.6682546215	january 2006
0.6682539316	prevention trial
0.6682276984	cox proportional hazards model
0.6681900386	regression analyses
0.6681613189	tunnel fontan
0.6680415177	woman presented
0.6680075992	micra ¬Æ
0.6679209039	receiver operating characteristic curve analysis
0.6679144739	hospital admission
0.6678853018	exercise test
0.6678729673	positive and negative
0.6676442605	stand alone
0.6675602647	clock proteins
0.6675078334	surgical af ablation
0.6674216960	ventricular dysfunction
0.6673043951	retrospective analysis
0.6671724330	safe and effective
0.6669207458	deaths occurred
0.6668157046	early or late
0.6666927584	transapical access
0.6664723817	valve type
0.6663862300	clock neuron
0.6662796257	society of thoracic surgeons score
0.6658615726	hour holter
0.6658043555	minor vascular complications
0.6657588144	society of cardiology
0.6657052096	metal artifact
0.6655787960	battery voltage
0.6655486050	pacemakers and defibrillators
0.6654837948	significant differences
0.6651400684	january 2003
0.6650115296	composite outcome
0.6650008794	¬† min
0.6648813924	anomalous pulmonary
0.6648290626	symptomatic aortic stenosis
0.6644931030	subclavian venous
0.6643000697	using fluoroscopic landmarks
0.6642660821	potential benefits
0.6641991462	coronary flow
0.6641724276	evolut r
0.6641323712	cardiac pacemaker
0.6639453144	ml min
0.6639205084	annular calcification
0.6638682730	adjusted hr
0.6637042706	random effects model
0.6636053833	electrical activities
0.6635725686	critically ill
0.6635472804	epicardial pacing wire
0.6635431779	molecular weight
0.6634884793	repositionable and retrievable
0.6633485399	multicenter observational
0.6632971658	active implantable medical
0.6631384260	shorter hospital stay
0.6631264923	left subclavian vein
0.6631213953	device related infections
0.6629301029	undergoing tavr
0.6629186161	clinical and hemodynamic
0.6629024493	annual report
0.6628849128	cied implantations
0.6628666351	x rays
0.6628329770	minor complication
0.6628075444	self expandable
0.6626159181	simulation model
0.6624378369	retrospectively studied
0.6624188853	gain of function
0.6623624932	septal defect closure
0.6621787196	inward rectifier potassium
0.6620132088	current clamp
0.6619797695	savr and tavr
0.6619497913	pacing mode
0.6618899940	vvi pm
0.6618521709	porcine model
0.6616343396	person years
0.6615851024	mortality and morbidity
0.6615457219	disease progression
0.6615188980	Œºmol l
0.6614417093	multivariate analyses
0.6613930179	atrial and ventricular
0.6613900439	neonatal period
0.6612384430	resistant staphylococcus aureus
0.6612353287	prospective multicenter
0.6610230055	intravenous drug
0.6609962806	current guidelines
0.6608151473	regression models
0.6606737808	light responses
0.6606093382	¬† years
0.6605780777	perioperative complications
0.6605461423	duke criteria
0.6601519131	valve sizes
0.6601001121	electrical slow waves
0.6599704797	per cent
0.6599441126	ppm insertion
0.6599355836	structural and functional
0.6599146665	comorbidity index
0.6597335834	septal leaflet
0.6597029165	common finding
0.6596278315	ventricular pacing percentage
0.6594325439	ventricular function
0.6592516556	after multivariable adjustment
0.6592090542	b cell lymphoma
0.6591689345	seizure related
0.6591663615	perceval valve
0.6591217608	neuronal network
0.6590787319	vein puncture
0.6590286460	systemic ventricle
0.6588766571	preoperative and postoperative
0.6588197776	moderate to severe
0.6586793647	chronic heart failure
0.6585012282	qrs complex duration
0.6584689584	inter electrode
0.6584156073	node dysfunction
0.6583088827	contractile activity
0.6582272606	electrophysiological effects
0.6581157227	severe aortic valve stenosis
0.6580305386	high dose
0.6579797322	d tga
0.6577037965	positive predictive value
0.6572470327	hcn4 gene
0.6571832248	spontaneous action potentials
0.6571693160	transfemoral transcatheter aortic valve implantation
0.6571451641	lv synchrony
0.6570936289	atrial undersensing
0.6570848290	high grade atrioventricular
0.6570487189	internal carotid
0.6568588610	guided axillary
0.6567291172	adverse cardiac events
0.6566629467	micra transcatheter
0.6566179897	tax tavr
0.6566016329	positron emission tomography computed tomography
0.6565879771	molecular mechanisms
0.6565446030	oscillation frequency
0.6565016370	preserved left ventricular ejection fraction
0.6564315055	paced rhythm
0.6563847273	baseline rbbb
0.6563765938	hazards regression
0.6563529663	workup revealed
0.6562023111	left subclavian
0.6561403149	conservative treatment
0.6560581244	¬† days
0.6559292936	isolated aortic valve replacement
0.6558576458	european system for cardiac operative risk
0.6555855217	lead malfunction
0.6553431471	aging population
0.6552635768	left ventricular outflow
0.6551791225	clock output
0.6551623613	wearable cardioverter
0.6551085161	circadian entrainment
0.6549661165	effective orifice
0.6548932426	fold increased risk
0.6548685925	symptomatic bradyarrhythmias
0.6547807006	troponin t
0.6546545916	mortality rates
0.6545414912	mouse sinoatrial node
0.6545029662	rapid deployment aortic valves
0.6544559192	echocardiography guided
0.6541960631	age and sex
0.6541930972	extra scn
0.6541123430	potentially life threatening complication
0.6540118462	lower odds
0.6539524340	meier survival
0.6539251850	electrical and mechanical
0.6538538569	infection prevention
0.6537989785	active and passive
0.6537125608	left main coronary
0.6535015117	heart rates
0.6532991838	left main
0.6530641945	mortality rate
0.6530419441	connexin 43
0.6528806868	membrane clock
0.6528757926	transvenous vvi
0.6528412094	crt upgrade
0.6527941140	current density
0.6527207402	end diastolic
0.6526900416	acute renal failure
0.6526763896	ganglion cells
0.6525162390	data suggest
0.6524907808	propensity score analysis
0.6524898143	neural control
0.6523282517	moderate or severe paravalvular
0.6523126172	left anterior fascicular
0.6520756893	hf hospitalizations
0.6520401254	hospital visits
0.6520288746	acute kidney
0.6519753868	post interventional
0.6519608200	slow wave activity
0.6517728365	relative bradycardia
0.6516414414	anticoagulation therapy
0.6515748398	electrocardiographic abnormalities
0.6513359066	male and female
0.6513356611	real world experience
0.6513029570	cied implantation
0.6512771731	receptor stimulation
0.6512399985	related hospitalizations
0.6510840430	intention to treat
0.6510443370	assisted extraction
0.6510176005	functional class iii or iv
0.6510111638	safe and feasible
0.6510013273	pacing and sensing
0.6509823420	cut off
0.6509401567	prospective evaluation
0.6509148837	minimalist tavr
0.6508179510	annular area
0.6508099458	superior vena cava stenosis
0.6507978579	gender differences
0.6507655563	three dimensional
0.6507589110	sapien 3
0.6507318480	electrical remodeling
0.6506304083	native valve
0.6505535518	induced diabetic
0.6504593355	optimal management
0.6504148431	aortic valve disease
0.6503280905	index admission
0.6501893476	ventricular escape rhythm
0.6500611751	mild to moderate
0.6499504037	safe alternative
0.6497415393	clinical success
0.6497187146	temperature cycle
0.6496407145	drug therapy
0.6496201599	substantially reduced
0.6496048012	circadian behavioral
0.6495140383	symptomatic bradyarrhythmia
0.6492960573	head up tilt test
0.6490851600	feasible and safe
0.6490810709	surgical risk
0.6489739076	ll pm
0.6488377602	potential mechanisms
0.6483869514	ca2 +
0.6483841073	lv dyssynchrony
0.6483787979	sensing amplitude
0.6482320762	month period
0.6481324908	epicardial lead placement
0.6480429940	moderate and severe
0.6479985548	effective and safe
0.6478918554	icd shocks
0.6477335139	ecg monitoring
0.6475830290	nationwide study
0.6475028360	hf hospitalization
0.6474581103	rv to lv interval
0.6472596233	qrs interval
0.6471640052	temporary epicardial
0.6470269865	wire placement
0.6466947355	complex chd
0.6466216760	meta analysis of randomized controlled trials
0.6465909455	orifice area
0.6465076451	adverse outcome
0.6464919327	pm or icd
0.6464705413	heart blocks
0.6464632263	sensing and pacing
0.6463295075	valve embolization
0.6463190081	permanent epicardial pacemaker
0.6462066810	ho 1
0.6462056354	pacemaking activity
0.6460311197	trans septal
0.6460052487	demographic and clinical
0.6459105200	clinical manifestation
0.6459090282	temporary transvenous
0.6455444497	tricuspid aortic valve
0.6454116830	lead impedances
0.6454048242	6 min walk
0.6453322222	surgical myectomy
0.6450917436	cardiac rhythm device
0.6450057712	growth factor
0.6449597469	rv septal pacing
0.6449156377	pacemaker or defibrillator
0.6448875891	optimal medical therapy
0.6448862072	second degree
0.6448839237	aimed to evaluate
0.6448740315	prolonged qt
0.6448655000	cross sectional study
0.6448196291	current generation
0.6448186192	structural heart
0.6445425652	device related
0.6445118713	electrical properties
0.6443469870	treatment option
0.6443428056	vein access
0.6442832658	collected and analyzed
0.6441542060	conventional transvenous
0.6440887232	electrocardiogram monitoring
0.6440719543	expandable valves
0.6439577210	acute and chronic
0.6439467465	proportional hazard model
0.6439339133	life support
0.6437721658	cavopulmonary connection
0.6436574675	injury syndrome
0.6436296136	first degree atrioventricular block
0.6433922835	calcium channel
0.6432939787	vivo studies
0.6432831790	transcatheter closure
0.6432298828	body surface
0.6432256984	aortic cross clamp times
0.6431615065	functional tr
0.6430869471	arrhythmic event
0.6430769071	cardiac troponin
0.6430594359	bundle branch
0.6429759921	undergoing radiotherapy
0.6429079057	rr interval
0.6429048799	valvular dysfunction
0.6427569425	surgical removal
0.6426750864	femoral venous
0.6426459886	requiring dialysis
0.6426071305	ecg cd
0.6425872665	december 2014
0.6425192400	development and function
0.6425067369	cardiopulmonary bypass and aortic
0.6424864928	see text
0.6423856683	atrial contraction
0.6423339189	cell lymphoma
0.6423099980	previous reports
0.6422022120	aimed to assess
0.6420804507	invasive approaches
0.6419996657	symptomatic improvement
0.6419949879	mechanical rotational
0.6419851305	prospective trial
0.6418808690	december 2016
0.6418659770	primary and secondary
0.6418522077	pocket closure
0.6418189830	care unit
0.6417886605	early onset
0.6417679665	complete atrioventricular
0.6417230476	ictal bradycardia
0.6415713862	stroke volume
0.6413123556	general hospital
0.6412804570	kaplan meier survival analysis
0.6412396891	¬† mv
0.6412134915	annulus area
0.6412133751	multicentre registry
0.6411642658	patient centered
0.6411240616	first degree av block
0.6410654147	pulmonary stenosis
0.6409578875	mechanical synchrony
0.6407957475	vitamin k
0.6406198316	pacemaker requirement
0.6406020460	av junction
0.6405697915	high intensity
0.6404940185	atrial myocytes
0.6402532187	anterior chest
0.6402116275	standard of care
0.6401538536	micra av
0.6400908728	january 2007
0.6399969622	cardiovascular risk
0.6399815118	s3 valve
0.6399404390	september 2015
0.6398608278	prognostic impact
0.6398484687	a concentration dependent manner
0.6397988507	left ventricular ejection
0.6397897021	undergoing mri
0.6396533037	hyperpolarization activated cyclic nucleotide gated channel
0.6394670676	current literature
0.6393073186	body size
0.6392304877	battery replacement
0.6391184078	canine model
0.6389042250	left circumflex
0.6388887820	surgical approach
0.6388118490	cardiovascular autonomic
0.6386209089	moderate or severe
0.6384183246	stepwise approach
0.6384134574	electrophysiological recordings
0.6381103361	lv apex
0.6377922725	valve in valve
0.6377736027	practice guidelines
0.6377589756	multivariable regression analysis
0.6376491476	temporary cardiac pacing
0.6376112153	hypoventilation syndrome
0.6375717767	mean aortic valve gradient
0.6375483578	systemic infection
0.6373879372	bioprosthetic aortic valve
0.6373586727	atp sensitive k
0.6373430929	potentially life threatening
0.6373417153	major complication rate
0.6373393657	adjusted analyses
0.6372837246	procedural and clinical
0.6370677350	valve degeneration
0.6370644274	prospective registry
0.6370602388	pacemaker implant
0.6370288566	electrical signals
0.6369865074	underlying mechanism
0.6367548063	pacemaker leads
0.6367393169	controlled trial
0.6367182563	transvenous approach
0.6365598903	cardioinhibitory vasovagal
0.6365082406	pacemaker induced cardiomyopathy
0.6364243173	mice expressing
0.6363880285	risk prediction
0.6363432980	primary pci
0.6363353190	mml:mo mml:mi
0.6363186533	surgical procedures
0.6361201740	clinical utility
0.6360891759	moderate severe
0.6359975508	clinical scenario
0.6358565576	body mass
0.6357232550	pacemaker accumulator
0.6354725915	retrospectively collected
0.6354384061	implanted cardiac devices
0.6354322294	purkinje cells
0.6353166717	vein occlusion
0.6351009641	syncope recurrence
0.6350816801	rarely reported
0.6350741121	hospital readmissions
0.6350532635	clock controlled
0.6350046412	medical devices
0.6349015779	& noteworthy
0.6348995406	conventional transvenous pacemakers
0.6348151414	mouse san
0.6348145768	‚ÄØ ‚ÄØ
0.6346396840	transcutaneous pacing
0.6346147942	calcium activated
0.6345387117	next generation
0.6343520847	low and stable
0.6342621852	partial anomalous
0.6341839358	mitral valve disease
0.6341734363	chronic dialysis
0.6341256024	human induced pluripotent stem cell derived
0.6340784030	june 2018
0.6339926870	c xrt
0.6339787277	heart transplant recipients
0.6338252769	atrial fibrillation with slow ventricular
0.6337508322	taking into account
0.6337196045	rvot septal
0.6336212072	patients undergoing transcatheter aortic valve replacement
0.6335267560	detection algorithm
0.6334823742	efficacy and safety
0.6334808989	patient concerns
0.6333623884	acute success
0.6332748595	kidney injury
0.6332231735	published guidelines
0.6332179691	biv pacing
0.6331448936	physiological functions
0.6329956803	mechanical delay
0.6329405721	tilt table
0.6328556677	leadless pacing
0.6326986719	arterial pressure
0.6326956242	metabolic rate
0.6326804934	all comers
0.6325831297	rat heart
0.6322290436	obstructive hypertrophic
0.6321760350	related admissions
0.6321608817	primary efficacy end
0.6321553527	mortality and stroke
0.6320804649	transfemoral approach
0.6320564799	evidence based
0.6319971608	post approval
0.6319432363	complex anatomy
0.6318611808	ictal syncope
0.6318404482	divided into two groups
0.6317897784	g protein coupled
0.6315627997	crucial role
0.6312453179	light entrainment
0.6312224213	pooled analysis
0.6309247660	moderate tr
0.6308522435	exercise induced
0.6307272002	alternative strategy
0.6306220535	surgical technique
0.6305195683	prosthetic aortic valve
0.6304600718	cardiac memory
0.6303789381	ventricular outflow tract obstruction
0.6303412751	years of age
0.6302322350	commercially available
0.6302246231	practice patterns
0.6302159441	rf ablation
0.6301711775	sectional study
0.6301311728	secondary endpoint
0.6300629100	sought to evaluate
0.6300495618	complications and mortality
0.6299238587	key role
0.6297585456	ischaemic stroke
0.6297328559	complex tachycardia
0.6296420786	valve implantation
0.6296062669	current practice
0.6295291344	post asa
0.6295126210	clinical improvement
0.6294272650	pacemaker neurons
0.6292485373	remain unknown
0.6292347178	arrhythmia recurrence
0.6291048874	end of life
0.6290932534	device infections
0.6289315944	physiologic pacing
0.6288743698	recent reports
0.6288586816	atrium and ventricle
0.6288199996	national inpatient
0.6288063873	micra leadless
0.6287278377	calcium clock
0.6284645041	improved survival
0.6283722673	adult mice
0.6283688155	minimally invasive approach
0.6283517866	pre bav
0.6283406018	channel protein
0.6282755734	calcium score
0.6281049996	ventricular myocardium
0.6278257366	cmr imaging
0.6277400013	self powered
0.6276699202	medical technology
0.6276175119	prospective randomized
0.6276009425	sleep apnea syndrome
0.6275674115	human heart
0.6275159967	95 confidence interval
0.6275147730	ventricular escape
0.6274902134	lpm implantation
0.6274365339	atrial antitachycardia pacing
0.6273301686	donor age
0.6272085261	pacing site
0.6271677847	transcatheter valves
0.6271643604	mechanical sheath
0.6270990637	number of leads extracted
0.6270820801	cumulative survival
0.6270395197	transvenous lead
0.6269918699	diastolic potential
0.6268494452	valvular surgery
0.6267403703	permanent af
0.6267149874	edwards sapien valve
0.6266488693	cox proportional hazard model
0.6265389386	lead repositioning
0.6264972935	qrs 120 ms
0.6263381658	branch area pacing
0.6262557844	april 2020
0.6261808782	transcatheter pacing system
0.6261654551	95 confidence intervals
0.6259928738	post implant
0.6257452665	significantly smaller
0.6255639056	lead insertion
0.6255375707	left superior vena cava
0.6254027516	randomized controlled
0.6253235613	ecg recording
0.6253165027	conduction system disease
0.6252321900	transvenous pacing
0.6251721962	induced cardiomyopathy
0.6250880442	previously healthy
0.6250432236	ischaemic attack
0.6248681125	clinical entity
0.6248624596	october 2016
0.6247475360	electrophysiological characteristics
0.6245769168	blood tests
0.6245587052	major adverse
0.6244471988	central hypoventilation
0.6244064250	mitral valve regurgitation
0.6242082747	vein thrombosis
0.6241932271	surface area
0.6240455424	rv apical
0.6240209887	january 2015
0.6238959257	chest computed tomography
0.6237970618	defibrillator leads
0.6237829161	diagnostic test
0.6237643825	large volume
0.6237237292	autonomic control
0.6237166107	non 24 hour sleep wake
0.6236190717	cardiac lymphoma
0.6235761463	left bundle branch area
0.6235717787	negative pressure
0.6233875576	thv in thv
0.6233211644	december 2015
0.6233010274	acute hemodynamic
0.6232928910	surface electrocardiogram
0.6232801103	free survival
0.6231431248	icc my
0.6231335924	december 2018
0.6230569009	micra implant
0.6230491992	septal defect
0.6229654876	mouse models
0.6228616786	statistically significant difference
0.6227396194	functional mitral regurgitation
0.6226454360	data sets
0.6226341277	related deaths
0.6226025036	administrative data
0.6224133903	g protein
0.6222678974	paced qrs complex
0.6222361740	matched controls
0.6221882733	isolated avr
0.6219000085	decreased significantly
0.6218412798	thoracic surgeons american college of
0.6217551014	ventricular synchrony
0.6217406405	single centre experience
0.6216687828	bypass and cross clamp
0.6215572373	cardiac nl
0.6214045453	rare disorder
0.6212626772	lead positioning
0.6211368570	device detected
0.6210671146	rare occurrence
0.6209350443	receiver operating
0.6207372714	early safety
0.6206769082	computer simulations
0.6206631100	gender related
0.6203276105	brain mri
0.6202292896	future studies
0.6201966053	interstitial cells
0.6200329230	patient safety
0.6198295298	australia and new zealand
0.6197177361	cardiac rhythm devices
0.6195372966	atrioventricular synchrony
0.6194339476	early stage
0.6193934347	mouse model
0.6192138203	follow ‚Äë up
0.6192113830	highest risk
0.6191338094	mass index
0.6191161946	voltage dependent
0.6190131859	multivariable model
0.6190101587	pacemaker and icd
0.6189892939	methicillin resistant staphylococcus
0.6188929189	clinical challenge
0.6187980304	retrospectively enrolled
0.6184814990	r wave amplitude
0.6183785826	coronary artery bypass
0.6183471529	patients with severe aortic stenosis
0.6182647816	adult mouse
0.6181742892	mir 132
0.6181514655	direct aortic
0.6180771610	valve leaflets
0.6179751644	lv dysfunction
0.6179734046	fluoroscopy duration
0.6179455874	light input
0.6179133960	septal reduction
0.6176873788	characteristics and outcomes
0.6174815859	treatment planning
0.6174048921	surgical repair
0.6171305135	rapid pacing
0.6170706730	next day discharge
0.6169856767	transcatheter avr
0.6169608108	electrical parameters
0.6169509420	valve sparing
0.6169254885	crt d
0.6166648895	lead related infective endocarditis
0.6163692535	premature atrial
0.6163355691	examination revealed
0.6161840461	diagnostic criteria
0.6161346567	echocardiographic examination
0.6160181729	rr ‚ÄØ = ‚ÄØ
0.6159224866	sinoatrial node dysfunction
0.6158419600	january 2004
0.6156289309	electronic devices
0.6156264796	rv lp
0.6154663549	right sided
0.6154400905	national inpatient sample database
0.6153987861	sought to investigate
0.6150220712	mitral repair
0.6150000565	invasive procedures
0.6149745635	event rates
0.6149493612	incident atrial fibrillation
0.6149043492	aimed to determine
0.6146332217	valve academic research consortium 2
0.6144795885	prosthesis size
0.6142183458	transposition of great arteries
0.6142106801	survival free
0.6142014632	trials comparing
0.6141951093	drosophila circadian
0.6141837319	related adverse events
0.6139972936	antiarrhythmic therapy
0.6139163888	circulatory support
0.6139012903	junction ablation
0.6138626816	therapeutic strategy
0.6136640701	treatment strategies
0.6135233023	electrophysiology studies
0.6133654759	chronic pain
0.6133272370	portico tavi
0.6133246900	hospital discharge database
0.6131421668	national registry
0.6130581987	atrial fibrillation burden
0.6128144355	predictive factors
0.6127351575	thoracoscopic surgery
0.6126300634	arrhythmia detection
0.6124784743	fontan failure
0.6122276536	lv function
0.6122026738	native aortic valve
0.6121551109	mild tr
0.6120141742	implantation height
0.6118633017	continuous monitoring
0.6114806708	observational cohort
0.6113232266	lv lp
0.6112484646	¬† months
0.6110513211	low frequency
0.6110452184	remained free
0.6108882462	september 2014
0.6108795269	medical treatment
0.6107848567	descending artery
0.6106288643	electrophysiology procedures
0.6103079844	sutureless aortic valve
0.6102365492	access site complications
0.6102168218	concomitant procedures
0.6101610248	december 2019
0.6101465243	hrs guideline
0.6101085007	clinical and procedural
0.6099207634	poor outcome
0.6098169425	december 2010
0.6097700818	crt response
0.6097676922	congenital heart
0.6097230934	internal thoracic
0.6097217626	infectious complications
0.6096787203	low volume
0.6096551981	remains challenging
0.6095939374	peripheral clock
0.6095473623	january 2001
0.6094774698	comparative studies
0.6093491281	evidence suggests
0.6092343810	food and drug
0.6092341446	¬† cm
0.6089130089	5 ht
0.6088783268	biventricular icd
0.6088360399	clinical response
0.6087564245	cardiovascular implantable electronic device infections
0.6087413929	mechanism underlying
0.6087061245	observational registry
0.6085611361	incident af
0.6085363037	¬† bpm
0.6085331261	type 2 diabetes mellitus
0.6083293644	control subjects
0.6081971837	major adverse cardiac and cerebrovascular
0.6080579970	receptor activation
0.6077490934	mean logistic european
0.6076865191	fully repositionable
0.6076725652	savr + cabg
0.6076656775	perceval sutureless aortic valve
0.6075908326	atrial high rate
0.6074758123	channel activation
0.6073101988	tle procedures
0.6072541229	right ventricle
0.6071514786	fontan procedure
0.6069029440	left ventricular end diastolic
0.6068859323	perioperative management
0.6068591710	medical care
0.6068490316	corrected transposition
0.6068374814	survival rates
0.6066367468	adjusted hazard
0.6065947482	patients receiving
0.6064563500	cardiac magnetic resonance
0.6064431367	gastric electrical
0.6064305279	sought to assess
0.6064196516	advanced atrioventricular block
0.6063892911	type ii
0.6063572573	transvenous pacemakers
0.6063340123	cardiovascular surgery
0.6063175555	patient population
0.6063146872	sought to compare
0.6061714616	pacemaker interrogation
0.6061394523	ventricular premature
0.6060979304	hybrid ablation
0.6060908624	electrophysiology study
0.6058037526	symptomatic aortic valve stenosis
0.6057850096	lv end systolic volume
0.6057387823	surgical aortic bioprostheses
0.6057050510	early mortality
0.6056545976	¬† of ¬†
0.6055137103	medtronic inc
0.6054639001	stable condition
0.6054133029	ppm placement
0.6052530818	light sensitivity
0.6050769492	total cavopulmonary
0.6049253810	acute and long term
0.6048135094	echocardiogram revealed
0.6047961012	per million population
0.6047299148	aged ‚â• 80 years
0.6046861193	c statistic
0.6046184616	significantly elevated
0.6045183232	device selection
0.6043964654	december 2017
0.6043129093	prospective studies
0.6042326995	january 2016
0.6041048692	low power
0.6040657250	device extraction
0.6040554777	pacing wires
0.6038397479	balloon expandable prosthesis
0.6037661020	echocardiographic measurements
0.6037573462	positive blood cultures
0.6037358525	main outcome
0.6037261873	bypass surgery
0.6034769453	device upgrade
0.6033442396	guided approach
0.6030755032	large scale
0.6029796368	activity pattern
0.6026803732	¬† = ¬†
0.6025599764	transapical tavi
0.6024151893	clinical benefits
0.6023498070	bicuspid valve
0.6022688102	left lateral
0.6021227019	mrna levels
0.6018781650	significantly larger
0.6018589162	conduction tissue
0.6018449962	independent predictors
0.6018185968	highly effective
0.6018152637	sub saharan
0.6014707088	hemodynamic parameters
0.6014516850	multicenter cohort
0.6014037951	z score
0.6012236704	successfully implanted
0.6012115337	functional properties
0.6011122385	type natriuretic peptide
0.6010650135	locomotor activity rhythms
0.6008473511	moderate paravalvular leak
0.6007134460	electrode placement
0.6006420826	outcome measure
0.6005420260	human sinoatrial node
0.6004901323	symptom rhythm
0.6004663970	sinus arrhythmia
0.6003940356	cell patch
0.6002400816	aortic valve replacements
0.6001494681	ahre ‚â•
0.6000896312	conventional aortic valve replacement
0.6000775616	fold higher
0.5998922671	vascular access site
0.5998729472	electrical abnormalities
0.5998306507	post transcriptional
0.5998281558	arrhythmia therapies
0.5998224571	july 2019
0.5997864849	‚â• 30 seconds
0.5996919348	november 2019
0.5996835110	college of cardiology transcatheter valve therapy
0.5995906263	parkinson white
0.5995313796	master pacemaker
0.5994777894	implantation technique
0.5993962090	late deaths
0.5993700372	95 ¬† ci
0.5993170570	protein levels
0.5992775376	physiological conditions
0.5992617542	3f enable
0.5992016532	full sternotomy
0.5991300871	shift work
0.5989857877	mr conditional cieds
0.5989293914	global longitudinal
0.5987299705	tp e
0.5984093377	implanted electronic device
0.5984014453	protein losing
0.5983929359	multicentre study
0.5983646482	diagnosis and treatment
0.5982701608	crt ds
0.5982045976	patients with bradycardia and cardiac
0.5979267606	device removal
0.5978367736	heart failure hospitalization
0.5977878913	study population consisted
0.5976914131	pacing parameters
0.5976690961	sinoatrial node cells
0.5976275032	advanced age
0.5976207335	surgical revision
0.5976035030	lead malposition
0.5975767969	nationwide cohort
0.5971891496	secondary outcomes included
0.5971641629	longer hospital stay
0.5971499370	fluoroscopy times
0.5971346720	reduced ef
0.5971281432	rhythm generation
0.5970241978	calcium channels
0.5969147724	the past decade
0.5968536737	performed safely
0.5967728238	aged ‚â•
0.5967163408	june 2016
0.5966194967	ventricular apex
0.5965383856	comparative analysis
0.5964195146	long pr interval
0.5963955597	renal disease
0.5961315108	device interrogations
0.5960326199	clinical signs
0.5958777148	95 confidence interval ci
0.5958289973	significantly decrease
0.5956929089	temporary pacemaker insertion
0.5956670377	cardiac metastasis
0.5950800012	heart failure with preserved ejection fraction
0.5946547692	bundle branch area pacing
0.5946101624	activated cyclic nucleotide gated
0.5945913580	procedure codes
0.5944409338	inappropriate therapy
0.5943002919	january 2000
0.5942723263	retrospective observational
0.5942163511	sensitivity and specificity
0.5941610001	rate and rhythm
0.5941567207	lead revisions
0.5940870315	lung disease
0.5939727120	hospitalization costs
0.5938303957	animal studies
0.5938293344	interventional procedures
0.5937253760	phase delay
0.5936150684	t wave
0.5935808057	electrocardiogram revealed
0.5932836571	ecg abnormalities
0.5931736856	electrocardiographic findings
0.5929192033	tavr + pci
0.5927968202	cardiac events
0.5927413676	complete resolution
0.5927069000	cardiovascular implantable
0.5926153591	pacemaker lead
0.5923307235	advanced heart failure
0.5921733518	low risk patients with symptomatic
0.5920915958	index hospitalization
0.5920789771	lead impedance
0.5920246893	pacemaker and subcutaneous implantable
0.5919702650	mild paravalvular leakage
0.5919673173	limited evidence
0.5917425612	rate variability
0.5914796951	electrocardiogram showed
0.5914261053	valve thrombosis
0.5914186079	cardiovascular interventions
0.5910960724	hospital length of stay
0.5910195946	cardiac pacemaking
0.5906187322	left atrioventricular valve
0.5904834278	piezoelectric energy
0.5904803482	portico valve
0.5904033611	prosthetic heart
0.5903899016	long term outcomes
0.5902512926	echocardiographic assessment
0.5902253403	maintenance of sinus rhythm
0.5901433434	rate control
0.5901369989	¬† weeks
0.5901050279	‚ÄØ days
0.5900986812	valve types
0.5900087302	surgical ablation of atrial fibrillation
0.5899688636	initial evaluation
0.5895869563	rva pacing
0.5895068901	threshold values
0.5891245288	single center observational study
0.5889775184	eligible studies
0.5889735251	mitral surgery
0.5889458095	high sensitivity
0.5889049591	clinical profile
0.5888802719	hospital mortality
0.5888380327	icd shock
0.5887449457	rv free wall
0.5885872505	wound infection
0.5882760377	rhythmic activity
0.5881507544	procedure related
0.5880566958	af episodes
0.5880204013	bleeding events
0.5879945402	atrial capture
0.5879732758	rest activity
0.5879655693	echocardiographic evaluation
0.5879520649	tricuspid valve stenosis
0.5879348759	adverse clinical outcomes
0.5877887628	implantable electrical devices
0.5875128448	high volume centers
0.5873590046	atrioventricular interval
0.5873408094	higher odds
0.5872885536	aimed to compare
0.5872288635	lamin a c
0.5872161263	responses to light
0.5870998764	heart center
0.5870883630	baseline variables
0.5869536227	prolonged hospitalization
0.5868699643	undergoing transcatheter aortic valve replacement
0.5868310952	cardiac pacemaker cells
0.5868188421	late discharge
0.5868183358	pulmonary valve
0.5865954449	april 2019
0.5865208349	mri examination
0.5864331758	ppmi rate
0.5863752611	trans catheter aortic valve
0.5863701548	clinical importance
0.5862071492	free running period
0.5861864952	left anterior
0.5859889143	rate variation
0.5858636911	cardiac rhythm management devices
0.5858606695	corevalve evolut r
0.5858178077	temporary transvenous cardiac
0.5858004903	l type ca
0.5857204768	lv mass
0.5856610364	‚â• 120 ms
0.5856436536	ventricular remodeling
0.5856391978	clinically important
0.5856111433	spontaneous action potential
0.5855798991	effective dose
0.5855642617	lead positions
0.5855195409	stress test
0.5855144570	maze iii
0.5855017979	nervous system
0.5854919635	comparative study
0.5851798205	active fixation lead
0.5848692801	size reduction
0.5847473419	warfarin therapy
0.5847452815	pocket site
0.5846273724	device type
0.5846065772	rv septum
0.5843020662	embryonic stem
0.5842704813	activity patterns
0.5841987995	clinical endpoints
0.5841934275	¬∞ c
0.5841110031	hcn4 channel
0.5840655562	systemic venous
0.5839745427	valve replacements
0.5838911237	life threatening arrhythmias
0.5837696577	event free
0.5837638867	ecg gated
0.5837625779	degree heart block
0.5836707052	re exploration
0.5836508606	major vascular
0.5835082544	pattern generator
0.5834261032	june 2019
0.5831838560	atrial wall
0.5831138079	moderate aortic regurgitation
0.5830710537	significantly reduce
0.5829744906	genetic ablation
0.5828961907	parameters remained stable
0.5827660346	biological pacemaker
0.5827152572	modified duke
0.5826328035	retrospectively identified
0.5826306869	clinical significance
0.5825206381	studies evaluating
0.5824479050	december 2013
0.5823200751	severe symptomatic aortic stenosis
0.5821999144	moderate severe paravalvular leak
0.5820984365	additional information
0.5820398439	atrial cardiomyopathy
0.5820288633	severe tr
0.5819707681	biventricular repair
0.5819539366	outflow tract gradient
0.5818641020	sudden unexpected
0.5816793343	icc network
0.5814012578	ventricular cardiomyocytes
0.5813969141	matched groups
0.5813743057	lead location
0.5813353920	il 6
0.5812922623	italian association of arrhythmology and cardiac
0.5809712840	treatment effect
0.5809373497	cardiac arrhythmia
0.5808903954	undergoing transfemoral tavi
0.5808660450	echocardiography revealed
0.5807541856	loss of capture
0.5806117397	n ‚ÄØ = ‚ÄØ
0.5804773021	scheduled to undergo
0.5803710118	premature ventricular
0.5802927561	confidence interval ci
0.5801493241	mid term survival
0.5801389441	cox maze iv procedure
0.5801362044	parkinson white syndrome
0.5800671150	pacemaker pocket infection
0.5798410372	april 2014
0.5798312842	v 0.24 ms
0.5792314354	egfp w
0.5790427987	standard approach
0.5789919799	taken together
0.5789291137	postoperative outcomes
0.5786824948	lead dwell time
0.5784393872	cardiac monitoring
0.5784377333	transvenous pacemaker
0.5784066762	right parasternal
0.5783620040	tricuspid valve endocarditis
0.5783347183	pre specified
0.5783069254	matched analysis
0.5782047821	network activity
0.5781779887	pacing dependency
0.5781743641	second generation
0.5781581362	acurate neo transcatheter heart
0.5777375803	transfemoral tavr
0.5777156156	daily rhythms
0.5776680107	hypertrophic obstructive
0.5776654849	implant site
0.5776485461	right atrium
0.5776151930	device closure
0.5775276473	ano 1
0.5773569690	perceval s
0.5773469127	heart diseases
0.5772014355	recurrence rate
0.5771120246	lv systolic dysfunction
0.5769646600	early detection
0.5766956508	short term outcome
0.5766440027	real time
0.5764416270	¬© 2016
0.5764381277	baseline ecg
0.5763212691	mechanical valve
0.5763156368	patients undergoing transcatheter aortic valve implantation
0.5762795326	cardiac rehabilitation
0.5762513453	f fdg pet
0.5761918238	society of thoracic surgery
0.5761858935	¬† mgy
0.5759299831	quality evidence
0.5757374802	management strategy
0.5756413884	night shift work
0.5756280258	cardiac manifestations
0.5753245425	cross clamp time
0.5752951409	maximum heart rate
0.5751831942	complete device removal
0.5751676276	major complication
0.5751074043	calcium imaging
0.5750987542	underwent tavi
0.5750231926	logistic regression analyses
0.5750184834	procedure duration
0.5749578960	valve prosthesis
0.5748732616	electrical activation
0.5748217185	frequency range
0.5747906160	cardiac device related infective endocarditis
0.5747103301	pm icd
0.5746046907	mitral and tricuspid
0.5745210978	acute ischemic stroke
0.5743684635	surgical treatment
0.5741810590	demonstrated excellent
0.5741741475	r2 =
0.5740503321	af afl
0.5740099580	undergoing elective
0.5739114809	aortic and mitral
0.5736509261	sex specific
0.5735931940	firing frequency
0.5735019777	randomized studies
0.5733290158	experienced centers
0.5732885383	minimally invasive techniques
0.5732081492	experimental studies
0.5730847121	heart failure with reduced ejection fraction
0.5729561349	readmission rate
0.5728591669	requiring ppi
0.5727571892	provide evidence
0.5726241710	gi tract
0.5723930328	hospital costs
0.5722916138	cost utility
0.5721235066	remains limited
0.5720745260	recalled lead
0.5718901953	field potential
0.5718621448	mv repair
0.5718212829	lead fractures
0.5718161558	lead fixation
0.5714482937	treatment modality
0.5712400690	third degree
0.5712262324	device implantations
0.5711252541	june 2015
0.5711058709	procedural success rate
0.5710074768	pacemaker lead endocarditis
0.5708900825	patient specific
0.5708269106	activity rhythms
0.5707877278	electrophysiological studies
0.5706675626	cardiac magnetic resonance imaging
0.5705791349	diagnostic performance
0.5705148043	prospective observational
0.5703757872	patients with severe symptomatic aortic stenosis
0.5703200937	low voltage
0.5702901955	mid term outcome
0.5702892046	procedural safety
0.5702775645	surgical strategy
0.5702658184	conduction disturbances requiring
0.5702131749	rhythm monitoring
0.5701180817	left bundle
0.5700790101	qrs area
0.5700596137	october 2018
0.5700171219	cultured interstitial cells of cajal
0.5699404026	per 1000
0.5698919633	early diagnosis
0.5696199705	procedure related complications
0.5695802030	septal position
0.5692872477	icd therapy
0.5692598997	af occurrence
0.5690593844	dose response
0.5689808654	ng l
0.5689755798	medtronic evolut
0.5686535423	young age
0.5686246083	november 2013
0.5683988312	general population
0.5683805272	claims data
0.5683588749	persistent new onset lbbb
0.5682331105	regression model
0.5681186572	fontan surgery
0.5680924744	risk of bias
0.5680100377	right ventricular
0.5679884015	adult congenital
0.5679779847	ventricular lead
0.5678921602	sensitivity analysis
0.5678725542	final analysis
0.5678188391	acurate neo prosthesis
0.5677531622	stroke rate
0.5677280723	poor outcomes
0.5676840563	atrial lead fixation
0.5676326220	heart surgery
0.5675068439	medical management
0.5674071769	off pump
0.5672895118	year old man
0.5672090552	worse outcomes
0.5671608177	intracardiac devices
0.5670184748	september 2017
0.5669972110	edwards sapien 3
0.5669830912	cardiac implantable electric
0.5668294463	b type natriuretic
0.5666715623	aortic valve surgery
0.5665956593	total occlusion
0.5665628243	transapical transcatheter aortic valve replacement
0.5664370561	larger studies
0.5661446653	moderate regurgitation
0.5660206311	expression levels
0.5658335831	balloon expandable transcatheter heart valve
0.5655815324	wild type mice
0.5653662598	large tertiary
0.5652069062	vascular complication
0.5651590232	lead damage
0.5649591045	continuous variables
0.5648382504	left axillary
0.5647401348	rv pacing burden
0.5646369892	aortic valvular
0.5646361908	implantation or replacement
0.5646156935	redo tavr
0.5645805446	patch technique
0.5645663449	intrinsic conduction
0.5644678664	related infections
0.5642317409	device malfunctions
0.5640415136	¬† ‚â§ ¬†
0.5640006586	permanent cardiac pacing
0.5638863219	viable alternative
0.5638784260	dual site
0.5637441981	preoperative characteristics
0.5637213039	thirty day mortality
0.5636443685	reduced lvef
0.5635696132	ventricular asystole
0.5634978862	cell type
0.5634785160	generation transcatheter heart valves
0.5634680083	pacemaker potentials of iccs
0.5634129763	clock function
0.5633654083	underwent transfemoral tavi
0.5633471431	expandable transcatheter heart valve
0.5631762996	pacing lead
0.5631693485	ecg parameters
0.5631597538	device migration
0.5630785067	cardiac computed tomography
0.5629265237	comparative outcomes
0.5628337824	narrow qrs complex
0.5627573315	human san
0.5625673033	left ventricular end systolic volume
0.5625587389	thoracic surgeons predicted risk of
0.5624378876	clock protein
0.5622551487	mild paravalvular leak
0.5622239710	high burden
0.5621560667	prior studies
0.5620562608	electrophysiological procedures
0.5620466051	baseline differences
0.5619819090	pre existing right bundle branch block
0.5619656670	average heart rate
0.5619438879	ventricular pacing threshold
0.5619066388	severe pvl
0.5616733271	aortic valve replacement for severe aortic
0.5615544091	crt defibrillator
0.5615334571	assigned to receive
0.5614994635	valve deployment
0.5614593634	warden procedure
0.5612381797	local infection
0.5611860301	pacemaker and implantable cardioverter
0.5610396405	october 2013
0.5610326453	serious adverse events
0.5609911174	patients in group
0.5609536196	af ablation
0.5609307407	lead dysfunction
0.5608926254	previously implanted
0.5608687715	surgical procedure
0.5607794842	adult male
0.5607576558	surgical interventions
0.5606724949	active fixation coronary sinus
0.5606284779	new onset
0.5605716836	i2 = 0
0.5604368304	permanent cavb
0.5602518110	procedural variables
0.5601243203	age related
0.5600250143	november 2011
0.5597087310	treatment weighting
0.5593624878	ppi rates
0.5593444469	coronary disease
0.5590590421	total dose
0.5589523724	artery bypass graft
0.5589056770	cied extraction
0.5588293321	repeated procedures
0.5587859864	august 2018
0.5586882933	cied recipients
0.5586336361	local ca
0.5585289939	open surgical
0.5582991026	the proposed method
0.5581356801	pacemaker function
0.5580996574	successfully treated
0.5580540800	g dl
0.5580243856	redo surgery
0.5578459372	center experience
0.5577810475	human subjects
0.5577554921	times higher
0.5576984435	elderly patients
0.5576570008	aortic valvuloplasty
0.5574238353	year old woman
0.5574234314	cardiac motion
0.5573969643	spontaneous ca
0.5573448837	genetic analysis
0.5572849529	cardiac biomarkers
0.5572750346	procedural times
0.5572683834	mild aortic regurgitation
0.5569848350	rapid deployment valve
0.5569585091	retrospective cohort analysis
0.5569137562	mid term outcomes
0.5569022639	cardiac and cerebrovascular events
0.5568984853	induced effects
0.5567856554	edwards intuity valve system
0.5565545704	minimally invasive surgery
0.5561913040	october 2015
0.5560092184	cardiovascular complications
0.5558273459	transvenous pacemaker insertion
0.5557959901	underwent isolated avr
0.5557728806	nonsustained ventricular
0.5554201532	high amplitude
0.5554065782	severe mitral regurgitation
0.5553380019	device related complications
0.5552610695	insight into
0.5551506011	june 2011
0.5550274606	pediatric and congenital
0.5550258752	single center study
0.5550105678	october 2014
0.5549484789	leadless pacemaker implant
0.5548437570	april 2018
0.5548016577	clinical consequences
0.5547375134	january 2017
0.5547304795	long term prognosis
0.5547040601	propensity matched cohort
0.5545041991	march 2013
0.5544752496	echocardiography showed
0.5544558301	post fontan
0.5543959267	baseline and procedural
0.5543556779	channel function
0.5543477322	temporary cardiac pacemaker
0.5542934372	valve area
0.5542154285	combined procedures
0.5542082420	environmental light
0.5540553030	pediatric population
0.5540279167	cardiovascular magnetic resonance imaging
0.5539953279	‚â• mild
0.5539446214	third generation balloon expandable
0.5539053980	ventricular pacing burden
0.5538515731	ct imaging
0.5538279533	hcn4 expression
0.5535431782	temporary pacemaker implantation
0.5534137903	network meta analysis
0.5533767635	open surgery
0.5532639633	stand alone cox maze
0.5532043346	lv endocardial
0.5531378397	mild paravalvular regurgitation
0.5530840587	october 2019
0.5529637192	atrial or ventricular
0.5528557712	hb pacing
0.5528316735	requiring intervention
0.5527467802	1.5 tesla
0.5526349513	central nervous
0.5525486908	cardiac transplant
0.5523266486	early generation
0.5522935046	electrophysiologic study
0.5522167639	miniature pacemaker
0.5520345611	muscle cells
0.5520319781	procedure times
0.5519550960	p 0.0001
0.5518702299	‚â• 75 years
0.5518084612	stroke transient ischemic attack
0.5517778490	threshold increase
0.5516750490	clinical settings
0.5516609540	atrioventricular valve
0.5516381925	data collected
0.5516148049	inferior vena
0.5514346609	late death
0.5513894392	cardiovascular outcomes
0.5513586201	lv lead
0.5511549240	rhythm abnormalities
0.5509452642	reduced left ventricular ejection fraction
0.5508806665	multiple comorbidities
0.5508417498	apical pacing
0.5505071688	thoracic surgeons score
0.5505053383	chronic atrial fibrillation
0.5504787721	logistic regression models
0.5500720455	cardiac implantable electronic
0.5500002631	extraction techniques
0.5499998486	pacing leads
0.5499566912	inpatient sample database
0.5499511942	pro b type natriuretic peptide
0.5499128016	x linked
0.5499124931	isolated tv
0.5498661599	cardiac death
0.5498316433	icd implantations
0.5498166622	shorter length of stay
0.5498125740	epicardial pacemaker
0.5497813390	july 2014
0.5496926164	rhythm and rate
0.5495916785	biventricular implantable cardioverter defibrillator
0.5494559047	heart models
0.5493857818	mechanical lead extraction
0.5493823823	95 ci
0.5492127585	w w
0.5491417133	ischemic attack
0.5491100742	implanted devices
0.5491079570	kaplan meier survival
0.5489012910	conventional avr
0.5487953245	pre tavr
0.5487543390	transcatheter aortic
0.5486818488	new onset left bundle branch block
0.5486374247	related events
0.5485333092	ventricular assist devices
0.5484976410	low grade
0.5484947559	requiring pacemaker implantation
0.5484866501	valve leaflet
0.5484094551	vvi pacing
0.5483625893	pharmacological therapy
0.5483009707	march 2018
0.5482576171	significant improvement
0.5481996488	matched comparison
0.5479430646	n terminal pro
0.5479130337	real world setting
0.5475879119	implant procedure
0.5472206535	lvot ca
0.5470514890	covid 19 pandemic
0.5470232952	incidence and predictors
0.5469396697	undergoing cardiac surgery
0.5468851384	ablation procedure
0.5467307091	lead parameters
0.5466953935	inpatient mortality
0.5463954670	p ‚ÄØ ‚ÄØ 0.001
0.5462988710	sutureless versus
0.5462903913	defibrillator lead
0.5461060371	patient populations
0.5459160179	clinical events
0.5458698879	failure rate
0.5458248445	biological pacing
0.5457394844	repair techniques
0.5452333999	functional classification
0.5451989025	clinical practice guidelines
0.5451271720	cardiac electrophysiology
0.5450917824	dark cycle
0.5449765902	dual chamber pacemaker implantation
0.5449161550	icd implantation
0.5445188424	coronary syndromes
0.5445022403	tricuspid valve intervention
0.5444530924	ventricular activation
0.5442403302	atrial remodeling
0.5442129983	effective in reducing
0.5441177767	risk difference
0.5439175738	24 hour
0.5437979667	march 2017
0.5437738066	post operative pain
0.5437641675	acurate neo valve
0.5435205071	survival rate
0.5433620637	postoperative pacemaker implantation
0.5433288590	diaphragmatic pacemaker
0.5432948372	multivariate logistic
0.5431588492	clinical symptoms
0.5430277713	valve insufficiency
0.5428881889	follow up
0.5428687921	device therapy
0.5428402504	p wave duration
0.5426692211	epicardial lead
0.5426367648	september 2013
0.5425581091	differentiation of escs into pacemaker like
0.5424439993	device longevity
0.5424286241	control group
0.5423934670	percutaneous extraction
0.5422338008	ppi rate
0.5421867695	mv surgery
0.5421245122	isolated surgical aortic valve replacement
0.5420640954	preserved left ventricular
0.5420150193	surgical techniques
0.5419142494	ventricular sensing
0.5418888655	high grade avb
0.5417928281	clinical status
0.5415578580	contemporary outcomes
0.5414964948	cardiac surgeries
0.5412918964	rvot pacing
0.5412497217	hcn4 channels
0.5412276667	real world practice
0.5411727267	reactive protein
0.5411346313	lead vegetations
0.5410611905	persistent left bundle branch block
0.5409373091	routine clinical practice
0.5409337265	central pattern
0.5408896471	freedom from
0.5407689358	death in epilepsy
0.5407116918	the hypothalamic suprachiasmatic
0.5405893361	leadless pm
0.5401575578	ddd pacing
0.5401189073	cardiac device infections
0.5399058997	s lnvs
0.5396751146	aortic prosthesis
0.5396473224	icd recipients
0.5395988731	divided into
0.5395429117	transient loss of consciousness
0.5393945658	electronic device infections
0.5393692409	implantable device
0.5393526987	conditional cieds
0.5393309349	dose dependent
0.5392874595	rare complication
0.5391327348	transcatheter versus surgical
0.5390948684	ventricular conduction
0.5390878821	atrial appendage
0.5390825330	transcatheter mitral
0.5387242763	safety outcomes
0.5387196060	so far
0.5387188631	vascular disease
0.5386726090	tv surgery
0.5384814793	becoming increasingly
0.5383885490	severe tricuspid
0.5383718893	deep brain
0.5382592666	circadian period
0.5381207274	generation devices
0.5379580834	cardiac conduction
0.5377541570	ventricular paced
0.5377442466	biventricular pacemaker
0.5376807921	march 2015
0.5376310205	reoperation for bleeding
0.5372189887	san dysfunction
0.5370621797	vdd pacing
0.5369620321	p ‚ÄØ = ‚ÄØ
0.5368723266	asymptomatic atrial fibrillation
0.5368020821	experimental data
0.5367067943	atrial fibrillation flutter
0.5366855143	limited data
0.5365670599	valvular heart
0.5364875226	systematic review and meta
0.5364444579	permanent atrial fibrillation
0.5363947530	january 2010
0.5363778316	‚ÄØ months
0.5363732950	non syndromic
0.5363335781	atrial fibrillation recurrence
0.5363253305	moderate or severe aortic regurgitation
0.5362079233	small sample
0.5361802633	aortic valve prostheses
0.5360162603	pacemaker pocket
0.5359579153	‚â• 5 ¬† min
0.5358926256	prolonged qrs duration
0.5358467272	upper rate
0.5356925617	qrs duration ‚â•
0.5356188431	left ventricular wall
0.5356153230	autonomic nervous
0.5355583532	an updated meta analysis
0.5355372160	outcomes after transcatheter aortic valve replacement
0.5355214170	prior ppm
0.5355143180	severe sinus bradycardia
0.5354312977	balloon expandable valve
0.5353484399	icd leads
0.5353466770	treatment strategy
0.5353074345	symptomatic sick sinus syndrome
0.5352993463	increased significantly
0.5352123052	symptomatic sinus bradycardia
0.5352034264	ablation catheter
0.5351933094	action potential duration
0.5351919287	risk scores
0.5351477120	24 hour holter monitoring
0.5350894260	repair or replacement
0.5350755295	cardiac progenitor
0.5348975482	pulmonary venous connection
0.5348713338	pm implantations
0.5348445494	atrioventricular synchronous
0.5348226295	divided into 2 groups
0.5347926390	entire cohort
0.5347768790	routinely performed
0.5341933941	july 2011
0.5341708102	clinical factors
0.5340695397	generation valves
0.5338023732	sino atrial
0.5337909177	intrinsic period
0.5337718565	cell membrane
0.5337299014	two thirds
0.5337214269	january 2008
0.5335693594	life threatening condition
0.5334280178	valve related dysfunction
0.5331402332	rv lead tip
0.5331094298	low to intermediate
0.5330332236	hcn4 overexpressing
0.5329605217	6 minute walk
0.5329492218	sought to examine
0.5329189727	aortic valve gradients
0.5328861081	clinical decision making
0.5328538436	cardiac resynchronisation
0.5326914796	device settings
0.5326057090	sequential pacing
0.5324856731	well tolerated
0.5324716541	temporary epicardial pacing
0.5321271605	san function
0.5321212747	demographic data
0.5321090428	late complication
0.5320878636	pacemaker implants
0.5320159841	higher cost
0.5319313940	off label
0.5319266357	post implantation
0.5318251995	degree atrioventricular block
0.5317927065	cied related infections
0.5317871756	embryonic stem cell derived
0.5317223289	valve function
0.5316691419	propensity score matched analysis
0.5316215405	san tissue
0.5314932342	physiological pacing
0.5314782694	findings provide
0.5313631539	daily af burden
0.5313618238	orthostatic tachycardia
0.5310298263	cardiac implantable electronic device infection
0.5308768208	same day discharge
0.5308360941	acute complications
0.5307281760	whole cell patch clamp configuration
0.5307000768	propensity matched analysis
0.5306465997	patient management
0.5306291946	free rate
0.5305478082	drug induced
0.5304971565	medical device
0.5303819782	retrospective single center
0.5303000340	significantly older
0.5301936502	valve intervention
0.5301266063	secondary endpoints included
0.5300500295	myocardial dysfunction
0.5299757566	light induced
0.5298774938	sleep episodes
0.5298630295	high rate episodes
0.5298625518	underwent tle
0.5298083250	volume centers
0.5297675566	zero fluoroscopy
0.5296071338	cell based
0.5295451498	the vast majority
0.5293928244	device programming
0.5293047349	pacing burden
0.5289927052	all cause mortality
0.5289920591	congenitally corrected transposition of
0.5289700322	valve repair
0.5288094596	complete left bundle branch block
0.5287706293	complications requiring
0.5285883776	freedom from reoperation
0.5285215447	no significant difference
0.5284473204	¬† Œºm
0.5282851292	far field
0.5281969309	electronic apex
0.5281509381	pacemakers or implantable cardioverter defibrillators
0.5281445832	female patient
0.5281390585	november 2018
0.5279147126	p 0.01
0.5275248858	j valve ‚Ñ¢
0.5274838817	left ventricular systolic
0.5274683504	post transplant survival
0.5274435269	tc tavr
0.5273848795	new onset lbbb
0.5272265912	heart tissue
0.5271646846	matched control
0.5271174398	severe stenosis
0.5271151122	circadian expression
0.5269861034	lead dwell
0.5269283929	previous myocardial infarction
0.5267795637	meta analysis comparing
0.5264876933	transvenous pacing leads
0.5264869257	class i ii
0.5264693358	the umbilicus
0.5263790380	prevention of sudden cardiac death
0.5262784641	implant duration
0.5262606613	rapid deployment aortic valve
0.5261460674	‚â• 70
0.5258505507	a systematic search
0.5258308625	300 Œºm
0.5256000071	implantable cardiac
0.5255602903	atrioventricular valve replacement
0.5255050736	ca release
0.5254065338	higher risk
0.5253732951	age ‚â•
0.5252712463	secondary outcome
0.5252640993	systolic heart failure
0.5251442631	depending on
0.5251142721	p 0.00001
0.5250649315	divided into three groups
0.5249305784	pacing inhibition
0.5245390155	epicardial pacemakers
0.5244672349	procedural success rates
0.5244548425	device revision
0.5242793589	studies involving
0.5242098445	p ¬† ¬† 0.001
0.5235480017	nursing facility
0.5234238749	p ¬† ¬†
0.5233768435	analysis revealed
0.5231187290	pacemaker dependence
0.5229190448	long duration
0.5229092484	mean aortic gradient
0.5228442670	device size
0.5228241722	the drosophila circadian clock
0.5226166605	atrial septum
0.5224751802	persistent lbbb
0.5223904404	high density
0.5222662339	liver failure
0.5221417069	left sided valve surgery
0.5221412906	prospective cohort study
0.5221358226	postoperative bleeding
0.5219957608	degree av block
0.5219285977	single centre retrospective
0.5218785638	varc 2
0.5218027352	dose rate
0.5217025993	clinical composite
0.5216651355	¬† vivo
0.5216198554	assist device
0.5215366808	atrial activation
0.5215058545	electronic device implantation
0.5214713651	cardiovascular implantable electronic
0.5214683349	back pain
0.5214666079	feasibility study
0.5213757991	pacing wire
0.5213251851	undergoing transcatheter aortic valve implantation
0.5211761318	late mortality
0.5210621156	high cost
0.5210054253	defined device success
0.5210015747	clinical effectiveness
0.5208856919	march 2011
0.5208194729	year old girl
0.5203361307	node artery
0.5202798334	myocardial tissue
0.5202337787	induced tricuspid regurgitation
0.5202206792	independent risk factors
0.5202124118	device types
0.5201037802	cls pacing
0.5200283421	cied malfunction
0.5199509753	february 2020
0.5199028254	pacemaker dependent
0.5198223486	life threatening complication
0.5197324301	ventricular rate
0.5194907266	cied removal
0.5193819421	with repaired tetralogy
0.5193104134	membrane oxygenation
0.5192667576	self expanding transcatheter aortic valve
0.5192598297	patients died
0.5192134126	curve analysis showed
0.5189554830	third generation
0.5186909193	patients underwent
0.5185680285	lost to follow up
0.5184014188	anti platelet
0.5183234738	rv septal
0.5178163616	right atrial appendage
0.5177325207	pacemaker generator
0.5175677745	sustained ventricular
0.5175662320	population based study
0.5172470384	studies published
0.5171555858	branch block
0.5169454612	right heart catheterization
0.5169408015	combined approach
0.5167284549	isolated savr
0.5166900237	underwent successful
0.5166211096	lead related complications
0.5164897159	transvenous single chamber
0.5164603660	periprocedural mortality
0.5164363298	concomitant tricuspid
0.5164182584	higher mortality
0.5164124035	pacing indication
0.5163959716	central circadian pacemaker
0.5163525278	device detected af
0.5163109595	primary outcomes
0.5161884707	activity onset
0.5161069667	cied interrogation
0.5160549476	pacemaker wires
0.5160330861	cardiology transcatheter valve therapy
0.5159357010	atrial arrhythmia
0.5157097813	january 2019
0.5155880636	v @
0.5155829726	rv lead
0.5155109311	pacemakers or implantable cardioverter
0.5154837898	remote monitoring of cardiac implantable
0.5153760708	report highlights
0.5152934678	high degree atrioventricular
0.5152709260	effective therapeutic
0.5152488540	successfully performed
0.5152159072	june 2014
0.5151743110	conventional pacemakers
0.5150533348	device failure
0.5150002202	median interval
0.5149135360	clamp times
0.5148773152	randomized study
0.5148140939	volume index
0.5147621261	atrial lead
0.5147283205	january 2009
0.5145439758	pacing percentage
0.5143143390	new york
0.5142751737	vvi pacemaker
0.5140985194	cardiac electronic device implantation
0.5140719598	march 2020
0.5139957596	high voltage
0.5139748516	april 2017
0.5138625822	p 0.05
0.5137632129	based algorithm
0.5137229931	activated potassium
0.5136853157	lead insulation
0.5135856554	infection rates
0.5134477887	consecutive days
0.5132040675	tavi registry
0.5131190377	high energy
0.5130457060	pulse rate
0.5129073583	san cell
0.5126940232	r wave
0.5126387499	‚ÄØ years
0.5125544352	sought to characterize
0.5125344338	randomized to receive
0.5124911022	patients undergoing tavr
0.5124654303	micra tps implantation
0.5122152750	pocket related complications
0.5121478219	heart failure hospitalizations
0.5120879459	refractory atrial fibrillation
0.5119426945	pacing systems
0.5119326703	recently developed
0.5117027437	consecutive patients receiving
0.5115237786	coronary intervention
0.5114713455	accompanied by
0.5114102061	pacemaker neuron
0.5114066025	sought to identify
0.5113044621	cardiac device implantation
0.5109145156	patient outcomes
0.5107866615	patients undergoing elective
0.5106879348	icd implants
0.5103640136	positive response
0.5102541111	electrical conduction
0.5101331398	prospectively included
0.5100911887	analysis showed
0.5098707743	february 2017
0.5098486760	early postoperative
0.5097954120	cardiac device
0.5096652061	device reprogramming
0.5093443530	device replacement
0.5093407742	atrial fibrillation ablation
0.5093200654	transcatheter leadless
0.5091745315	low surgical risk
0.5091352334	icd registry
0.5091350574	department of cardiology
0.5090172405	lead performance
0.5089080627	aortic valve intervention
0.5088113308	transvenous pacemaker implantation
0.5088011695	mean ¬± sd
0.5087933037	patients with cardiac implantable electronic devices
0.5086240369	wave frequency
0.5085898983	maze iv
0.5085418595	mri safety
0.5085197900	¬† ‚â•
0.5083929149	oral anticoagulation therapy
0.5082407913	patient cohort
0.5082186094	september 2019
0.5079478572	cardiac mri
0.5079391654	light conditions
0.5078910615	valve performance
0.5076313435	pacemaker cell
0.5075947795	clinical and echocardiographic outcomes
0.5074723010	published data
0.5074617215	transapical transcatheter
0.5074234974	heart failure symptoms
0.5074072982	thirty day
0.5073593137	cervical spinal
0.5072941696	rd avr
0.5072619476	post discharge
0.5071683420	an independent core laboratory
0.5071459860	transaortic transcatheter aortic valve implantation
0.5070064890	hospitalization rates
0.5069200939	july 2015
0.5069167501	third degree heart block
0.5066966554	cardiac vein
0.5066635207	june 2012
0.5065314032	main outcomes
0.5065286744	percutaneous approach
0.5065155573	revalving system
0.5065062089	ventricular stimulation
0.5064159647	related symptoms
0.5064041746	atrioventricular conduction disturbances
0.5062410820	extraction difficulty
0.5061747719	complete removal
0.5061464888	per 100,000
0.5061269142	adjusted analysis
0.5059694176	improved significantly
0.5059677932	million population
0.5059089281	age groups
0.5057959913	pre syncope
0.5056012827	ablation procedures
0.5055808766	new or worsening
0.5055109125	adults with congenital heart disease
0.5051564831	response rate
0.5050362485	se tavr
0.5050049416	sinus rate
0.5046466708	af progression
0.5045713644	non inferiority
0.5044387188	primary diagnosis
0.5044324236	defibrillator implantation
0.5043950187	pm dependent
0.5043430344	lobe epilepsy
0.5042910254	class i
0.5042115194	randomly divided into
0.5040825121	american college of
0.5040268151	next generation self expanding
0.5039794638	pre implant
0.5038927577	atrial mass
0.5038341073	intuity group
0.5036397159	chronic renal failure
0.5033841911	therapeutic approach
0.5029812159	tavi procedures
0.5027295470	needed to confirm
0.5026306605	lead implant duration
0.5025705558	transapical transcatheter aortic valve implantation
0.5025175472	anterior mini thoracotomy
0.5023472750	interval prolongation
0.5022652371	inward currents
0.5022236026	gated channels
0.5020934801	nationwide inpatient
0.5018817975	stress induced
0.5018102669	derived stem
0.5015949715	valve operations
0.5015937289	epicardial pacing lead
0.5015885918	artery occlusion
0.5014345229	baseline lvef
0.5013628044	bipolar lead
0.5013416918	post tavi ppi
0.5013306749	34 mm evolut r
0.5012178636	induced tr
0.5011669191	cardiac differentiation
0.5009743507	patient care
0.5009573108	significant predictor
0.5007850413	short and long
0.5007318893	artifact reduction
0.5006336829	interrogation revealed
0.5005888958	underwent tavr
0.5004416530	hemodialysis patient
0.5004073705	180 ¬∞
0.5002492338	insights into
0.5001525582	rheumatic fever
0.4999628027	focuses on
0.4998703686	chamber icd
0.4998389029	p 0.001
0.4996878853	¬† nm
0.4995727839	¬† mg kg
0.4994033296	relevant studies
0.4993481325	versus rvp
0.4993351717	divided in two groups
0.4989664363	device pocket
0.4986274996	male patient
0.4986107152	endocardial pacemaker
0.4984549802	necessitating permanent pacemaker
0.4983431734	transvenous lead extraction procedures
0.4981444561	aortic valve regurgitation
0.4981375157	stroke risk
0.4981330476	old girl
0.4981314349	implantable electronic device
0.4980301418	micra implantation
0.4978192857	p ¬† 0.001
0.4978189286	u l
0.4976821962	cardiac asystole
0.4976768016	t type calcium
0.4975561760	year old
0.4974304745	survival analysis
0.4973039235	atrioventricular conduction disorders
0.4972595565	surgical aortic valve
0.4972422756	february 2014
0.4971005383	survival and freedom from
0.4970842224	cardiac tissue
0.4970134778	aimed to explore
0.4968249394	composite of death
0.4966321470	p ¬† ¬† 0.01
0.4965938375	international normalized
0.4963492157	lead implantation
0.4960680268	mortality and major
0.4960231629	activated cyclic nucleotide gated channel
0.4958760273	intrinsic heart rate
0.4953211915	cardiovascular risk factors
0.4953104582	aortic cross clamp time
0.4953030537	pacemaker programming
0.4952791683	late survival
0.4952338788	college of cardiology
0.4950187877	right minithoracotomy
0.4949004969	cav 3
0.4947843818	baseline qrs duration
0.4947020776	sleep duration
0.4945766654	requiring permanent pacemaker
0.4942414036	undergoing tle
0.4941196529	echocardiogram showed
0.4940187132	current evidence
0.4939657567	long term follow up
0.4938860592	cied related
0.4938032421	clinical benefit
0.4937554130	acute heart failure
0.4937078503	group ii
0.4936966199	gated channel
0.4936753453	adverse cardiac
0.4936569787	firing activity
0.4932422350	s icd
0.4932231238	multi electrode
0.4932031287	lead related
0.4930764772	human body
0.4928303793	atrial threshold
0.4928183350	alternative approach
0.4927866499	lead extraction procedures
0.4925645975	increasingly performed
0.4925294731	the nordland
0.4922541825	american college of cardiology transcatheter valve
0.4922102416	concomitant cardiac surgery
0.4921918841	prospective cohort
0.4920602570	¬† mmhg
0.4917094114	infected leads
0.4916877451	requiring permanent pacemaker implantation
0.4916437946	w kg
0.4915592504	operative outcomes
0.4913223249	1 ¬† week
0.4912202994	end stage heart failure
0.4912068080	score ‚â•
0.4910705374	robust circadian
0.4910346877	ddd pacemaker implantation
0.4910285205	mortality risk
0.4908961714	incidence rates
0.4908470836	efficacy end point
0.4908122069	undergoing tavi
0.4907759772	logistic regression model
0.4907621668	pacing modality
0.4906802481	november 2015
0.4905787125	unipolar pacing
0.4905238270	venous approach
0.4904466838	24 hours
0.4904101334	230 ms
0.4901296254	few reports
0.4900414030	vein stenosis
0.4898730434	postoperative atrial fibrillation
0.4897482667	high volume center
0.4896530965	lead electrocardiography
0.4895918826	added value
0.4895852828	underwent elective
0.4895659289	reduced ejection fraction
0.4894554360	transcatheter aortic valve in valve implantation
0.4893971310	right ventricular pacing
0.4893481541	the other hand
0.4893399874	pacemaker currents
0.4893038041	average age
0.4892264577	stenosis or occlusion
0.4891071295	depth of implantation
0.4890748022	performed to identify predictors
0.4890175700	implant rates
0.4889410275	t box
0.4888856562	mechanism of action
0.4888039784	ppm implant
0.4887591090	normal cardiac function
0.4887371206	re entry
0.4886749201	cied placement
0.4885171121	lv end systolic
0.4884747199	does not
0.4884240517	anterior descending
0.4883505803	in vitro
0.4883192631	respiratory complications
0.4882754991	none trace
0.4882117622	pacemaker implantation rate
0.4880620799	single center retrospective study
0.4880489402	cardiac myocytes
0.4879310008	cardiovascular implantable electronic device infection
0.4877625162	intra cardiac
0.4877232679	in group a
0.4876363360	procedure related major complications
0.4874421504	percentage of ventricular pacing
0.4874040436	rather than
0.4873438751	pacing sites
0.4873409773	higher degree
0.4871621394	lp implantation
0.4869062210	pacemaker lead perforation
0.4868217050	early experience
0.4867067888	data demonstrate
0.4864562444	coronary interventions
0.4864451877	baseline right bundle branch block
0.4863834588	march 2016
0.4863646553	this case highlights
0.4862055595	versus surgical aortic valve replacement
0.4860416109	48 hours
0.4859161093	p ¬† 0.0001
0.4858843069	complete extraction
0.4857828760	free solution
0.4857361921	procedure success
0.4856610827	circadian neurons
0.4856584357	the present study
0.4854184747	cardiac resynchronization therapy device
0.4853530179	lower risk
0.4853149746	long term mortality
0.4852902378	academic medical
0.4852843649	effective method
0.4852703245	major cied infection
0.4851723842	safely performed
0.4851075223	maze iv procedure
0.4849327990	cardiac operations
0.4848701493	hundred fifty
0.4848041422	july 2018
0.4847443708	extracted leads
0.4846364670	self expanding transcatheter heart valve
0.4846298614	reported previously
0.4845727945	none or trace
0.4843097711	the poniente study
0.4843003644	¬† hz
0.4842832139	clinical setting
0.4841740716	stem cell derived
0.4840840992	lead vegetation
0.4840274518	¬† kg
0.4840069568	patients undergoing avr
0.4839514054	cardiac monitors
0.4837958346	august 2016
0.4837760154	device reimplantation
0.4837757906	september 2018
0.4833674914	diastolic diameter
0.4833406254	mammalian circadian
0.4833131637	july 2016
0.4830030371	ventricular outflow tract
0.4829843483	april 2015
0.4829204509	two dimensional
0.4826586355	atrioventricular block requiring
0.4826333135	dddr pacing
0.4825718909	ventricular free wall
0.4823244837	new generation
0.4822009712	transvenous extraction
0.4820559028	requiring pm implantation
0.4819957208	invasive surgical
0.4818786819	complex congenital heart disease
0.4817211816	extraction procedures
0.4816931338	national health
0.4816245596	so called
0.4810464895	underlying rhythm
0.4810439724	mean transvalvular gradient
0.4808599543	patient suffered
0.4806277510	the last decade
0.4804782803	self limiting
0.4804737128	trial comparing
0.4801741387	cied procedures
0.4801725552	atrial pacemaker lead
0.4800211004	lower rate
0.4799136323	electrophysiological activity
0.4799041022	self expandable valves
0.4798360418	cied insertion
0.4798193928	automatic implantable cardioverter
0.4797548670	patient mismatch
0.4797432291	study demonstrates
0.4796702827	univariate and multivariate logistic
0.4795593924	clinical efficacy
0.4795543618	icc pacemaker activity
0.4794603168	cardiac implantable
0.4791718692	implanted leads
0.4789907053	pacemaker generators
0.4789465239	expression of clock genes
0.4788583081	‚Äë induced
0.4788391318	cardiac implantable electronic device implantation
0.4788169392	mean logistic euroscore
0.4787333772	valve annulus
0.4785188181	atrioventricular block requiring permanent pacemaker implantation
0.4785076595	translated into
0.4784614577	transfemoral transcatheter aortic valve
0.4782968875	transcatheter tricuspid
0.4782736599	pulmonary disease
0.4781721741	underwent savr
0.4781519499	clinical assessment
0.4781453122	single chamber ventricular
0.4778184478	stent implantation
0.4777768810	left ventricular pacing
0.4777530689	complete heart block requiring
0.4776997373	a priori
0.4776065839	findings support
0.4775783846	february 2015
0.4775680123	studies suggest
0.4775251617	pericardial space
0.4770949741	single center cohort
0.4770592249	clinical information
0.4769621382	remain poorly
0.4769534776	delivery system
0.4768429462	negative impact
0.4768392102	bioprosthetic aortic
0.4768343668	cardiac automaticity
0.4766640356	¬† œâ
0.4763505771	cardiac rhythm
0.4762670523	pacemaker properties
0.4761721162	accounts for
0.4761206162	permanent dual chamber
0.4760591443	clinical condition
0.4760122770	case illustrates
0.4757627290	side effects
0.4757323980	clinical findings
0.4756481179	left ventricular lead placement
0.4755406441	lbbb post tavr
0.4754950295	january 2020
0.4754357143	long term performance
0.4753973566	pacemaking cells
0.4753376081	patients undergoing tle
0.4752817205	‚Äë activated
0.4752001529	defibrillation leads
0.4749790906	valve regurgitation
0.4749676224	aimed to examine
0.4748639843	pacemaker requirements
0.4746860111	pre existing ppm
0.4744745745	valve replacement surgery
0.4744370501	cardiac history
0.4742355428	hundred and fifty
0.4741630032	¬± standard deviation
0.4741170309	cardiac rhythm abnormalities
0.4740714938	12 lead ecg
0.4737584484	echocardiographic characteristics
0.4737384951	health problems
0.4733349389	¬† + ¬†
0.4732707399	scn function
0.4731101937	younger patients
0.4729778348	multivariate analysis showed
0.4729474226	potential complications
0.4728952272	tle procedure
0.4728853815	prospectively collected data
0.4721834874	multiple logistic regression
0.4720180344	ventricular leads
0.4719827816	ranged from
0.4719094504	utilization and outcomes
0.4719094504	trends and outcomes
0.4719032915	patient died
0.4718933021	to ascertain
0.4718735765	‚â§ 35
0.4718276641	high quality
0.4715294281	risk of developing
0.4712083642	incidence and outcomes
0.4712064823	august 2015
0.4709865874	left to right
0.4709418606	septal ablation
0.4706702585	infected device
0.4705286890	implantable loop
0.4702434454	retrospectively included
0.4701749694	cardiac electronic
0.4699283762	isolated san
0.4698951694	clinical data
0.4698005220	refers to
0.4697839730	eligible patients
0.4697770300	right atrial
0.4697113159	heart valve
0.4696592712	postoperative stroke
0.4695203689	implanted cardiac device
0.4693829385	major or life threatening
0.4692035976	independent predictors of
0.4682201137	observational analysis
0.4682000118	apical rv
0.4679987119	june 2017
0.4679255670	society of thoracic surgeons predicted risk
0.4678503355	crt implantations
0.4677916005	nearly half
0.4677095693	lead thrombus
0.4675890889	f fdg
0.4675598849	circadian pacemaker
0.4675425192	related complication
0.4673958642	dwelling time
0.4670092221	nstemi patients
0.4667832766	right internal jugular
0.4666912007	left ventricular end systolic
0.4662807048	axillary venous
0.4662154031	this case illustrates
0.4660544669	device related infective endocarditis
0.4660143890	pacemaker implantation rates
0.4660081330	contrast enhanced cardiac
0.4659767944	polymorphic ventricular
0.4659063576	peripheral vascular
0.4657470954	device replacements
0.4656771982	pacing catheter
0.4656193534	pacemaker electrode
0.4655959221	single lead
0.4654300699	device success rates
0.4653704593	november 2014
0.4652742096	pacemaker lead placement
0.4650314617	pacemaker lead implantation
0.4649815652	per tim
0.4646354725	implanted electronic devices
0.4644699947	low density
0.4644605791	elderly patient
0.4643761322	cardiac device infection
0.4642441357	percutaneous coronary
0.4641274257	long standing persistent atrial fibrillation
0.4640673974	case control
0.4638393363	na√Øve patients
0.4637232699	epicardial pacemaker implantation
0.4636917924	crt devices
0.4636222733	ilr implantation
0.4635004560	february 2016
0.4634565598	24 hour holter
0.4634272487	standard ecg
0.4631803449	multivariate analysis revealed
0.4628874345	length of hospitalization
0.4628020480	high morbidity
0.4627882285	cardiac dysfunction
0.4627174056	underwent catheter ablation
0.4626341036	important role
0.4625782199	severe complications
0.4622405880	low complication rates
0.4622372776	28 day mortality
0.4622193194	pacemaker or cardioverter
0.4621707891	concentration dependent
0.4620966227	af duration
0.4618635136	autonomic nervous system
0.4617362050	surgical valve replacement
0.4615149398	valve related
0.4614869482	p = 0.002
0.4614737188	balloon expandable tavr
0.4612648771	transvenous pacemaker lead
0.4611966110	prone to
0.4611209552	an 86 year old
0.4610552312	prospective single center
0.4609831183	endpoints included
0.4608649925	right ventricular perforation
0.4607697491	severe left ventricular dysfunction
0.4606772433	clinical indications
0.4606590029	right to left
0.4606329751	without compromising
0.4604409216	invasive treatment
0.4602703681	device success rate
0.4600628160	perioperative mortality
0.4600409853	pacing capture threshold
0.4598767879	hundred sixty
0.4596905495	heart function
0.4592663467	year old boy
0.4591781239	even though
0.4589642472	case shows
0.4587817708	cied implants
0.4584187228	infections occurred
0.4583301133	implantable cardiac device
0.4583069234	results suggest
0.4580551774	cardiac index
0.4580261209	large animal
0.4580189005	crt implantation
0.4576492674	cardiac diseases
0.4574007214	single lead pacemaker
0.4569572005	p ¬† ¬† = ¬† ¬†
0.4568623061	warfarin group
0.4568556613	rapid ventricular
0.4568183819	left atrial size
0.4567344410	corevalve evolut
0.4566494175	effective treatment
0.4565615050	cardiac disease
0.4564760089	cardiac pacemaker cell
0.4561767730	the italian association of arrhythmology and
0.4557976937	individual cells
0.4554326182	pacemaker activities
0.4553810032	perioperative period
0.4552905235	mortality or stroke
0.4550443569	second degree atrioventricular block
0.4550236064	further investigation
0.4549743782	valve disease
0.4549240626	pacemaker wire
0.4549018660	prior coronary artery bypass
0.4548576677	functional outcome
0.4547021217	tav group
0.4546529615	artery bypass
0.4544662903	cell carcinoma
0.4541691206	consecutive patients with severe aortic stenosis
0.4540831103	january 2012
0.4540807429	cied related infection
0.4539940603	in vivo
0.4539382547	did not
0.4538547848	time consuming
0.4537810463	first rib
0.4537217708	atrial rhythm
0.4535985891	less invasive
0.4534675699	owing to
0.4534516498	adverse events occurred
0.4533602337	march 2012
0.4533478691	wise crt system
0.4532520549	¬† mg
0.4531301232	p ‚ÄØ ‚ÄØ
0.4529490187	requiring temporary
0.4528160667	kinds of
0.4527623263	sinus node function
0.4527565895	bav group
0.4525400924	cardiac cycle
0.4525257776	irrespective of
0.4524035757	more frequent
0.4523423293	tv tavi
0.4521431092	implanted cardioverter defibrillator
0.4521117781	heart model
0.4520958560	multiple linear
0.4519166944	due to
0.4516843085	as opposed to
0.4516829650	vast majority of
0.4512053585	low ejection fraction
0.4511914983	resynchronization devices
0.4511308179	death or stroke
0.4508191801	following transcatheter aortic valve replacement
0.4507867121	prolonged pr
0.4507381388	low cardiac output
0.4505175042	conventional crt
0.4505121033	infection risk
0.4504718971	january 2013
0.4503519337	clinical and hemodynamic outcomes
0.4502011425	p ¬† =
0.4501844950	the danish pacemaker and icd
0.4501607555	aortic valve implantation
0.4496637273	ventricular septal
0.4494680767	greater than
0.4493783819	as soon as
0.4493741788	1 ¬† month
0.4493638922	related factors
0.4493260695	early clinical outcomes
0.4492251112	12 lead electrocardiogram
0.4487073262	conflicting results
0.4487059850	transcatheter tricuspid valve
0.4485636700	international classification
0.4485435104	active fixation pacing
0.4484957727	normal mice
0.4484797603	conditional pacemaker
0.4480532692	seizure like
0.4479506398	f fluorodeoxyglucose
0.4479391116	¬† hours
0.4479332678	pacing induced
0.4475567608	anterior fascicular block
0.4475395879	n ¬† =
0.4474465281	one hundred
0.4474225486	dose received
0.4472289047	insights from
0.4471649303	¬† minutes
0.4470090939	single chamber ventricular pacemaker
0.4468038483	v at 0.24
0.4467947242	cardiac autonomic
0.4466687429	suspicion of
0.4465659504	permanent cardiac pacemaker
0.4462507835	underwent isolated
0.4459153329	previous cardiac surgery
0.4456190209	triple valve
0.4450619728	the number of collaborating centers
0.4450470459	hbp implantation
0.4448125316	¬† mm hg
0.4447628967	patients received
0.4447412336	24 ¬† h
0.4447291014	sixteen patients
0.4446348442	‚â• 80 years
0.4446081418	focusing on
0.4444795094	previous coronary artery bypass
0.4444686721	inhibitory effects
0.4444259320	years or older
0.4443251086	ppm or icd
0.4442067854	af history
0.4441483071	clinical examination
0.4441133898	failure to capture
0.4440266456	reference group
0.4439840447	undergoing mitral
0.4439201101	death occurred
0.4439032031	multicenter retrospective
0.4436805103	in hospital outcomes
0.4434839984	march 31
0.4433872200	early outcomes
0.4433819302	additional studies
0.4433811569	n =
0.4433301012	functional outcomes
0.4432340101	degenerated aortic
0.4432167502	asymptomatic patient
0.4431773658	postoperative period
0.4431542073	follow up visit
0.4431396203	significant tr
0.4430692785	diagnosis and management
0.4430507046	april 2016
0.4426945612	conventional biventricular
0.4426193903	¬† seconds
0.4425414573	pace group
0.4421850686	aortic valve prosthesis
0.4421789501	implantable cardioverter defibrillator implantation
0.4420987409	definitive pacemaker
0.4420729719	central nervous system
0.4420149894	required permanent pacemaker implantation
0.4419717772	heart rhythm association
0.4419340732	good agreement
0.4418145378	underwent dual chamber pacemaker implantation
0.4416488921	cardiac anatomy
0.4415958030	survey ii
0.4413771826	ecg findings
0.4411979018	cs leads
0.4411770386	according to
0.4411525671	hospitalization for heart failure
0.4409711492	invasive procedure
0.4408857485	relationship between
0.4407999728	pacemaker rate
0.4406166051	tricuspid valve disease
0.4404391768	pacemaker syndrome
0.4402323666	transcatheter leadless pacemaker
0.4402055215	left and right
0.4400896513	coupled clock system
0.4400842823	requiring ppm
0.4398276806	not well understood
0.4397819982	24 h
0.4396385670	age dependent
0.4396257761	√ó 10
0.4395047729	significant paravalvular leak
0.4392921619	commonly used
0.4392843262	echocardiographic data
0.4388928878	versus tricuspid
0.4388242660	the poniente
0.4388178285	commonly reported
0.4387684168	aimed to
0.4385786306	september 2016
0.4385758334	permanent cardiac pacemakers
0.4384924928	clinical success rate
0.4384161270	t waves
0.4383532953	light dependent
0.4382536659	cardiac conduction disease
0.4381881448	adverse cardiac and cerebrovascular events
0.4381528047	av block requiring
0.4379089284	concomitant mitral
0.4376913936	node ablation
0.4372604616	low complication rate
0.4367008714	self expanding valves
0.4366087764	pacemaker recipients
0.4365528886	circadian pacemaker in mammals
0.4363101864	percutaneous retrieval
0.4362861952	cardiac failure
0.4362165478	atp sensitive
0.4361531110	coronary sinus lead
0.4361055605	paroxysmal supraventricular
0.4360018299	days postoperatively
0.4359382460	the advent
0.4356473015	seventeen patients
0.4356231466	atrial fibrillation episodes
0.4355513487	normal range
0.4354513516	patients with symptomatic severe aortic stenosis
0.4351216656	fluoroscopy time
0.4350352232	increased mortality
0.4349372180	c + d
0.4349020979	3d tee
0.4345507013	january 2014
0.4345133411	patient experienced
0.4345057151	heart block requiring
0.4344388957	left ventricular lead
0.4343162829	potentials of iccs
0.4340609976	depends on
0.4337972371	versus conventional
0.4337561244	coronary sinus leads
0.4336970244	‚â• 18 years
0.4336722076	a 10
0.4336375809	long term monitoring
0.4335080312	day night
0.4333774973	generation self expandable
0.4331750861	late gadolinium
0.4330773727	evaluation revealed
0.4329747088	permanent av block
0.4328597504	heart catheterization
0.4328229439	after transcatheter aortic valve implantation
0.4327869296	cardiac pacemaker activity
0.4327798547	clinical management
0.4326477253	correlation between
0.4325899871	lead endocarditis
0.4325700730	severe aortic regurgitation
0.4325451505	cell specific
0.4325016381	lotus device
0.4324132797	cost of hospitalization
0.4323867901	procedural mortality
0.4323736363	aimed at
0.4322908169	population based
0.4322640172	higher rates of
0.4319280265	as well as
0.4318513750	commonly performed
0.4317188472	left heart
0.4315643122	after transcatheter aortic valve replacement
0.4314470070	ventricular apical pacing
0.4313740126	upgrade to cardiac resynchronization therapy
0.4312002074	complications occurred
0.4311130993	known about
0.4310636770	follow up visits
0.4309809182	pacemaker therapy
0.4309175277	an unusual presentation
0.4308792610	caused by
0.4306658467	epicardial pacing leads
0.4305659948	clinical experience
0.4305461684	crt p
0.4305453396	independent predictor
0.4305331786	thirty seven
0.4302271477	clinical decision
0.4302234478	bypass times
0.4300371656	study population
0.4300158116	less frequently
0.4299933891	retrospectively compared
0.4298739494	cardiac resynchronization therapy devices
0.4298155867	30 day
0.4296310775	same day
0.4295706609	eeg monitoring
0.4289046083	months of follow up
0.4288485069	single centre study
0.4284947476	congenital complete atrioventricular
0.4284257787	early phase
0.4283157915	march 2014
0.4282948617	regression analysis revealed
0.4282294574	before htx
0.4279611276	mortality and stroke rates
0.4278932101	loss of function
0.4277972596	third degree atrioventricular
0.4275576076	more frequently
0.4275343910	closure of perimembranous
0.4274792610	defined as
0.4273458395	in terms of
0.4273153555	primary composite
0.4271416346	an 82 year old
0.4271343478	responsible for
0.4267717935	study period
0.4266558400	epicardial pacemaker lead
0.4265343723	stroke rates
0.4264938776	artificial pacemaker
0.4264560154	concomitant mitral valve
0.4264467366	p = 0.02
0.4263415531	generation self expanding
0.4263354877	p = 0.003
0.4262692373	p = 0.001
0.4262493476	did not differ
0.4260831792	valve prostheses
0.4259426258	underwent cied implantation
0.4256021457	diastolic ca
0.4255689646	this article
0.4251865208	large cohort of patients
0.4251769618	cardiac procedures
0.4251062222	single arm study
0.4250845384	implant related complications
0.4247708045	cardiac abnormalities
0.4246603602	new onset atrial fibrillation
0.4244585258	device parameters
0.4244316502	transcatheter versus surgical aortic valve
0.4243366011	age matched
0.4241954419	p = 0.008
0.4241622759	¬† ‚â• moderate
0.4241193697	conventional pacing
0.4240987352	l type calcium
0.4239193015	patient age
0.4237043767	in conjunction with
0.4235965775	significantly correlated
0.4234929621	outcome data
0.4232268928	diaphragm pacemaker
0.4231733088	significant tricuspid regurgitation
0.4229451262	echocardiography demonstrated
0.4225042077	hundred thirty
0.4224992269	concerns about
0.4224677429	degree block
0.4222640883	p ‚â§ 0.001
0.4222146728	old boy
0.4221688812	short term mortality
0.4215798685	sex related
0.4215407366	cardiac structures
0.4215077277	rare complications
0.4214299076	served as
0.4214152783	temporary transvenous pacemaker
0.4213276810	pacemaker or implantable cardioverter defibrillator
0.4212646076	extraction procedure
0.4211132759	device implants
0.4210717495	pacemaker firing
0.4209433738	this paper
0.4209367977	out of hospital cardiac arrest
0.4208856281	implanted pacemakers
0.4202300797	pacemaker battery depletion
0.4202181860	twenty four
0.4201621345	device placement
0.4201195422	subjected to
0.4200816721	normal conduction
0.4200567251	¬† ‚â• ¬†
0.4200307669	native aortic
0.4199056163	non mri conditional
0.4197696444	inappropriate pacing
0.4197631871	conventional pacemaker
0.4196075490	index procedure
0.4195893406	single chamber icd
0.4195750988	a case report
0.4193012866	the united states
0.4191963372	kaplan meier method
0.4191479354	san pacemaker cells
0.4191066838	mean age
0.4190273884	rhythms in drosophila
0.4188777170	single chamber pacemaker
0.4187260389	initial procedure
0.4185757523	performed successfully
0.4185039270	long pr
0.4182076106	consecutive patients undergoing tavr
0.4181780624	cied pocket
0.4181611666	remote device
0.4181609498	contralateral side
0.4181184128	pm registry
0.4179570228	able to
0.4179098549	cieds undergoing
0.4178119028	p =
0.4174760528	into account
0.4173894625	wcd use
0.4173592396	left coronary cusp
0.4168409747	p = 0.005
0.4166951759	qt syndrome
0.4165948136	a 4
0.4165856759	ventricular endocardial
0.4165222829	comparing tavr
0.4165199826	mean gradient
0.4163511812	no significant differences
0.4158154168	potential risks
0.4157857179	to lv interval
0.4155136605	human pluripotent
0.4154354613	ventricular high rate
0.4153780141	activity rhythm
0.4151164073	in 6
0.4151097649	long term effects
0.4149574600	data exist
0.4148937954	clinical case
0.4146711856	congenital cardiac
0.4145689627	median survival
0.4143082732	alternative to conventional
0.4142382685	p = 0.03
0.4140710876	complete right bundle branch block
0.4139716061	bipolar pacing
0.4138539835	clinical impact
0.4137925909	curve analysis
0.4137399315	all cause death
0.4135916346	an 83 year old
0.4135678052	ventricular apical
0.4132876954	electronic device leads
0.4129634502	1 ¬† year
0.4128397522	in favor of
0.4125543481	contribute to
0.4124859893	main indication
0.4124836027	safety and effectiveness
0.4124761483	p = 0.01
0.4122401843	nodal ablation
0.4121580164	single center prospective
0.4121502387	obese patients
0.4120381771	cyclic nucleotide gated channel
0.4119255393	single institution
0.4117717326	cardiac deaths
0.4117288261	the placebo group
0.4117224494	permanent pacemaker implantation rate
0.4116892424	single chamber pacemakers
0.4116667389	study protocol
0.4116503810	the balloon expandable edwards sapien
0.4116236214	a dose dependent manner
0.4113113513	cardioverter defibrillator implantation
0.4110366024	early development
0.4109973390	well characterized
0.4109155907	patients aged
0.4104938748	p ¬† = ¬†
0.4103027173	two hundred
0.4101224680	transcatheter valve in valve implantation
0.4100989282	whole body
0.4099465678	severe paravalvular regurgitation
0.4099290902	cell population
0.4098745102	patient developed
0.4097624114	ranging from
0.4096955371	short term outcomes
0.4096862720	used to record
0.4096442435	patients aged ‚â•
0.4095868497	right bundle branch
0.4093786686	p = 0.004
0.4090361147	moderate to severe paravalvular leak
0.4088133062	years earlier
0.4087956248	lead replacement
0.4087147426	patients undergoing cied implantation
0.4083695147	pacing impedance
0.4081192007	patients undergoing pacemaker implantation
0.4080827459	chamber pacemaker
0.4077836527	rv function
0.4076546115	the repositionable lotus
0.4075310444	median survival time
0.4074423817	p wave
0.4073852485	more than mild paravalvular leak
0.4072634439	transient ischaemic
0.4072309761	contributes to
0.4072274197	intermediate risk patients
0.4071292843	defibrillator lead implantation
0.4069381136	study shows
0.4068872602	pacemaker nucleus
0.4066890614	varc 2 defined
0.4064721095	excellent hemodynamic
0.4063431415	time perception
0.4061661458	pacemaker site
0.4060544886	transvenous temporary
0.4058659661	a useful tool
0.4058455253	30 day readmission
0.4058092049	bleeding requiring
0.4058007309	acute inferior
0.4056064127	moderate to severe paravalvular
0.4055249576	thanks to
0.4053171426	in addition
0.4052945331	an 80 year old
0.4052417959	weeks later
0.4047774176	association between
0.4047368826	hf san
0.4045410143	france 2
0.4045061784	clinical studies
0.4044186287	pacemaker ‚Äë like cells
0.4043254565	under constant darkness
0.4041396050	new lvsd
0.4040807836	n ‚ÄØ =
0.4040136984	mean sts score
0.4038881735	a 6
0.4035864708	procedural and clinical outcomes
0.4035585807	n ¬† = ¬†
0.4033164126	long term clinical outcome
0.4027938429	study enrolled
0.4025947378	induced pacemaker potential
0.4024732826	thirty nine
0.4024700878	permanent pacemaker implant
0.4023070087	patients undergoing tavi
0.4023032598	tended to
0.4022512271	right ventricular septal pacing
0.4020292889	atrial septal
0.4018996686	valve calcification
0.4016082664	fourteen patients
0.4013683749	pacemaker pulses
0.4011094640	rare cases
0.4003128142	into pacemaker ‚Äë like cells
0.4002747249	alcohol septal
0.4001261422	initial diagnosis
0.4000750786	patients meeting
0.3999872405	pacing algorithms
0.3998911469	than or equal to
0.3997859971	significant morbidity and mortality
0.3997822100	pacemaker mediated
0.3997722114	st segment elevation myocardial
0.3996323107	cardiac interventions
0.3994762505	days post
0.3994739806	remained significant
0.3993825563	to evaluate
0.3993083028	the visual system
0.3992125185	first description
0.3990371519	a case report and review
0.3989894302	a single center experience
0.3989796241	the results of
0.3988992519	p ¬† ¬† 0.0001
0.3988430678	incidence rate
0.3987857040	to assess
0.3987382334	myocardial cells
0.3986003143	median follow up duration
0.3985601974	thoracic surgery
0.3985293491	independent core laboratory
0.3985015288	information about
0.3983888291	implanted successfully
0.3982778085	significant association
0.3981529821	case demonstrates
0.3978905706	the appropriateness of
0.3970856817	these findings suggest
0.3968856229	i lao
0.3968383371	1 month
0.3966620247	trend towards
0.3965883000	older than 80 years
0.3963995260	effects model
0.3963473618	tissue specific
0.3960392165	second degree av block
0.3959926878	underwent pacemaker implantation
0.3959169216	first in human
0.3957235598	related infection
0.3956831403	channel activity
0.3955819380	pacing indications
0.3950561133	pacemaker defibrillator
0.3945871862	congenitally corrected transposition of great
0.3945324186	promising results
0.3943247209	based on
0.3942264327	bradycardia requiring
0.3942173156	embase databases
0.3941679891	volume center
0.3941509526	postoperative permanent pacemaker
0.3941097708	hcn4 current
0.3937248859	ci 95
0.3936912470	classified into
0.3935000706	48 ¬† h
0.3934234992	january 2011
0.3933450726	duration of hospital stay
0.3933269134	ectopic pacemaker
0.3933029330	residual paravalvular
0.3931899935	undergoing mitral valve surgery
0.3931219761	ventricular electrode
0.3930242561	responsive pacing
0.3926421737	did not affect
0.3925876652	suspicion for
0.3924761156	predicted risk of mortality score
0.3923552119	valve endocarditis
0.3923380916	a single center
0.3922447029	red blood
0.3920920316	electronic device
0.3920363602	review of literature
0.3914919929	third degree avb
0.3914150425	differentiation of escs
0.3914105018	widely used
0.3913334820	nineteen patients
0.3911723629	safety outcome
0.3906912947	lead survival
0.3906765071	inward current
0.3905512669	days post procedure
0.3905317469	¬† ‚â§
0.3904520939	‚â• 50
0.3904027115	surgical outcomes
0.3902936889	whole cell
0.3901656002	early stages of
0.3901145933	intracardiac device
0.3900193454	compared with savr
0.3900072035	under local anesthesia
0.3898596279	access for transcatheter aortic valve replacement
0.3898258804	cut off value
0.3897711154	pacemaker systems
0.3897590314	n ¬† ¬† = ¬†
0.3897394993	high risk patients
0.3897290900	leadless pacemaker and subcutaneous implantable
0.3897188927	long term clinical outcomes
0.3897058979	analyses showed
0.3895745786	electronic device infection
0.3894028785	af detection
0.3893401587	clinical evaluation
0.3893249213	atrial tissue
0.3892534519	epicardial lv
0.3891866772	permanent epicardial
0.3891649640	categorized into
0.3891520124	pacemaker channel
0.3890344543	transvenous cardiac pacing
0.3889252650	hundred and forty
0.3887182306	interfere with
0.3887064760	cell function
0.3886987316	the university of
0.3886337480	transapical transcatheter aortic
0.3885624066	procedure related mortality
0.3883766293	early postoperative period
0.3880590736	p = 0.04
0.3880085797	appropriate icd therapy
0.3876546976	marvel 2
0.3875513858	translate into
0.3875072821	pre procedure
0.3873971906	cardiac complications
0.3871126664	do not
0.3870930246	cardiac implantable devices
0.3869657147	vena cava syndrome
0.3867517464	cied dysfunction
0.3866933076	this study
0.3865718549	resource use
0.3864299891	cardiac conduction abnormalities
0.3864187758	p value
0.3863836810	mri conditional pacemaker
0.3863180719	pacemaker stimulation
0.3862608738	mid term clinical
0.3861946003	cardiac electronic device
0.3861104293	low risk patients
0.3860714114	leadless micra
0.3859830468	pacing rate
0.3858468023	combined endpoint
0.3858128134	updated meta analysis
0.3857937557	thoracic artery
0.3856790599	surviving patients
0.3856526606	patients met inclusion criteria
0.3855487991	implant success
0.3855340984	society of thoracic
0.3854921030	30 day mortality
0.3854530575	p ‚ÄØ =
0.3850013632	the size of
0.3846572524	not fully understood
0.3846454420	paroxysmal atrioventricular
0.3843990798	aortic gradient
0.3843950542	clinical variables
0.3842531267	implantation success
0.3839868005	hemodynamic outcomes
0.3839753773	patch clamp technique
0.3838576544	unable to
0.3838348972	non phf
0.3834310162	channel expression
0.3833674768	a 7
0.3833042116	pacing electrode
0.3832477332	surgical aortic
0.3831145521	in situ
0.3830920468	these results suggest
0.3828859596	outcomes after transcatheter aortic valve implantation
0.3828471535	in 3
0.3827054989	presence or absence
0.3826179005	balloon expandable sapien 3
0.3825846965	the findings of
0.3825846965	the group with
0.3825284982	balloon expandable transcatheter heart
0.3825062076	permanent pm
0.3824198648	alternative to surgical aortic valve replacement
0.3823480198	differences in baseline characteristics
0.3823428865	more pronounced
0.3823424805	index of suspicion
0.3822832837	cardiac pacemaker function
0.3822791717	common complication
0.3822205792	attributed to
0.3821567270	atrioventricular nodal re
0.3816080156	29 mm
0.3810422865	per 100 person years
0.3809851657	an overview
0.3809599113	implantable cardioverter defibrillator therapy
0.3809543425	sapien 3 transcatheter heart valve
0.3809340649	transcatheter mitral valve
0.3807007841	post procedural complications
0.3805624660	underwent permanent pacemaker implantation
0.3804267509	clinical performance
0.3800607792	mouse small
0.3799451108	hospital outcome
0.3799019467	ventricular lead placement
0.3796927621	fetal heart
0.3796098227	infection rate
0.3796003733	or high surgical
0.3791138338	dwell time
0.3785680095	frequent complications
0.3782294275	to investigate
0.3781425886	atrial rate
0.3778265951	wave duration
0.3778208190	dm1 patients
0.3777652663	effective option
0.3777156758	dddr pacemaker
0.3776625689	led to
0.3773597995	catheter placement
0.3773517248	ventricular pacemaker lead
0.3771870296	pacemaker frequency
0.3770437330	check up
0.3766117590	thirty five
0.3764489900	increased risk of
0.3764228554	atrioventricular heart block
0.3763701116	an 84 year old
0.3763167073	cardiac implantable device
0.3759525931	effectiveness and safety
0.3756959288	with versus without
0.3756923851	cardiac pacemaker implantation
0.3756690953	surgical replacement
0.3756335533	leading to
0.3753851680	june 30
0.3753507462	all cause and cardiovascular mortality
0.3753056320	n ¬† ¬† = ¬† ¬†
0.3752773870	¬± sd
0.3752758331	at 30 days
0.3752602300	independent core
0.3752575175	hospitalized patients
0.3751707327	patient survival
0.3749790630	‚â• 65 years
0.3749258302	suffering from
0.3748990804	complicated by
0.3747106186	devices implanted
0.3745550577	new lbbb
0.3743713999	underwent transcatheter aortic valve implantation
0.3743506703	ii study
0.3741650452	mr conditional pacemaker
0.3741512994	independent predictive
0.3741398788	few studies
0.3740774200	to determine
0.3740651221	late period
0.3737242083	cardiac electronic devices
0.3736270318	subsequently underwent
0.3736009980	aimed to identify
0.3734723019	lv wall
0.3733375332	non sustained ventricular tachycardia
0.3732977310	outcomes of patients undergoing
0.3732417819	grade av block
0.3732388169	incorporated into
0.3731816548	p ¬† ¬† 0.05
0.3731457029	a total of
0.3729339390	the group of
0.3728912060	significantly higher than
0.3728063618	from january 2012 to
0.3725267485	acute stroke
0.3724494752	ecg revealed
0.3723649292	cardiovascular event
0.3722852304	pediatric heart
0.3721327762	months postoperatively
0.3721265034	fold increased
0.3720334677	concerns regarding
0.3719691920	the mayo
0.3719448387	in 10
0.3718033979	long term safety
0.3716119078	rva group
0.3715104044	induced bradycardia
0.3715004058	optimal treatment
0.3712704283	‚ÄØ ¬±
0.3712676464	cardiac ct
0.3710620403	well established
0.3708598053	overview of
0.3707188367	pacemaker induced
0.3707053046	related infective endocarditis
0.3706559763	mean euroscore ii
0.3706522062	this report describes
0.3706294000	median length of hospital stay
0.3705968124	expression analysis
0.3704892030	gated contrast
0.3701535509	circadian regulation
0.3700163244	no statistically significant difference
0.3699686080	serve as
0.3699237163	implantation site
0.3698254769	¬† ¬† = ¬† ¬†
0.3696737575	to better understand
0.3696691146	pacemaker like cells
0.3696619103	at least
0.3696222948	heart defect
0.3693934382	full recovery
0.3693654659	under general anesthesia
0.3692779698	patient level
0.3691485593	l type
0.3689821724	clinical parameters
0.3689189462	respiratory disturbance
0.3687197686	lv pacing
0.3686401542	lead age
0.3683764458	well known
0.3683540200	degree atrioventricular
0.3683108555	conduction system
0.3682547241	observational data
0.3680352349	of suspicion
0.3678498180	¬± 13 years
0.3678163441	non invasive
0.3678142032	regional wall
0.3675479111	dose dependent manner
0.3675073417	leading cause of
0.3672959707	sixty seven
0.3667327637	regardless of
0.3665092846	peak and mean
0.3664914196	self expanding transcatheter aortic
0.3664686333	doppler imaging
0.3664657917	p = 0.006
0.3661637854	sutureless and rapid deployment aortic valve
0.3659266946	in vitro and in vivo
0.3656114731	direct current
0.3655950421	new permanent pacemaker implantation
0.3655043312	study suggests
0.3654061805	standard therapy
0.3650997919	systemic right ventricle
0.3650706403	study participants
0.3650474485	postoperative ppm
0.3646462336	characterized by
0.3644946014	surgical extraction
0.3643568906	ventricular perforation
0.3643088605	entered into
0.3643057074	between april
0.3640320680	implantation techniques
0.3640198270	role in regulating
0.3639947035	mouse sinoatrial
0.3638444135	atrial leads
0.3637783775	a 20
0.3635392387	baseline and at
0.3633989040	at discharge and at
0.3632861170	new york heart association functional
0.3631545354	device insertion
0.3631359685	governed by
0.3631133913	high risk for surgery
0.3628492206	angiography revealed
0.3628369824	the odds of
0.3627613423	ventricular ejection fraction
0.3626369824	the practice of
0.3626033586	hospitalization for hf
0.3624285327	rationale and design
0.3623657259	one patient died
0.3623316269	undergoing lead extraction
0.3622238196	previous study
0.3622104048	leads extracted
0.3621777011	sleep related
0.3620621788	old gentleman
0.3620186687	left ventricular mass
0.3619692786	first attempt
0.3619473862	pacemaker potential
0.3616804868	in 2
0.3615969648	purkinje system
0.3615958816	clinical predictors
0.3615189128	cardiac muscle
0.3613798589	balloon expandable sapien
0.3611155712	medtronic evolut r
0.3610389847	mean arterial pressure
0.3610054956	significant decrease
0.3609773417	new generation devices
0.3607463029	fontan patients
0.3606979192	mean difference
0.3606411034	patients experienced
0.3604345206	greater risk
0.3603977638	first degree
0.3602644732	major stroke
0.3602392820	events occurred
0.3601730205	tr ‚â•
0.3601529244	independently associated with
0.3600493369	a study of
0.3598282130	years of follow up
0.3595392387	implantation and at
0.3595050880	amiodarone use
0.3593661213	crt d and crt p
0.3593431479	synchronous pacing
0.3592958901	lvef 35
0.3592631762	cied leads
0.3592420755	micra transcatheter pacemaker
0.3590866738	significantly lower than
0.3588931818	dual chamber pm
0.3587422125	lead threshold
0.3585389951	p = 0.023
0.3585348289	successful implantation
0.3584988191	and complications in
0.3583914545	in light of
0.3583691341	right coronary artery
0.3582916966	invasive technique
0.3582896751	6 weeks
0.3574292694	transcatheter aortic valve in valve
0.3573787755	p = 0.007
0.3570950113	specific absorption
0.3569865418	accounting for
0.3569820679	most commonly
0.3568369824	the complications of
0.3568322749	cardiopulmonary bypass time
0.3567950012	subjective day
0.3566080886	forty eight
0.3564598021	patients required
0.3563573837	treated patients
0.3563266337	p ¬† = ¬† 0.02
0.3561620661	resulted in
0.3561519390	valve operation
0.3559725770	new left bundle branch block
0.3559651018	safe procedure
0.3558170808	case suggests
0.3558136615	emerged as
0.3557224977	minimally invasive surgical
0.3556420316	human cardiac
0.3556263402	study evaluates
0.3554675496	bundle branch pacing
0.3553999695	the behavior of
0.3553342705	100 patient years
0.3549962025	pediatric and congenital heart
0.3548140045	the care of
0.3548131607	independent risk factor
0.3548041466	explained by
0.3546752755	mm corevalve
0.3543981282	in 4
0.3542673235	pacemaker battery
0.3542573124	prognostic value
0.3542367073	sustained atrial fibrillation
0.3542074664	cord injury
0.3541611109	months of age
0.3540414816	interplay between
0.3540157851	between january 2010 and
0.3539598174	torsades de
0.3538945971	edwards sapien 3 valve
0.3538433322	total mortality
0.3537635222	depend on
0.3536723417	successful treatment
0.3535712742	right ventricular apex
0.3533999695	the objectives of
0.3533730224	aware of
0.3530231581	patients undergoing isolated
0.3527473651	dual chamber permanent pacemaker implantation
0.3520744246	indications included
0.3519785180	pacing output
0.3518231526	valve gradient
0.3517589126	successfully treated with
0.3516701475	within 30 days
0.3516506924	pacing dependent
0.3514869177	significant difference
0.3514706494	death rates
0.3513459241	varc 2 criteria
0.3512040235	patients with symptomatic severe
0.3511894750	critically ill patients
0.3507345712	classified as
0.3504168381	less than
0.3504095093	hundred and twenty
0.3500033664	48 h
0.3500004480	procedural data
0.3499790978	clinical evidence
0.3499154751	compared with
0.3498460992	case describes
0.3498177278	initial implantation
0.3497788371	increased risk of developing
0.3497665028	twenty seven
0.3496575726	permanent transvenous
0.3496082156	model based
0.3495884440	single chamber pacing
0.3494037470	p ¬† 0.01
0.3491105382	as follows
0.3490201927	multiple logistic
0.3487745908	r wave sensing
0.3486265693	patients met
0.3485785480	onset left bundle
0.3485697379	resynchronization device
0.3485496263	intrinsic heart
0.3484612339	activated protein
0.3482547057	postoperative course
0.3482473435	the only independent predictor
0.3482355626	review and meta analysis of
0.3481449731	forty six
0.3480125739	real world data
0.3478139286	eighteen patients
0.3477824809	self expanding prosthesis
0.3477051536	ecg showed
0.3474447078	hazard model
0.3474281469	a 3
0.3473494920	fibrillation ablation
0.3473012517	important implications for
0.3468557984	a 12
0.3465018005	intra aortic
0.3464696687	group b
0.3464388565	required ppm
0.3462973328	vein isolation
0.3462106036	balloon expandable and self
0.3460305351	such as
0.3460303956	year old lady
0.3457635533	heart rate control
0.3456580299	rate ratio
0.3455052894	1 year
0.3453858246	ablation for atrial fibrillation
0.3453479002	imaging studies
0.3452561462	risk of electromagnetic interference
0.3452533796	underwent minimally invasive
0.3452313633	inpatient database
0.3448074518	between january 2012 and
0.3447902235	thirty day outcomes
0.3444984227	¬± 12 years
0.3442772585	us guided
0.3439425373	area under
0.3438540790	the national inpatient sample database
0.3438062096	kg m
0.3436833663	mid term results
0.3433005291	conventional surgery
0.3432246639	the suprachiasmatic nucleus
0.3429240593	long term complications
0.3428077778	intracardiac lead
0.3425968504	access related complications
0.3425302095	disturbances requiring
0.3424053118	to compare
0.3422861110	to treat
0.3420928646	and 5
0.3420523221	of tavr in
0.3420275835	risk of sudden cardiac death
0.3418592680	accounted for
0.3418374302	mild paravalvular
0.3417765683	3 dimensional
0.3416178938	inpatient sample
0.3413513713	the national inpatient sample
0.3413371007	crt p recipients
0.3412728766	mechanical complications
0.3408817478	individual differences
0.3408651922	chronic chagas
0.3407913834	working group
0.3407442655	consecutive patients underwent
0.3403252577	complications included
0.3402786007	associated with
0.3402556300	compared to
0.3402113089	early complications
0.3398213500	positive predictive
0.3397612106	examination showed
0.3397276722	sinoatrial pacemaker
0.3396393085	patients underwent tavr
0.3394404263	cardiac imaging
0.3394016494	coronavirus disease
0.3391219522	the human circadian pacemaker
0.3390968121	2010 and december
0.3390381645	treatment groups
0.3390305300	p = 0.043
0.3389442249	into pacemaker ‚Äë like
0.3386474985	left coronary
0.3385117490	pacemaker infection
0.3383485220	¬† ml
0.3383164719	reported cases
0.3382447631	between baseline and
0.3381193539	computer simulation
0.3378481282	a 5
0.3378244332	¬† 000
0.3377422330	n terminal
0.3377167593	implantable cardiac electronic
0.3376537430	pacemaker cardiomyocytes
0.3372948313	pacing capture
0.3371826879	non responders
0.3371270157	independent risk factors for
0.3370609311	direct oral
0.3370271129	mitral valve in valve
0.3370204180	p = 0.013
0.3364530493	forty five
0.3363979202	open heart
0.3360225933	systemic ventricular
0.3359847273	retrospective data
0.3359075186	af incidence
0.3359058817	covid 19 infection
0.3358430417	p value 0.001
0.3356732504	months after operation
0.3356491426	pacemaker dysfunction
0.3355384371	all cause and cardiovascular
0.3355271088	single center retrospective
0.3353404500	p ‚ÄØ = ‚ÄØ 0.002
0.3352705039	a pm and
0.3352605853	under conscious sedation
0.3351635735	significant predictors
0.3351580219	i2 =
0.3351349952	gastric pacemaker
0.3351275869	¬± 6 years
0.3349972760	the great arteries
0.3349879654	care center
0.3349829904	‚Äë like cells
0.3348933748	disorder characterized by
0.3348339750	device implant
0.3347327735	3d mapping
0.3346951381	health related
0.3346431707	data analysis
0.3346308124	influenced by
0.3346206447	showed similar
0.3344320558	history of malignancy
0.3343112825	thirty patients
0.3342777423	1.5 t mri
0.3342680083	the only predictor
0.3342586813	cardiac stimulation
0.3342469159	12 months
0.3341076674	pacing electrodes
0.3337432097	aortic valve gradient
0.3333035471	consisted of
0.3331297673	month follow up
0.3331221197	electrical devices
0.3330127498	patients requiring
0.3328873906	data obtained
0.3326582903	pacemaker clinic
0.3326158623	cardiomyocytes derived from
0.3325932198	very low
0.3325711986	unusual presentation
0.3325330095	ventricular systolic function
0.3323281054	failed aortic
0.3322502996	per year
0.3320347270	adjusting for age
0.3318399140	seventy four
0.3317926977	average number
0.3317348033	treated with
0.3317149529	one year
0.3314252811	between january 2014 and
0.3313736900	6 ¬† months
0.3312976907	p = 0.016
0.3312813806	elevated risk
0.3308726223	external pacemaker
0.3308695974	clinically indicated
0.3307497585	implantable electrical device
0.3304506392	assist devices
0.3303225706	widespread use
0.3303151816	pacemaker lead induced
0.3302513190	lead ecg
0.3301531019	whole cell patch
0.3301297996	¬± 8 years
0.3300172941	end points included
0.3299646886	implantable cardioverter defibrillator leads
0.3297751947	1.5 t
0.3297468909	primary cardiac
0.3296099875	cardiac syncope
0.3295559921	expandable valve
0.3295532482	device registry
0.3292846445	the master circadian
0.3291919674	versus standard
0.3291441927	clinical study
0.3289314453	device performance
0.3287651840	pacemaker tissue
0.3287567608	circadian gene
0.3287517805	thirty six
0.3286063656	single patch
0.3285743980	between january
0.3285285847	pre existing right bundle
0.3281291304	in hospital mortality
0.3280720008	clinically useful
0.3280566710	lead management
0.3280070209	right and left
0.3275466837	thirteen patients
0.3274811910	thirds of
0.3274158026	related adverse
0.3272835119	originating from
0.3271857453	to identify
0.3271560042	cied mri
0.3271089673	hr =
0.3267742621	similar outcomes
0.3266720176	patients without pre existing
0.3265376559	immediately after
0.3265319390	impact on
0.3265038265	system for cardiac operative risk evaluation
0.3264624804	consists of
0.3264441036	forty nine
0.3263250265	patient related
0.3259406669	impaired left ventricular
0.3257925339	1 year mortality
0.3257778052	related endocarditis
0.3256676775	well recognized
0.3256539901	life threatening complications
0.3255495212	savr in low risk patients
0.3254196372	defibrillator implant
0.3254118622	regression analysis showed
0.3253598147	24 h holter monitoring
0.3251992400	serious adverse
0.3251239784	thirty four
0.3250259913	isolated tricuspid valve
0.3249844889	severe symptomatic
0.3249532819	¬† ¬†
0.3248545898	sixty nine
0.3247809036	structural valve
0.3247536050	150 ms
0.3246412330	2 +
0.3245322851	device implantation procedures
0.3244275593	both groups
0.3243149324	during and after
0.3239503038	pediatric patient
0.3238717951	higher likelihood
0.3238293435	of hcn2 and
0.3234077872	10 Œºm
0.3232034708	ppi after tavi
0.3227009005	= ¬† 0
0.3225925353	t type ca
0.3225550628	and 12
0.3225529423	adult congenital heart
0.3224058349	the nationwide inpatient sample
0.3223395353	clinical outcomes after transcatheter aortic
0.3222450344	undergoing transcatheter
0.3221472325	postoperative af
0.3220620149	driven by
0.3218974248	stratify patients
0.3217566490	risk for developing
0.3216396703	days post tavr
0.3215966664	re intervention
0.3215901453	controlled study
0.3215476907	p = 0.018
0.3213334736	¬† beats min
0.3211221162	become increasingly
0.3210366460	study group
0.3203905603	transcatheter pacemaker
0.3203294630	at 2
0.3202130957	sapien 3 valve
0.3200594790	ventricular lead perforation
0.3198996246	n methyl d
0.3197191667	following transcatheter aortic valve implantation
0.3194769850	cardiac resynchronization therapy pacemaker
0.3194039907	implantable medical
0.3193908212	concern about
0.3193855640	this case
0.3193722219	6 months
0.3191181840	an independent predictor of
0.3189546728	degenerated surgical
0.3189492144	congenital central
0.3188727285	heart defects
0.3187687155	sapien 3 valves
0.3187308544	‚â• 90 years
0.3186332603	activity dependent
0.3183005673	median length of stay
0.3181506827	new onset af
0.3179697495	cardiac device related
0.3175829228	high success rate
0.3175740421	the united
0.3175315738	per minute
0.3175187954	node cells
0.3173375792	years and older
0.3172867928	rank test
0.3172658951	acute renal
0.3171329765	outcomes of interest
0.3170331204	nyha functional
0.3170095095	data exist regarding
0.3168749119	crt pacemaker
0.3168034794	chamber pacemakers
0.3166373252	both sexes
0.3165090761	a v block
0.3164461856	preoperative conduction
0.3162954812	surgical aortic valve replacement in low
0.3162510087	outcomes of transcatheter aortic
0.3161490758	p = 0.042
0.3159917075	transplant free
0.3157366096	to avoid
0.3157193999	patients suffered
0.3156710102	and mortality of
0.3155572996	follow up period
0.3154712497	functional class iii
0.3153027821	2011 to 2014
0.3152256433	and 6
0.3151826381	fifty five
0.3151437074	documented af
0.3149832427	undergone pacemaker implantation
0.3149275148	improved quality of life
0.3148710102	of arrhythmia and
0.3146646168	case study
0.3145591604	¬± 9 years
0.3143642551	scoring system
0.3141936423	with respect to
0.3141412860	less frequent
0.3140823115	early and late outcomes
0.3139156723	underwent transcatheter aortic valve replacement
0.3138317451	the primary endpoint
0.3137515943	focused on
0.3137052528	isolated left
0.3136297207	higher frequency
0.3131003413	mediated syncope
0.3130587457	conditional cardiac implantable electronic devices
0.3128492547	imaging revealed
0.3126157615	related death
0.3125893811	independent predictors of ppi
0.3125524874	work up
0.3123997789	more often
0.3122747242	pacemaker population
0.3121442106	years old
0.3120487071	racial disparities in
0.3120335695	72 hours
0.3119315552	site infection
0.3116772352	a 67 year old
0.3115320079	unclear whether
0.3114952992	cied function
0.3113928632	late outcomes
0.3113714392	transient left
0.3112755220	normal sinus
0.3104055900	haemodynamic results
0.3103559793	january 1
0.3103093341	excellent long term
0.3101143084	conditional pacemakers
0.3097926454	this subgroup of patients
0.3095753863	single photon
0.3094927890	study aimed
0.3094376974	did not reach
0.3092837508	rely on
0.3088670535	hospital death
0.3087508118	regarded as
0.3085617501	underwent avr
0.3082319114	pacing therapy
0.3081376222	did not receive
0.3081303609	cardiac defibrillator
0.3079894670	in 16
0.3077567269	an effective alternative
0.3076620693	regulated by
0.3076022739	differentiate into
0.3074686330	more prevalent
0.3071524356	the purpose of
0.3070632719	five hundred
0.3069686304	cardiac injury
0.3068598234	pacemaker implantation following transcatheter aortic valve
0.3068258455	a 2
0.3067895076	population based cohort
0.3066862278	between january 2009 and
0.3064253005	cardiac electrical
0.3063492710	of icc in
0.3062995828	balloon expandable transcatheter aortic valve
0.3062867169	pacemaker or icd implantation
0.3061362030	lead extraction procedure
0.3056568160	between january 2008 and
0.3054600490	developed complete heart block
0.3053709187	30 day and 1 year
0.3053576032	transcatheter valve in valve
0.3050741086	months later
0.3049257597	patients undergoing lead extraction
0.3047305458	preoperative atrial fibrillation
0.3045896187	bioprosthetic tricuspid
0.3044632733	the most common
0.3043074771	duration of hospitalization
0.3041846799	undergoing surgical aortic valve replacement
0.3038075357	between october
0.3036552250	related infective
0.3035427212	both genders
0.3033197922	p = 0.017
0.3032928946	= ¬† 0.003
0.3031525902	implantable pacemaker
0.3029961906	left side
0.3029893529	outcomes included
0.3028906957	cell death
0.3026346555	electrocardiographic changes
0.3026267083	more likely to
0.3025441777	rv leads
0.3025138349	vascular complications occurred
0.3024247652	cardiac arrest induced
0.3022665541	activity levels
0.3022488959	to achieve
0.3021885346	implanted pacemaker
0.3021799072	icd lead
0.3021404648	patients with severe symptomatic
0.3021320304	adjusted risk
0.3021126900	response to crt
0.3020309379	normal heart
0.3019390117	cell derived cardiomyocytes
0.3019015166	study groups
0.3018739854	30 ¬† days
0.3018233260	per 100 person
0.3017883266	12 month
0.3016820412	risk evaluation
0.3016433008	pacemaker rhythm
0.3015176091	response to cardiac resynchronization therapy
0.3014683506	af group
0.3013259320	comparable between groups
0.3012571951	three hundred
0.3012060127	feasible option
0.3011394614	fibrillation episodes
0.3010782210	defibrillator therapy
0.3010147173	leadless cardiac
0.3009472348	cied implant
0.3008563148	‚â§ 40
0.3008293579	a 15
0.3008164752	results reveal
0.3006341686	patients with single ventricle physiology
0.3003268120	‚â• 20
0.3002559458	pacemaker or icd
0.3002422943	between tavr and
0.3001558709	long term effect
0.3001556019	well described
0.3001278527	120 ms
0.2998712768	recurrent episodes
0.2997872061	implantation of cardiac implantable electronic devices
0.2997632529	implantation rates
0.2996938555	p = 0.040
0.2996656984	clamp technique
0.2995509983	p = 0.020
0.2994337216	ppm rate
0.2994180775	academic research consortium 2
0.2993985973	the study period
0.2993540508	preoperative af
0.2990770434	of 30
0.2990176272	self expandable valve
0.2988029909	related complications occurred
0.2987762974	ventricular pacemaker
0.2985825031	paced group
0.2985323229	self expanding transcatheter aortic valve replacement
0.2983471017	mean transprosthetic
0.2983024780	inoperable patients
0.2980561764	bicuspid as
0.2980018838	outcomes of transcatheter aortic valve implantation
0.2979630407	young patients
0.2978339478	first line treatment
0.2976586118	prolonged qrs
0.2975793269	a 1
0.2971260805	and death in
0.2971146562	pacemaker related
0.2969215785	similar between groups
0.2969144959	a systematic review and meta analysis
0.2967135807	consisting of
0.2965542945	23 mm
0.2964120902	at 30 ¬† days
0.2963718326	recent years
0.2963037247	significant pocket hematoma
0.2960164096	symptoms of heart failure
0.2959541755	these findings
0.2958520993	retrospective study included
0.2958403654	propensity score matching resulted in
0.2957766109	‚ÄØ h
0.2957651965	stable pacing
0.2956524403	composed of
0.2956401066	p = 0.014
0.2956324140	link between
0.2956317916	long term pacing
0.2955550628	and 24
0.2954928479	block after transcatheter aortic valve replacement
0.2954909663	pacing failure
0.2954817548	¬± 13.1
0.2954649829	12 ¬† hr
0.2953487655	cardiopulmonary bypass times
0.2951784709	pacemaker and defibrillator implantation
0.2951121943	crt device
0.2949066819	arising from
0.2947701708	weeks after implantation
0.2947112132	‚â• 65
0.2947015584	30 days
0.2946933286	a strong predictor
0.2946696336	of mortality and
0.2945289158	pacemaker current
0.2944801128	early death
0.2941428173	¬± 6.2 years
0.2940233747	catheter ablation of atrial fibrillation
0.2940086136	pacemaker implantation in neonates
0.2938333725	device surgery
0.2937266482	does not appear
0.2936938572	between september
0.2936674264	leadless transcatheter
0.2936614389	patient years
0.2936374835	children with congenital
0.2935263873	block requiring pacemaker implantation
0.2934449029	12 ¬† months
0.2933233216	in 19
0.2932886273	requiring pm
0.2932696259	pacemaker lead extraction
0.2931056800	mean patient age
0.2930185734	postoperative atrioventricular block
0.2929426058	in 17
0.2928231889	ranged between
0.2927450724	scn neuronal
0.2927376267	clinical af
0.2926540797	across species
0.2926504695	high risk patients undergoing
0.2924223834	main indications for
0.2923070271	major adverse cardiac
0.2923055591	versus transapical
0.2922770063	pacemakers implanted
0.2921446019	an implantable cardioverter defibrillator
0.2921299904	prospective data
0.2919660005	‚â§ 21
0.2917314500	cohort included
0.2917043612	an implantable loop recorder
0.2916394111	paced patients
0.2916249574	f wave
0.2914584285	p = 0.049
0.2911510948	procedures performed
0.2911385121	treated with antibiotics
0.2910399430	chd patients
0.2909775551	hypertensive patients
0.2902107397	pediatric patients
0.2901227396	died in hospital
0.2900736310	patients with severe aortic valve stenosis
0.2900724105	new pacemaker implantation
0.2900485068	head up
0.2899864635	patient reported
0.2898600046	lower risk patients
0.2898338588	prior af
0.2897625240	significant correlation
0.2896198440	high index of suspicion
0.2894975700	p ¬† = ¬† 0.003
0.2894055279	after alcohol septal ablation
0.2890087327	hr ¬† = ¬†
0.2890061837	mice showed
0.2889402036	tavr patients
0.2889380043	fifty four
0.2889333314	underwent ppm implantation
0.2887671251	to savr in
0.2886707671	of arrhythmology and
0.2886535773	an attractive
0.2884566478	aged 65
0.2883819480	more than
0.2882175782	between 2011 and 2015
0.2881787196	related to
0.2881171404	pacemaker replacement
0.2880683348	ventricular rhythm
0.2879831878	risk patients with symptomatic severe
0.2879291152	ventricular systolic dysfunction
0.2878521837	analysis comparing
0.2877456887	freedom from atrial fibrillation
0.2877200053	ml m
0.2874700596	moderate or higher
0.2873167934	significant arrhythmias
0.2871573330	re savr
0.2870663554	the danish pacemaker and
0.2870300308	e e
0.2869268664	increasing age
0.2867911705	aortic valve replacement in low risk
0.2866750343	venous pressure
0.2866453640	120 ¬† ms
0.2866424445	induced ca
0.2865057858	amenable to
0.2864771044	experimental results
0.2862835895	block requiring permanent pacemaker
0.2861698947	tavr procedures
0.2860923220	new york heart association class iii
0.2859022168	new ppi
0.2858544419	history of af
0.2855609430	lead type
0.2853204898	sought to
0.2852347347	symptomatic sinus
0.2851548393	tavr procedure
0.2851391699	between january 1
0.2850614181	left atrioventricular
0.2850446390	¬± 10 years
0.2849904227	a 54 year old
0.2849407540	of 22
0.2848189696	p ¬† = ¬† 0.008
0.2845707787	compared to controls
0.2845243867	chronic obstructive
0.2845151990	and 2
0.2844748266	patients with implanted cardiac devices
0.2843824628	common complications
0.2843646800	midterm follow up
0.2842403233	lead characteristics
0.2842195976	pacemaker and defibrillator leads
0.2837234006	this study evaluates
0.2836407133	lvef ‚â§
0.2835725532	atrial pacemaker
0.2834089767	and 10
0.2831903878	required pacemaker implantation
0.2831041455	device function
0.2830918306	well understood
0.2829941398	absorption rate
0.2828476511	forty four
0.2826042890	¬± 0.2
0.2825176351	ddd pacemaker
0.2824844506	whole cell patch clamp technique
0.2824721063	¬† kg m
0.2823545156	daily activity
0.2822424408	required temporary
0.2822226528	lead implant
0.2821673839	180 days
0.2821430460	cardiac surgical
0.2820834193	referred to
0.2817178362	before and after
0.2815972641	report describes
0.2814782137	severe heart failure
0.2814601255	year old female
0.2814328253	from january
0.2814324295	a 63 year old
0.2814094721	health care system
0.2814065694	compared to rvp
0.2812892412	to examine
0.2812281258	outcomes of transcatheter aortic valve replacement
0.2811872283	procedural complication
0.2811566908	no statistically significant differences
0.2811471184	undergoing transfemoral
0.2811020204	twenty nine
0.2808009675	and savr in
0.2807509812	in order to avoid
0.2805217304	background noise
0.2804950933	designed to evaluate
0.2804705481	cied procedure
0.2803667619	p = 0.036
0.2801337901	transapical transcatheter aortic valve
0.2799883345	mid term follow up
0.2799814624	term outcomes
0.2798402759	related mortality
0.2798187749	showed significant
0.2797169758	lower rates of
0.2797008357	continues to
0.2794693895	and 14
0.2794007466	versus balloon expandable
0.2792270560	p = 0.028
0.2789179972	data support
0.2786532748	relies on
0.2786494879	the european heart rhythm association
0.2785927667	p = 0.009
0.2785630946	underwent redo
0.2785451282	higher than
0.2784554094	twenty eight
0.2784245026	investigated whether
0.2783972062	implanted device
0.2783747403	self expanding transcatheter
0.2782381120	‚â• 40
0.2780144783	p = 0.048
0.2779890402	co morbidity
0.2779365069	appears to
0.2776880213	non apical
0.2774956432	shortly after
0.2768814861	post ppm
0.2767260312	¬± 14 years
0.2766590128	at least one
0.2765566808	activated k
0.2765286124	identified as independent predictors
0.2763362977	4 weeks
0.2763220960	an uncommon complication
0.2758839339	circadian timing system
0.2756939909	lower baseline
0.2752021748	independent predictors for
0.2751439615	in 13
0.2751149335	single ventricular
0.2749620191	compared to savr
0.2749608621	lead induced
0.2749514906	tachycardia syndrome
0.2749101498	thirty three
0.2748383354	new ppm
0.2747263864	at baseline
0.2745667269	atrial and ventricular leads
0.2745552949	p = 0.010
0.2745379531	new onset conduction disturbances
0.2744038962	findings indicate
0.2742346497	undergoing surgery
0.2740117227	followed by
0.2739556759	risk of death
0.2737765919	between tavi and
0.2737519717	underwent surgical
0.2735544377	12 month follow up
0.2735329038	high grade av
0.2732963402	a 48 year old
0.2732347005	non ischaemic
0.2731453651	twenty six
0.2729322046	lbbb after tavi
0.2726456762	more common
0.2726332387	left ventricular diastolic
0.2724717652	outcomes of transcatheter
0.2724590668	study included
0.2724264667	requiring permanent
0.2723587111	high risk patients with severe
0.2722644783	p = 0.022
0.2722482294	additional risk
0.2722203677	re hospitalization
0.2720989993	a 24
0.2720557930	¬± 9.3
0.2720248898	ppi after tavr
0.2720216400	icd crt d
0.2719761126	improve outcomes
0.2719461069	matched population
0.2717459507	valve bioprosthesis
0.2716799314	hcm patients
0.2715581519	deep vein
0.2715580576	control groups
0.2713126780	significantly higher among patients
0.2710225185	management of cardiac implantable electronic
0.2708511577	commonly seen
0.2706902291	lv systolic
0.2706763608	right superior vena cava
0.2705446852	the primary end point
0.2705416504	thought to
0.2704645686	cardiac cells
0.2704280188	pacemaker implantation for sick sinus syndrome
0.2703280644	pacemaker indications
0.2703157460	the same
0.2702445433	p ¬† = ¬† 0.002
0.2701242070	a 71 year old
0.2700591582	frequent complication
0.2699650448	study aims to investigate
0.2698438204	auc =
0.2697375331	in ¬† vitro
0.2696739736	remote follow up
0.2696381762	the 2
0.2694984776	severe paravalvular leakage
0.2693886728	no statistical difference
0.2692673776	lower in hospital mortality
0.2692471747	expression of genes
0.2691443910	patients undergoing transcatheter
0.2689426284	down syndrome
0.2688095392	p = 0.012
0.2687607342	children with pacemakers
0.2687385531	lotus valve system
0.2686012162	¬± 6.7
0.2684872544	still unclear
0.2683855991	three dimensional echocardiography
0.2683329398	signs of infection
0.2679976956	working group on
0.2679631407	after cardiac surgery
0.2678496519	leadless device
0.2678100259	pacemaker mechanisms
0.2678097860	prohibitive surgical
0.2677727280	right anterior mini
0.2677591346	recurrent episodes of
0.2676144463	underwent aortic valve replacement
0.2675434691	¬± 11
0.2674387181	a 57 year old
0.2673384226	currently available
0.2672192181	cardiac conditions
0.2671410163	risk factors for
0.2671020614	an important
0.2669358799	admitted to
0.2666841486	well defined
0.2666378211	serves as
0.2665846342	a single institution
0.2663512265	cardiac sodium
0.2663379488	ventricular response
0.2663298279	the aim of
0.2662721200	patients treated
0.2662555276	higher in hospital mortality
0.2662248142	undergoing isolated
0.2661234527	de novo crt
0.2660792798	into pacemaker like cells
0.2660727804	lvef 50
0.2660478989	underwent ppi
0.2660367328	white blood
0.2659002973	expanding valve
0.2658542405	first line therapy
0.2656832211	at low surgical risk
0.2654423072	not statistically different
0.2653952469	lv leads
0.2653675271	not significantly different
0.2653605773	a systematic review
0.2652799642	between march
0.2652568655	acts as
0.2652119118	funded by
0.2650559648	p = 0.045
0.2650490857	classified according to
0.2648828479	no differences
0.2647816702	g m
0.2647336259	prior to
0.2645958939	a dual chamber pacemaker
0.2645801116	peak oxygen
0.2644910960	increased risk of stroke
0.2644465447	statistically significant difference between
0.2643367156	hemodialysis patients
0.2642514252	patients with aortic stenosis
0.2642229451	p = 0.041
0.2642219209	increased heart rate
0.2641012932	cohort studies
0.2640863391	undergoing aortic valve replacement
0.2640687118	¬± 9.1
0.2640076603	left atrial volume
0.2639461526	one patient
0.2639225389	events committee
0.2638935910	independent predictors of mortality
0.2638542092	‚â• 90
0.2638503351	analysis demonstrated
0.2637755421	late complications
0.2637152868	implantable electronic
0.2636405332	long term follow up data
0.2633654540	twenty five
0.2632977061	underwent surgery
0.2631909685	cause of death
0.2630992131	female patients
0.2630966841	a single centre
0.2628440428	related tr
0.2627735929	generated by
0.2627071217	pacemaker potentials in cultured
0.2620445326	pacemaker or defibrillator implantation
0.2620133786	expression of hcn4
0.2617316168	adult patients
0.2617180758	rr =
0.2616854884	permanent pacemaker lead
0.2613552102	associations between
0.2612192151	effects on
0.2611027083	number of
0.2610452159	¬± 4.4
0.2610045868	procedural and 30 day
0.2608129740	long term results
0.2608067359	30 day readmissions
0.2606809648	p = 0.034
0.2604234548	including death
0.2603030240	age group
0.2601102861	conduction system pacing
0.2601098754	longer than
0.2600355212	affected by
0.2600215374	older patients
0.2599603343	grade atrioventricular block
0.2599258472	p = 0.021
0.2597680484	median follow up period
0.2597228918	0.4 ¬† ms
0.2596798666	type 1
0.2596225452	pacemaker patients
0.2595441686	trend toward
0.2595301978	resolution of symptoms
0.2593761025	induced syncope
0.2593464783	positively correlated with
0.2591382802	transcatheter valve therapy
0.2591178813	back up
0.2590913668	p = 0.046
0.2590045031	self reported
0.2587451236	‚â• 75
0.2586995462	further studies
0.2583666582	l min
0.2582206879	significantly higher rates of
0.2580302620	faster than
0.2579952961	submitted to
0.2578463656	presence of
0.2577995790	this retrospective study
0.2577790683	of 6
0.2577756766	studies including
0.2577666019	results demonstrate
0.2577229208	very small
0.2576865199	undergoing pacemaker implantation
0.2575345232	risk of sudden death
0.2575289217	patients with cieds
0.2574850265	patient required
0.2574765846	¬± 7.6
0.2574076868	severe aortic stenosis undergoing
0.2573098485	predictive value
0.2572480310	atrial cells
0.2572041115	predictors of permanent pacemaker implantation
0.2569771088	nodal cells
0.2567013268	p = 0.035
0.2563222237	pacemaker endocarditis
0.2561661440	30 kg m
0.2560784663	¬± 10.7
0.2559983142	severe paravalvular leak
0.2558761938	excellent results
0.2558445782	did not differ between
0.2555690700	very few
0.2554854341	compared with rvp
0.2554425542	overall survival
0.2551791569	acurate neo transcatheter
0.2551645316	significant difference between
0.2551609639	occurring within
0.2551583660	cells of cajal
0.2551557524	hospital cardiac arrest
0.2551466256	year period
0.2550587584	average length
0.2549828222	in 1
0.2549753797	tga patients
0.2549738050	and 1
0.2549631854	differences between
0.2549260499	logistic regression analysis showed
0.2548903323	‚â• 2
0.2548530108	atrioventricular block requiring permanent pacemaker
0.2546563900	a 28 year old
0.2545600874	a 60 year old
0.2545578695	retrospective cohort
0.2545184721	latest follow up
0.2543714957	factors including
0.2542815061	according to varc 2 criteria
0.2536809648	p = 0.011
0.2535814666	similar between
0.2535457254	suffer from
0.2535411697	underwent lead extraction
0.2535317889	society of thoracic surgeons predicted
0.2534094385	p = 0.027
0.2533804982	at 5
0.2533567025	¬± 3.1
0.2531587099	safety and performance
0.2530420936	an independent predictor for
0.2530343718	four hundred
0.2530254757	successfully underwent
0.2530196325	chamber pacing
0.2529763494	interaction between
0.2528942935	between june
0.2528627490	postoperative permanent pacemaker implantation
0.2528423431	pacemaker implantation after transcatheter aortic valve
0.2528392113	near syncope
0.2525496178	pacemaker dependent patients
0.2524417635	in 5
0.2524279526	p = 0.025
0.2524129817	performed to identify
0.2524106366	used to treat
0.2523147791	included studies
0.2523042766	the first reported case
0.2521351812	response to light
0.2519802416	cieds implantation
0.2517728019	the german aortic valve registry
0.2517282091	pre implantation
0.2516596613	registry included
0.2516553673	less likely to
0.2515512499	cardiac specific
0.2515116315	10 mg kg
0.2514435036	results confirm
0.2509841207	with or without
0.2507891956	block persisted
0.2507805684	recovered well
0.2506693446	prior to discharge
0.2505684449	motion abnormalities
0.2504088669	this study aimed
0.2503279006	‚â• 5
0.2503066583	patients treated with crt
0.2502943642	access to mri
0.2502696878	relating to
0.2499869453	further research
0.2499660941	¬± 0.6
0.2498919929	hocm patients
0.2497187817	italian association of
0.2496962926	at discharge
0.2494351676	self expanding valve
0.2493778815	this case report
0.2493626998	secondary to
0.2493543080	unknown origin
0.2493001471	resulting in
0.2492155701	hazard analysis
0.2490896862	24 h holter
0.2489947072	d transposition
0.2489054419	of 8
0.2488965248	patients with cardiovascular implantable electronic devices
0.2485839753	6 month
0.2485301870	non rva pacing
0.2484522831	similar in hospital mortality
0.2484320591	every 6 months
0.2484169402	5 year survival
0.2484086678	a 46 year old
0.2483958134	performance and safety
0.2483589451	freedom from death
0.2482822621	follow up data
0.2481692548	likely to receive
0.2479540613	tavi patients
0.2479459179	free solution or
0.2478611677	post pacemaker implantation
0.2478150978	obstructive pulmonary
0.2477869613	within 30 ¬† days
0.2477803255	a 68 year old
0.2477733104	cied lead
0.2477366787	equipped with
0.2477241286	gated channel 4
0.2476763791	linked to
0.2474483883	non mr conditional
0.2474450126	all patients
0.2473245821	presented with
0.2472956075	type 0
0.2472801948	a novel
0.2470833888	pacemaker implantation after tavr
0.2469893519	0.5 ms
0.2468871354	70 bpm
0.2468470171	in 8
0.2467984765	chronic pacing
0.2467790683	of 5
0.2466923862	with preserved ejection
0.2466202746	day length
0.2465107430	¬± 0.9
0.2464281890	this topic
0.2463651909	cardiac intervention
0.2463627957	clinical outcomes after transcatheter
0.2462561419	postoperative mortality
0.2460392975	preoperative risk
0.2458484157	significant risk factor for
0.2458232540	higher likelihood of
0.2457812168	a 69 year old
0.2457598413	median duration of
0.2455978091	clinical safety
0.2455834063	patient risk
0.2452974615	to prevent
0.2452745364	atrial and ventricular pacing
0.2452591727	individual differences in
0.2451140109	patients with obstructive hypertrophic cardiomyopathy
0.2450801649	predictors of
0.2450399015	patients underwent tavi
0.2450023034	the most common reason
0.2449975868	in 12
0.2449955072	dual chamber permanent pacemaker
0.2449845479	randomly assigned to
0.2448938720	years after implantation
0.2448753785	post cardiac
0.2448606347	six months
0.2448174829	days after surgery
0.2447767300	cardiac contractility
0.2447499648	micra pacemaker
0.2446670706	in 15
0.2446497808	the most frequent
0.2446477121	cied patients
0.2445803798	¬± 0.4
0.2444490587	an increased risk of
0.2444481034	novel method
0.2443964767	and 3
0.2442228154	in comparison to
0.2441861656	rate of major complications
0.2441647048	patients aged 80
0.2441041430	occurred more frequently
0.2440325703	systolic blood
0.2439086301	pacemaker specific
0.2438257106	pacemaker treatment
0.2438103547	consecutive patients with severe
0.2435621809	ventricular contraction
0.2434477389	ci 1.01
0.2434418661	tof patients
0.2433283465	¬± 14.2
0.2432642331	a 26 year old
0.2432536002	very elderly
0.2432265683	undergoing concomitant
0.2432086406	corrected transposition of
0.2430455571	patient underwent
0.2429609081	t test
0.2428666502	a trend toward
0.2428226532	t type
0.2424025498	needed to determine
0.2423682687	anticoagulant use
0.2422871479	systematic search of
0.2422250607	p ¬† = 0.02
0.2421681655	¬± 12.4
0.2420986915	the scn clock
0.2419853593	hbp group
0.2418942714	patients with symptomatic severe aortic
0.2418732164	¬± 9.7
0.2417553701	m mode
0.2416183772	repair versus
0.2415966626	pacemaker network
0.2414813259	direct tavr
0.2414016237	pacemaker implantable cardioverter defibrillator
0.2413923066	valve stenosis
0.2412614041	correlations between
0.2412072813	heart failure related
0.2410893517	safety and feasibility
0.2409416393	¬± 2.6
0.2408328753	left ventricular assist
0.2407942644	patients with degenerated
0.2407204590	for 5
0.2405293285	prior history of
0.2404259006	valve in valve procedures
0.2404075286	a prospective single center
0.2404029420	membrane pacemaker
0.2403193535	surgical complications
0.2402482990	in 20
0.2401115594	mediated tachycardia
0.2399754536	lead based
0.2399661757	atrioventricular block requiring pacemaker
0.2399306852	af events
0.2399206555	right anterior
0.2398554698	to determine whether
0.2396530573	these data support
0.2396342022	classification of diseases
0.2396341816	first generation
0.2395971408	collected data
0.2393353917	after htx
0.2393244980	p = 0.047
0.2392898839	compared with surgical aortic valve replacement
0.2392113692	an 81 year old
0.2391579714	potential risk factors
0.2390984915	chronic sleep
0.2390024306	2012 and 2017
0.2389113581	peripheral artery
0.2387464601	registry data
0.2387291952	two case reports
0.2386447621	on clinical practice guidelines
0.2385741037	tps implantation
0.2384537660	interacts with
0.2382942617	ct group
0.2381705222	a rare case of
0.2380985679	aged 40
0.2380432833	serious complications
0.2379931468	thirty two
0.2379427076	comparison between
0.2376697025	a 59 year old
0.2375999726	¬± 0.3
0.2375018525	associated with increased mortality
0.2374620537	key results
0.2373764758	p = 0.024
0.2373056856	lvef ‚â•
0.2370917773	young patient
0.2370828399	self expanding corevalve
0.2370316259	and 30
0.2369844344	¬± 9.2
0.2369101018	obtained from
0.2368546026	patients developed
0.2365938177	p = 0.032
0.2365141915	cardiac symptoms
0.2364070615	tavi procedure
0.2363898960	study evaluated
0.2363417539	device data
0.2362709334	p ¬† = ¬† 0.005
0.2361752766	the early postoperative period
0.2360197348	transfemoral aortic
0.2357998016	after transfemoral transcatheter aortic valve implantation
0.2357871950	¬± 10.2
0.2357632374	a single centre experience
0.2357321196	¬± 12.3
0.2357099949	advantages over
0.2356259867	p waves
0.2356011751	a median follow up of
0.2355894650	12 weeks
0.2355052305	indications for pacemaker implantation
0.2353696130	severe ar
0.2352904366	prosthesis implantation
0.2352624651	l pm
0.2350342311	mean society of thoracic surgeons score
0.2349222595	further investigations
0.2347814534	mean pressure gradient
0.2346544219	ventricular dimensions
0.2345204867	investigate whether
0.2344496715	p ¬† = ¬† 0.01
0.2343598646	p ¬† = 0.03
0.2343583059	¬± 1.1
0.2342937478	recent data
0.2342205260	by means of
0.2342161290	sarcoidosis patients
0.2342100319	‚â§ 0.001
0.2340707283	compared with men
0.2339766568	26 mm
0.2339519599	a 79 year old
0.2339173850	¬± 9.9
0.2338808964	between 2008 and
0.2338482530	atrial electrical
0.2338259019	upgrade to cardiac resynchronization
0.2337706949	mean aortic valve area
0.2336414660	higher prevalence of
0.2335831984	previously described
0.2334487663	‚â• 60
0.2333436506	patients with
0.2333378365	a case of
0.2333172709	resynchronisation therapy
0.2333103045	dialysis patients
0.2331770725	endpoint of death
0.2331750561	increased risk
0.2329356098	lv mechanical
0.2328048678	at 1 year
0.2327870106	in order to
0.2327119317	percent of patients
0.2326767067	for 10
0.2326700717	implantation of permanent pacemaker
0.2326193411	cied surgery
0.2325994161	emphasis on
0.2325971732	recurrence of af
0.2325213868	= 0.98
0.2325039830	device lead
0.2323992131	rate of complications
0.2319993129	in three
0.2319749880	these results demonstrate
0.2319446129	interrogation data
0.2319184828	year old caucasian
0.2318843079	leads implanted
0.2318718084	the following day
0.2318261238	treated with intravenous
0.2317428249	of 15
0.2317040327	at 4
0.2316486145	persistent left
0.2316424739	consistent with
0.2314983314	ppm after tavr
0.2314613268	p = 0.038
0.2313923306	p = 0.0002
0.2313726072	ablation group
0.2313541229	= 0.77
0.2313379979	after adjusting for
0.2311825342	the safety
0.2311705259	patient groups
0.2309245720	did not differ significantly
0.2308142228	benefit from
0.2306449631	from mouse small intestine
0.2304787229	require permanent pacemaker
0.2304699849	a 76 year old
0.2304451518	help identify
0.2303987867	those without
0.2303955250	versus redo
0.2303900734	gradient decreased from
0.2303794025	‚â• 15
0.2303492484	p ¬† = ¬† 0.001
0.2302898230	novel self expanding
0.2302121431	in 7
0.2302052770	referred for
0.2301984440	200 ms
0.2300560117	between july
0.2300384464	micra transcatheter pacing
0.2300332969	to analyze
0.2296948962	data from
0.2296536432	icd 9
0.2294776094	‚â§ 6
0.2294151658	results showed
0.2293641225	transferred to
0.2293502394	mean gradients
0.2292630542	freedom from af
0.2291372187	valve gradients
0.2289493178	¬± 5.4
0.2289305023	fatal complications
0.2289254951	at 30days
0.2288396234	p 0.005
0.2288386077	one month
0.2288292742	p ¬† = ¬† 0.004
0.2287240274	group differences
0.2287161670	cardiac related
0.2285924538	drug use
0.2284967288	¬± ¬†
0.2284702045	rhythmic expression
0.2281323605	to ensure
0.2280166651	first line
0.2279544186	scan revealed
0.2278414501	feasibility and safety
0.2277684021	meta analysis of randomized
0.2277659884	adjusted for age
0.2275736948	differences between groups
0.2274915954	focus on
0.2274763289	a 73 year old
0.2274430655	clinical outcomes in patients
0.2273059830	tavr outcomes
0.2273020863	¬± 11 years
0.2272865824	comparison of
0.2272562014	evaluation and management
0.2271281318	a permanent pacemaker
0.2270854366	selected patients
0.2270786736	and 4
0.2269960977	the covid 19 pandemic
0.2269794071	practice regarding
0.2269455133	undergoing transvenous lead extraction
0.2268992624	patients with severe
0.2268395404	the s3 thv
0.2267264979	over time
0.2267128578	¬† ¬±
0.2264270457	sub analysis
0.2264041751	surgical management
0.2262803654	in 18
0.2261644458	challenging because
0.2260860637	rate of device success
0.2260512844	permanent pacemaker implantation after
0.2260410751	expanding valves
0.2260121155	year old male
0.2259869439	a prospective cohort study
0.2259651670	predictors of mortality
0.2259003703	beats per
0.2258744279	qualified for
0.2258256946	p ¬† = 0.003
0.2258131153	interactions between
0.2256597047	echocardiographic follow up
0.2256486434	absence of
0.2256271221	right ventricular pacemaker lead
0.2255176582	cardiac mortality
0.2253852672	underwent dual chamber
0.2252667270	complete left bundle branch
0.2252606196	conditional devices
0.2251539960	an alternative
0.2250282324	data showed
0.2247870106	the objective of
0.2246671651	remaining patients
0.2246549730	patients without previous
0.2246227836	aged 18
0.2245415040	routinely used
0.2245386740	the two groups
0.2243582908	non rva
0.2242775151	icd patients
0.2242219189	after tavi
0.2241308904	interesting case of
0.2241269142	an unusual
0.2241220913	implantation procedures
0.2240933352	more than half
0.2239731192	consist of
0.2238772941	tavr in low risk
0.2238712754	6 month follow up
0.2238267699	¬± 7.8
0.2237636248	included age
0.2235302602	a major role
0.2235212920	¬± 8.6
0.2234562018	a limited number of
0.2234495687	¬± 6.6
0.2233080956	compared with standard
0.2232615107	procedural results
0.2231668428	wide range
0.2231382459	current era
0.2230618176	relatively low
0.2230379056	one year mortality
0.2229090200	analysis included
0.2228348589	¬± 7.9
0.2227545480	range 0
0.2226494933	patients with pre existing
0.2225293010	¬± 11.3
0.2224140254	patients with obstructive hypertrophic
0.2223400150	age at surgery
0.2222555111	device procedures
0.2221787701	serious complication
0.2219556747	heart failure patients
0.2216744531	pacemaker implantation for complete
0.2216552834	minimally invasive mitral
0.2216005001	associated with increased
0.2215281394	a 72 year old
0.2214347585	a 58 year old
0.2212967997	identify patients at
0.2212262645	¬† = ¬† 0.002
0.2211846886	after tavr
0.2210636315	¬± 6.4
0.2209298416	group than in
0.2208877660	‚â• 10
0.2208542635	and 15
0.2208104673	ppm group
0.2208027596	developed af
0.2205871074	patients with preexisting
0.2203821267	close proximity to
0.2203540349	patients with pacemakers
0.2203371241	from 1
0.2201555588	¬† ¬† 0.001
0.2200797805	with regard to
0.2200005270	at 12
0.2199777624	high rate
0.2198153004	¬± 7.7
0.2197744368	the present case
0.2197560083	¬± 4.3
0.2197483296	complete right bundle branch
0.2197277599	in 29
0.2196936011	¬± 10.4
0.2195451338	european society of
0.2194649416	effect on
0.2193821605	clinical course
0.2192926546	0.24 ms
0.2192331904	second degree atrioventricular
0.2190545464	years after surgery
0.2187986337	¬± 8.1
0.2187628336	invasive approach
0.2187417999	ventricular outflow
0.2186738359	‚â• 3
0.2186066555	potential risk
0.2185543853	circadian activity
0.2184515421	characterised by
0.2184252751	encoded by
0.2183332378	acs patients
0.2183253626	agreement between
0.2183061089	the icc dmp
0.2181227026	correlated with
0.2179846647	¬± 6.9
0.2179004862	attributable to
0.2178635438	pacemaker registry
0.2176948662	non ischemic
0.2176890570	allocated to
0.2175739013	previous pacemaker
0.2174657216	31 mm
0.2174146758	¬± 15 years
0.2173662337	select patients
0.2173172738	1.73 m
0.2172510904	¬† years of age
0.2171982510	¬± 4.9
0.2171868554	risk for surgical aortic valve replacement
0.2170109750	following tavr
0.2169898390	¬± 8.9
0.2169758235	¬± 5.2
0.2169648668	baseline risk
0.2169635450	for patients with severe aortic
0.2168200446	p = 0.019
0.2167939712	replacement surgery
0.2167679189	pacemaker channels
0.2167169743	treatment of severe aortic stenosis
0.2166565057	¬± 8.7
0.2166204258	pediatric cardiac
0.2165954806	¬± 5.9
0.2164738768	in ¬† vivo
0.2164631121	persistent permanent
0.2164464961	‚â• 1
0.2164178832	in 30
0.2164123780	received crt
0.2163120911	high risk group
0.2162887348	act as
0.2162470724	patients without prior
0.2162131619	supported by
0.2161897200	0.5 cm
0.2161880355	xt valve
0.2160963467	incidence of cied infection
0.2160150814	¬± 4.8
0.2159935051	¬± 3.4
0.2159755689	log rank p ¬† = ¬†
0.2159744862	tavi devices
0.2159036879	per patient year
0.2158273656	a mean follow up of
0.2155587677	long term implanted
0.2155221951	one week
0.2155008997	pacemaker technology
0.2154256572	repair of complete
0.2153875907	effective pacing
0.2153869769	median follow up
0.2153190139	an implantable cardiac device
0.2151730733	the need
0.2151403142	aortic stenosis undergoing
0.2150212891	progressive cardiac
0.2149544875	increased morbidity
0.2149400652	after 1
0.2148237534	lateral neurons
0.2148135276	and 20
0.2148111337	¬± 7.3
0.2148046776	acute coronary
0.2147902843	healthcare system
0.2147837642	at rest
0.2147241661	aortic valve in valve implantation
0.2146810636	previous work
0.2145758800	‚â• 30
0.2143972539	¬± 7.1
0.2143416979	3 weeks
0.2143301710	valve replacement in high risk patients
0.2142503066	of 10
0.2141628066	in 9
0.2141415556	to address
0.2140877940	information regarding
0.2138878191	did not change
0.2138327673	a viable alternative
0.2136872919	but not
0.2136478314	standard group
0.2136283174	p ¬† = ¬† 0.03
0.2135647399	included patients
0.2134498505	the pineal gland
0.2134447827	concomitant cardiac
0.2134174192	increasing number of
0.2133060827	transfemoral transcatheter
0.2132820826	between february
0.2131191701	majority of patients
0.2130887830	hospital deaths
0.2129871385	presenting with
0.2129446688	between 2005 and
0.2129259053	venous catheter
0.2129139414	strong predictor of
0.2127464237	at mayo clinic
0.2126919461	a patient with
0.2126906593	7 ¬† days
0.2126731764	¬± 5.1
0.2124687155	rare condition
0.2124373423	manifesting as
0.2123820578	¬† = ¬† 0.01
0.2123757726	more likely to receive
0.2122806422	complication of pacemaker implantation
0.2121931794	proportion of patients
0.2120785887	of 20
0.2119113167	¬± 10.5
0.2118732336	a 74 year old
0.2118270814	¬± 8.0
0.2118261111	four weeks
0.2117356353	contributing to
0.2117345234	new conduction abnormalities
0.2116467850	symptomatic severe as
0.2116440129	transcatheter versus
0.2115391028	pacemaker infections
0.2114386881	primary efficacy
0.2113895988	used to identify
0.2109759766	ninety one
0.2108769939	single tertiary
0.2107421733	did not reveal
0.2104555162	key pacemaker
0.2104330158	the treatment of severe aortic
0.2103812007	paucity of data
0.2102857363	hospital mortality rate
0.2102517404	cohort consisted of
0.2102073506	episodes of syncope
0.2100657980	to understand
0.2099165831	the risk
0.2098605761	even if
0.2098569379	isolated surgical aortic valve
0.2097717743	time points
0.2096605065	identify risk factors
0.2096224222	in most
0.2095076632	this meta analysis
0.2094424988	and 9
0.2093343391	¬± 3.7
0.2090729839	the acurate neo prosthesis
0.2090020391	enable valve
0.2089460263	a good alternative
0.2088338540	failed surgical
0.2087715207	device leads
0.2085833490	to visualize
0.2085663098	connected to
0.2085644712	severe pulmonary
0.2085246762	relatively rare
0.2082755879	death rate
0.2082707331	= 0.44
0.2082532946	between january 2011
0.2082134808	to perform
0.2081815331	suggestive of
0.2081261365	covid 19 pandemic on
0.2081247134	¬± 3.8
0.2080943490	self expandable transcatheter aortic
0.2080851193	complications including
0.2080260533	significant paravalvular
0.2080241759	used to calculate
0.2079686690	contributed to
0.2078833468	requiring pacemaker
0.2078060792	pacing system
0.2077664754	¬± 7.4
0.2076977163	1 propensity score matching
0.2076307050	high levels of
0.2076094025	the primary outcome
0.2076048704	a rare complication
0.2075436480	in five
0.2075321927	the time
0.2074434646	younger than
0.2074231408	a significantly lower rate of
0.2074050798	an innovative
0.2073616019	not clear
0.2072835582	performed at baseline
0.2071860178	p = 0.030
0.2071437157	a 53 year old
0.2071124867	patient data
0.2070822051	¬± 5.0
0.2069848178	a narrow qrs complex
0.2069531709	7 days
0.2069330267	the current study
0.2068853767	transvenous extraction of
0.2068587256	this case demonstrates
0.2068265525	adrenergic stimulation
0.2068199067	based upon
0.2066311542	and 8
0.2065793450	at 1
0.2064719053	post mri
0.2064630158	selection of patients
0.2064048150	older than
0.2062006469	cancer patients
0.2061711788	used to measure
0.2061590799	diagnosed with
0.2059715308	ventricular lead implantation
0.2059420014	used to estimate
0.2058316231	no significant difference between
0.2058039373	the day
0.2057926094	and cardiopulmonary bypass times
0.2056521738	aortic valve replacement with
0.2054900854	¬± 5.7
0.2052478704	clinically significant pocket
0.2052409931	no difference in
0.2051530852	epicardial left ventricular
0.2051414003	mean cross clamp
0.2050986943	a single center retrospective
0.2047715578	this retrospective cohort study
0.2047596119	tavr in low risk patients
0.2047222724	risk of ppm implantation
0.2047078536	significantly higher risk
0.2045809886	= 0.46
0.2045175132	impact of
0.2045131383	electronic pacemaker
0.2045041129	per 100 patient
0.2044693166	¬± 6.1
0.2044017532	new onset persistent left
0.2043558265	determine whether
0.2043546226	pacing rates
0.2043304769	days later
0.2043300657	risk of stroke
0.2041943277	a single
0.2041802204	developed atrial fibrillation
0.2040185777	suitable for
0.2040183852	chronic atrial
0.2040100401	a 50
0.2039977977	mg day
0.2039827548	in 27
0.2039353862	a retrospective chart review
0.2038636526	¬± 3.9
0.2038633134	central circadian clock
0.2038527664	treatment group
0.2036653377	¬± 8
0.2036311542	and 7
0.2035700462	long term outcomes of
0.2035672511	examine whether
0.2035602982	outcomes in patients undergoing
0.2034877513	loss of
0.2034629666	avr group
0.2034563768	originate from
0.2034075812	¬± 4.6
0.2033726031	odds ratio or
0.2033331697	paced heart
0.2032300896	following cardiac surgery
0.2031924006	need for
0.2031483438	more than mild paravalvular
0.2028540147	a significantly
0.2028210097	¬± 2.9
0.2027220938	the central circadian pacemaker
0.2027060509	= 0.005
0.2025398842	evolut r valve
0.2023909177	induced by
0.2023850281	savr in low risk
0.2023803729	d transposition of
0.2021292657	to explore
0.2021136810	inappropriate icd
0.2020973845	portion of
0.2020542206	p ¬† = ¬† 0.04
0.2020019615	patients with chd
0.2019714812	system in
0.2019266176	valve in valve implantation
0.2018698662	from october
0.2017402496	relationships between
0.2017060982	surgical valve
0.2017037984	pacing strategy
0.2016420053	improved outcomes
0.2015874790	study showed
0.2015760533	severe paravalvular
0.2012425087	¬± 5.6
0.2011856266	adult fontan
0.2011478590	lead electrocardiogram
0.2011308745	stratified by
0.2010067752	group showed
0.2009215603	diagnostic value
0.2008269479	baseline clinical
0.2008028433	a rare
0.2007947744	this retrospective study included
0.2007836902	= 0.31
0.2006764418	to minimize
0.2006374193	patients with congenital heart disease
0.2005990350	versus surgical aortic
0.2005473857	tavr device
0.2005219380	the freedom solo
0.2004842377	icd crt
0.2004753834	a meta analysis
0.2004643630	very high
0.2003254073	p = 0.0001
0.2001888807	time cues
0.2001517348	cied group
0.2001376029	implantation after transcatheter
0.2001325360	clinical results
0.2001150601	cells isolated from
0.2000867758	crt d implantation
0.2000822051	¬± 6.2
0.2000775782	of 4
0.1999292678	p = 0.015
0.1998552410	cohort of patients
0.1998136216	the modified duke criteria
0.1997848338	occurred in
0.1997644150	non fatal
0.1996746862	preceded by
0.1996536337	¬± 7.5
0.1996353577	observation group
0.1996270727	day case
0.1996224222	in four
0.1996167142	6 hours
0.1996078253	an established treatment
0.1995940996	p = 0.06
0.1995880922	an implanted pacemaker
0.1995735897	p ¬† = 0.0001
0.1995118199	relate to
0.1994741839	appear to
0.1994564218	upregulation of
0.1993961846	studies showed
0.1993645420	an interesting case of
0.1993256493	after pacemaker implantation
0.1992794973	to verify
0.1992489364	high percentage
0.1991891988	pacemaker devices
0.1991616706	pacemaker implanted
0.1991529623	data on
0.1991030911	¬± 0.7
0.1990800858	¬± 4.2
0.1990079181	study aimed to evaluate
0.1989720460	lower than
0.1989371443	high mortality
0.1989060604	age at implantation
0.1988344237	recovery time
0.1988151529	tavr group
0.1987090205	at 3
0.1987062194	risk of complications
0.1986757909	daily rhythms in
0.1986366768	triggered by
0.1984026218	case report and review of
0.1982857688	paced av
0.1982831475	pacemaker failure
0.1979792826	lower incidence of
0.1978476101	a randomized controlled trial
0.1977815403	patients with permanent af
0.1977575508	of unknown origin
0.1977146752	opted for
0.1976670623	stage 3
0.1976012504	pacemaker complications
0.1975287545	male patients
0.1975059480	from human induced pluripotent stem cells
0.1973590222	to maintain
0.1973365424	the control group
0.1972809826	unrelated to
0.1972635752	of 16
0.1972599968	infected cardiac
0.1971836417	require pacemaker implantation
0.1970218857	snd patients
0.1968758864	higher in women
0.1968372818	¬± 4.7
0.1968270064	significant complications
0.1968255339	a 65 year old
0.1967287200	significantly higher risk of
0.1966311779	patients with cardiac sarcoidosis
0.1966078103	procedure rates
0.1965735606	thirty one
0.1965651323	compared between
0.1965324189	¬± 7 years
0.1965166865	¬± 4.0
0.1964673788	in hospital mortality rate
0.1964399092	isolated mitral
0.1964347764	an increase in
0.1964222506	patients with implanted pacemakers
0.1962407983	in hospital and 30 day mortality
0.1958397339	pm lead
0.1958030783	patients at low
0.1957261733	patients with bicuspid
0.1956339445	significantly associated with
0.1956190950	a 14
0.1954916386	pretreatment with
0.1954697260	between august
0.1954342306	for pacemaker
0.1953995697	to date
0.1952517012	a well
0.1952347585	a 61 year old
0.1951560793	relation between
0.1951396787	detected by
0.1949469707	from 1998 to
0.1949288419	¬† ¬∞ c
0.1948423229	between november
0.1947975868	and 18
0.1947907785	p = 0.031
0.1947058374	leadless pacemaker system
0.1946635412	absent right
0.1944891712	in silico
0.1944034996	risk of infection
0.1943690150	these findings provide
0.1943646405	suffered from
0.1943319336	a retrospective cohort study
0.1939353084	¬± 0.1
0.1938855261	in two
0.1937669376	¬± 4.5
0.1937157488	after rapid deployment aortic
0.1937065715	¬± 6.3
0.1936739457	hbp lead
0.1936475189	useful tool for
0.1934338905	study demonstrated
0.1934280654	the left coronary cusp
0.1934097080	pacemaker mode
0.1933335259	derived from
0.1932728212	¬± 8.5
0.1931912586	to detect
0.1931130149	time series
0.1930962983	ventricular pacing lead
0.1930317525	the entire cohort
0.1929465483	a cross sectional study
0.1929228752	underwent extraction
0.1928295487	1.0 v
0.1928187025	the latter
0.1927713824	¬± 0.5
0.1927035905	m s
0.1927016592	p = 0.033
0.1926929472	rhythm devices
0.1926596925	hemodynamic results
0.1926570552	fifty one
0.1925694957	the sts acc
0.1925302255	patients treated with tavr
0.1924468088	the kaplan meier method
0.1924264816	significantly better
0.1924146086	medication use
0.1923398816	rates of stroke
0.1923270231	8 weeks
0.1923245575	sought to describe
0.1922576780	non vitamin k
0.1922113676	tf patients
0.1921940271	consecutive patients treated with
0.1920662748	to diagnose
0.1919303389	kind of
0.1919114953	permanent pacemaker implantation after transcatheter
0.1918588333	in 14
0.1918472984	underwent implantation of
0.1917904157	centre experience
0.1917744878	at 0.4 ms
0.1917229576	clinical impact of
0.1917163452	the thalamus
0.1914955430	in 28
0.1914647211	a pacemaker
0.1914128545	months after implantation
0.1913777826	a minimally invasive approach
0.1913409021	in 11
0.1912904828	for severe aortic stenosis
0.1912221279	major complications occurred in
0.1911595066	calcified aortic
0.1911279192	‚ÄØ 0.001
0.1911211920	¬± 5 years
0.1910151108	fifty two
0.1909634957	ecg data
0.1909171975	higher proportion of
0.1909097219	new pacemaker implantations
0.1909083935	important implications
0.1908252134	¬± 17
0.1908101164	did not alter
0.1907742908	differed between
0.1905970832	patients aged ‚â• 80
0.1905908898	¬± 2.7
0.1905446719	per 100 patient years
0.1904536290	apart from
0.1903014443	standard 12 lead
0.1901479297	conduction disorders after
0.1901333832	the evolution rl
0.1901087979	all cause
0.1899996352	subgroup of patients with
0.1899981894	implantation procedure
0.1899965114	factors associated with
0.1896031169	undergone permanent
0.1895720046	= 0.73
0.1895699103	within 1
0.1895454366	no difference
0.1895239931	developed new onset
0.1894340687	higher incidence of
0.1893645855	j valve
0.1893611783	2 or 3
0.1892193130	after 12
0.1891840285	seems to
0.1891525976	¬± 2.4
0.1891070516	¬± 1.2
0.1890505173	long term clinical
0.1889046116	¬± 3.0
0.1888373242	patch clamp recordings of
0.1888219018	an independent risk factor
0.1885699546	induced af
0.1884986349	congenital complete
0.1884136987	rates of permanent pacemaker implantation
0.1883230548	per million
0.1882854942	these patients
0.1882630489	¬± 3.6
0.1882156598	preserved lv
0.1881339557	patients operated
0.1880659644	pairs of patients
0.1879009021	old lady
0.1878717683	into consideration
0.1878241560	of 18
0.1876308015	rate of permanent pacemaker implantation
0.1874552069	with pacemakers
0.1874367522	¬± 8.8
0.1873909075	inserted into
0.1873471304	successful leadless
0.1872144410	bypass time
0.1871702146	v at 0.4
0.1871626667	t mri
0.1871524970	following cardiac implantable electronic device
0.1871220025	‚â• 6
0.1871115464	and 13
0.1870786179	transcatheter closure of
0.1870436707	successful percutaneous
0.1870033898	¬± 0.8
0.1869896188	difference in in hospital mortality
0.1869838693	¬± 5.5
0.1869333819	the central circadian clock
0.1869191839	significantly higher in
0.1868839484	¬± 4.1
0.1868169433	a dual chamber permanent pacemaker
0.1868006133	reduced mortality
0.1867762961	patient mortality
0.1867480085	receipt of
0.1866702297	n methyl
0.1864979022	san pacemaker
0.1864359820	mean follow up duration
0.1864274864	this patient population
0.1864216091	major complications occurred
0.1864137070	complained of
0.1863728268	a feasible option
0.1862578302	history of hypertension
0.1862529788	in 2017
0.1862313242	pacing group
0.1861847904	in hospital death
0.1861654843	hf patients
0.1861206372	uncommon complication
0.1860050670	transcatheter aortic valve replacement in low
0.1860004850	¬± 13
0.1859909128	complete resolution of
0.1859750606	qrs 120
0.1859432333	compared with traditional
0.1858314163	valve in valve procedure
0.1858297165	of two
0.1857997857	a leadless cardiac pacemaker
0.1857212202	right femoral
0.1856016636	imaging in patients with cardiac
0.1855043409	60 bpm
0.1853390245	significantly higher rate of
0.1853298920	mediated by
0.1851863564	= 0.51
0.1851786522	herein report
0.1851685681	high level
0.1850786545	24 month
0.1850644418	¬± 7
0.1850593651	early discharge after
0.1848579011	a high volume center
0.1848424865	re implantation
0.1847906506	still unknown
0.1847835806	exist regarding
0.1846667140	of 25
0.1846371642	valve systems
0.1844437095	patients implanted with
0.1841507303	patients presented
0.1839402565	rate episodes
0.1838872714	from 2012 to 2017
0.1838852241	regular follow up
0.1838243634	transvenous right ventricular
0.1837690088	presented with syncope
0.1837577850	= 0.33
0.1836658864	no bav group
0.1836417870	the time of
0.1835827304	treatment of atrial fibrillation
0.1834454862	longer follow up
0.1834216414	effects models
0.1833970762	valve damage
0.1833820885	a two
0.1833471668	the 2 groups
0.1832985567	significantly more
0.1832454100	grade 3
0.1831234381	excellent clinical
0.1830493055	patients at intermediate
0.1828574677	directly related to
0.1828418534	ventricular pacemakers
0.1828276590	this systematic review
0.1827878832	‚â§ 3
0.1826352651	group received
0.1826317041	within 24 hours
0.1825612346	time for
0.1825587187	72 h
0.1825561606	most frequently
0.1825225976	¬± 1.8
0.1824866684	significantly lower in
0.1823775249	underwent concomitant
0.1823557891	+ cabg
0.1823551233	an effective
0.1822509390	= 0.022
0.1822134119	effects of
0.1822106118	complete av
0.1820910557	p = 0.026
0.1819976897	incidences of
0.1819695669	previous history of
0.1818940947	at 10
0.1818755710	acute kidney injury requiring
0.1818495243	during follow up
0.1818301307	a variety of
0.1818126769	stratified into
0.1817587537	identifying patients at
0.1816030361	undergoing cied implantation
0.1815551332	woman with
0.1813857122	¬± 15
0.1812731418	transcatheter aortic valve replacement with
0.1811273334	rhythmic expression of
0.1809044583	outcomes in patients
0.1808419276	tested whether
0.1806802570	right heart
0.1806009537	the united kingdom
0.1805435663	sought to determine whether
0.1804965826	prior pacemaker
0.1804866655	between 2011 and
0.1803904118	implantation after transcatheter aortic valve replacement
0.1803483534	surgical risk patients
0.1802342710	a random effects model
0.1801981970	3830 lead
0.1801291656	routine follow up
0.1801108898	¬± 1.7
0.1799999608	considered as
0.1799428041	long term data
0.1799185243	higher burden of
0.1798788219	an uncommon
0.1796784375	year follow up
0.1796404922	because of
0.1796256477	significant morbidity
0.1796150536	a temporary pacemaker
0.1794813806	patients with implantable cardioverter defibrillators
0.1793160705	¬± 6.5
0.1792882267	much less
0.1792443858	patients with new onset persistent
0.1791937943	used to
0.1791815036	used to assess
0.1790952657	p = 0.037
0.1790852415	h r
0.1789760160	twenty two
0.1789125872	¬± 12
0.1788715160	atrial ablation
0.1787850470	¬± 5.3
0.1785870553	high risk patients with aortic
0.1785752487	month old
0.1785025976	¬± 2.3
0.1784572937	in 40
0.1784400201	days after implantation
0.1783681835	according to valve academic research consortium
0.1783625855	¬± 8.3
0.1782447887	¬± 3.5
0.1782429849	after surgical aortic valve replacement
0.1782404112	early detection of
0.1782386661	exposed to
0.1781483942	this study aimed to assess
0.1780516970	channel 4
0.1778685284	controlled by
0.1778114981	long term results of
0.1777824824	¬± 2.2
0.1776848692	an important role
0.1776841092	in pacemaker dependent patients
0.1776583100	revealed significant
0.1776450132	clinical risk
0.1773977004	90 days
0.1773788378	30 day and 1 year mortality
0.1772913252	twenty one
0.1771901041	medical records of patients
0.1771492247	and two
0.1771443483	a propensity matched analysis
0.1771085868	similar results
0.1770954800	independent predictors of ppm
0.1770784626	the presence of
0.1770770101	¬± 6.8
0.1769931336	percutaneous retrieval of
0.1769540854	more efficient
0.1769267665	= 0.67
0.1769007286	= 0.002
0.1768458721	the lp group
0.1768428434	¬± 5.8
0.1768178700	procedure time
0.1768150636	¬± 3.3
0.1767842575	n = 7
0.1767243670	= 0.024
0.1766815718	cardiac monitor
0.1765301219	the main factor
0.1765256324	the united network for organ sharing
0.1765228298	aim to evaluate
0.1764929784	implantable cardioverter defibrillator lead
0.1763751833	and 11
0.1763169477	cm s
0.1763159910	data indicate
0.1761374251	with one
0.1760480995	per patient
0.1759735444	complete procedural
0.1759036653	patients admitted
0.1758418579	a propensity score matched analysis
0.1758108086	type i
0.1757831063	differ significantly
0.1757704135	inhibitory effects of
0.1755938849	valve dysfunction
0.1754751915	transcatheter aortic valve implantation with
0.1754519022	patients completed
0.1752803327	the patients in
0.1751968524	these findings indicate
0.1751332878	in patients
0.1751023185	p = 0.05
0.1751022204	¬± 2.8
0.1750656167	indication for
0.1750350370	increased odds of
0.1748791412	severe mitral
0.1748679459	account for
0.1748665511	¬± 2.1
0.1748118282	6 week
0.1748040781	difference between
0.1746702092	data exist on
0.1746458482	assessed by
0.1746177251	data regarding
0.1744643911	12 hours
0.1744120876	ten year
0.1743642949	minor vascular
0.1741579399	a retrospective study
0.1741253673	an icm
0.1741187922	log rank p ¬† =
0.1740648503	use of
0.1740356327	for transcatheter aortic valve implantation
0.1739872196	hospital course
0.1739784046	‚â• 80
0.1739452565	= 0.047
0.1738758647	in high risk patients
0.1738594399	no difference between
0.1738532818	3 months
0.1738209781	differences in
0.1737713521	non linear
0.1737434232	p = ns
0.1736071348	cost per
0.1735531798	the present
0.1735099634	an additional
0.1733663032	right ventricular function
0.1733192305	permanent pacemaker implantation following
0.1733166851	the indications
0.1732624619	the master circadian pacemaker
0.1732325268	an uncomplicated
0.1732177562	patients undergoing transvenous lead extraction
0.1731695029	cardioverter defibrillator lead
0.1731237962	1 month post
0.1731194762	pacing device
0.1730057635	p = 0.029
0.1729982235	unit admission
0.1728456077	increased risks of
0.1727520534	0.5 v
0.1726916487	to participate
0.1726696581	= 0.008
0.1725692725	the main
0.1725111533	¬± 1.6
0.1723318063	between 2002 and
0.1722405018	to overcome
0.1722244161	relatively common
0.1722089360	two distinct
0.1721624016	intrinsic pacemaker
0.1721534444	mean society of thoracic surgeons
0.1721131934	not uncommon
0.1719681676	the first
0.1718916510	patients with symptomatic
0.1718688464	the valve academic research consortium
0.1718055609	log rank p =
0.1717507121	implantation after cardiac surgery
0.1717269342	a prospective
0.1717187290	patients undergoing transvenous
0.1717127791	5 year follow up
0.1717122916	a higher rate of
0.1716906378	in 2014
0.1716677970	long term effects of
0.1716402496	patients with implanted cardiac
0.1716252808	the incidence of
0.1715833513	the emergency department
0.1715164485	implantation versus surgical aortic valve replacement
0.1714799496	mri related
0.1714297116	for 6
0.1714280968	aortic disease
0.1714057948	non home
0.1714051173	block requiring
0.1713923592	higher risk of
0.1713747899	introduced into
0.1713254672	at 6
0.1712494807	in low surgical risk patients
0.1711050838	comparable between
0.1709003746	more comorbidities
0.1708540511	¬± 1.4
0.1708465395	mortality in patients undergoing
0.1707742467	pacemaker implantation after tavi
0.1707684957	mapping system
0.1706981399	independent risk factor for
0.1706626262	‚â• 4
0.1705966615	attached to
0.1705386652	appropriate therapy
0.1705040598	patients showed
0.1704409471	in 46
0.1704400338	older than 80
0.1703987983	of cardiac implantable electronic devices
0.1703653596	comparison of outcomes
0.1703576010	¬± 1.5
0.1703213794	an integral
0.1701437850	compared to conventional
0.1700439393	previous aortic
0.1700368028	cardiac leads
0.1700334839	surgical management of
0.1700330814	the superior vena cava
0.1698870679	than with
0.1698836655	differential diagnosis of
0.1698302791	incidence of postoperative
0.1697708142	r r
0.1697619770	this study aims to
0.1695990053	overall mortality
0.1695940121	bav patients
0.1695463509	grade 1
0.1695128336	to obtain
0.1695088196	in 2015
0.1695074082	well documented
0.1694397316	determined by
0.1693436579	seem to
0.1692594515	a cardiac implantable electronic device
0.1692223985	a wide range of
0.1691383863	right bundle
0.1690845809	increasingly used
0.1690537065	very rare
0.1690269234	patients underwent isolated
0.1689751553	a 10 year period
0.1689532060	to improve
0.1689005714	believed to
0.1688466123	a pilot study
0.1688334812	right ventricular septum
0.1688139504	variety of
0.1687830618	history of
0.1687291578	paediatric patients
0.1686901010	study aimed to identify
0.1686797580	low surgical risk patients
0.1685612805	fifty patients
0.1685411054	outcomes of transvenous
0.1685209391	group 1
0.1685089817	subset of patients
0.1684534820	treated by
0.1683231573	= 0.028
0.1683052195	guided by
0.1681258425	in accordance with
0.1681052887	resonance imaging
0.1680645470	right ventricular apical
0.1680593017	patients with paroxysmal af
0.1679619268	n = 1
0.1679349477	monitoring of cardiac implantable electronic devices
0.1678771134	mean society of thoracic
0.1678065170	those with
0.1677122980	patients undergoing surgery
0.1676953633	a leadless pacemaker
0.1676932026	this issue
0.1674789173	very good
0.1674618874	did not require
0.1674154257	elective pacemaker
0.1674124716	ventilation time
0.1672962697	hr ¬† =
0.1670743470	a single tertiary
0.1670281094	at least 1
0.1670208908	conversion to
0.1669679553	results support
0.1668668508	an active fixation
0.1668145862	episodes of af
0.1666757914	pacemaker dependency after
0.1666454602	the study
0.1666018893	significant risk factor
0.1665071384	and 16
0.1664833170	aged 80
0.1663585203	= 0.37
0.1663141012	at 15
0.1661825518	replacement therapy
0.1661023790	pacemaker indication
0.1660881297	‚â§ 1
0.1660084156	and 100
0.1660077850	= 0.28
0.1659768499	dependent patients
0.1659712501	a day
0.1658950230	an 87 year old
0.1657551229	routine clinical
0.1657475864	at 2 years
0.1657246007	from april
0.1654512469	forty two
0.1653479780	acting as
0.1653418043	time to event
0.1653215766	independent predictor of
0.1652419253	in routine clinical practice
0.1652381452	non diagnostic
0.1651892442	model group
0.1651806632	following pacemaker implantation
0.1651397623	the right ventricular
0.1651286302	risk factors for mortality
0.1650091775	the rastelli procedure
0.1649391209	group 2
0.1648706505	a known complication
0.1648003055	underwent percutaneous
0.1647912430	pm group
0.1647900759	the period
0.1647562967	the patient
0.1647474514	the setting of
0.1646769017	the current era
0.1646724181	= 0.71
0.1646710392	major cardiac
0.1645620545	resynchronization therapy device
0.1645197281	at 5 years
0.1644665093	multidisciplinary heart
0.1643139679	human experience
0.1642918468	Œ≤ =
0.1641535682	the warden procedure
0.1636587436	combined endpoint of
0.1636422070	these devices
0.1636328794	in 60
0.1636129388	complications related to
0.1635720536	evidence regarding
0.1635660757	6 and 12 months
0.1635472543	low mortality
0.1635022166	anesthetic management of
0.1634780511	this prospective observational study
0.1634435606	symptomatic patients
0.1633429025	odds ratio =
0.1633283921	time of day
0.1633203340	does not affect
0.1632985695	hospital from january
0.1632570852	indications for
0.1631594346	lbbp group
0.1630588262	history of syncope
0.1630160600	= 0.036
0.1629001413	¬† ¬† 0.05
0.1627802419	rastelli procedure
0.1626015639	patients with prior
0.1625956011	10 mg
0.1625909725	cardiac implanted
0.1625775528	man presented with
0.1625698503	procedural time
0.1625010879	fluoroscopic time
0.1623727456	in hospital
0.1623286885	the next day
0.1623114373	only in
0.1622685063	5 years
0.1622393392	underwent dual chamber pacemaker
0.1622387623	into 2 groups
0.1621977191	n = 6
0.1621713836	at high surgical risk
0.1620772098	90 day
0.1620698317	27 mm
0.1619839671	capable of
0.1617183532	on exertion
0.1616654205	received ppm
0.1616300120	twenty three
0.1615950586	these observations
0.1615770633	at hospital discharge
0.1615340769	before discharge
0.1613446190	tavi device
0.1613297165	before and
0.1613217895	a 62 year old
0.1613122443	a common complication
0.1612915341	rvp group
0.1612466856	produced by
0.1612433452	a mathematical model
0.1612229706	no significant
0.1612026531	two weeks
0.1611277888	after heart transplantation
0.1611259180	all patients undergoing
0.1611230741	surgical site
0.1610242836	the gi tract
0.1609527712	with coronary artery bypass grafting
0.1608875072	the active
0.1608519893	grade 2
0.1608324344	outcomes of transcatheter versus
0.1607613065	require permanent
0.1607454705	¬± 14
0.1607225241	an unexpected
0.1606318391	p ¬† = 0.01
0.1605823702	self expanding tavr
0.1605580998	patients with ami
0.1603305863	sd =
0.1603180247	80 years of age
0.1602434225	af patients
0.1602334415	a real world setting
0.1601426498	five year
0.1601006697	a propensity score matching
0.1600438384	a 39
0.1599527460	follow up duration
0.1598666949	alternative treatment
0.1598636487	in 22
0.1598625229	¬† years old
0.1597902306	information on
0.1597416993	more commonly
0.1596674367	a 70
0.1595994708	intrinsic circadian
0.1595555350	the entire
0.1595115348	this work
0.1594970795	risk for surgery
0.1594189652	this population
0.1593348089	in recent years
0.1591299478	independent risk
0.1590660795	the cause
0.1590573340	cardiac event
0.1590404946	= 0.043
0.1590160162	median age at
0.1589220448	to reduce
0.1589098215	occurred in 3 patients
0.1589027929	provides evidence
0.1588081460	long term outcomes after
0.1586792798	from january 2015 to
0.1586691754	¬± 1.3
0.1585662095	right ventricular lead
0.1584693674	balance between
0.1584407900	extraction of leads
0.1584326405	in real world practice
0.1584020508	in patients undergoing
0.1583962076	compared to control
0.1582768622	with two
0.1581738908	¬± 9
0.1581570802	the rv
0.1581437299	different types
0.1581082133	= 1.000
0.1579894490	pacemaker implantation after
0.1578763627	and 25
0.1578692702	and 1 year
0.1578023189	¬± 1.0
0.1577989063	low rates of
0.1577251417	each patient
0.1576892647	manifestation of
0.1576425562	baseline data
0.1576271771	replacement procedures
0.1576225787	an ilr
0.1576209866	right atrial lead
0.1575970003	effective alternative
0.1575969308	this study aimed to evaluate
0.1575149547	an mri conditional
0.1575124423	rare case
0.1574801301	less common
0.1574602567	underwent transcatheter aortic
0.1573866462	in patients with
0.1572567037	upgraded to
0.1571715245	30 ¬∞
0.1571226700	¬± 3.2
0.1571095589	a prospective study
0.1570807604	adult patients with
0.1569590711	versus replacement
0.1569202801	did not show
0.1568504251	the association
0.1567901398	data provide
0.1567888225	a pacemaker dependent patient
0.1567688726	presented with symptomatic
0.1567101265	the cha2ds2 vasc score
0.1566703691	association with
0.1565799391	lead infection
0.1565522463	among patients with
0.1565280549	1 week
0.1564378579	isolated congenital
0.1564266349	to deliver
0.1564175906	during or after
0.1564027397	the three
0.1564021610	a young patient
0.1563903218	retrospective analysis of
0.1562990973	patients undergoing aortic valve replacement
0.1562816901	central pacemaker
0.1562816710	tend to
0.1562252991	type 2
0.1562203178	japanese patients
0.1562064188	from september
0.1561649864	more accurate
0.1561592555	ventricular wall
0.1561015417	and 90
0.1560107947	underwent crt
0.1559987194	the remainder
0.1559222431	savr patients
0.1558345971	during transvenous lead extraction
0.1558202310	the substantia nigra
0.1557668809	a 42 year old
0.1556593890	contribution to
0.1556259780	a large
0.1556257611	patients included
0.1554949184	utility analysis
0.1554936333	the pericardial space
0.1554053869	unknown whether
0.1553977721	study aimed to compare
0.1553849639	in older
0.1553545218	available evidence
0.1552472955	paucity of
0.1552186450	that of
0.1551832029	the central pacemaker
0.1551452904	the whole cell patch clamp configuration
0.1548763451	transcatheter aortic valve implantation using
0.1548487391	increasing number of patients
0.1547726387	30 seconds
0.1547430945	these results provide
0.1547292567	mrna levels of
0.1546615881	hospital outcomes of transcatheter
0.1546577979	large population
0.1546375598	major cardiovascular
0.1546076596	surgical atrial fibrillation
0.1545933934	on gi motility
0.1544947429	millions of
0.1544664220	the incidence
0.1543331404	year old female presented
0.1542824227	during transcatheter aortic valve implantation
0.1542767815	a propensity score matched
0.1542684940	= 0.47
0.1541426135	identified as independent predictors of
0.1540915506	one year follow up
0.1540906624	and 40
0.1540830167	a new
0.1540176586	term follow up
0.1540113616	patients with hocm
0.1538484471	60 min
0.1538331340	elevated risk for
0.1538163578	the scn
0.1535993608	any of
0.1535504328	system revision
0.1534841467	patients with heart failure
0.1534630379	aortic valve in valve
0.1534421136	average length of
0.1533880938	median time from
0.1531170126	the majority of
0.1530654349	a model
0.1530496693	well studied
0.1530475873	unresponsive to
0.1529808831	area increased from
0.1529383539	first degree atrioventricular
0.1528868964	underlying cause
0.1528808122	a permanent cardiac pacemaker
0.1528482895	for sick sinus syndrome
0.1527298238	from december
0.1527175871	whole heart
0.1526906573	after asa
0.1525657148	adjusted risk of
0.1525337545	longer duration of
0.1525126837	the different
0.1525043517	at 30 day follow up
0.1524397943	the authors
0.1524222921	therapeutic option for
0.1523937390	per 100
0.1523606993	2 weeks
0.1523480674	patients with cardiac pacemakers
0.1523162079	the only
0.1522411603	infected pacemaker
0.1522337267	increased morbidity and mortality
0.1522177661	non conditional
0.1520305394	established treatment
0.1520147793	differ between
0.1519755888	a different
0.1518236003	and embase databases
0.1518115909	few days
0.1517894699	implantable cardioverter defibrillator registry
0.1517522421	the study population included
0.1516820916	a multicenter
0.1516454364	a high success rate
0.1515387138	july 1
0.1515285101	multiple episodes of
0.1515222855	collected data on
0.1514621391	sapien 3 device
0.1514552259	the general population
0.1513895472	decreased from
0.1513597041	a feasibility study
0.1513574585	this cross sectional
0.1513538397	in 2016
0.1513297165	and less
0.1513035120	proximity to
0.1512989195	compared with baseline
0.1512275397	of patients with cardiac implantable electronic
0.1511804568	score matching
0.1511415643	all cases
0.1511205430	for 8
0.1510438744	= 0
0.1510266063	consecutive patients with
0.1509778278	effect of
0.1508928167	normalization of
0.1508861910	four cases
0.1508306577	changes in
0.1507705728	¬± 2.0
0.1507365164	100 person
0.1507136093	after dual chamber pacemaker implantation
0.1505649888	transition from
0.1505256734	day and 1 year outcomes
0.1505192528	significantly correlated with
0.1504382943	‚â§ 30
0.1503390597	the 3
0.1502770175	followed up
0.1501148846	predictors of death
0.1500386602	multiple pacemaker
0.1500282000	circadian regulation of
0.1500224877	induced heart failure
0.1500049421	= 0.56
0.1499204511	a higher risk of
0.1499182050	from 2005 to
0.1498947523	‚ÄØ year
0.1497701853	¬± 1.9
0.1497419022	coexistence of
0.1496281972	patients treated with
0.1496155212	treatment option for
0.1495867353	presented with recurrent
0.1495776365	san like
0.1495348758	patients undergoing implantation of
0.1494797589	demonstrated significant
0.1494745395	distance between
0.1494689001	each other
0.1494666329	a 31
0.1494200498	artery disease
0.1494180062	pacemaker lead associated
0.1493561368	self expanding devices
0.1493460166	year old japanese
0.1493200580	all of
0.1492903628	and 21
0.1492717328	during transcatheter aortic valve replacement
0.1492394059	an elderly patient
0.1491717283	between groups
0.1491516781	history of atrial fibrillation
0.1491128352	pacing devices
0.1491036683	implant rate
0.1490752762	implantation rate
0.1490613890	year survival
0.1490373776	automatic mode
0.1490351192	expression of
0.1489912023	retrospective study of patients
0.1489618338	result in
0.1488682135	at 1 year follow up
0.1488512889	safety and efficacy of transcatheter
0.1488130074	common clinical
0.1487854548	‚â§ 1 year
0.1487738431	aimed to describe
0.1487417952	risk factor for
0.1487329569	an unusual case of
0.1486788090	third degree av
0.1486739852	venous system
0.1486622076	like cells
0.1485612231	the data of
0.1485335748	the other
0.1485135394	favorable clinical
0.1484094067	aortic valve replacement using
0.1483490341	year old man presented
0.1482951273	between 2003 and
0.1482772159	remote monitoring system
0.1481965682	device group
0.1481959835	the rdavr group
0.1481785673	10 min
0.1481483277	successful implantation of
0.1480748025	for patients
0.1479940705	a single center retrospective study
0.1479628898	ms pulse
0.1479299591	and 50
0.1477996038	for transcatheter aortic valve replacement
0.1477781359	away from
0.1477546466	between 1
0.1476403654	and 30 day
0.1476222948	the non
0.1476219087	from 2006 to
0.1475487060	modulated by
0.1475475520	divided into 3
0.1475025795	= 0.52
0.1474424992	right ventricular pacing induced
0.1473981975	a 30
0.1473904470	the new
0.1472336900	directly into
0.1472254695	the micra transcatheter pacemaker
0.1471742458	a right
0.1471707058	determine risk factors for
0.1471283034	clamp time
0.1470888768	natural history of
0.1470755357	¬† = ¬† 0.004
0.1470320855	alternative to surgical
0.1470050681	1 to
0.1469528462	man with
0.1468817832	significant effect
0.1468798856	aortic cross
0.1467746512	an infant
0.1467550969	right axillary
0.1467374426	atrial diameter
0.1466545780	one or more
0.1466261799	the importance of
0.1466096873	limited data on
0.1466080845	in mammals
0.1465853219	a temporary transvenous pacemaker
0.1465443965	differences in baseline
0.1465420699	incidence of new permanent pacemaker
0.1464874698	the suprachiasmatic nuclei
0.1464527072	compared with controls
0.1464067344	most common
0.1464048312	pacemaker rates
0.1463982143	single center experience with
0.1463715950	pacemaker like
0.1462062763	in utero
0.1462005097	combined with
0.1461431252	underwent tv
0.1460740426	of symptoms
0.1460647919	the sinoatrial node
0.1460444681	an asystolic
0.1459989299	a history of
0.1459847356	new onset left bundle branch
0.1459383053	enrolled patients
0.1459381069	lower prevalence of
0.1458981341	following permanent pacemaker implantation
0.1458773098	treatment of aortic stenosis
0.1458316734	right ventricular outflow
0.1458297669	higher rate of
0.1457323050	10 years
0.1457116608	after propensity score matching
0.1456967330	after cardiac implantable electronic device
0.1456534116	¬± 2.5
0.1456294541	an observational study
0.1456239427	5 year
0.1455794705	the left anterior descending artery
0.1455426345	stage 2
0.1455331134	incidence of
0.1455254076	evaluation and management of
0.1454937976	16 h
0.1454279902	conventional follow up
0.1454225462	the left subclavian vein
0.1453703286	device device
0.1453604982	new ppm implantation
0.1453498390	patients with sick sinus syndrome
0.1452987014	the patient underwent
0.1452186626	patients with atrial fibrillation
0.1451700221	increasing number
0.1450894088	from november
0.1450759375	of 3
0.1450650287	response to
0.1450013447	sex differences in
0.1449872463	a rare congenital
0.1449863125	lower risk of
0.1449307619	rdavr group
0.1448667220	n = 3
0.1448416358	a case study
0.1448233916	‚Äë year
0.1448102672	an infrequent
0.1447425719	‚Äë 1
0.1446455367	year old male with
0.1446188427	a 60
0.1445354380	very limited
0.1444977712	age 66
0.1444752009	age 75
0.1444085759	alternative treatment for
0.1443961957	self expandable transcatheter
0.1443596722	alcohol septal ablation for
0.1443321572	line treatment
0.1442129565	these 2
0.1441322715	clinical predictors of
0.1440956610	af related
0.1440655648	time dependent
0.1439768039	main results
0.1439739373	use in
0.1438444997	atrial conduction
0.1437665935	required permanent pacemaker
0.1437576613	from june
0.1436639868	relative to
0.1436588638	the 30 day
0.1436151122	¬† ¬± ¬† 10
0.1435879324	to calculate
0.1435247845	not statistically significant
0.1435109453	gender differences in
0.1434814261	increase in tr
0.1434706248	an adjunct
0.1433453709	acute myocardial
0.1432691972	study describes
0.1432469042	m ppm
0.1432451037	the gold standard
0.1432360533	complaining of
0.1432162085	the optimal cut
0.1431716760	from 2
0.1431651324	after propensity matching
0.1431613860	difference between groups
0.1431507218	without affecting
0.1430373399	a frequent complication
0.1430049719	no significant association
0.1429388399	results from
0.1428449841	transposition of
0.1428245776	valve group
0.1428117443	rates of permanent pacemaker
0.1427860739	the need for
0.1427644465	assigned to
0.1427383427	after 2
0.1426732233	4 fold
0.1426506216	¬± 16
0.1426504085	significant effect on
0.1426167414	remained stable during
0.1425367601	‚ÄØ +
0.1425053457	pacemaker dependent patient
0.1424824206	in low risk patients
0.1423923515	patients with atrioventricular block
0.1423858363	international classification of
0.1423514077	of patients
0.1423495465	treatment of symptomatic
0.1421569432	exposure to
0.1421302971	the patient recovered
0.1420376523	some cases
0.1420326253	1 to 5
0.1419773538	= 0.95
0.1419595099	not significantly different between
0.1419535606	in 25
0.1418430886	the study aim
0.1418388508	important clinical
0.1416790331	and also
0.1415933562	required in 3
0.1415286111	adherence to
0.1415278344	elimination of
0.1414669254	examined whether
0.1413892708	with 1
0.1413868282	10 kg
0.1413613712	and 17
0.1413041819	a retrospective cohort
0.1412970292	protein 1
0.1412779420	n = 4
0.1411542658	perioperative management of
0.1411353807	higher percentage
0.1411240859	significant reduction of
0.1410703321	n = 10
0.1410607783	¬± 27
0.1409601591	old female patient
0.1409117223	6 minutes
0.1407907907	in patients with permanent
0.1407744187	in hospital outcome
0.1407204508	measured by
0.1406731467	and 48
0.1406623325	¬± 5
0.1406608350	and three
0.1406503908	the use of
0.1406430724	prosthetic aortic
0.1406012348	showed normal
0.1405391232	role of
0.1404741470	survival at 1
0.1404636397	expression of hcn
0.1403769829	na +
0.1403664308	clinical follow up
0.1403013251	died during follow up
0.1402732422	no significant change
0.1402568622	day of
0.1401650196	computational model of
0.1401413562	a single center study
0.1401213904	ventricular like
0.1400559375	of 13
0.1400547228	echocardiographic outcomes
0.1400324899	shorter than
0.1400182369	versus 0
0.1399581165	to mitigate
0.1399335568	a case series
0.1398560930	than for
0.1397908686	downregulation of
0.1397827767	a stepwise approach
0.1397539249	amount of
0.1396945017	unique case
0.1395820264	anti tachycardia
0.1395519968	right side
0.1394969345	a past medical history
0.1394602763	high success
0.1394567336	¬± 6
0.1394454691	alternative to
0.1394255987	patients with versus without
0.1394159258	between 2012 and
0.1393892708	of 24
0.1393721919	isolated surgical
0.1392817458	associated to
0.1392492730	the study population
0.1392264502	with preserved ejection fraction
0.1392041044	not yet
0.1391807139	predictors of ppi
0.1391212401	composite endpoint of
0.1390895306	at higher risk
0.1390736410	75 years
0.1390644123	new dialysis
0.1390458444	and 22
0.1390443089	a balloon expandable valve
0.1390436981	in turn
0.1389969407	number of patients
0.1389841590	utilization and outcomes of
0.1389830386	these data suggest
0.1389049384	effective alternative to
0.1388912034	group required
0.1388468225	the acurate neo
0.1388198488	incidence of complications
0.1388096003	the right
0.1387797262	related procedures
0.1386849063	of transcatheter aortic valve replacement
0.1386483700	moderate tricuspid
0.1386063408	monitoring device
0.1385344531	facilitated by
0.1385255907	after transvenous lead extraction
0.1384801322	cardiac resynchronization therapy with
0.1384254386	rhythm management
0.1384160170	and only
0.1383875968	type of device
0.1383851369	high rates of
0.1383435330	complications of cardiac
0.1383160746	found to
0.1382906296	under constant
0.1382568622	with more
0.1381507983	expression levels of
0.1381043983	median duration
0.1379550604	early results
0.1378875305	the study included
0.1378502016	a rare condition
0.1376527999	chronic kidney
0.1376134350	occurrence of
0.1375443373	significantly less
0.1374901053	during childhood
0.1374808740	chance of
0.1374445830	25 mm
0.1373625217	the implantation
0.1373612782	occurred in one patient
0.1373497690	the intensive care unit
0.1372460284	involved in
0.1371943245	at prohibitive
0.1371038463	this study highlights
0.1369781186	for 12
0.1369656798	the clinical
0.1369000580	in one
0.1368972852	age 69
0.1368629142	a crucial role
0.1367682202	new insights into
0.1367356636	the gastrointestinal tract
0.1365338624	a high risk
0.1365329419	cut off value of
0.1365315868	experience with
0.1365055010	surgeons score
0.1364829035	this study sought to evaluate
0.1364541790	prognostic impact of
0.1363430271	significant change
0.1363345564	cumulative incidence of
0.1362579726	higher baseline
0.1361155948	patients with mr conditional
0.1360554309	identify predictors of
0.1360310879	savr group
0.1360032269	75 ¬† years
0.1359735583	= 0.023
0.1359643238	prognosis of patients with
0.1358708818	av valve
0.1358569430	reduced expression of
0.1357990398	p = 0.08
0.1356766207	patients with persistent
0.1355585188	patients in sinus rhythm
0.1355071805	neuronal pacemaker
0.1354424193	days after
0.1354316622	study highlights
0.1354014901	surgical aortic valve replacement in patients
0.1353520878	mean sd
0.1353346128	the heart rhythm society
0.1351618968	ci ¬† = ¬†
0.1351225817	in combination with
0.1349473407	from july
0.1349198825	the german aortic valve
0.1348924200	the timing
0.1348863808	a 75
0.1348834446	this study aimed to identify
0.1348795412	and one
0.1348276869	the eq 5d
0.1348086556	predictive factors of
0.1347686014	clock gene expression in
0.1346280226	a novel approach
0.1346213271	first implants
0.1346176848	increased risk for
0.1346048460	respond to
0.1345743483	18 months
0.1345345611	for 2
0.1344787257	leadless pacemaker implantation in
0.1344446907	of transcatheter aortic valve implantation
0.1343958395	the study cohort
0.1343523259	the diagnosis
0.1342779420	n = 5
0.1341718448	a significant difference
0.1341565173	corevalve system
0.1340048074	implantation of permanent
0.1338984607	characterization of
0.1338453891	similar rate
0.1337945022	3 month follow up
0.1336985944	except for
0.1336776237	versus savr
0.1335554748	not associated with
0.1335200462	amounts of
0.1335142325	comparative outcomes of
0.1335061707	1.5 v
0.1334974777	discharged without
0.1334096790	of 1
0.1334038378	device induced
0.1333618923	with cardiac implantable electronic devices
0.1333386107	primary pacemaker
0.1333168497	and 0
0.1333050524	guidelines regarding
0.1333036245	regulation of
0.1332438333	3 ¬† months
0.1331960101	patients underwent surgical
0.1331376434	voltage dependence of
0.1331368534	safety of mri
0.1330837901	a network meta analysis
0.1330815124	valve infective endocarditis
0.1330689684	right heart failure
0.1329302840	up to
0.1329291983	= 0.68
0.1328417735	algorithm based on
0.1327943499	the 1 year
0.1327684830	essential for
0.1327454290	the difference
0.1327041803	high incidence of
0.1327024721	= 0.36
0.1326364698	significant association between
0.1325842172	unusual cause of
0.1325662523	patients with unexplained syncope
0.1324842554	versus surgical aortic valve replacement in
0.1324751928	a matter of
0.1324374785	into three groups
0.1324003816	similar rates of
0.1323465754	predictive factors for
0.1323449841	contribution of
0.1323142922	associated tricuspid regurgitation
0.1323133578	with severe
0.1322920171	verified by
0.1321857775	in 21
0.1321779104	observed in
0.1321412474	correlates with
0.1319719471	significant increase in
0.1318444560	in 24
0.1318032576	years post
0.1317199527	the pacemaker
0.1316671879	long term risk of
0.1316176586	¬± 10
0.1315370935	the aim
0.1315083502	significant differences between
0.1315048645	more likely to develop
0.1314684285	the clock
0.1314318281	in group 1
0.1313974998	one third
0.1312230600	device implanted
0.1311659668	postoperative pacemaker
0.1311364320	the whole cell patch clamp technique
0.1310860233	understanding of
0.1309394318	patients submitted
0.1308900243	patients with ckd
0.1308852801	to manage
0.1308639917	new permanent pacemaker
0.1308631329	severe left
0.1308549172	the possibility of
0.1308492395	low incidence of
0.1308349368	greater risk of
0.1308181156	high rate of
0.1307276403	significant predictors of
0.1306218363	sutureless aortic
0.1306185878	21 mm
0.1305633082	a result of
0.1305394771	patients with non mri conditional
0.1305364823	susceptible to
0.1305347539	alteration of
0.1305220983	high incidence
0.1305028226	consecutive pacemaker
0.1304884795	3 ¬† weeks
0.1304019496	did not undergo
0.1302700625	with severe aortic stenosis
0.1302376611	to optimize
0.1301312018	subset of
0.1301308165	low rate of
0.1299832918	60 years of age
0.1299723377	concomitant surgical
0.1299599063	day 7
0.1299358302	the most
0.1298067825	pediatric patients with
0.1297849693	an alternative approach
0.1297827121	new conduction disturbances
0.1297576352	prophylactic pacemaker
0.1296940073	consequence of
0.1296809512	with and without
0.1296687267	the lbbp group
0.1296651953	identification of
0.1295803499	the light dark cycle
0.1295094316	primary safety
0.1293769700	those receiving
0.1293710055	in relation to
0.1293624804	long term outcome of
0.1293483785	device based
0.1293255551	on multivariable analysis
0.1293023293	different mechanisms
0.1292477036	all patients underwent
0.1292368785	100 person years
0.1291828428	electric devices
0.1291220628	implantation of
0.1290893220	in 31
0.1290595762	this group of patients
0.1290403474	significant reduction in
0.1290307192	a higher
0.1290129431	significant improvement in
0.1289888969	p ‚â§
0.1289585174	heart failure with reduced
0.1288528143	needs further
0.1288456583	patients with chronic
0.1288382422	patients with previous
0.1288021019	a 70 year old
0.1287608931	returned to
0.1287059744	new insights
0.1286899040	the evolut pro
0.1286837301	p = 0.09
0.1286779022	the acute
0.1286665082	18 years
0.1286157195	previous history
0.1286058366	in office
0.1285982254	in 23
0.1285389354	data concerning
0.1285309191	a very
0.1284880134	of 12
0.1284875836	associated with higher
0.1284550121	non obstructive
0.1283603205	covid 19 patients
0.1283552753	the atrioventricular
0.1283474686	test results
0.1283017998	unsuitable for
0.1282827624	or not
0.1282657195	left internal
0.1282572633	implantation of pacemakers
0.1281747850	several studies
0.1281335897	feasibility and safety of
0.1281213551	cardiac conduction system
0.1279499586	valve deterioration
0.1279459461	treatment option for patients
0.1279401654	a permanent
0.1279226862	no significant difference in
0.1278282536	logistic european system for
0.1277877083	more effective
0.1277583336	most recent
0.1277308323	immediately following
0.1277191945	one year survival
0.1277147786	an integrated
0.1277016672	the long term
0.1277009554	along with
0.1276783665	logistic european system for cardiac
0.1276775694	designed to
0.1276584461	outcomes after
0.1276331255	1 year survival
0.1276151630	no statistically significant
0.1276012963	increased risk of death
0.1275942617	number of procedures
0.1274838075	the circadian pacemaker
0.1274732238	rates of pacemaker implantation
0.1274391635	cause of
0.1274155712	the subcutaneous implantable cardioverter defibrillator
0.1273849455	the literature
0.1273433019	high risk patients with
0.1273284619	not always
0.1273016338	responded to
0.1272755747	the control
0.1272336431	patients with abandoned leads
0.1272035964	performed to assess
0.1271967077	to characterize
0.1271908574	health system
0.1271058507	mitral valve replacement with
0.1270610782	between december
0.1270282036	children with
0.1269368392	related differences in
0.1267797317	failure with preserved
0.1267579980	and need for
0.1267263288	k antagonist
0.1267126138	the mouse small intestine
0.1266985818	the potential
0.1266647341	median time to
0.1265458657	an extremely rare
0.1263372682	a population based
0.1263347598	the procedure
0.1263077982	the case of
0.1262430679	median follow up time
0.1262039461	individual patients
0.1262013430	arrhythmogenic right ventricular
0.1261793093	significant predictor of
0.1261503745	time of
0.1261200395	from january 2014 to
0.1260577982	the risk of
0.1260569374	of hipsc cms
0.1260423646	ecg changes
0.1260368925	indicative of
0.1260291003	subsets of
0.1260265915	average follow up
0.1259542570	the perceval sutureless
0.1259520809	the left ventricular outflow tract
0.1259219758	¬† v
0.1259189742	rate of death
0.1258791133	¬± 21
0.1258780795	parameters remained
0.1258472668	primary objective
0.1258139811	6 ¬† h
0.1257906172	retrospective case
0.1257300009	= 0.58
0.1257141976	group d
0.1256158728	year old female patient
0.1256153448	valve in valve transcatheter
0.1256005289	aspect of
0.1255771985	procedures included
0.1255768570	of 70
0.1255528836	year of age
0.1255461484	this study investigated
0.1254893249	the left
0.1253685353	matched comparison of
0.1253372048	at 30 days and 1 year
0.1253141818	decreased over time
0.1253073374	the edwards sapien xt
0.1252965819	with increased
0.1252110431	from march
0.1251637937	undergoing avr
0.1251210155	= 0.009
0.1251159942	valve procedures
0.1251056949	group of patients
0.1250817814	the cha2ds2 vasc
0.1250724530	a 67
0.1250657460	the micra tps
0.1249891979	log rank p
0.1249661050	14 days
0.1249089023	by 10
0.1249068443	the balloon expandable edwards sapien 3
0.1248878786	= 1
0.1248760930	used with
0.1248278528	rates at 1
0.1246873978	data about
0.1246822637	approved by
0.1246463912	a lower rate of
0.1246097724	cs lead
0.1245223285	within 3
0.1244717543	n = 2
0.1244046482	unaffected by
0.1243920052	study population included
0.1243793196	soon after
0.1243205331	complete removal of
0.1243115566	during magnetic resonance imaging
0.1242917775	to elucidate
0.1242555865	after excluding
0.1242399697	extracted from
0.1242392474	from 4
0.1242182450	similar mortality
0.1241773648	0.4 ms
0.1241708864	at 30
0.1240479244	follow up echocardiography
0.1239928660	= 0.045
0.1239928660	= 0.034
0.1239902882	this study describes
0.1239689490	from february
0.1239393783	tachycardia induced
0.1239233111	participated in
0.1238412603	1 hour
0.1237435201	determination of
0.1237240094	15 min
0.1237142859	patients with dual chamber pacemakers
0.1236252318	using logistic regression
0.1235930376	or =
0.1235856486	to present
0.1235693929	usefulness of
0.1235564558	arise from
0.1235554801	electronic medical
0.1234994710	10 ¬† years
0.1234873348	n = 8
0.1234604276	ap vs
0.1234564564	patients with myotonic dystrophy type 1
0.1234467847	the kaplan meier
0.1234338832	relatively high
0.1234120469	scn clock
0.1233895440	the internal jugular vein
0.1233655441	study aimed to investigate
0.1233317035	a leadless
0.1232467123	elderly patients with
0.1232386824	significant differences in
0.1232364453	the cohort
0.1231985606	female patient with
0.1231964279	a safe and effective procedure
0.1231730725	before pacemaker implantation
0.1231075611	a risk
0.1230208596	the past
0.1229589770	heart failure with preserved
0.1228812134	randomized clinical
0.1228556275	the receiver operating
0.1227300009	= 0.23
0.1226947055	the context of
0.1226535735	significant impact on
0.1225696243	patients developing
0.1225653946	duration ‚â•
0.1225476476	a single chamber pacemaker
0.1225363493	concomitant aortic
0.1225259671	2 patients
0.1224880134	of 50
0.1223962252	no patient required
0.1223832246	time course
0.1223718825	regulator of
0.1223328600	a middle aged
0.1223310899	18 ¬† years
0.1222710197	two cohorts
0.1222444444	36 months
0.1222000668	patients enrolled
0.1221942263	fibrillation in patients
0.1221881261	a subcutaneous implantable cardioverter defibrillator
0.1221608508	patients with left bundle branch block
0.1221496436	still limited
0.1221454665	p = 0.07
0.1221289645	clinical outcomes between
0.1221140305	eligible for
0.1221094818	approach group
0.1221076074	= 0.55
0.1221029779	in hospital deaths
0.1221020144	increased incidence of
0.1221004872	a first
0.1220485073	12 h
0.1220035951	baseline qrs
0.1220018377	women undergoing
0.1219768723	a poor prognosis
0.1218996459	occurred in 4
0.1218540693	no deaths
0.1218322987	adapt to
0.1218194728	the receiver operating characteristic
0.1218191281	non specific
0.1217955664	increased odds
0.1217490869	patients with implanted
0.1217143380	ci 1.16
0.1216801573	resulting from
0.1216331745	compared to baseline
0.1215429714	percentage of patients
0.1214756764	¬± 3
0.1214632730	an elderly
0.1214579022	the implant
0.1214538366	an effective treatment
0.1214418875	the myenteric plexus
0.1214395179	more favorable
0.1214216611	results suggested
0.1214061243	underwent epicardial
0.1213695791	a 55 year old
0.1213426380	the rvp group
0.1213233597	retrospective review of
0.1213084878	unexpected death
0.1212669706	a high index of suspicion
0.1212415048	associated costs
0.1212364826	quarter of
0.1211706155	by analyzing
0.1211320299	the treatment
0.1210893232	required permanent
0.1210785350	rv systolic
0.1209738759	radiofrequency catheter ablation of
0.1209175899	pacemaker system
0.1208948005	in 2018
0.1208294260	few cases
0.1207425281	hazard ratio =
0.1207286943	right ventricular dysfunction
0.1207160136	significant association with
0.1206767645	and 71
0.1206747445	to facilitate
0.1206470621	fixation lead
0.1205808817	shown to
0.1205426753	an independent risk factor for
0.1204899313	matching resulted in
0.1204603717	5 ¬† years
0.1204486231	tavi group
0.1203889778	patients at higher
0.1203880508	prognostic significance of
0.1203412456	= 0.60
0.1203197042	every year
0.1203174185	acute procedural
0.1203052439	presenting as
0.1201213249	6 min
0.1200356011	the patient presented
0.1200081576	risk of persistent
0.1199928075	activation time
0.1199907518	a persistent left superior vena cava
0.1199582398	one year outcomes
0.1199572616	at 6 months
0.1199505422	proximity of
0.1199335738	7.2 years
0.1199308053	right subclavian
0.1199196216	undergoing dual chamber
0.1198865900	a single chamber
0.1198755455	lead to
0.1198740823	higher burden
0.1198502145	light entrainment of
0.1197248125	a retrospective observational study
0.1197130844	of hyperpolarization activated cyclic nucleotide gated
0.1197046801	of 60
0.1196951515	possible causes
0.1196590331	and more
0.1196432828	old male patient
0.1196103858	this case series
0.1195280878	¬± 23
0.1195268622	in both
0.1195153386	this study aimed to investigate
0.1194848272	both cohorts
0.1194713337	inability to
0.1194461177	significant clinical
0.1194264114	into two groups
0.1194200925	1 and 2
0.1192395828	old man presented with
0.1192103351	2 dimensional
0.1192063702	institution between
0.1190785350	baseline pr
0.1190558464	outcomes of transcatheter aortic valve
0.1190366371	patients presenting to
0.1190110799	calcium current
0.1189527405	the absence of
0.1188827715	twelve lead
0.1188567084	prior to tavi
0.1188191039	performed to evaluate
0.1188134435	2 ¬† weeks
0.1187745732	non infected
0.1187331557	1 year follow up
0.1187114693	events occurred in
0.1186876922	year old gentleman with
0.1186827405	the impact of
0.1186794616	circadian system
0.1186736939	next generation self
0.1186413968	electromagnetic interference with
0.1186375243	each of
0.1184995984	chronic right ventricular
0.1184724173	induced tricuspid
0.1184174032	to predict
0.1183229808	no adverse events
0.1183210517	weeks before
0.1183141123	as well as in
0.1183138890	outcomes after tavr
0.1182568609	close to
0.1182079327	large population of
0.1181618827	temporal trends in
0.1181562725	a significant decrease
0.1180612496	outcome of patients
0.1180481522	this retrospective single center
0.1180386700	an interesting
0.1180303837	a total
0.1179816223	in 2012
0.1179641698	no statistically significant difference between
0.1179202884	year of follow up
0.1179015732	the hyperpolarization activated
0.1178663672	patients with rbbb
0.1178642987	with regards to
0.1178218053	communication between
0.1178184952	background population
0.1177197142	in 26
0.1177178945	after 3
0.1177055213	patients hospitalized with
0.1177006952	for isolated avr
0.1176878215	a retrospective
0.1176676168	100 consecutive patients
0.1176095281	patients with sarcoidosis
0.1175902493	clinical experience with
0.1175889013	reserved for
0.1175839611	heart pacemaker
0.1175677455	knock in
0.1175349455	the patient's
0.1175012278	of 11
0.1174035122	used for
0.1173930074	two cases
0.1173570710	freedom from atrial
0.1173253774	this document
0.1172296296	risk of
0.1172061406	complete heart block with
0.1171738967	1 year of follow up
0.1171684147	predictor of mortality
0.1171460426	of 2
0.1171225933	categorized as
0.1170195513	and therefore
0.1169825729	n = 9
0.1169531864	frequently reported
0.1169512034	three cases
0.1168266830	did not influence
0.1167661759	and without
0.1167290836	pacemaker icd
0.1166770047	without fluoroscopy
0.1166289620	a 73
0.1165920365	to analyse
0.1165909374	human circadian
0.1165789915	an external
0.1165311705	alternative to surgery
0.1165046792	patients with permanent pacemakers
0.1164984646	early post
0.1164970194	a complete atrioventricular block
0.1164928139	a history of malignancy
0.1164579369	and 92
0.1164146168	minimally invasive aortic
0.1164130334	and 26
0.1163597244	clinical utility of
0.1163353318	between 2000 and
0.1162145049	difference in mortality
0.1162053241	¬± 4
0.1161683063	¬± 19
0.1161560162	patients with af
0.1161144570	better prognosis
0.1161118115	an essential
0.1160347521	= 0.27
0.1159233886	1 2
0.1159134890	this review
0.1158717165	distance from
0.1158448250	complications occurred in
0.1158210083	renal replacement
0.1157911399	high prevalence of
0.1157904366	in particular
0.1157822705	converted to
0.1157382780	patients with bav
0.1156946875	median hospital
0.1156868719	scheduled for
0.1156855437	with reduced ejection fraction
0.1156780280	this study demonstrates
0.1156560540	the left ventricle
0.1156365022	system upgrade
0.1156320299	the early
0.1156300086	cause of syncope
0.1155779618	rare case of
0.1155594344	an 85 year old
0.1155461050	rare presentation of
0.1154916834	permanent pacemaker implantation in
0.1154871744	in drosophila
0.1154341337	on multivariate analysis
0.1153659870	many of
0.1153318909	assessment of
0.1153297658	a 62
0.1153284202	p trend
0.1152659345	the primary efficacy
0.1152303475	one third of
0.1151818720	a 78
0.1151595946	replacement in high risk patients
0.1150749092	ci 1.05
0.1150291127	the prevalence
0.1149716694	data collected from
0.1148803278	perforation caused by
0.1148497258	a diagnosis
0.1148350950	or without
0.1148249416	better understand
0.1148194274	year mortality
0.1147908899	outcomes among patients
0.1147819560	the repositionable
0.1147725328	¬† mm ¬†
0.1147586970	patients demonstrated
0.1145557924	evoked by
0.1145375350	the right ventricle
0.1145161759	the four
0.1145145221	outcome of transcatheter
0.1145013724	rates of complications
0.1144947183	the right atrium
0.1144484486	more than mild
0.1144176945	days after tavr
0.1143998310	acute phase
0.1143758590	iqr 1
0.1143741953	acute ischemic
0.1143163341	increase in heart rate
0.1143032223	a 64
0.1142850372	similar across
0.1142266518	in lower risk patients
0.1142210067	defined according to
0.1141844001	‚â§ 10
0.1141519578	non selective
0.1141226862	conventional surgical
0.1140703490	increased from
0.1140093142	the tricuspid valve
0.1139233634	in guinea pig
0.1139183884	= 0.63
0.1138561318	part of
0.1138429613	outcomes of permanent
0.1137818731	performed in
0.1137471154	increase in
0.1137196549	not only
0.1136581925	65 years old
0.1135465853	this complication
0.1135151284	a ¬†
0.1134967319	an ideal
0.1134735224	the same period
0.1134168954	the mammalian circadian
0.1133307062	implantable electrical
0.1133058770	and one year
0.1132216790	a significantly higher risk
0.1132212226	patient with
0.1131569386	the 3f enable
0.1131406688	negative predictive
0.1131362451	outpatients with
0.1130636915	the centera
0.1130582159	the first case report
0.1130398200	diagnostic yield of
0.1130307034	independent predictor for
0.1130164458	this phenomenon
0.1129418211	study compares
0.1129218312	for sinus node dysfunction
0.1128805858	long term clinical outcomes of
0.1127859184	a single lead
0.1126645611	for 1
0.1126594280	a canine model
0.1126355703	caused by mutations in
0.1126263143	an opportunity
0.1126231569	the last
0.1126133154	an unselected
0.1125907732	tricuspid regurgitation after
0.1125897826	5 mg
0.1125832864	3 ¬†
0.1125714832	in hospital and 30 day
0.1125653388	with situs inversus
0.1125516359	and 32
0.1125354619	february 1
0.1124901167	by 3
0.1124839892	the cell
0.1124838651	pacemaker dependent patients with
0.1124665002	the patient's symptoms
0.1124631897	than men
0.1124384984	during mitral valve surgery
0.1124256049	short term outcomes of
0.1124096790	the 5
0.1123958469	the primary safety
0.1123916519	an emerging
0.1123511198	a significant risk factor
0.1123459695	the autonomic nervous system
0.1123430164	study reports
0.1123344497	percutaneous extraction of
0.1123139631	95 ci 1.23
0.1122670861	or implantable cardioverter defibrillator
0.1122468781	by inhibiting
0.1122345813	calculated using
0.1122319372	mean cardiopulmonary bypass
0.1122282395	a retrospective analysis
0.1122053649	patient with previous
0.1121825251	conduction abnormalities following
0.1121670581	and safety
0.1121477778	seemed to
0.1121279871	initial experience with
0.1121182229	to validate
0.1120974252	a high level
0.1120741510	implanted into
0.1120641936	any cause
0.1120627779	the ability
0.1120329335	up to 2
0.1120328786	acute respiratory
0.1120229474	sapien valve
0.1118843576	rationale and design of
0.1118722245	the electrical
0.1118282104	the heart team
0.1117435557	interact with
0.1117435186	according to varc 2
0.1117384253	higher number of
0.1117375422	need for ppi
0.1117036136	high prevalence
0.1116660716	the end of
0.1116121394	concomitantly with
0.1115745493	induced ventricular
0.1115001503	modulation of
0.1114958519	in patients with cardiac
0.1114599403	similar to
0.1114376008	and 37
0.1114127707	the number of
0.1114096790	the 12
0.1113837540	implanted with
0.1113631867	the intervention group
0.1113351811	differences in outcomes
0.1113021585	first described
0.1112322521	a mean
0.1112105137	ci 1.1
0.1111949474	new left bundle branch
0.1111863808	in 2013
0.1111740783	this single center
0.1110679778	examples of
0.1110302453	in hf san
0.1110288744	the resting membrane potential
0.1110213023	and 51
0.1110044987	study aimed to determine
0.1109668578	the early stages
0.1109264588	the rv septum
0.1109088480	a surgical
0.1108990786	months after pacemaker implantation
0.1108345246	analysis of
0.1108162531	34 mm
0.1107893435	= 0.019
0.1107506502	the medtronic corevalve
0.1107383798	to cause
0.1107255206	the available
0.1107068867	implanted cardiac
0.1106953704	from january 1
0.1106631461	an update
0.1106465793	an inherited
0.1105798249	safety of transvenous
0.1105427596	system with
0.1104699806	more complex
0.1104427911	and 76
0.1104332155	in humans
0.1103683327	at 12 months
0.1103455957	an easy
0.1103390009	detected af
0.1102912957	blocked by
0.1102371224	n = 11
0.1100544670	obtained through
0.1100521230	n = 14
0.1099669604	during pregnancy
0.1099486408	of death
0.1099375914	3 patients
0.1099327405	the effect of
0.1098967749	6 ¬†
0.1098844872	and 41
0.1098648642	in 50
0.1098368501	the role of
0.1098364622	prior to implantation
0.1098184226	operated ca
0.1097676418	a complete
0.1097363172	entrained by
0.1097090819	the follow up period
0.1096719497	¬± 25
0.1096614194	a literature search
0.1096563700	known regarding
0.1096251523	by activating
0.1096037963	associated with worse outcomes
0.1095901767	patients with sss
0.1095753739	potential risks of
0.1095707877	the micra
0.1095578893	sensitive k
0.1095404440	higher frequency of
0.1095317437	an increased risk
0.1095284417	coupling between
0.1095270627	the acute phase
0.1095262442	application of
0.1095207225	collected from
0.1094934907	survival rates at
0.1094882906	¬± 26
0.1094856568	vs 3
0.1094779689	underwent viv
0.1094665332	this effect
0.1094434744	transfemoral tavi with
0.1094415126	no ppm
0.1094309281	showed good
0.1094213111	engaged in
0.1094131622	high surgical risk patients
0.1093919749	did not differ between groups
0.1093807820	= 0.033
0.1093776432	and 55
0.1093696261	3 month
0.1093569436	in 36
0.1093408667	p ‚ÄØ
0.1092946991	common indication for
0.1092704695	the left atrium
0.1092510639	candidates for
0.1092355232	icd group
0.1092240137	results indicate
0.1092205165	the modified duke
0.1092100191	an independent core
0.1092030105	rate of pacemaker implantation
0.1091829157	the device
0.1091645051	all consecutive patients
0.1091279464	significantly higher in patients with
0.1091260930	a three
0.1091079768	this prospective study
0.1091041703	every 3
0.1090930947	the outcomes
0.1090866164	included consecutive
0.1090433535	an icd
0.1090262970	reversed by
0.1089852918	reason for
0.1089826001	the analysis
0.1089335991	in most cases
0.1089323506	proved to
0.1089321924	in patients with severe
0.1089273372	a 45
0.1089218008	two patients required
0.1089036823	performed using
0.1088925482	more sensitive
0.1088903584	the baseline
0.1088656711	a cardiac
0.1088419588	perforation by pacemaker
0.1088289843	progressed to
0.1087840992	study protocol for
0.1087362915	significantly different
0.1087019313	the postoperative
0.1086617418	mortality at 30 days
0.1086559920	= 2
0.1085737674	to differentiate
0.1085494095	increased risks
0.1084962535	implanted via
0.1084705384	between 2007 and
0.1084671272	one patient required
0.1084456601	kg min
0.1084333130	after matching
0.1084327405	the treatment of
0.1083993529	after hospital discharge
0.1083968247	causes of death
0.1083753548	two patients died
0.1083512465	savr groups
0.1082922510	potential depolarization
0.1082886483	the most important
0.1082878117	¬± 18
0.1082729426	list of
0.1082668260	onset lbbb
0.1082564832	transcatheter aortic valve replacement using
0.1082186392	patients at high risk of
0.1082141811	implications for
0.1082127589	5 year mortality
0.1081917704	excluded from
0.1080970547	for heart failure
0.1080624548	changes of
0.1080428238	determinant of
0.1080419836	studies reported
0.1080023075	found for
0.1079905762	with congenital complete heart block
0.1079770402	this study reports
0.1079582505	at 1 ¬† year
0.1079565025	did not correlate with
0.1079455736	performed to compare
0.1079351492	early ppm
0.1078953605	¬† years of follow up
0.1078664259	this finding
0.1077776366	immediate postoperative
0.1077461003	of cieds
0.1077188449	80 years
0.1077161419	role in
0.1077012653	a population
0.1076830272	placement of
0.1076435096	patients undergoing tavr with
0.1076337022	the inferior vena cava
0.1076298726	a 77 year old
0.1076113286	and six
0.1076004872	to use
0.1075801130	a 27
0.1075653524	ci 1.2
0.1075324800	day 0
0.1075276492	the primary
0.1075108860	restricted to
0.1074262178	¬± 38
0.1074108968	after adjustment for
0.1074077815	less often
0.1073865951	this retrospective
0.1073367582	an increase
0.1073347830	clinical significance of
0.1073284588	a significant proportion
0.1073198556	safety and efficacy of
0.1073153742	and long term outcomes
0.1072275317	a significant
0.1072230872	at 20
0.1071984799	lower incidence
0.1071851879	with lower
0.1071799014	or hf hospitalization
0.1071741318	in hospital complications
0.1071637662	treatment for severe
0.1070207674	care costs
0.1069856832	= 0.14
0.1069756179	patients required permanent
0.1069465522	95 ci 1.16
0.1069419998	the rate of
0.1069262806	performed under
0.1068634220	40 hz
0.1068445930	required implantation of
0.1068225102	¬± ¬† 12
0.1068202846	patients with hypertrophic cardiomyopathy
0.1068075151	did not find
0.1067488142	the heart
0.1067338667	a 16
0.1066702436	and four
0.1066693663	receiving tavr
0.1066541597	a real world
0.1066221746	2 vs
0.1065959861	complete atrioventricular block after
0.1065657286	analysis confirmed
0.1065613627	ventricular end
0.1065567226	n = 15
0.1065515266	each group
0.1064522874	determine if
0.1063832958	a cardiac pacemaker
0.1063827302	trends and outcomes of
0.1063576914	patients with lbbb
0.1063270461	at 24
0.1063016140	letter to
0.1062866363	a promising
0.1062783150	30 day and 1
0.1062738056	chronic lung
0.1061787619	10 mm
0.1061666992	early clinical
0.1061488427	a 53
0.1061469875	during long term follow up
0.1061253117	series of patients
0.1061098209	two patients
0.1059900202	¬† h
0.1059662542	implantation following transcatheter aortic valve replacement
0.1059551527	efficacy and safety of
0.1059456552	two groups
0.1059378562	95 ci 1.02
0.1059327405	the development of
0.1058472128	a significantly higher
0.1058208926	an attempt
0.1058064593	value of
0.1057977968	in constant darkness
0.1057976827	after tf tavr
0.1057932356	the secondary endpoint
0.1057859408	under fluoroscopy
0.1057320245	to provide
0.1057224867	retrieved from
0.1057194180	a significant risk
0.1056972676	those in
0.1056871775	among patients undergoing
0.1056799065	into clinical practice
0.1056558595	a 25
0.1055304783	i r
0.1055145508	a known
0.1054809128	and five
0.1054503906	a 76
0.1054295187	system removal
0.1054215337	a porcine model
0.1054094670	per 10
0.1054064633	the tempo
0.1053914234	¬± 22
0.1053850538	to define
0.1053243208	ten years
0.1053194135	a late
0.1052695616	available regarding
0.1052387170	from january 2013
0.1052369297	performed to determine
0.1051919687	the surgical
0.1051739224	for hypertrophic obstructive cardiomyopathy
0.1050956312	to guide
0.1050644908	screw in
0.1050270016	expressed in
0.1050228908	patients with paroxysmal atrial fibrillation
0.1049641920	patients with high
0.1049464049	according to varc
0.1049405989	to develop
0.1049403456	the s icd
0.1048847292	recognized as
0.1048417549	a 9
0.1048004099	3 d
0.1047487611	after tle
0.1047089860	adverse clinical
0.1046933780	a cardiac resynchronization therapy defibrillator
0.1046323449	group versus
0.1046240137	discharged from
0.1046206617	used as
0.1046199760	first reported case of
0.1046034500	by 2
0.1046032587	a 26
0.1045359160	the edwards intuity
0.1044994070	= 0.59
0.1044900351	after birth
0.1044878624	24 months
0.1044347667	easy to
0.1044104861	the emergency room
0.1044079022	the normal
0.1043685670	an established
0.1043682622	did not develop
0.1042789252	the standard
0.1042386967	patients needed
0.1041173332	in 63
0.1040891195	and 95
0.1040865179	operation time
0.1040597057	and 60
0.1040553473	group c
0.1040380850	a low
0.1040124008	option for
0.1039992037	a 68
0.1039934549	this study aimed to determine
0.1039814912	at 1 month
0.1039694382	p = 0.16
0.1039592504	the active group
0.1039135343	¬† = ¬† 0.001
0.1038925270	time to first
0.1038571576	reductions in
0.1038498174	unusual presentation of
0.1038454059	a multicenter experience
0.1038326765	rates of major
0.1038264049	p = 0.13
0.1038172866	at 8
0.1037975718	including pacemakers
0.1037947971	in children
0.1037781186	of 7
0.1037205301	aortic valve replacement through
0.1037178206	and 29
0.1036999822	and lower
0.1036582392	a 74
0.1036542762	reduced risk of
0.1036101976	aortic stenosis treated with
0.1035625881	to recognize
0.1035565485	one half
0.1035344286	the pacemaker current
0.1034424201	n = 16
0.1034324153	group included
0.1034032632	normal qrs
0.1033961711	current density of
0.1033928416	5 and 10
0.1033865504	an implanted
0.1033751001	and higher
0.1033174295	to preserve
0.1033108706	a rare presentation
0.1032897647	patients undergoing crt
0.1032641676	all patients received
0.1032600016	total occlusion of
0.1032512822	suppressed by
0.1032248548	the circadian clock
0.1032181153	patients younger than
0.1032168999	incidence of acute kidney injury
0.1031520711	¬† =
0.1031126297	did not differ significantly between
0.1031008001	outcomes after tavi
0.1030924913	study population consisted of
0.1030572007	explanation for
0.1030337243	a complete heart block
0.1030283500	compared with conventional
0.1030257269	a significantly higher incidence of
0.1030215885	prevalence of
0.1029977210	discovery of
0.1029675185	in contrast
0.1029372438	patients undergoing pacemaker
0.1028847401	of 83
0.1028172375	the patient developed
0.1027468859	2012 to 2017
0.1027460944	this prospective
0.1027395957	in shift workers
0.1027217043	the san
0.1027178206	and 28
0.1026925347	the ascending aorta
0.1026842825	underwent permanent pacemaker
0.1026789620	a 71
0.1026330338	patients with cavb
0.1025695317	in patients undergoing transfemoral
0.1025422952	the interventricular septum
0.1024870585	with single ventricle physiology
0.1024201151	the rm
0.1023733571	two year
0.1023686589	associated with significant morbidity
0.1023473210	preservation of
0.1023176664	abolished by
0.1022863212	this pilot study
0.1022818204	the human circadian
0.1022429060	‚â• 18
0.1021901670	the membranous septum
0.1021809654	an important cause of
0.1021632180	case 2
0.1021462390	= 0.016
0.1021444293	a left
0.1021326230	for further
0.1021280289	case 1
0.1020700420	to confirm
0.1020592980	from 10
0.1020451527	peripheral circadian
0.1020010245	a 79
0.1019999428	‚â• 7
0.1019568076	the second
0.1019333582	a case
0.1019247153	higher in patients
0.1018868372	this study aimed to compare
0.1018806543	complaint of
0.1018211455	¬± 36
0.1018063748	per procedure
0.1017828648	for most
0.1017819936	a literature review
0.1017773372	with 100
0.1017628648	system to
0.1017617791	successfully implanted in
0.1017259850	the influence of
0.1017101803	does not increase
0.1016970119	higher risk for
0.1016949279	hospitalized for
0.1016122031	i ii
0.1015454587	p = 1.00
0.1015349811	at 5 ¬† years
0.1015214772	removal of
0.1014540183	the first year
0.1014464468	to simulate
0.1014418737	a mean age of
0.1014235355	the two
0.1014042797	a higher incidence of
0.1013992660	in 2011
0.1013581010	pacemaker detected
0.1013555224	stroke occurred
0.1013358845	or hisbp
0.1012441399	the inclusion criteria
0.1011732646	one case
0.1011628516	the first 3
0.1011550825	associated with lower in hospital
0.1010475586	patients with suspected
0.1010338341	system for
0.1010235856	incidence of major
0.1009795724	= 0.010
0.1009180229	n = 57
0.1007927596	a time
0.1007105560	circadian rhythms in
0.1006759380	patient group
0.1006194331	a median follow up period of
0.1006055441	one patient developed
0.1006028157	n = 29
0.1005915636	12 patients
0.1005818875	r ¬† = ¬†
0.1005774465	p = 0.10
0.1005770364	65 years
0.1005442237	these issues
0.1004783414	indication for pacemaker implantation
0.1004621767	a composite of
0.1004494513	included in
0.1004235114	the occurrence of
0.1003746023	the changes in
0.1003359588	5 patients
0.1003107152	rates of mortality
0.1002860591	in 38
0.1002454810	the effect
0.1002279282	a long term
0.1000809186	in 41
0.1000689429	valve registry
0.0999926669	a minimally invasive
0.0999782661	further evaluation
0.0998744961	a key role
0.0998658022	a 66
0.0998612802	ischemic heart
0.0998210473	necessity for
0.0997806869	inhibited by
0.0997799701	more challenging
0.0997798620	the lead
0.0997764720	these cells
0.0997672281	higher among patients
0.0997039873	compared with control
0.0996948007	confirmed by
0.0996728055	asymptomatic atrial
0.0996719504	followed with
0.0996344421	results revealed
0.0996295669	the first 30
0.0996029552	1 3
0.0995808235	a tertiary referral
0.0995755510	2010 and
0.0995726872	between 2014 and
0.0995556416	a significant proportion of
0.0995415224	at af
0.0995379507	in up to
0.0994906159	the lotus valve
0.0994293968	unusual case of
0.0994223499	a significant increase in
0.0994193068	patients with sinus node dysfunction
0.0994081079	implantation in
0.0994001111	aims to
0.0993818823	per day
0.0993446596	family history of
0.0993056555	represented by
0.0993037997	after discharge
0.0992495204	patients with symptomatic aortic stenosis
0.0992461993	a high
0.0992424722	used to determine
0.0992191372	for example
0.0991927480	incidence and predictors of
0.0991880158	tachycardia ablation
0.0991154708	the wise crt
0.0990682043	risk of atrial fibrillation
0.0990592285	up to 10
0.0990495490	site infections
0.0990482144	low morbidity
0.0990451400	less than 10
0.0989120475	short term clinical
0.0989118358	most likely
0.0988936927	invasive surgery
0.0988628452	in turkey
0.0987841599	with narrow qrs
0.0987546031	this patient group
0.0987158630	but not with
0.0986933365	procedures performed in
0.0986763906	female with
0.0986533324	of patients undergoing
0.0986281851	the optimal cut off
0.0985918338	a 39 year
0.0985909061	a cross sectional
0.0985785343	underwent transcatheter aortic valve
0.0985577427	this single centre
0.0985573518	mm s
0.0984964240	a significant reduction in
0.0984940597	an mri
0.0984626627	in patients with right
0.0984368909	consecutive patients treated
0.0984363007	need for permanent pacemaker
0.0984061560	early outcomes of
0.0983922117	long term prognosis of
0.0983897926	a second
0.0983283800	evaluation of
0.0983219637	the majority of patients
0.0982737294	as well as for
0.0981989365	18 ¬†
0.0981888123	longer length of
0.0981685360	inhibition of
0.0981613774	used safely
0.0981539639	predictors of ppm implantation
0.0981330471	with bradycardia
0.0981306699	clinical outcomes of patients
0.0981191615	and one patient
0.0980585458	clinical diagnosis
0.0979789176	development of
0.0979435732	a left ventricular ejection fraction
0.0978131282	a non
0.0977618232	occurred in 1
0.0977330811	number of leads
0.0976381100	patients at risk
0.0975603544	a prospective registry
0.0975407350	from inception to
0.0974614621	95 ci ‚ÄØ = ‚ÄØ
0.0974604130	0.0 vs
0.0974123843	the observation group
0.0974053098	the perioperative period
0.0974038045	data of patients
0.0973890785	patients with myotonic dystrophy
0.0973637799	by modulating
0.0973206323	a 61
0.0972549786	incidence of adverse events
0.0972049218	half of
0.0971399396	the efficacy
0.0971313028	powered by
0.0971286459	mean left ventricular ejection fraction
0.0971250363	in 47
0.0971207647	a major cause of
0.0971076414	with slow ventricular response
0.0970832886	the heart rate
0.0970691610	ecg based
0.0970553478	lack of
0.0970262962	in 33
0.0969862818	patients with cied
0.0969773914	n = 22
0.0969735311	time since
0.0969551160	p = 0.31
0.0969122099	right ventricular leads
0.0969061845	study cohort
0.0968904050	positioned at
0.0968861036	alternative for patients
0.0968820032	activation of
0.0968764049	p = 0.53
0.0968224134	by two
0.0968188589	better than
0.0968041857	and better
0.0967813944	the pre
0.0967661360	risk of pacemaker implantation
0.0967477694	associated protein
0.0967178668	all 3
0.0966724884	after pacemaker
0.0966714562	patients presenting with
0.0966547576	dependent on
0.0966320819	at 50
0.0966131311	than savr
0.0966022712	this approach
0.0965802330	patients hospitalized
0.0965639926	clinical outcomes of
0.0965456696	5 min
0.0965130283	in patients with implanted
0.0965051066	a potential
0.0965016964	first time
0.0964737065	a prior
0.0964632871	history of coronary artery
0.0964630226	with known
0.0964298580	a propensity score
0.0963870999	proportion of
0.0963832633	transvenous cardiac
0.0963352633	respiratory syndrome
0.0963342357	in patients undergoing tavr
0.0963241064	most common complication
0.0962463613	p = 0.62
0.0962342663	the groups
0.0962310489	quantified by
0.0961481519	more physiological
0.0960975772	95 confidence
0.0960817319	¬† 2.2
0.0960121574	2 4
0.0959961909	susceptibility to
0.0959557521	and 62
0.0959233705	year experience
0.0958965264	need for permanent pacemaker implantation
0.0958881134	complex congenital
0.0958844016	the overall
0.0958779623	study aims to
0.0958602302	2012 and
0.0958418337	forms of
0.0958336828	better understanding
0.0957996995	vs 0
0.0957648428	the small intestine
0.0957580119	medical records of
0.0957515669	2 3
0.0957372037	a second valve
0.0957333981	a randomized trial
0.0957052833	more than 50
0.0956764252	safe and effective procedure
0.0956684496	in 34
0.0956398780	woman presented with
0.0956287147	significantly higher among
0.0956233999	only one patient
0.0955977536	patients with syncope
0.0955917992	lower body
0.0955820991	vs 4
0.0955561969	implant related
0.0955508033	on average
0.0954853779	directly related
0.0954816936	operated on
0.0954772039	underwent transcatheter
0.0954541725	transient loss of
0.0954487771	before crt
0.0954240249	all cause mortality at
0.0954235114	the prevalence of
0.0954090046	standard deviation of
0.0953654863	¬† mm vs
0.0953124334	management of atrial fibrillation
0.0952958856	a 20 year
0.0952122609	implantation in patients undergoing
0.0951622600	patients with sick sinus
0.0951529837	a further
0.0951453080	high burden of
0.0951403295	a severe
0.0951385276	from 30
0.0951049788	achieved in
0.0950792211	a unique case of
0.0950584167	outcomes including
0.0950235743	day 1
0.0950136431	by applying
0.0949676295	caused by mutations
0.0949551160	p = 0.11
0.0949039061	measured using
0.0948926312	the study group
0.0948835212	with implanted cardiac devices
0.0948652164	cause for
0.0948634076	high implantation
0.0948467644	¬± 2
0.0948117701	= 0.19
0.0947676267	a comprehensive
0.0946945193	studies demonstrated
0.0946778788	in pediatric patients
0.0946616314	year after
0.0946333576	the novel
0.0946076355	capture threshold at
0.0945872587	6 h
0.0945746771	a method
0.0945654383	utility of
0.0945373502	improvement in
0.0945278661	the long
0.0945225573	outcomes of
0.0944939053	this time
0.0944878114	¬† g
0.0944303356	the renal pelvis
0.0944186795	the mean
0.0944016308	in conclusion
0.0943762620	5 ¬† min
0.0943585502	rare clinical
0.0943356637	the primary objective
0.0943260278	likelihood of
0.0943221445	similar rates
0.0943110860	to create
0.0942760945	a 65
0.0942733605	k +
0.0942623064	study revealed
0.0942198862	during hospitalization
0.0941858956	this study sought to determine
0.0941787890	¬† 0.008
0.0941596066	tool for
0.0941521620	population of patients
0.0941445402	vs 6
0.0940965727	induced complete
0.0940936423	and 80
0.0940909216	all p 0.05
0.0940832088	within 2
0.0940568420	in clinical practice
0.0940424912	the association between
0.0940317548	device closure of
0.0939702094	an increased
0.0939481975	of 100
0.0939215883	and 1 year mortality
0.0939187923	conduction disturbances following
0.0939153734	5 days
0.0938905926	a rare case
0.0938756436	vs 8
0.0938734302	ventricular pacing leads
0.0938595227	a series of
0.0938473328	6 patients
0.0938364323	major cied
0.0938292980	after 6
0.0937904995	pacemaker implantation in
0.0937881600	a valid
0.0937802401	15 mm
0.0937737403	magnetic resonance imaging in patients with
0.0937586342	patients with bicuspid aortic valve
0.0937112183	and 5 years
0.0936767744	the savr group
0.0936519204	and at 1
0.0936445115	success rate of
0.0936408718	development of af
0.0936389870	results provide
0.0936238367	no bav
0.0935869804	young patients with
0.0935864718	following tavi
0.0935853917	after exclusion
0.0935169520	¬± 1
0.0934796946	p = 0.56
0.0934792980	of 21
0.0934347715	balloon aortic
0.0934340861	p = 0.21
0.0933667946	five patients underwent
0.0933575866	95 ci 1.01
0.0933416216	established treatment for
0.0933365920	a 46
0.0932888858	ablation of atrial
0.0932442793	a pacemaker lead
0.0932050260	patients at high
0.0931891914	out of
0.0931799195	standard 12
0.0931650709	and 85
0.0931632358	rate of
0.0931247083	a prospective multicenter
0.0931095656	¬± 31
0.0931064931	6 minute
0.0931042457	the human body
0.0930750662	mean follow up
0.0930723252	n = 32
0.0930657671	in 37
0.0929888499	patients with hypertrophic obstructive cardiomyopathy
0.0929686626	male presented
0.0929249733	the safety of
0.0928612530	pacemaker implantation for
0.0928593664	outcomes for
0.0928549744	a miniaturized
0.0928439378	these data
0.0928352633	receptor potential
0.0928208901	used in
0.0928105225	a large scale
0.0927738408	p = 0.14
0.0927420730	the micra transcatheter pacing system
0.0927091570	risk of in hospital
0.0926950691	by measuring
0.0926902098	in 2019
0.0926723521	rare complication after
0.0926354606	60 years
0.0926132382	to eliminate
0.0926094661	require further
0.0926011391	the mean age
0.0925975231	a 69
0.0925380495	to stabilize
0.0925300380	with conscious sedation
0.0924920013	an mr conditional
0.0924815916	control patients
0.0924192624	for ie
0.0924005576	at 11
0.0923433363	a large number of
0.0923289843	continue to
0.0923215924	identified as
0.0922950538	mean time from
0.0922876972	5 mm
0.0922757395	concomitant coronary
0.0922437153	within 1 year
0.0921552907	wide range of
0.0921500823	septal myectomy for
0.0921304670	types of
0.0921140584	all adult patients
0.0921076900	this hypothesis
0.0920743133	rates of
0.0920647022	4 patients
0.0920220267	surgical treatment of
0.0920200808	pacemaker activity in
0.0919981291	range 1
0.0919774834	records of patients
0.0919104917	degree of
0.0918391467	adjudicated by
0.0918140698	reduction in
0.0918027439	episodes of
0.0917701827	the long term outcome
0.0917036772	outcome in patients
0.0917033250	european lead extraction
0.0916887621	in 32
0.0916024529	one patient underwent
0.0915768227	sa group
0.0915184864	the cox maze
0.0914583148	a 3d
0.0914327887	symptomatic severe
0.0914281855	implanted in patients
0.0914246289	incidence of in hospital
0.0914245732	= 0.11
0.0914111907	up to 30
0.0913370786	days after tavi
0.0913216724	an extremely
0.0911328513	permanent av
0.0911045435	located at
0.0910662744	chamber pm
0.0910558629	the time to
0.0909588812	ablation for atrial
0.0909561687	a 58
0.0909357589	an external pacemaker
0.0909019552	management of
0.0909006333	in patients receiving
0.0908889509	various types of
0.0908500533	complete atrioventricular block in
0.0908463314	the feasibility
0.0907557884	of 26
0.0907548086	isolated tricuspid
0.0907391384	from 20
0.0907225881	with less
0.0907025926	year old woman with
0.0906540547	the value of
0.0906516962	percent of
0.0906239453	to exclude
0.0905830215	tavr versus savr in
0.0905779484	an alternative to
0.0905730640	function in
0.0905363576	appropriate treatment
0.0905153684	in 54
0.0904668691	the brachiocephalic vein
0.0904623621	rhythmic activity in
0.0904587720	group compared to
0.0904405333	access to
0.0904080632	a significant increase
0.0904050484	a median of
0.0903867765	return to
0.0903754208	predictive value for
0.0903391845	treated with tavi
0.0902963470	patients with hcm
0.0902617462	the population
0.0902428577	to observe
0.0902206946	a 54
0.0902107049	3 days
0.0901495220	the major
0.0901266329	the european society of cardiology
0.0901143187	or higher
0.0900851290	= 0.06
0.0900555230	the propensity score matched
0.0900444855	an acceptable
0.0900293573	¬† 0.001
0.0900271806	and 86
0.0899899412	the mammalian
0.0899813107	baseline conduction
0.0899186795	than in
0.0899100325	those of
0.0899086109	interference between
0.0899032587	a 55
0.0898712524	7 years
0.0898222862	of cases
0.0897216913	from 2003 to
0.0897135609	a real
0.0897084582	second degree av
0.0897060306	vs 1.5
0.0896934921	between tavi and savr
0.0896769804	n = 20
0.0896764366	mrna expression of
0.0896324459	1993 to
0.0896273314	a lower
0.0896216502	associated with lower
0.0896092002	taken into
0.0895956881	the extent of
0.0895891843	the pediatric population
0.0895872866	a 28
0.0895871230	known to
0.0895790702	adoption of
0.0895549833	pocket related
0.0895391540	re used
0.0895160836	in 100
0.0895141481	the final analysis
0.0894899450	long term right ventricular
0.0894725913	an important role in
0.0894683279	the most common type
0.0894642599	= 0.04
0.0894336271	although rare
0.0894324826	mean euroscore
0.0894002085	patients with implantable cardiac devices
0.0893961885	but also
0.0893712840	and followed for
0.0893696317	an unusual cause
0.0893304359	at night
0.0892928743	in 93
0.0892550052	rate of major
0.0892456461	resulted from
0.0892299197	with higher
0.0891635388	nerve activity
0.0891334284	significant independent
0.0891257927	and 6 months
0.0891114278	the appropriate
0.0890600263	death occurred in
0.0890112655	other than
0.0889937650	exercise capacity in
0.0889806229	asystole during
0.0889739053	than after
0.0889630656	an 8
0.0889609216	the s3
0.0889596461	an atypical
0.0889554008	an independent predictor
0.0889403244	transvenous pacemaker implantation in
0.0889335108	divided into three
0.0889214811	patients requiring pacemaker
0.0889156714	treating patients with
0.0888825230	not sufficient
0.0887479617	longer duration
0.0887078760	without significant differences
0.0886895986	severe cardiac
0.0886605148	of 34
0.0886527350	p = 0.17
0.0885409297	this study examined
0.0885327951	a complication
0.0885323015	patient with severe
0.0885187842	the fontan procedure
0.0885151762	the international
0.0884866583	left superior
0.0884562020	two different
0.0884337162	non 24
0.0884303868	the brain
0.0883871949	vs 1.4
0.0883857444	influence on
0.0883788603	the treatment of severe aortic stenosis
0.0883447371	10 minutes
0.0883310489	prevented by
0.0882895947	on outcomes
0.0882195638	occurred within
0.0882144215	and 94
0.0882053924	no avb
0.0881762674	a heart rate
0.0881447869	responsiveness to
0.0881432041	seven studies
0.0881085641	risk of mortality
0.0880662744	chamber ppm
0.0879657842	implantation strategy
0.0879599176	multiple valve
0.0879457802	‚Äë like
0.0879175922	underwent left
0.0878763802	patients require
0.0878402862	died within
0.0878396523	underwent transfemoral
0.0878026040	the allegra
0.0877624482	the time of implantation
0.0877560306	vs 1.6
0.0877442968	conventional right ventricular
0.0877268540	for 4
0.0877225235	patients with cied infection
0.0876768013	the partner
0.0876705290	a 42
0.0875663442	most prevalent
0.0875627050	right superior
0.0875617307	patients with chronic kidney disease
0.0875486568	versus self
0.0875377033	a meta analysis of randomized
0.0875133245	past medical history of
0.0875004150	but not in
0.0874633238	this observational study
0.0874459761	within 72
0.0874151760	a 72
0.0874015660	and in vivo
0.0873417340	compared with patients without
0.0873295044	the total
0.0873005566	used to analyze
0.0872944454	a high mortality
0.0872760555	at 18
0.0872550022	an increased risk for
0.0872362341	patients discharged
0.0872294889	the postoperative period
0.0871939562	all consecutive
0.0871709777	managed with
0.0871479321	more recently
0.0871418951	reasons for
0.0871304729	a 66 year old
0.0870819492	prior coronary
0.0870145990	low incidence
0.0869949938	this analysis
0.0869879245	the second case
0.0869653455	a retrospective review
0.0869410957	79 years
0.0869316311	in germany
0.0869188287	hospital because of
0.0868928854	the intervention
0.0868828904	for studying
0.0868760552	at 1.5
0.0868758880	the light
0.0868432888	adverse device
0.0868408817	diagnosis of
0.0868392240	higher in
0.0868332802	in nine
0.0868170902	three months
0.0868146494	to describe
0.0867962953	vegetations on
0.0867936443	implantation of leadless
0.0867538355	n = 25
0.0867532333	the best
0.0867262395	patients with aortic valve stenosis
0.0866841496	during pacemaker implantation
0.0866820120	n = 13
0.0866781087	patients with permanent
0.0866744043	presented to
0.0866645385	the edwards
0.0866525926	year old man with
0.0866492400	a safe procedure
0.0866486807	especially if
0.0866200908	at 7
0.0866077184	patients without
0.0865994738	associated with more
0.0865892318	an epicardial pacemaker
0.0865832385	well with
0.0865808265	60 months
0.0865570410	a better prognosis
0.0865346772	low rate
0.0864969446	approach for transcatheter
0.0864532072	non af
0.0864512811	electrical activity in
0.0864077786	non sustained ventricular
0.0863970571	12 lead
0.0863395313	implantation of pacemaker
0.0863216530	an emergency
0.0863022862	a patient
0.0862852571	in hospital stroke
0.0862758799	up to 1
0.0862706816	vvi pacemakers
0.0862400620	the possible
0.0861759142	pathway ablation
0.0861404619	patients with cardiac devices
0.0861105640	outcomes in
0.0861065334	retrospective cohort study of
0.0860950344	these results
0.0860844097	a pre
0.0860688425	‚â§ 2
0.0860334528	postoperative day
0.0860324643	of leads
0.0860257604	no significant differences in
0.0860008256	did not occur
0.0859729900	between 2013 and
0.0859345692	from 2012
0.0859152666	risk factors for permanent pacemaker
0.0859135545	nature of
0.0858452818	complete heart block in
0.0858259466	to remove
0.0858242077	a higher risk
0.0857370589	a clinical
0.0857204659	a pediatric patient
0.0857044555	the feasibility of
0.0856558524	the molecular clock
0.0856090453	n = 28
0.0855386852	emergence of
0.0855068345	and western blot
0.0854936705	age 68
0.0854886795	found in
0.0854600124	bleeding occurred
0.0854295932	started on
0.0853604233	located in
0.0853531988	meta analysis of
0.0853504684	this multicenter study
0.0853280445	the majority of cases
0.0853197342	same period
0.0853065287	in drosophila melanogaster
0.0852874870	the core clock
0.0852861612	used to evaluate
0.0852612947	vs 14
0.0852574760	and at 3
0.0852569827	a common
0.0852519634	the left atrial appendage
0.0852260472	following transcatheter aortic valve
0.0852140193	in 52
0.0851248945	required for
0.0851203077	the aims of
0.0851125728	the hospital
0.0850954177	appropriate icd
0.0849808235	ablation of af
0.0849641558	a multicentre
0.0849426958	risk of ppi
0.0849132448	in younger
0.0848558990	age 65
0.0848538155	new onset persistent
0.0848372866	of 48
0.0848291370	time to
0.0848210984	on postoperative day
0.0847828419	admitted with
0.0847124660	risk of 30 day
0.0846927035	reduction in left ventricular
0.0846871936	to determine if
0.0846262654	failure requiring
0.0846133156	a major complication
0.0845969427	common cause of
0.0845807762	the relationship between
0.0845721802	last follow up
0.0845710755	to further
0.0845699953	a multi
0.0845328648	with three
0.0845179507	the day and
0.0845106111	less than 1
0.0845097294	most frequent
0.0844897127	to pace
0.0844890025	vulnerable to
0.0844600124	primary percutaneous
0.0844285785	in order
0.0843552811	uncommon but
0.0843000545	did not significantly
0.0842712463	clinical value of
0.0842589068	passage of
0.0842477854	vs 2
0.0842343687	the promri
0.0842060282	superior to
0.0841850559	the time from
0.0841790739	this question
0.0841429134	crt survey
0.0841171269	of 66
0.0841119515	ventricular contractions
0.0840909265	provided by
0.0840894841	and 31
0.0840891492	mortality score
0.0840820642	used to compare
0.0840578316	outcomes following
0.0840377467	= 0.03
0.0840158917	30 min
0.0840138958	¬± 24
0.0840125653	3 years
0.0840100030	the most common indication for
0.0840006487	population consisted of
0.0839676054	predictor for
0.0839428284	this report
0.0839306908	and efficacy of
0.0839248390	and in hospital mortality
0.0838924206	at 40
0.0838908932	the coronary sinus
0.0838796203	advanced atrioventricular
0.0838323572	and long term mortality
0.0838286729	30 s
0.0838262322	the effects of
0.0838118151	the evolut r
0.0838105670	from 0
0.0837707489	the above
0.0837383146	high procedural
0.0837316672	the prosthesis
0.0837235333	isolated septal
0.0837195619	the case
0.0836917896	first case
0.0836897805	difference in in hospital
0.0836714545	an inverse
0.0836529837	that time
0.0836484097	by using
0.0836389232	group i
0.0835650729	not known
0.0835524070	the reprise
0.0835308814	in patients with atrial fibrillation
0.0835096461	and fluoroscopy times
0.0835086734	a limited
0.0834929392	in patients with severe aortic stenosis
0.0834843391	incidence of death
0.0834637646	patients undergoing mitral
0.0833552786	managed by
0.0833506908	three patients
0.0833003184	twenty seven patients
0.0832957451	95 ci 1.03
0.0832748392	the right atrial
0.0832592048	significant increase
0.0832499415	this study sought to assess
0.0832486265	15 ¬† years
0.0832407080	percentage of
0.0831961149	safety and feasibility of
0.0831903072	clinical outcomes after
0.0831444554	non 24 hour
0.0831293018	approach in patients
0.0831200024	or need for
0.0831164924	= 0.29
0.0830995522	five patients
0.0830782311	implicated in
0.0830395341	associated with significant
0.0830133943	analyzed using
0.0830083320	and thus
0.0830014819	the national inpatient
0.0829872961	variation in
0.0829700756	outcomes of patients
0.0829655630	underwent cied
0.0829210597	groups according to
0.0828596294	the axillary vein
0.0828268520	applied to
0.0828139893	improved quality of
0.0828119964	performed by
0.0828093488	provision of
0.0827994127	complex duration
0.0827673877	divided into 2
0.0827651262	patients died during
0.0827493408	n = 73
0.0827489023	more than two
0.0827317673	patients with chf
0.0827276348	patients with refractory
0.0826945155	the frequency
0.0826669988	indication for pacing
0.0826616699	addition of
0.0826312876	changes during
0.0826161981	not to
0.0825977940	= 3
0.0825484259	the cephalic vein
0.0825209847	needs to
0.0825141781	the model
0.0825063816	improvements in
0.0824761951	a rare cause of
0.0824568916	events included
0.0824522431	composite outcome of
0.0824517841	the editor
0.0824482891	evidence of
0.0824222916	= 0.45
0.0824165437	in patients with unexplained syncope
0.0824000588	from 6
0.0823932779	patients with and without
0.0823857011	none of
0.0823772654	vulnerability to
0.0823615644	completion of
0.0823475299	after transcatheter
0.0822866902	only 1
0.0822732564	follow up of
0.0822428916	advancements in
0.0822142454	organization of
0.0822069436	and 2014
0.0821931936	with 95
0.0821817621	screen for
0.0821665590	the circadian
0.0821492491	no clear
0.0821363747	this difference
0.0820936423	and 73
0.0820683530	electrophysiological properties of
0.0820615432	knockdown of
0.0820571485	20 mmhg
0.0820131848	right coronary
0.0819956243	the risk factors
0.0818942701	= 0.54
0.0818685489	the national
0.0818560949	reduced left ventricular
0.0818401022	in intermediate risk patients
0.0818214534	need for new pacemaker
0.0818080089	two or more
0.0818006544	the perceval prosthesis
0.0817907398	and 5 year
0.0817901619	overexpression of
0.0817789277	t =
0.0817775737	center registry
0.0817211842	month later
0.0817038305	a significantly lower
0.0816736992	the standard treatment
0.0816631402	higher in hospital
0.0816506137	implantation remains
0.0816459962	the total number
0.0816355231	patient undergoing
0.0816294679	analysis indicated
0.0815926834	access related
0.0815914926	= 0.89
0.0815175470	= 0.08
0.0815161981	from two
0.0814817633	rate increased
0.0814167576	advanced av
0.0814041244	vs 12
0.0814033719	calculated from
0.0813830916	in men
0.0813728854	the short
0.0813671382	the j valve
0.0813435518	group 3
0.0813090886	temporal trends of
0.0813002534	6 days
0.0812937150	the first time
0.0812780038	95 ci 1.11
0.0812564800	to conduct
0.0812136809	expressed as
0.0811847248	study conducted
0.0811783123	underwent aortic valve
0.0811735417	the pacemaker leads
0.0811526240	proportions of
0.0811425907	in 42
0.0811304470	other forms of
0.0810809186	in 74
0.0810414325	atrial volume
0.0809723654	management of cardiac
0.0809656015	diagnostic value of
0.0809517191	a conventional
0.0809403559	no significant differences between
0.0809200774	outcomes of tavr
0.0808981460	lower mortality
0.0808816037	not statistically
0.0808400395	the age of
0.0808338498	safe and
0.0808020438	in pacemaker patients
0.0807967121	the long term prognosis
0.0807564124	the average number of
0.0807545730	epicardial pacemaker implantation in
0.0807262374	cardiac perforation by
0.0807210826	risk factors for ppm
0.0807110508	circadian rhythmicity in
0.0806966150	implantation in patients
0.0806761076	a left bundle branch block
0.0806664568	in heart failure patients
0.0806655454	within 90
0.0806604278	avr +
0.0806498631	the first case
0.0806478100	divided by
0.0806356464	other brain
0.0806178661	+ pci
0.0805754017	in older adults
0.0805306760	epicardial permanent
0.0805278594	all cause mortality rates
0.0805058491	to estimate
0.0805043495	right ventricular septal
0.0804732288	a statistically significant
0.0804681912	developed complete
0.0804307717	2014 to
0.0804282603	severe aortic stenosis at
0.0804111028	patients with icds
0.0803803276	evaluated by
0.0803351871	30 day mortality rate
0.0803098904	underwent temporary
0.0803060052	level of
0.0802949066	most often
0.0802613847	this relationship
0.0802586016	occurred in 6
0.0802497833	possible to
0.0802492360	a trend towards
0.0802468353	ablation of atrial fibrillation
0.0802341013	aspects of
0.0802259934	may 2010
0.0802206427	four patients
0.0802108627	30 day outcomes
0.0802003964	the short term
0.0801868014	compared outcomes
0.0801809720	type channels
0.0801558428	pacemaker implantation in patients
0.0801179673	in patients undergoing tavi
0.0800735690	an implantable
0.0800694104	the effectiveness
0.0800558174	higher prevalence
0.0800553759	2 years
0.0800536742	preoperative right
0.0799977000	at 60
0.0799528079	the procedural success rate
0.0799281933	hours after
0.0798890442	common causes
0.0798494042	the 30 day mortality
0.0798389553	novel technique
0.0798336687	the mechanisms
0.0797774713	timing system
0.0797515108	discharge group
0.0797344319	the fda
0.0797148939	demonstrated high
0.0796945155	the index
0.0796905140	and 78
0.0796531943	small cell
0.0796487682	the sinus venosus
0.0796415354	restoration of
0.0796381335	the drosophila
0.0796371302	patients with advanced
0.0795939014	infection caused
0.0795828292	to study
0.0795376485	= 0.09
0.0795219592	these data indicate
0.0795167975	the pacemaker lead
0.0794647595	the subclavian vein
0.0794625638	= 1.00
0.0794622067	patients undergoing tavi with
0.0794617463	surgical repair of
0.0794458686	in elderly patients
0.0794406592	interval ‚â•
0.0794401261	risk of permanent pacemaker implantation
0.0794105665	high levels
0.0793596557	late pacemaker
0.0793315617	in addition to
0.0793306321	patient with complete atrioventricular block
0.0792808684	the majority
0.0792802918	30 days post
0.0792343429	78 years
0.0792204287	patients admitted for
0.0792146254	the 5 year
0.0791705718	for degenerated
0.0791675922	study assessed
0.0791625948	three groups
0.0791480206	a total of 5
0.0791164924	= 0.24
0.0791081642	r =
0.0790976533	previous cardiac
0.0790843036	together with
0.0790745497	time delay
0.0790646696	minutes vs
0.0790258362	an animal
0.0790235282	85 year old
0.0790062646	to quantify
0.0789628695	an updated
0.0789514881	individual risk
0.0789420058	did not increase
0.0788729948	the 24 h
0.0788563136	¬† month
0.0788559296	similar 30 day
0.0788238268	devices implantation
0.0788199396	the secondary
0.0787953277	rhythm device
0.0787861395	an 18
0.0787347695	= 0.10
0.0787294952	patients suffering
0.0787207550	of patients with
0.0787108829	nodal pacemaker
0.0786869853	a ddd pacemaker
0.0786831573	the fontan operation
0.0786735969	this condition
0.0786578991	of more than
0.0786417261	an infected
0.0786382992	high number
0.0785868731	switched to
0.0785836342	transcatheter aortic valve replacement in
0.0785741898	patients with small
0.0785651370	an absolute
0.0785328353	seen in
0.0785264532	the contralateral side
0.0785043047	the 6
0.0785030555	0 1
0.0784953518	underwent ppm
0.0784746720	resolution of
0.0784587584	months post
0.0784409714	and 2015
0.0784385151	subjects without
0.0784102158	10 year
0.0783550312	frequently used
0.0783525369	two thirds of
0.0783291205	treatment with
0.0783036600	81 years
0.0782753500	urgent pacemaker
0.0782366465	for up to
0.0782236539	associated with less
0.0782169418	survival of patients
0.0782121430	at home
0.0781401397	population of patients with
0.0781393830	a mechanical
0.0781005632	predisposing to
0.0780938987	n = 37
0.0780832385	need of
0.0780593529	with preserved lvef
0.0780127363	approach for
0.0780025485	the cell membrane
0.0779947781	to resolve
0.0779470278	the median
0.0779141286	n ¬† = ¬† 8
0.0779101136	to generate
0.0779073838	the left ventricular lead
0.0778998073	with severe symptomatic aortic stenosis
0.0778942701	= 0.20
0.0778927499	properties of
0.0778797564	within 48
0.0778722351	year clinical outcomes
0.0778582536	the uk
0.0778468846	the first study
0.0778455320	the 39
0.0778431989	history of heart failure
0.0778372866	a 34
0.0778288815	diagnostic accuracy of
0.0778193590	a high index of
0.0778170069	= 0.003
0.0778105179	ms vs
0.0777977405	correlate with
0.0777756972	twenty six patients
0.0777735156	predictors of late
0.0777635525	for primary prevention
0.0777603090	and 47
0.0777533793	a subset of
0.0777239190	the rv apex
0.0776838790	asked to
0.0776741745	a cardiac resynchronization therapy
0.0776603451	with left bundle branch block
0.0776233982	after implantation
0.0776210843	also associated with
0.0775826699	to identify patients
0.0775770405	in 44
0.0775735685	the average
0.0775374456	cost effectiveness of
0.0775135771	a predictor of
0.0775032075	in person
0.0775007852	and 1.9
0.0774879353	decrease in
0.0774792214	the electrocardiogram
0.0774750901	and in hospital outcomes
0.0774694331	a history of hypertension
0.0774345376	significantly different between
0.0774035100	the quality of life
0.0774004144	treatment for patients with
0.0773875436	degrees of
0.0773809344	not feasible
0.0773747555	the sf 36
0.0773728854	the expression
0.0773428079	13.1 vs
0.0772775603	the quality of life of
0.0772767690	= 0.90
0.0772457245	exacerbation of
0.0772244165	rate regulation
0.0771512961	of at least
0.0770924194	the composite endpoint
0.0770558907	implanted in
0.0770311171	roles in
0.0770067927	a 7 year
0.0769724187	and 34
0.0769490022	matched studies
0.0769487436	patients with diabetes
0.0769144556	the primary end
0.0768460783	in japan
0.0768456814	the icc network
0.0768155950	mortality in patients
0.0767361602	the most common complication
0.0766668769	the inability
0.0766546363	n = 34
0.0766303875	divided into two
0.0766056825	pacemaker device
0.0766004880	age 70
0.0765895426	at 24 months
0.0765483949	to assist
0.0765311310	‚â• ¬†
0.0765095241	induced changes in
0.0765079193	at 25
0.0764996637	in 2012 to
0.0764917034	a nationwide
0.0764599403	the tricuspid
0.0764537679	kg day
0.0764479964	the tip of
0.0764445155	the small
0.0764408319	strongly associated with
0.0764375258	eight patients
0.0764331144	predictors of in hospital
0.0763872368	n = 12
0.0763524397	after 10
0.0763281304	age ¬†
0.0763196970	occurred in 2
0.0763126189	the current
0.0762954827	syncope caused by
0.0762894634	ill patients
0.0762479935	to identify predictors
0.0762350854	the aortic annulus
0.0762221656	these effects
0.0762161981	as to
0.0761929557	savr +
0.0761865125	guided group
0.0761463265	all p 0.001
0.0761387138	five cases
0.0761153631	8.4 vs
0.0760852967	the micra leadless pacemaker
0.0760662261	vs 1
0.0760644674	developed severe
0.0760445745	this treatment
0.0760355665	standard treatment
0.0760225698	high risk for
0.0759989347	1 year outcome
0.0759944379	the most prevalent
0.0759619932	to establish
0.0759401285	compared to patients without
0.0759394271	the optic
0.0759315636	adjusting for
0.0759219113	associated with mortality
0.0759073183	spectrum of
0.0758881126	for patients with
0.0758717785	centre study
0.0758673768	septal lead
0.0758501270	4 8
0.0758469764	1.5 ¬†
0.0758254769	24 hr
0.0758179440	deletion of
0.0758137148	= 0.53
0.0757952474	year after implantation
0.0757938759	= 0.7
0.0757606705	a 23
0.0757558808	risk of cardiac
0.0757215344	deterioration of
0.0756813251	a small
0.0756733353	the portico
0.0756012200	a diagnostic
0.0755901339	sent to
0.0755887114	the 2 year
0.0755570595	born with
0.0755304367	week after
0.0755177560	a pacemaker or
0.0755101435	and 88
0.0755042451	a major
0.0755021345	small number of
0.0754976005	these results indicate
0.0754801166	permanent pacemaker implantation in patients
0.0754763993	savr ¬† = ¬†
0.0754528648	patients with complete atrioventricular block
0.0754497133	at two
0.0754194060	9 ¬† years
0.0753958240	requirement for
0.0753803953	overall 30 day mortality
0.0753605653	n = 26
0.0753450271	and larger
0.0753404568	a tertiary care
0.0752989956	early results of
0.0752942641	the crab
0.0752885103	in four patients
0.0752778850	and 12 months
0.0752620053	complicated with
0.0752613537	treated with tavr
0.0752444503	an aortic
0.0752366465	the need to
0.0752113506	n = 40
0.0751856932	a biological pacemaker
0.0751766206	a combination of
0.0751648155	years later
0.0751404489	this study evaluated
0.0751374314	odds ratio or =
0.0751209856	a custom
0.0750987867	transvenous lead extraction in
0.0750920927	total of 20
0.0750831422	underwent transvenous
0.0750352331	18 years of age
0.0750318779	dependent patient
0.0750272828	1 year of
0.0750111960	26 months
0.0750068792	20 mm
0.0749945198	slow waves in
0.0749592214	the algorithm
0.0749592208	the most effective
0.0749592073	needed permanent pacemaker
0.0749076146	ablation therapy
0.0749016196	from 2008 to
0.0748649056	of 42
0.0748155950	considered in patients
0.0747697976	assessed using
0.0747410262	or more
0.0747246465	a pacemaker implanted
0.0747192265	a three dimensional
0.0746597945	in patients with cieds
0.0746555448	the fast
0.0746386886	the proportion of
0.0746369933	85 years
0.0746196503	in patients undergoing transcatheter aortic valve
0.0746118083	lower risk for
0.0745981805	in patients with heart failure
0.0745632734	between tavr and savr
0.0745594087	independently associated with increased
0.0745339460	this technique
0.0745290827	dwell time of
0.0745175659	the frequency of
0.0745089770	parts of
0.0744945604	in sinus rhythm
0.0744740647	from august
0.0744683796	confirmation of
0.0744438264	quantification of
0.0744415336	enrolled into
0.0744254542	significant difference in
0.0744239412	mortality in
0.0743901479	subclinical cardiac
0.0743657007	detected in
0.0743491983	mean follow up time
0.0743345314	period 2
0.0743171340	higher percentage of
0.0743087073	persistence of
0.0743044608	an earlier
0.0742929753	ppm implantation after
0.0742729249	two patients underwent
0.0742574627	compatible with
0.0742405739	interruption of
0.0742220465	decided to
0.0742116119	permanent pacemaker implanted
0.0742042758	patients with unexplained
0.0741939167	in myotonic dystrophy type 1
0.0741764830	the conventional
0.0741582205	valve reoperation
0.0741318779	present study
0.0741069627	adjacent to
0.0740827152	cessation of
0.0740777049	at implant
0.0740695890	8.9 years
0.0740441088	reversal of
0.0740431804	the mean time
0.0740223857	for studies
0.0740067252	year of
0.0739835787	such patients
0.0739792431	several factors
0.0739660457	predictors of new onset
0.0739626366	year follow up period
0.0739464661	underwent primary
0.0739428169	left bundle branch block after
0.0739425929	at latest follow up
0.0739257502	developments in
0.0739131470	patients referred for
0.0739127552	no af
0.0739082916	unlikely to
0.0738869529	cohort of patients with
0.0738842887	diagnosed as
0.0738708727	within 5
0.0738619373	to gain
0.0738506115	af undergoing
0.0738326455	progression of
0.0738082816	at three
0.0737924898	a transient
0.0737832688	months after
0.0737715331	the sleep wake
0.0737683412	heart syndrome
0.0737642570	significantly higher in patients
0.0737504005	aortic valve implantation using
0.0737478479	gentleman with
0.0737306862	resistant to
0.0736689954	a low complication
0.0736574184	therapy for patients with
0.0736486442	a circadian
0.0736387335	after transcatheter aortic valve implantation with
0.0736375913	the perioperative
0.0736106430	cardiac resynchronization therapy in
0.0735876542	pacing versus
0.0735760335	total atrioventricular
0.0735735885	a primary
0.0735465270	the 10
0.0735388418	pacemaker patient
0.0735381421	patients submitted to
0.0735188081	an unusual case
0.0735115850	patients with isolated
0.0734872619	obtained using
0.0734855044	an indication for
0.0734791508	few data
0.0734567140	a paucity of data
0.0734488572	the heart's
0.0734248871	heart failure questionnaire
0.0733989611	risk for
0.0733806590	heart failure with
0.0733640505	and 44
0.0733503058	bradycardia syndrome
0.0733348343	underwent tavr with
0.0733259654	days before
0.0733136889	defined by
0.0733044608	this survey
0.0732046449	from 2007 to
0.0731969031	a random effects
0.0731929326	in 2009
0.0731909714	of 14
0.0731884464	patients with severe as
0.0731554497	and lv ejection fraction
0.0731318779	major clinical
0.0731054658	valve replacement using
0.0730989743	with severe aortic stenosis undergoing
0.0730939391	¬† m
0.0730851998	therapy in
0.0730800770	the hepatic
0.0730415006	a cohort of
0.0730242794	an internal
0.0730033584	performances of
0.0729952111	and new pacemaker implantation
0.0729668223	number of implanted
0.0729327515	the hv interval
0.0729304270	block after transcatheter aortic valve implantation
0.0728828648	at one
0.0728615756	this context
0.0728593557	by contrast
0.0728570444	persisted after
0.0728563760	entrained to
0.0728458008	no procedure related
0.0728282695	an average
0.0728155647	a novel technique
0.0728147009	fifteen patients
0.0728115879	and duration of
0.0728051660	¬† s
0.0728032834	aortic valve calcium
0.0727852350	n ¬† = ¬† 6
0.0727847384	the central
0.0727830453	patients with crt
0.0727468343	a prospective observational
0.0727456912	animal model of
0.0727347695	= 0.21
0.0727151214	to investigate whether
0.0727120168	analysis to compare
0.0727029921	the ventricular lead
0.0726846987	decreased over
0.0726801494	a 41
0.0726248266	to construct
0.0726248266	to summarize
0.0726172133	time from
0.0726136173	patients suffering from
0.0725886576	crucial for
0.0725855528	range iqr
0.0725511987	the final
0.0725125683	for 7
0.0725049384	to initiate
0.0724802693	disparities in
0.0724639929	v vs
0.0724636299	to enhance
0.0724333660	the phase
0.0724116361	this prospective observational
0.0724105704	closely associated with
0.0723894029	circadian period of
0.0723883580	in line with
0.0723807129	between 2009
0.0722960877	critical for
0.0722903818	days of
0.0722788585	increased over time
0.0722658761	the dose
0.0722493343	approach in
0.0722465841	the funny current
0.0722362325	p value =
0.0721491232	atrioventricular block occurred
0.0721446623	2012 to 2015
0.0721330613	other factors
0.0720989329	a self
0.0720910994	a defibrillator
0.0720724250	the central circadian
0.0720486888	history included
0.0720467565	2013 to
0.0720291257	evaluated in
0.0719847661	especially in
0.0719784696	the european
0.0719679038	safely performed in
0.0719661199	edge of
0.0719380864	may 2017
0.0718868322	an analysis
0.0718836316	died during
0.0718821410	successfully performed in
0.0718820759	transcatheter aortic valve implantation in patients
0.0718707220	in three patients
0.0718640340	even for
0.0718339598	determinants of
0.0718287331	obtained by
0.0718194135	the development
0.0718012141	induced pacemaker
0.0717843057	more likely
0.0717745482	normal coronary
0.0717649029	admitted for
0.0717567756	the transfemoral
0.0717556493	in seven
0.0717153527	the perceval
0.0717110000	‚â• 5 ¬†
0.0717043920	= 0.0001
0.0717001418	at high risk for
0.0716827274	cohort analysis
0.0716576609	implantation after tavr
0.0716481779	the av node
0.0716469572	significant change in
0.0716340549	an automated
0.0716251068	excluding patients with
0.0716204866	provide new
0.0716188643	to complete av block
0.0715689095	chinese patients
0.0715575720	a 64 year old
0.0715254355	incidence of permanent pacemaker implantation
0.0715239813	safety and effectiveness of
0.0714966335	and outcomes in
0.0714918510	a comparison
0.0714868741	treatment of
0.0714695922	evidence from
0.0714671557	signs of
0.0714198307	presence or absence of
0.0713936372	in 2008
0.0713924735	reduced cardiac
0.0713722886	a micra transcatheter pacing system
0.0713286040	the magnetic field
0.0713190259	the evolut
0.0713178850	73 years
0.0713049828	and 23
0.0712981849	the implantation procedure
0.0712514988	no ppi
0.0712488877	the tavr group
0.0712468417	advances in
0.0712340509	underwent implantation
0.0712151717	the diastolic depolarization
0.0712086454	p = 1.0
0.0712038499	not recommended
0.0711844523	associated with higher mortality
0.0711723492	pacemaker group
0.0711668317	all p
0.0711599665	evaluate whether
0.0711591205	model of
0.0711565517	responsive to
0.0711524831	care for patients with
0.0711514328	a good
0.0711020933	interval ci
0.0710908746	dual chamber pacemaker implantation in
0.0710835610	a previously implanted
0.0710694135	the medical
0.0710459017	of 40
0.0710447243	rate of permanent pacemaker
0.0710354791	and 91
0.0710256778	mortality at 30
0.0710217057	out of hospital
0.0710190558	or life threatening bleeding
0.0709995347	compared between patients
0.0709891343	case of
0.0709788010	significantly shorter in
0.0709754184	the combined endpoint
0.0709347538	similar in patients
0.0709264302	to induce
0.0709140252	treating patients
0.0709079914	these differences
0.0708947087	the safety and efficacy of
0.0708934662	not suitable
0.0708801231	a nationwide cohort
0.0708714383	associated with increased risk of
0.0708641806	valve system
0.0708472695	an excellent
0.0708257871	cases of
0.0708235593	this study included
0.0708168264	the pulse generator
0.0708067252	on two
0.0708052179	occurring during
0.0707362681	this procedure
0.0706865690	the right atrial appendage
0.0706692675	the most appropriate
0.0706642238	determined using
0.0706496654	the initial
0.0706151564	2013 and
0.0706139642	the real world
0.0705979130	a part of
0.0705943635	differences regarding
0.0705887543	targets for
0.0705886273	and changes in
0.0705664867	patients referred
0.0705187867	outcomes with
0.0704900343	within 12 months
0.0704865503	n ¬† = ¬† 15
0.0704686430	a dual
0.0704572599	society of
0.0704571454	no device related
0.0704524676	aortic valve implantation with
0.0704066421	excluded patients with
0.0703756451	at follow up
0.0703523031	in patients with new
0.0703522035	and 1 patient
0.0703452694	transfected with
0.0703396230	damage to
0.0703279237	long term cardiac
0.0703278054	between two
0.0703166695	in 3 patients
0.0703149741	¬† = ¬† 4
0.0702957197	to adjust
0.0702825356	assess whether
0.0702355875	4 years
0.0702182570	the membrane
0.0702123851	cells of
0.0702109319	duration of
0.0701835163	in 2 patients
0.0701719830	¬† 50
0.0701414001	contributions of
0.0701413179	the circadian system
0.0701284899	a need for
0.0701070856	predictors of permanent pacemaker
0.0701069456	an international
0.0701036615	between patients with and without
0.0700738343	in hospital outcomes of transcatheter
0.0700646265	for 3
0.0700506610	in heart failure patients with
0.0700490431	incidence of atrial fibrillation
0.0700481551	in patients with congenital heart disease
0.0700375819	median length of
0.0700353553	the course of
0.0700168262	a mean follow up period of
0.0699900527	not predict
0.0699578531	hcn channels in
0.0699490022	patient recovered
0.0699308711	pacemaker implanted for
0.0699242705	perforation during
0.0698925525	indication for ppm
0.0698446277	conduction disturbances after
0.0698018410	levels of
0.0697962327	the es3
0.0697594625	every patient
0.0697024187	and 42
0.0696996027	the number of patients
0.0696984500	from 3
0.0696889387	n ¬† = ¬† 5
0.0696258340	the occurrence
0.0696163632	appeared to
0.0696122011	aim of
0.0696063603	outcome after
0.0695908547	the full
0.0695773288	consecutive patients undergoing pacemaker
0.0695644771	predictors of long term
0.0695545707	underwent dual
0.0695403902	used to predict
0.0695209097	within 6 months
0.0695193611	in 87
0.0695075587	the existence of
0.0694978903	valve replacement in patients
0.0694801116	the mortality rate
0.0694707052	the index hospitalization
0.0694649056	of 0.5
0.0694493343	reduced in
0.0694243823	to report
0.0694241305	patients with dual chamber
0.0694122710	a transvenous pacemaker
0.0693951364	atrial pressure
0.0693605659	patients with sinus rhythm
0.0693339849	the results showed
0.0693195393	this study suggests
0.0693137148	= 0.26
0.0693028129	months follow up
0.0692565938	infection caused by
0.0692493343	demonstrated in
0.0692446229	vs 0.9
0.0692292083	significant impact
0.0692287633	management of patients with
0.0692269179	catheter ablation of
0.0692243777	at last follow up
0.0692089156	day 5
0.0692061421	showed complete
0.0692040217	of first implants
0.0691881555	from 2000
0.0691460865	an effective and safe
0.0691173507	significantly greater in
0.0691108460	in new zealand
0.0691097103	the micra ‚Ñ¢
0.0690766863	transfemoral tavr with
0.0690704924	postoperative conduction
0.0690373650	in 98
0.0690081378	the number
0.0690033584	dissemination of
0.0690032930	an unusual cause of
0.0689948833	21 days
0.0689887074	venous access for
0.0689522415	one month after
0.0689441737	the lead tip
0.0689402961	combinations of
0.0689151232	performed to
0.0688857759	a similar
0.0688713913	6 ¬† days
0.0688711213	a risk factor for
0.0688492882	a long
0.0688426961	no longer
0.0688361199	superiority of
0.0688331450	upgrade from
0.0688276753	the society of thoracic surgeons
0.0687490022	¬† beats
0.0687283643	showed significantly
0.0687082304	from inception
0.0686973566	population included
0.0686939384	83 years
0.0686848518	the day after
0.0686744070	interval between
0.0686711076	change in
0.0686529047	a randomized controlled
0.0686422734	in patients with persistent
0.0686415546	the basis of
0.0686156930	pm system
0.0686073332	de novo pacemaker
0.0686065366	analysis of pacemaker
0.0686022484	from 2004 to
0.0685934457	to better
0.0685920576	in patients ‚â•
0.0685857176	a 5 year
0.0685831195	iccs from
0.0685641301	the in vivo
0.0685545721	the patient population
0.0685495314	the use
0.0685448737	stroke occurred in
0.0685436478	evaluate if
0.0685366156	prospective clinical
0.0684847946	electrical activity of
0.0684830997	and 30 day mortality
0.0684724445	study suggest
0.0684587479	time between
0.0684494177	significantly lower with
0.0684352588	an in vivo
0.0683985805	underwent permanent
0.0683932813	between 2004 and
0.0683758952	into 3 groups
0.0683701473	achieved by
0.0683517957	this disease
0.0683226710	17 years
0.0683178363	3.0 ¬†
0.0683059207	approved for
0.0682920917	average time
0.0682843458	but not by
0.0682832861	the detection
0.0682592333	mmhg vs
0.0682458398	conventional aortic
0.0682122378	the general
0.0681978080	predictors of pacemaker implantation
0.0681550396	on admission
0.0681429990	the edwards sapien
0.0681336987	induced phase
0.0681318526	patients with left bundle
0.0681219599	on exercise capacity
0.0680688832	atrial fibrillation with
0.0680101726	the free running
0.0680075319	predicted by
0.0679758954	patients at risk for
0.0679725871	no change
0.0679592214	the direct
0.0679592214	the electrode
0.0679580126	this nationwide
0.0679545931	the cardiovascular system
0.0678729611	gold standard for
0.0678672133	this system
0.0678607642	a mean of
0.0678552281	for patients undergoing
0.0678515495	this study assessed
0.0678255320	and 83
0.0677998851	implantation for
0.0677973995	an 87
0.0677827181	a possible
0.0677562542	7.4 vs
0.0677455366	and at 30
0.0677290833	the precise
0.0677149348	other causes
0.0677050365	continuation of
0.0676817618	a retrospective review of
0.0676604303	and predictors of
0.0676388956	at 10 years
0.0676347110	33 ¬†
0.0675953018	= 12
0.0675784057	= 34
0.0675634266	between 2010
0.0675374695	under fluoroscopic
0.0675333992	implanted electronic
0.0675246341	three different
0.0675130043	a high percentage of
0.0674805082	1.9 vs
0.0674642035	in patients with prior
0.0674503046	follow up results
0.0674501154	a biventricular pacemaker
0.0674436244	atrioventricular block after
0.0674426134	applicability of
0.0674375258	seven patients
0.0674327419	in korea
0.0674274866	in hospital outcomes of
0.0674212688	gene expression in
0.0673849237	the voltage
0.0673806496	rare cause of
0.0673706039	the time of device
0.0673510083	an atrial
0.0673050633	decline in
0.0673049230	hospital outcomes
0.0673038571	and heart failure hospitalization
0.0672758131	the fs
0.0672627799	clinical signs of
0.0672438974	increased in
0.0672262705	stable during follow up
0.0672207835	20 years
0.0672206427	six patients
0.0672111961	6.9 ¬±
0.0672031063	¬± 20
0.0672030526	a femoral approach
0.0671949733	the efficacy of
0.0671941285	developed to
0.0671911711	and then
0.0671874946	a valuable
0.0671838734	a ppm
0.0671712840	of less than
0.0671180886	proof of
0.0671162903	a left sided
0.0670953018	= 10
0.0670909247	placed for
0.0670885643	patients with concomitant
0.0670713740	predictors for
0.0670419453	analyzed data
0.0670356736	used by
0.0670355691	a central pacemaker
0.0669806335	the master
0.0669731537	to aid
0.0669638161	a later
0.0669464979	70 years
0.0669457449	mathematical model of
0.0669455786	per 1
0.0669424840	the patient experienced
0.0669304703	incidence of stroke
0.0669171400	between 2009 and
0.0669062234	a safe
0.0668980254	patients with high degree
0.0668767111	regard to
0.0668670031	2015 to
0.0668335844	follow up time
0.0668323043	chamber device
0.0668230631	mortality at 1
0.0668207818	prognostic value of
0.0668110000	= 37
0.0668054591	45 year old
0.0667710916	the immediate
0.0667680130	participate in
0.0667601021	compared with other
0.0667424879	up to 1 year
0.0667303060	the secondary outcome
0.0667286542	after cied implantation
0.0667009714	1 year outcomes
0.0666800457	description of
0.0666772679	for pacemakers
0.0666519865	alteration in
0.0666498088	invasive cardiac
0.0666432348	trends in
0.0666382598	to restore
0.0666357593	3 6
0.0666267165	with congenital heart disease
0.0666245656	patients at high risk
0.0666157607	this study sought to
0.0666100991	to utilize
0.0665772722	the patient died
0.0665536743	4 cm
0.0665311105	a pacemaker dependent patient with
0.0665272337	a 59
0.0665256413	predictor of
0.0665195154	the left anterior descending
0.0665126829	the optimal
0.0665060430	establishment of
0.0664829971	the causes of
0.0664701231	on computed tomography
0.0664681753	to rule
0.0664585212	0 to
0.0664507100	all patients receiving
0.0664503680	mitral valve repair in
0.0664482853	corresponding to
0.0664360592	in females
0.0664210788	3 7
0.0664181360	significantly higher incidence of
0.0664136508	10 patients
0.0664057449	24 patients
0.0664025701	associations with
0.0664021092	for 1 year
0.0663832428	from 2010 to
0.0663808791	in five patients
0.0663663913	to identify risk factors
0.0663602527	the french
0.0663121889	induced atrial
0.0662809822	= 0.02
0.0662762863	from 2011 to
0.0662665621	a simulated
0.0662407513	function in patients
0.0662341695	a 2 year
0.0662171035	survival of patients with
0.0662006178	the median age
0.0661894925	matched patients
0.0661805243	patients with intermediate
0.0661693730	within 3 months
0.0661619509	of follow up
0.0661551280	only 3
0.0661434796	the acurate
0.0661110055	a reasonable
0.0660968843	at risk
0.0660743151	in patients with hypertrophic obstructive cardiomyopathy
0.0660507359	after crt implantation
0.0660245836	presented with severe
0.0660066410	also known as
0.0659789942	at time of
0.0659721520	of 39
0.0659588562	the activation
0.0659409860	to adjust for
0.0658978184	84 years
0.0658932813	between 2015 and
0.0658156990	the valve academic research consortium 2
0.0658124833	95 ci 1.2
0.0657783225	the american college of cardiology
0.0657674469	the introduction of
0.0657526902	a 50 year old
0.0657388368	valve implantation using
0.0657091298	3.1 ¬±
0.0656772019	remote monitoring of
0.0656277580	patients developed new
0.0656257635	higher with
0.0656086337	and three patients
0.0656054153	90 years
0.0655771879	the balloon expandable
0.0655733900	points included
0.0655729210	a cause of
0.0655613104	= 0.99
0.0655606467	¬± 30
0.0655532891	taking into
0.0655467612	required pacemaker
0.0655361539	on day
0.0655333992	severe sinus
0.0655201917	conduction abnormalities after
0.0655191107	the goal of
0.0655170897	in group 2
0.0655157782	the day of
0.0654984402	the present study aimed to
0.0654751797	this association
0.0654628648	time in
0.0654579094	the balloon expandable sapien 3
0.0654554854	late lead
0.0654516573	in vitro study
0.0654190212	may 2014
0.0654048044	findings from
0.0653977676	report of
0.0653921412	in 1 patient
0.0653674444	an 84
0.0653591506	complete device
0.0653408605	creation of
0.0653351536	pacemaker cells in
0.0653135861	valve in
0.0652990697	risk of heart failure
0.0652887200	40 patients
0.0652829922	with multiple comorbidities
0.0652803854	proposed as
0.0652800140	risk patients
0.0652607952	avoidance of
0.0652567791	for better
0.0652557032	a strong
0.0652166066	in patients with pacemakers
0.0651961981	day in
0.0651855615	to distinguish
0.0651393504	year old woman presented with
0.0651313500	option for patients with
0.0650944871	4.0 vs
0.0650748264	implantation with
0.0650729265	undergoing ppm
0.0650660164	the patient received
0.0650632041	clinical outcomes following
0.0650630828	ease of
0.0650485726	in 43
0.0650327689	an 85
0.0650188137	2.2 vs
0.0650129823	non randomized
0.0650075272	progress to
0.0649777479	the wcd
0.0649342284	without complications
0.0649329489	1.3 vs
0.0649299995	progression to
0.0649197767	‚Ñ¢ system
0.0649075846	evaluated with
0.0648924186	to keep
0.0648595700	root mean
0.0648589315	and outcomes of
0.0648359574	the atrioventricular node
0.0648160004	outcomes for patients
0.0648160004	extraction of pacemaker
0.0648010572	a randomized
0.0648006137	postoperative follow up
0.0647981726	an 81
0.0647793423	lead extraction using
0.0647584105	patients enrolled in
0.0647536327	dual chamber pacemaker implantation for
0.0647533886	even with
0.0647281563	in asia
0.0647277403	clinical implications of
0.0647108116	the technical
0.0647099303	n = 18
0.0646997932	distinct from
0.0646502081	a crt pacemaker
0.0646490089	incidence rates of
0.0646470405	a unique
0.0646420990	with sleep apnea
0.0646311228	stroke events
0.0646046107	first month
0.0645927219	an 83
0.0645715065	risks associated with
0.0645469303	at autopsy
0.0645429336	in two patients
0.0645346597	occurred in 3
0.0645243047	the 8
0.0645145015	the cause of
0.0645127263	an approach
0.0644937996	1 av block
0.0644747335	relief of
0.0644509641	the portico valve
0.0643982359	imaging of
0.0643799582	patients remained
0.0643467163	an intracardiac
0.0643383170	the introduction of transcatheter
0.0643289053	within 7
0.0643044397	4.3 years
0.0642785314	documentation of
0.0642590464	the sinus node
0.0642539590	advantage of
0.0642537284	weeks after
0.0642390096	normal cardiac
0.0642381207	this study shows
0.0642342266	the qrs
0.0642278951	the dp
0.0641972321	an infection
0.0641934364	increased rate
0.0641823851	total of
0.0641818615	using echocardiography
0.0641799311	this group
0.0641713109	and often
0.0641479620	after surgical repair
0.0641414860	an academic
0.0641208110	underwent coronary
0.0641201194	the human
0.0641148184	to promote
0.0640890764	a 17
0.0640858222	an initial
0.0640827021	new method
0.0640767241	consecutive patients without
0.0640737636	the analysis of
0.0640668727	the overall population
0.0640656608	the lotus
0.0640635697	the ccs
0.0640275529	to replace
0.0640051220	these cases
0.0639913883	the most common cause of
0.0639909190	rate of ppi
0.0639620214	screened for
0.0639466917	many studies
0.0639434421	compared with patients
0.0639357562	cardiac resynchronization therapy in patients
0.0639082741	at 30 day
0.0638956038	occurring after
0.0638925910	rise to
0.0638916181	mv vs
0.0638812411	the epicardium
0.0638717323	to implant
0.0638566344	recovered from
0.0638537690	showed sinus
0.0638417211	the leadless
0.0638253854	an experimental
0.0638089075	the perioperative management
0.0637998270	not required
0.0637702413	these procedures
0.0637691201	less likely
0.0637308538	survival compared with
0.0637248214	to undergo
0.0637076619	the total number of
0.0637009332	n = 31
0.0636807820	in 51
0.0636805435	from 2014
0.0636659483	and 19
0.0636622833	none in
0.0636546449	an inhibitor of
0.0636541575	10 20
0.0636438208	to sustain
0.0636379518	patient year
0.0635897626	¬† hr
0.0635832378	reports on
0.0635601188	in 19 patients
0.0635281028	within 24
0.0635265270	the 30
0.0635237894	not fully
0.0634623177	release from
0.0634587247	component of
0.0634458495	old female
0.0634275319	the superior
0.0634197385	a therapeutic
0.0633838169	different from
0.0633706361	with chd
0.0633396372	diagnosis of atrial
0.0633385018	n = 30
0.0633381169	the differential diagnosis
0.0633341096	in chinese patients with
0.0633256964	= 0.01
0.0633086169	a large cohort
0.0633067317	during exercise
0.0633023922	a pre existing
0.0632817360	the first reported case of
0.0632700846	monitoring of
0.0632384323	50 years
0.0632316805	before and during
0.0631676476	¬† 0.01
0.0631563423	outcome of
0.0631528481	valve procedure
0.0631490540	the most common arrhythmia
0.0631478290	to explain
0.0631431021	savr in patients
0.0631374094	a total of 20
0.0631171450	correlates of
0.0630976726	during covid 19
0.0630907638	treatment for
0.0630879676	no evidence of
0.0630838902	the mean follow up period
0.0630779594	the spanish
0.0630751335	to complete
0.0630674254	background aims
0.0630632809	over 3
0.0630449720	transition to
0.0630319352	minority of patients
0.0630095123	stable over
0.0630038037	1 mg
0.0629998711	prior cied
0.0629827053	patients with chb
0.0629739305	the role
0.0629721676	housed in
0.0629505347	exploration of
0.0629464763	the corevalve evolut
0.0629377894	2 year
0.0629165405	a central
0.0628860679	116 patients
0.0628801000	n = 17
0.0628713441	reported case
0.0628705331	and 2012
0.0628653062	performed without
0.0628614042	these experiments
0.0628612502	duration of follow up
0.0628530042	vs 7
0.0628426407	risk stratification for
0.0628375282	increased with
0.0628307680	to implement
0.0628241572	prognosis in patients
0.0628148306	intended to
0.0628109293	5 7
0.0628099776	the netherlands
0.0628074205	risk factors for permanent
0.0627996159	a median age of
0.0627763448	3.1 years
0.0627720963	3 4
0.0627672915	a normal
0.0627605257	in one patient
0.0627354159	n = 27
0.0627276160	undergoing pacemaker
0.0627057159	at 2 year follow up
0.0627006704	the right ventricular apex
0.0626797818	a difference
0.0626729686	and longer
0.0626707911	an 80
0.0626654915	hospitalizations due to
0.0626550409	risk factors for pacemaker
0.0626503985	¬† h after
0.0626280326	experience from
0.0626215799	significant changes
0.0626159479	a decade
0.0625623885	role for
0.0625584699	= 0.001
0.0625332700	this therapy
0.0625315885	with congenitally corrected
0.0625248468	50 patients
0.0625147726	statistically significant difference in
0.0624916519	in women
0.0624903790	p ¬†
0.0624872550	a multicenter registry
0.0624682126	1 patient
0.0624438219	heart block after
0.0624287680	a significantly higher rate of
0.0624217618	relation to
0.0624173587	this study demonstrated
0.0624161981	while in
0.0624050155	need for pacemaker implantation
0.0623981898	lvef ¬†
0.0623858084	the transcription factor
0.0623464208	free from
0.0623292493	evaluated using
0.0623229032	mean age of
0.0623009382	incidence of af
0.0622828132	associated with worse
0.0622748828	a network
0.0622712715	at one month
0.0622625413	p = 0.3
0.0622477399	the combined
0.0622211137	occurred only
0.0622183868	patients with congenital
0.0622052550	year old female with
0.0621950291	reported for
0.0621897664	year old patient
0.0621870971	in one case
0.0621852422	and vax1
0.0621746558	to test
0.0621686681	average age of
0.0621682167	patients with newly
0.0621531388	¬† days after
0.0621508320	required in
0.0621484022	sick sinus syndrome in
0.0621416989	the self expanding
0.0621288132	in patients with af
0.0621240183	no effect on
0.0620426447	higher among
0.0620409853	= 21
0.0620391946	result from
0.0620375657	pacing induced cardiomyopathy in
0.0620072543	efficacy of tavr
0.0619959916	an in vitro
0.0619915618	to examine whether
0.0619873562	this study aimed to
0.0619866575	and 2.1
0.0619711997	transplant patients
0.0619669237	the transfemoral approach
0.0619481534	continuous monitoring of
0.0619337999	leads to
0.0619182358	the mean logistic
0.0619120534	pacemaker dependent patient with
0.0619049848	an accurate
0.0619026728	mean peak
0.0618894653	a prolonged
0.0618843030	intracardiac pacemaker
0.0618511561	the management of
0.0618199843	therapy with
0.0618073576	robustness of
0.0617791665	= 4
0.0617754325	the right side
0.0617404604	among patients
0.0617357979	74 years
0.0617337475	in 85
0.0617236539	often associated with
0.0616884412	four groups
0.0616827568	the estimated
0.0616749469	from 2010
0.0616647530	analysis identified
0.0616538892	these neurons
0.0616341770	in patients with normal
0.0616322658	the tines
0.0616277786	instead of
0.0616237682	strategy for
0.0616078422	rhythms in
0.0616003921	a stepwise
0.0615894214	the right ventricular lead
0.0615888531	the clinical characteristics
0.0615879685	no device
0.0615708183	described in
0.0615691526	currently used
0.0615636658	the median time
0.0615552126	arrhythmias in
0.0615493625	a 29
0.0615465270	the 24
0.0615333242	and 2.0
0.0614922971	risk factors of
0.0614874549	the hypothalamus
0.0614694991	long term outcomes in
0.0614682881	the former
0.0614638974	these responses
0.0614530924	the sole
0.0614357604	post pacemaker
0.0613592478	the need of
0.0613569869	¬† 15
0.0613495377	6 mm
0.0613438317	first report
0.0613416991	the nanostim
0.0613345320	a larger
0.0613324096	or 2
0.0613317184	ability to
0.0613301304	significant changes in
0.0613292044	atrial fibrillation in patients
0.0612634013	a strategy
0.0612611564	the indication
0.0612556156	in 15 patients
0.0612124355	the tricuspid annulus
0.0612060211	patients presenting
0.0611868360	a highly
0.0611851743	reported in
0.0611814659	at 2 year
0.0611578662	groups based on
0.0611398330	the follow up
0.0611325884	without bav
0.0611218002	between patients
0.0611164299	from 2000 to
0.0610945045	in 13 patients
0.0610618555	randomized to
0.0610405049	in patients with small
0.0609998871	ventricular epicardial
0.0609939384	these rhythms
0.0609849398	patient with pacemaker
0.0609737154	extension of
0.0609716495	and 27
0.0609492739	h light
0.0609387866	become more
0.0609376914	the interplay
0.0609360653	this patient
0.0609245231	2.8 vs
0.0609225186	nine patients
0.0608659296	the hypothesis
0.0608588344	termination of
0.0608531101	in most patients
0.0608416148	of patients developed
0.0608156444	incidence of infection
0.0607853127	occur in patients
0.0607785959	in patients with implantable
0.0607757262	a high volume
0.0607708898	mortality after
0.0607613541	a 4 year
0.0607526902	a 78 year old
0.0607465472	the pathogenesis of
0.0607453872	but little
0.0607305984	the u.s
0.0607275960	5 10
0.0607269597	a rapid
0.0607096272	male patient with
0.0607078703	= 67
0.0607020198	differences in clinical
0.0606866409	and 10 years
0.0606852053	no adverse
0.0606629879	delivered by
0.0606478906	of life
0.0606358425	a need
0.0606300299	5.6 ¬±
0.0606071014	no patient
0.0606013261	performed at
0.0605961303	ppm within
0.0605943330	patients with cardiac implantable
0.0605882842	one year after
0.0605727761	an increase of
0.0605580410	system extraction
0.0605520658	present in
0.0605499630	to identify predictors of
0.0605492430	the loss of
0.0605477928	19 patients
0.0605447287	the mechanism underlying
0.0605377101	mean transvalvular
0.0605316456	the pore
0.0605273049	in 56
0.0605158156	30 day stroke
0.0605036744	disruption of
0.0604846817	twenty five patients
0.0604701509	n ¬† = ¬† 1
0.0604676615	in patients with advanced
0.0604567432	and shorter
0.0604442683	those at
0.0604207334	aortic stenosis in patients
0.0603948569	especially in patients
0.0603858770	either group
0.0603850744	of 104
0.0603673605	as part of
0.0603500375	radiofrequency ablation of
0.0603338518	the timing of
0.0603323761	patients with preserved
0.0603323540	criteria for
0.0603282076	made to
0.0603226210	isolated complete
0.0603049828	and 46
0.0603049384	during sinus rhythm
0.0602862247	initiation of
0.0602752194	at 5 and
0.0602514141	outcomes of surgical
0.0602381171	may 2019
0.0602334536	the activation of
0.0602272179	some of
0.0602251388	causes of
0.0602089792	a slight
0.0601701756	a powerful
0.0601551735	aortic valve replacement in
0.0601278985	intermediate risk patients with
0.0601215710	the other two
0.0601203264	the primary endpoints
0.0600970919	than did
0.0600826693	a feasible
0.0600806868	severe left ventricular
0.0600726388	showed severe
0.0600543603	3.1 vs
0.0600090826	groups in terms of
0.0599829597	dual chamber pacemaker with
0.0599817745	risk factors associated with
0.0599373468	a systemic
0.0599262701	two years
0.0599168386	of patients in
0.0599152078	min vs
0.0598988116	the cardiac conduction system
0.0598923764	alternative for
0.0598713157	significant reduction
0.0598627629	no significant changes in
0.0598533507	subsequent pacemaker
0.0598205544	added to
0.0598032032	to measure
0.0597808424	valve replacement through
0.0597788457	a new pacemaker
0.0597744791	a simple
0.0597736831	4.1 vs
0.0597643555	30 d
0.0597206734	option in patients
0.0597155456	all cied
0.0597136981	emergency department with
0.0597022093	the risk of infection
0.0596974578	may 2015
0.0596973482	the way
0.0596943516	intention to
0.0596798096	the network
0.0596686442	the outcome
0.0596418177	severe aortic valve
0.0596398497	a dedicated
0.0596383162	and 39
0.0596304367	1.5 vs
0.0596291983	an rv
0.0596202136	in cases
0.0595718591	a total of 11
0.0595506046	age 80
0.0595476688	the success rate
0.0595459725	7.8 years
0.0595419119	under direct
0.0595377398	type of cardiac
0.0595217405	high risk of
0.0595103817	after implantation of
0.0594940326	available in
0.0594911073	arrhythmias in patients
0.0594746321	and may 2015
0.0594727385	a control group
0.0594724446	¬† = 2
0.0594556182	a 5 ht
0.0594550487	3 +
0.0594325511	systemic right
0.0594223609	implantation after tavi
0.0594217696	significant decrease in
0.0594151720	the right ventricular outflow tract
0.0594092918	in patients aged
0.0593925633	implementation of
0.0593756828	a significant association
0.0593193538	ml vs
0.0593156118	performed on
0.0593079375	the femoral vein
0.0592902212	mean fluoroscopy time
0.0592890380	¬† = 1
0.0592430888	a cause
0.0592382570	the prognosis
0.0591849384	6 vs
0.0591660055	= 73
0.0591364447	of patients with cieds
0.0591344187	the light dark
0.0591291236	46 years
0.0591175847	the pacemaker group
0.0591053228	the mean age of
0.0591052475	differences among
0.0591011561	the diagnosis of
0.0590829971	and time to
0.0590552399	group compared with
0.0590489259	in nyha functional class
0.0590425570	the treatment of choice for
0.0590229084	for treating
0.0590112760	and thereby
0.0589900464	rates of in hospital
0.0589858264	catheter ablation for
0.0589751388	placed in
0.0589391843	a cox proportional
0.0589067384	follow up of patients
0.0589012601	from 2013 to
0.0588735671	performed with
0.0588593836	platform for
0.0588376570	= 5
0.0587997833	4 vs
0.0587977218	resolved after
0.0587900967	mouse model of
0.0587743014	and 3 patients
0.0587706002	within 30
0.0587164718	2.6 years
0.0587130244	discharged on
0.0587061604	to clarify
0.0587028235	recovery from
0.0587020219	the type of
0.0587018215	69 years
0.0587010157	the slow
0.0586916861	a low risk
0.0586822770	8.1 vs
0.0586774073	to extract
0.0586690416	of 80
0.0586656345	recognition of
0.0586407380	underwent tavi with
0.0586193005	n = 21
0.0585986158	of patients receiving
0.0585969122	patients with new onset
0.0585888135	in six patients
0.0585562180	reduced risk
0.0585499843	activity of
0.0585492706	without prior
0.0585398474	2011 and
0.0585265270	the 11
0.0585244947	at 15 years
0.0585242293	changes from
0.0585163366	firing rate of
0.0585138346	ablation in patients
0.0584954745	in neonates and infants
0.0584893645	sinus node dysfunction in
0.0584728530	2 months
0.0584585212	a better
0.0584458993	observed between
0.0584429113	10 cm
0.0584317914	16 patients
0.0584285342	patients with hf
0.0583948333	a combined
0.0583818482	the target
0.0583767145	permanent pacemaker implantation at
0.0583673822	¬† 4
0.0583575289	two groups based
0.0583504662	the atrial lead
0.0583442683	better in
0.0583413206	or implantable cardioverter defibrillators
0.0583369335	observed with
0.0583303432	in such patients
0.0583158414	after device implantation
0.0583066956	a minority of patients
0.0582922887	between 2010 and
0.0582684001	diagnosis and management of
0.0582324843	population of
0.0582055682	a median
0.0581931333	identifying patients
0.0581485555	¬† 0.05
0.0581470538	within 10
0.0581334499	with symptomatic severe aortic stenosis
0.0581228864	the evaluation of
0.0580754087	= 6
0.0580695211	seen with
0.0580567615	3.3 vs
0.0580394840	= 8
0.0580237382	without pre
0.0580088682	a slow
0.0579891298	2.2 ¬†
0.0579880662	patient presented with
0.0579848021	15 patients
0.0579804815	the rate of pacemaker implantation
0.0579785913	67 ¬±
0.0579780366	isolated from
0.0579694598	valve implantation with
0.0579600603	heart conduction
0.0579547793	the outcomes of
0.0579478985	vs evolut
0.0579425898	side of
0.0579419564	detection of
0.0579152555	stenosis treated with
0.0578927126	procedure for
0.0578908254	2 ¬† days
0.0578637571	symptoms in patients
0.0578635165	or placebo
0.0578598724	the femoral
0.0578427514	the source
0.0578366415	prognosis of patients
0.0578303432	in 5 patients
0.0578287524	p values
0.0578245282	76 years
0.0578143156	symptomatic patients with
0.0578102716	quality of life of patients
0.0578037813	complication of cardiac
0.0577941145	only one
0.0577724543	all cause mortality at 30 days
0.0577669773	assessed in
0.0577669614	surgical atrial
0.0577545746	in sav
0.0577530675	like activity
0.0577467357	predicted risk of
0.0577350312	allowing for
0.0577279318	increased rates of
0.0576882858	no statistical
0.0576866700	in need of
0.0576772845	the validity of
0.0576749570	66 years
0.0576745106	into 4
0.0576639534	differ from
0.0576451371	first 100
0.0576420824	associated factors
0.0576323981	this particular
0.0576264725	more than 5
0.0576130336	data show
0.0576066057	cardiac pacing in
0.0575875897	ten patients
0.0575859426	of 200
0.0575804464	magnetic resonance imaging in
0.0575775847	after transcatheter aortic valve replacement with
0.0575671869	72 years
0.0575652825	by immunohistochemistry
0.0575611635	be valves
0.0575589508	series of
0.0575588655	disturbances in patients
0.0575563083	roles of
0.0575557482	input from
0.0575552857	the pace
0.0575516199	2016 to
0.0575259464	outcomes of tavi
0.0575013353	advancement of
0.0574743460	ventricular cardiomyopathy
0.0574721979	at 3 years
0.0574551795	predictors of pm
0.0574503106	of 98
0.0574481674	= 24
0.0574446902	in six
0.0574440139	10 ms
0.0574423514	2.0 vs
0.0574273505	majority of
0.0574161160	outcomes in patients with
0.0574106582	in mice
0.0574062467	early after
0.0574050216	young patient with
0.0573857258	the principal
0.0573709939	coordination of
0.0573646998	the utilization
0.0573631137	the physiological
0.0573272337	a 57
0.0573117756	survival in
0.0572849770	a lower incidence of
0.0572565736	pacemaker implantation in patients with
0.0572435523	alterations in
0.0572405106	1 h
0.0572382048	a few cases
0.0572220079	the need for pacemaker
0.0572140610	any complications
0.0572096103	study provides
0.0571873623	the lotus valve system
0.0571734661	a significant effect
0.0571672173	at higher
0.0571529449	available for
0.0571455312	the temporal
0.0571320482	no need for
0.0571093552	after adjusting
0.0571081193	adaptation to
0.0570980287	an age
0.0570934724	in patients with non
0.0570724902	0.8 vs
0.0570549884	the pacemaker generator
0.0570457746	higher incidence
0.0570264101	factors of
0.0570262869	opportunity for
0.0570245589	approach using
0.0570210109	with most
0.0570027237	treatment of severe
0.0569944866	beating rate of
0.0569891298	1.9 ¬†
0.0569826128	not associated with increased
0.0569521735	at one year
0.0569139043	5.5 vs
0.0568998210	expected to
0.0568997543	dual chamber pacemaker for
0.0568995558	contact with
0.0568841519	the diagnostic
0.0568753769	time interval
0.0568605837	the composite outcome
0.0568599507	8.5 years
0.0568504141	and 70
0.0568232193	a 62 year
0.0568072718	these criteria
0.0568038515	a conserved
0.0568011712	under local
0.0567661031	1 point
0.0567243902	0.5 vs
0.0567110970	at 0.24
0.0567108265	a subset of patients
0.0567096551	repair of
0.0567041244	a 63
0.0566794732	an abnormal
0.0566617963	with heart rhythm disorders
0.0566607493	example of
0.0566383965	cardiac implantable electronic devices in
0.0566293301	in rats
0.0566138342	unique case of
0.0566042280	of 36
0.0565987335	and 89
0.0565952546	to receive
0.0565925000	over 5
0.0565920128	on t
0.0565823012	aid in
0.0565698358	components of
0.0565693760	comparable to
0.0565608937	an overview of
0.0565571551	valve ie
0.0565560020	in 8 patients
0.0565375613	of 32
0.0565267790	mean sts
0.0565173222	a few
0.0565170808	a 48
0.0564911073	therapy in patients
0.0564810402	the rv lead
0.0564758844	effective treatment for
0.0564714719	between 2006 and
0.0564557423	in 2001
0.0564441002	due to lead
0.0563773335	living with
0.0563746180	a substantial
0.0563670432	30 patients
0.0563592702	in 77
0.0563417488	into 3
0.0563381887	to complete heart block
0.0563203018	new pacemaker
0.0563171456	of 69
0.0563105003	a full sternotomy
0.0563103432	in 4 patients
0.0563091803	need to
0.0563085060	a report
0.0563016845	day after
0.0562828315	at increased risk for
0.0562828315	an increased incidence of
0.0562813841	inception to
0.0562681342	a dual chamber
0.0562534257	disease in patients
0.0562460167	a specific
0.0562094269	from 2007
0.0562029418	several days
0.0561974578	may 2018
0.0561838573	asymptomatic patients
0.0561769879	the e
0.0561600895	95 ci 1.1
0.0561578742	or severe aortic regurgitation
0.0561486573	clock system
0.0561450873	occurred more frequently in
0.0561386978	mri in patients with
0.0561384568	the tavi procedure
0.0561350245	the need for new
0.0561290700	a retrospective analysis of
0.0561235420	the presence
0.0561187417	1 day
0.0561053088	either by
0.0560756629	persistent new
0.0560433947	in patients with bradycardia
0.0560359209	no major complications
0.0560321578	higher in group
0.0560070727	and efficacy of transvenous
0.0560069386	the german
0.0560054027	the front
0.0559973823	not different between
0.0559935789	of 171
0.0559912261	over 1
0.0559893311	1 year after
0.0559879353	insertion of
0.0559866317	= 17
0.0559733716	the next
0.0559438401	in 6 patients
0.0559308589	100 consecutive
0.0559238960	during device implantation
0.0559203667	the traditional
0.0559154637	options for
0.0559072932	compared with crt p
0.0559003098	a mechanism
0.0558874578	a 77
0.0558713559	outcomes of patients with
0.0558462034	a modified
0.0558261556	enrolled in
0.0558125400	by cmr
0.0558024583	a cardiac device
0.0558013805	from 2012 to
0.0557857829	and in hospital
0.0557763559	p ¬† ‚â§
0.0557749215	associated with lower rates of
0.0557700135	the treatment of choice
0.0557569592	to review
0.0557497133	method for
0.0557316045	observed during
0.0557232921	similar risk
0.0556787277	predictors of ppm
0.0556693314	or 1 year
0.0556690798	a significant decrease in
0.0556629879	synchronized by
0.0556538037	6.2 years
0.0556522944	ppi after
0.0556435767	11 patients
0.0556205266	the safety of mri
0.0556164515	placed on
0.0556147599	framework for
0.0556135485	a new device
0.0556123923	both cases
0.0556119123	bundle branch block after
0.0555969511	in 18 patients
0.0555864969	200 ¬†
0.0555718212	in patients with hypertrophic cardiomyopathy
0.0555609862	patients with severe aortic stenosis at
0.0555602348	more than 3
0.0555566477	this subset
0.0555552694	from 2004
0.0555550633	localization of
0.0555494496	in patients at high
0.0555215514	in patients requiring
0.0555120752	cases reported
0.0554984175	an endogenous
0.0554962821	delay between
0.0554937324	evidence for
0.0554919266	83 ¬†
0.0554801000	enough to
0.0554683015	without balloon
0.0554377815	a greater
0.0554070395	the factors associated with
0.0553982359	studied in
0.0553833212	a cost
0.0553793618	1.8 vs
0.0553713534	the rapid
0.0553671599	6 years
0.0553574256	the inner
0.0553490833	the sutureless
0.0553226210	atrial size
0.0553189452	in 10 patients
0.0553013546	2 days
0.0552852872	at 12 ¬† months
0.0552716068	to take
0.0552591958	rehospitalization for
0.0552567244	a consequence
0.0552362454	¬† = ¬† ¬†
0.0552344561	an episode of
0.0552085163	early diagnosis of
0.0552059040	the risk of electromagnetic
0.0552055983	all cause 30 day
0.0551946164	between january 2013
0.0551785170	and review of
0.0551756965	the annual
0.0551725636	n ¬† = ¬† 10
0.0551703750	this period
0.0551655762	in children and adolescents
0.0551635856	via transfemoral
0.0551605077	conduction time
0.0551579669	3.4 vs
0.0551296461	for noninferiority
0.0551292269	likely to
0.0551225437	the clinical and
0.0550780570	patients with complete atrioventricular
0.0550459522	safety and performance of
0.0550373398	the edwards sapien 3 valve
0.0550368325	a whole
0.0550223857	a cied
0.0550196307	this cohort
0.0549945118	this technology
0.0549891298	0.6 ¬†
0.0549866575	and 2.2
0.0549753632	ablation for
0.0549514976	sum of
0.0549444486	pacemaker implantation via
0.0549424534	sudden cardiac death in
0.0549407981	patients with failed
0.0549393513	a subgroup of patients
0.0549168720	a previous
0.0549147384	recorded during
0.0549139043	3.0 vs
0.0548994254	circadian clocks in
0.0548967959	sufficient to
0.0548948294	66 year old
0.0548947354	a sub
0.0548847561	under general
0.0548847561	mean arterial
0.0548689593	occurring at
0.0548662853	3.2 vs
0.0548592841	4 6
0.0548478579	in such cases
0.0548383839	the right ventricular septum
0.0548369821	candidate for
0.0548312082	the study population consisted of
0.0548280103	19 months
0.0548279211	magnetic resonance imaging of
0.0548276910	associated with increased risk
0.0548105599	¬† vs
0.0548093085	group 1 vs
0.0548006185	plasticity of
0.0547918978	no long term
0.0547864726	the primary outcomes
0.0547547989	a higher mortality
0.0547546730	119 patients
0.0547452748	a rate of
0.0547409042	a control
0.0547129294	group consisted of
0.0546889315	in 14 patients
0.0546788298	not well known
0.0546755539	combination of
0.0546727057	management of patients
0.0546659283	after surgery
0.0546554189	a balloon expandable
0.0546504790	of 46
0.0546414804	to collect
0.0546314320	complications such as
0.0546023798	the incidence of complications
0.0545814169	a transvenous
0.0545780570	impact of permanent pacemaker
0.0545768024	of af in
0.0545686338	hospital complications
0.0545617231	this new
0.0545579742	an event
0.0545525490	a surrogate
0.0545490557	the same time
0.0545400185	the whole cell patch clamp
0.0545371480	a safe and effective
0.0545138299	patients with impaired
0.0545046277	important for
0.0545043649	recorded using
0.0544980282	a prototype
0.0544940546	incidence of pacemaker implantation
0.0544917997	62 years
0.0544697385	a delayed
0.0544589218	also increased
0.0544568947	monitored by
0.0544503106	of 3.0
0.0544293651	2.4 years
0.0544025271	a high prevalence of
0.0543823048	an institutional
0.0543793618	0.9 vs
0.0543752967	a subpectoral
0.0543701717	patients with picm
0.0543648492	2011 to
0.0543622218	outcomes associated with
0.0542603703	a serious complication
0.0542388446	members of
0.0542175213	therapy in patients with
0.0542087879	from 2009 to
0.0542087222	1.7 vs
0.0542071064	a descriptive
0.0542019794	risk of cied
0.0541989613	between two groups
0.0541804350	severe aortic
0.0541703155	tailored to
0.0541625367	of in hospital mortality
0.0541491162	in older patients
0.0541489117	10 ‚ÄØ
0.0541004141	and 53
0.0540946966	0.5 ¬†
0.0540903104	or less
0.0540875435	from four
0.0540761059	the pocket
0.0540752130	characteristics and outcomes of
0.0540654767	regulators of
0.0540588530	the art
0.0540484553	for use in
0.0540342240	a previously
0.0540303293	the operation
0.0540174684	15 vs
0.0540172655	indication for pacemaker
0.0539940817	associated with decreased
0.0539846106	in patients with chd
0.0539818862	the clinical data
0.0539718393	year old male patient
0.0539655774	a propensity matched
0.0539654245	given to
0.0539624452	a case report of
0.0539621180	a detailed
0.0539413616	a concomitant
0.0539409188	in selected patients
0.0539065497	a thorough
0.0539058900	from 2003
0.0539031419	5.4 years
0.0539003755	h day
0.0539003098	13 patients
0.0538992967	after fontan
0.0538877635	in patients with sick sinus syndrome
0.0538852842	a high degree
0.0538729265	ratio hr
0.0538578675	the hippocampus
0.0538295104	transcatheter aortic valve implantation for
0.0538155183	major adverse cardiac and
0.0538053852	over 12
0.0538036636	known complication
0.0537699843	present with
0.0537614994	a general
0.0537529800	the pyloric
0.0537466885	68 ¬±
0.0537309688	important cause of
0.0537149498	the stomach
0.0537083504	to control
0.0537047334	2 h
0.0536859771	the need for permanent
0.0536437286	discontinuation of
0.0536323457	third of patients
0.0536267499	pacemaker potentials in
0.0536225437	the right atrium and
0.0536126467	a case of successful
0.0536114063	1.1 vs
0.0536074836	the performance
0.0535965739	in patients with aortic stenosis
0.0535703616	followed in
0.0535656598	patients at
0.0535448319	to monitor
0.0535414725	2.2 ¬±
0.0535398474	necessary in
0.0535391447	no clinical
0.0535314725	the proportion of patients
0.0535312735	in japanese patients
0.0535204008	a complex
0.0535199805	2.9 years
0.0535055157	the reference
0.0534960709	an indicator of
0.0534900672	a preliminary
0.0534866317	= 19
0.0534820221	after 1 year
0.0534608292	at 3 months
0.0534586033	planned for
0.0534536523	associated with reduced
0.0534125088	1999 to
0.0534023006	five years
0.0533895488	14 months
0.0533840105	the american
0.0533524138	the perceval s
0.0533496527	67 ¬†
0.0533423292	from 2002 to
0.0533422066	the possibility
0.0533204906	78 ¬±
0.0532931891	type of
0.0532861752	complete atrioventricular block with
0.0532856573	and main results
0.0532835419	of patients with pacemakers
0.0532775890	in 34 patients
0.0532651741	a narrow qrs
0.0532641616	severe as
0.0532626221	the new generation
0.0532471844	more than 2
0.0532452848	2.4 ¬†
0.0532201130	adolescents with
0.0532072643	from 2001 to
0.0532057821	one third of patients
0.0531901362	2003 to
0.0531814108	the primary diagnosis
0.0531796728	the free wall
0.0531740676	no major
0.0531684112	the amount of
0.0531397462	an acute
0.0531161802	only two
0.0531004141	and 67
0.0530657880	surgical aortic valve replacement in
0.0530654767	excision of
0.0530466209	the need for permanent pacemaker implantation
0.0530187674	predictors of 30 day
0.0530023857	a post
0.0529998159	the risks
0.0529990521	25 vs
0.0529912181	report from
0.0529901717	a ¬† pacemaker
0.0529852996	the pacemaker potentials
0.0529716834	6 and 12
0.0529570552	and others
0.0529549878	following transcatheter
0.0529543548	to power
0.0529439334	¬† weeks after
0.0529367293	value for
0.0529226291	an asymptomatic
0.0529161680	a positive
0.0529138379	10 ¬†
0.0529074054	the mean society of
0.0529014316	4.4 vs
0.0528936508	those patients
0.0528740210	hospital and 30 day
0.0528676984	the mechanism
0.0528663392	the long term clinical
0.0528634602	in patients with isolated
0.0528614957	the implantation of
0.0528489848	between patients with
0.0528422636	a new permanent pacemaker
0.0528356360	developed in
0.0528281983	underwent tricuspid
0.0528253061	an online
0.0528185085	lower rate of
0.0528053852	over 10
0.0527824969	100 vs
0.0527684236	versus savr in
0.0527524538	n = 19
0.0527502704	group vs
0.0527459750	the dorsal
0.0527447133	mean lvef
0.0527094441	some patients
0.0527072589	the third
0.0526971898	performed safely in
0.0526948414	known as
0.0526912647	the use of transcatheter
0.0526553569	using propensity score
0.0526539259	clock function in
0.0526358708	frequently in patients
0.0526288708	7 patients
0.0526255312	the molecular
0.0526190118	cells via
0.0525973977	lead placement in
0.0525725927	common causes of
0.0525650922	rate of 30
0.0525482453	in dogs
0.0525446890	3.7 vs
0.0525446890	3.8 vs
0.0525184981	two types of
0.0525119266	15 years
0.0524933389	more than one
0.0524923125	a randomised
0.0524877351	patient presenting with
0.0524811639	the surface
0.0524806694	management of atrial
0.0524751388	the whole
0.0524588779	2.1 vs
0.0524544781	the swedish
0.0524544439	after adjustment
0.0524481831	19 vs
0.0524465059	plasticity in
0.0524421843	the chest
0.0524346430	to increase
0.0524339728	causes for
0.0524143886	= 14
0.0523968196	and 81
0.0523942962	4 days
0.0523840056	12 ¬†
0.0523793632	the coronary arteries
0.0523793073	common among
0.0523792338	consisted of patients
0.0523734716	extraction of
0.0523720111	of 35
0.0523494230	first implantation
0.0523387628	7.1 years
0.0523238948	‚â§ ¬†
0.0523202409	64 ¬†
0.0523190565	and sometimes
0.0522861236	high ventricular
0.0522707417	an independent
0.0522579879	patients with moderate to
0.0522498934	long term mortality in
0.0522423313	patient with persistent
0.0522384273	no differences in
0.0522240354	incidence of ppi
0.0521902824	presentation of
0.0521880837	approximately one
0.0521799450	3.9 years
0.0521323137	patients at high risk for
0.0521252979	of gestation
0.0521182767	year old man presented with
0.0521164963	at 90
0.0521130629	at 6 ¬† months
0.0521116317	= 31
0.0521090492	the most frequently
0.0520957610	in patients with cardiac resynchronization therapy
0.0520937250	the sapien 3
0.0520814889	chamber pacemaker implantation
0.0520703133	lower in
0.0520537822	use in patients with
0.0520501483	overall success
0.0520265776	the self expandable
0.0520109236	failed to
0.0519928686	64 year old
0.0519669342	through december
0.0519601582	the circadian rhythm
0.0519590099	4 ¬† years
0.0519487958	in patients with preserved
0.0519283062	tle at
0.0518877002	a history of atrial fibrillation
0.0518874269	initiated by
0.0518811313	the guidewire
0.0518702703	70 year old
0.0518658462	81 ¬±
0.0518504141	and 66
0.0518501861	in patients with bav
0.0518353866	the effect on
0.0518273515	the in hospital
0.0518053852	within 6
0.0517998365	patients with obstructive
0.0517934952	estimation of
0.0517721012	surgical aortic valve replacement for
0.0517277252	the pacemaker cells
0.0517261857	other cardiac
0.0516874871	and echocardiographic data
0.0516839528	the analysis included
0.0516732724	pacemaker activity of
0.0516728490	tavi using
0.0516658462	76 ¬±
0.0516596904	in vertebrates
0.0516574958	similar in
0.0516436398	7.5 ¬±
0.0516346128	spontaneous pacemaker
0.0515956782	common in patients with
0.0515918222	non sustained
0.0515547354	the incidence of permanent pacemaker implantation
0.0515417945	on long term outcomes
0.0515367128	icd pacemaker
0.0514996554	16 year
0.0514895177	survival after
0.0514863067	no difference in mortality
0.0514595214	a reversible
0.0514492628	tav in
0.0514481081	7.0 ¬±
0.0514369076	1.7 ¬†
0.0514169153	and 84
0.0513969903	help in
0.0513952996	time course of
0.0513929550	and 30 day outcomes
0.0513839451	the liver
0.0513799058	= 13
0.0513796606	technique used
0.0513762684	54 patients
0.0513750726	5 ¬†
0.0513726291	an individual
0.0513662853	3.5 vs
0.0513223264	implantation after transcatheter aortic valve implantation
0.0513130113	moderate or
0.0513050633	probability of
0.0513000418	patients with snd
0.0512998286	non cardiac
0.0512847899	over time in
0.0512803202	the micra transcatheter pacing
0.0512796569	and control groups
0.0512673416	the risk of af
0.0512509178	of patients undergoing tavi
0.0512507699	the evolut r valve
0.0512363325	an observational
0.0512268558	the department of cardiology
0.0512238068	1 cm
0.0512220983	1 case
0.0511983512	a group of
0.0511895832	the vast majority of
0.0511878172	further study
0.0511870219	as such
0.0511718427	and 79
0.0511452616	to assess for
0.0511322483	the mouse
0.0511271666	to consider
0.0511217240	a longer
0.0511199513	significant coronary
0.0510861647	the rise
0.0510627585	6.3 years
0.0510329818	clinical outcomes in patients with
0.0510131535	end point of
0.0509891298	5.5 years
0.0509869064	the femoral approach
0.0509792444	the plateau
0.0509754935	detected during
0.0509683138	a tertiary
0.0509680678	in detail
0.0509583924	known af
0.0509550264	available data
0.0509388775	aortic valve implantation in
0.0509385479	similar among
0.0509347603	cardiovascular system
0.0509310927	light on
0.0509229421	an outpatient
0.0509221843	the generator
0.0509203155	equal to
0.0508879845	and treatment of
0.0508700891	71 years
0.0508066638	only few
0.0508015717	reliability of
0.0507994338	most important
0.0507890439	using multivariable
0.0507806692	by computed tomography
0.0507524538	n = 35
0.0507466885	83 ¬±
0.0507291813	moderate to
0.0507089247	three patients with
0.0507027969	the uterus
0.0506505455	completed by
0.0506504859	care for patients
0.0506445974	treated with transcatheter
0.0506411934	a unique case
0.0506316951	the rate
0.0506292259	128 patients
0.0506187841	the survival rate
0.0505993273	patients with bradycardia
0.0505860808	treatment of patients with
0.0505812477	after catheter ablation
0.0505795723	little data
0.0505733450	the sinus
0.0505585771	26 patients
0.0505319027	or ¬† = ¬†
0.0505310959	the maze procedure
0.0505108076	an estimated
0.0505052715	existence of
0.0504981869	for 24
0.0504951885	than previously
0.0504944365	1.2 vs
0.0504808861	approach to
0.0504655549	to meet
0.0504649563	the prognostic
0.0504572275	a 75 year old
0.0504406596	the most commonly used
0.0504402177	risk of af
0.0504188520	first pacemaker
0.0504160305	equivalent to
0.0504007338	seen on
0.0503994571	ratio of
0.0503955686	a national
0.0503693425	in patients with impaired
0.0503641724	interstitial cells of cajal from
0.0503380070	discharged after
0.0503289922	technique for
0.0503277434	a significantly increased
0.0503181933	contraindication to
0.0503094935	after excluding patients
0.0502946305	a negative
0.0502908206	9 patients
0.0502714502	lower with
0.0502687866	in patients with lbbb
0.0502127627	the effectiveness of
0.0502030911	mainly due to
0.0501987467	increased to
0.0501922378	the internal
0.0501913269	rare but
0.0501842454	but serious
0.0501795986	53 ¬±
0.0501556407	disturbances following
0.0501553537	all tested
0.0501507495	with pre existing
0.0501372612	18 cases
0.0501239847	the same day
0.0501239310	an optimal
0.0501080608	fetuses with
0.0500988400	a prominent
0.0500878778	the clinical outcomes
0.0500687222	in seven patients
0.0500654767	predominance of
0.0500606423	the curve
0.0500598197	characteristics of patients
0.0500514347	higher in patients with
0.0500489589	died due to
0.0500443459	form of
0.0500402740	a circadian pacemaker
0.0500328552	intervention group
0.0500306525	of in hospital
0.0500169068	to include
0.0500146710	implantation of cardiac
0.0500142165	4 cases
0.0499828737	the sub
0.0499796865	the levels of
0.0499791796	1.2 ¬†
0.0499635257	a standard
0.0499628272	a wide
0.0499538865	the resting membrane
0.0499526359	with at least
0.0499321297	an implantable cardioverter
0.0499300739	one hundred and
0.0499175763	the corresponding
0.0499106672	tavr in patients with
0.0499094065	low risk patients with
0.0498886190	the subclavian
0.0498798588	helpful in
0.0498752898	recovery of
0.0498494617	a critical role in
0.0498337253	the impact on
0.0498314156	a much
0.0498275789	for at least
0.0498249416	in patients with syncope
0.0498195580	attention to
0.0498161917	these factors
0.0498133107	8 days
0.0498044924	3 vs
0.0497769579	a lesser
0.0497749015	in 26 patients
0.0497720545	patients with lower
0.0497572493	the rat
0.0497495104	9 months
0.0497447276	the exact
0.0497418566	a critical
0.0497384045	old man with
0.0497206938	0 vs
0.0497066895	reduced by
0.0496760548	patients scheduled for
0.0496722969	any other
0.0496713948	searched for
0.0496654664	performed before
0.0496453713	variables associated with
0.0496453565	the mechanisms underlying
0.0496326809	2 cases
0.0496239309	the expense of
0.0496237332	identified by
0.0496080365	appearance of
0.0496042721	definition of
0.0495913313	and management of
0.0495737432	selected patients with
0.0495660319	3 cases
0.0495632311	74 ¬±
0.0495497912	a life threatening
0.0495467098	a viable
0.0495409882	subgroup of patients
0.0495361236	underwent atrioventricular
0.0495326389	needed to
0.0495098070	the relative
0.0495060463	in nine patients
0.0494927428	bridge to
0.0494853950	with congenital complete atrioventricular block
0.0494774928	functions as
0.0494758145	89 patients
0.0494618405	the fact
0.0494572493	the tv
0.0494561154	an epicardial
0.0494510569	procedures such as
0.0494333984	mainly by
0.0494276695	these studies
0.0494227669	55 ¬†
0.0494188686	= 7
0.0494162694	= 15
0.0494104091	systematic review of
0.0493883558	most serious
0.0493857139	rotation of
0.0493852585	influence of
0.0493838899	a direct
0.0493812200	a micra
0.0493766242	‚Äë lead
0.0493681306	with low mortality
0.0493528036	3 cm
0.0493406355	higher for
0.0493312325	an average follow up
0.0493219894	13 months
0.0493204129	s vs
0.0493163330	in patients with cardiac pacemakers
0.0493148613	the iphone
0.0493142100	the distal
0.0493108412	at 4 years
0.0493008781	to decrease
0.0492899496	a successful
0.0492820468	associated with greater
0.0492556360	a failed
0.0492494357	89 years
0.0492422617	34 patients
0.0492392655	increased rate of
0.0492337475	in 65
0.0492270633	report here
0.0492043055	an incidental
0.0492037446	the mean aortic
0.0492031049	an efficient
0.0491516864	no early
0.0491513506	patients presented with
0.0491444561	a 24 h
0.0491340645	2 year follow up
0.0491299645	cohort study of
0.0491063611	a thin
0.0491056497	¬† 8
0.0491035580	time from implantation
0.0491029743	in response to
0.0490646714	increased over
0.0490533580	day discharge
0.0490446672	no complications
0.0490361236	prior cardiac
0.0490351201	a condition
0.0490240430	in adult patients
0.0489832293	106 patients
0.0489744408	potential for
0.0489738334	diagnosed by
0.0489601618	actions of
0.0489563736	safe in
0.0489398876	underwent tavi at
0.0489310120	analysis from
0.0489198644	the membrane pacemaker
0.0489107860	most appropriate
0.0489092211	the pm group
0.0488923722	feasible in patients
0.0488569896	all cause mortality rate
0.0488547435	increased by
0.0488530157	the emergency
0.0488439332	the differential
0.0488433593	developed for
0.0488252599	73 ¬±
0.0488157626	safety of
0.0488153223	from 2002
0.0487909713	21 vs
0.0487834162	an open
0.0487665999	underwent tavr at
0.0487529931	an ecg
0.0487501245	the proximal
0.0487443214	2007 and
0.0487364429	121 patients
0.0487210369	clock genes in
0.0487087681	the proper
0.0486997737	clinical features of
0.0486881824	in eight patients
0.0486838832	death among
0.0486801716	significant proportion of
0.0486729249	between 2004
0.0486398711	20 vs
0.0486322483	the body
0.0486240412	of four
0.0486131806	by echocardiography
0.0486089212	2.0 ¬±
0.0485907423	pandemic on
0.0485617659	and 1 ¬†
0.0485533796	course of
0.0485524539	useful for
0.0485499843	period of
0.0485085858	room with
0.0485034852	incidence of permanent
0.0484848893	8 patients
0.0484606382	in 49
0.0484507295	the first report
0.0484324127	associated with improved
0.0484279219	new devices
0.0483974418	even more
0.0483830310	necessary to
0.0483619153	to identify risk factors for
0.0483402942	the differences
0.0483261725	13 vs
0.0483255995	4 ¬†
0.0483200322	monitoring system
0.0483149492	the cut off
0.0483144222	the implantation site
0.0483052126	channels in
0.0482949513	55 patients
0.0482776423	100 patients
0.0482698759	complete heart block after
0.0482484323	clinical value
0.0482422628	the kaplan
0.0482166764	contraindication for
0.0482127627	the association of
0.0482034886	2008 to
0.0482009001	similar between patients
0.0481930518	2.5 years
0.0481721102	a protocol
0.0481629319	49 ¬±
0.0481471736	for more than
0.0481450978	acceptance of
0.0481349728	to reproduce
0.0481342098	twelve patients
0.0481298603	of 17
0.0481261103	8.8 years
0.0481232642	as compared to
0.0481196198	no mortality
0.0481168156	sensitivity and specificity of
0.0481101874	of 9
0.0481060280	aortic valve replacement for
0.0481051863	within one year
0.0481012465	the clock genes
0.0480862931	the pacemaker's
0.0480795020	all children
0.0480785095	1 ‚Äë
0.0480702409	72 ¬±
0.0480699080	the incidence of new onset
0.0480685895	a pacemaker for
0.0480430263	the risk of sudden
0.0480428917	improved in
0.0480245967	2 mm
0.0480182605	for detecting
0.0480174106	risk of bleeding
0.0480119919	associated with heart failure
0.0480101420	the outcomes of tavr
0.0479770260	in 9 patients
0.0479715767	the ppm group
0.0479712876	of 22 patients
0.0479356116	8 years
0.0479353123	in patients with congenital
0.0479169772	all leads
0.0479128031	this multicenter
0.0479127442	numbers of
0.0479053099	a large cohort of
0.0479003098	35 patients
0.0478998457	survival time
0.0478863843	a significant improvement
0.0478658462	2.1 ¬±
0.0478358068	84 ¬±
0.0478214476	1 v
0.0478195580	refractory to
0.0478182270	no more
0.0478114657	mean qrs
0.0477644923	in hemodialysis patients
0.0477596461	ppm following
0.0477539718	in patients with dual
0.0477525367	the diagnostic accuracy
0.0477482005	the sympathetic
0.0477465420	those not
0.0477448222	noted on
0.0477324298	these changes
0.0477321654	30 day in hospital
0.0476954887	and fewer
0.0476855236	standard of care for
0.0476601382	a 12 year
0.0476445767	increased use of
0.0476327467	patients suffered from
0.0476322429	calculated by
0.0476106117	investigated in
0.0475945274	the internal jugular
0.0475893797	in 20 patients
0.0475810170	the rate of permanent pacemaker implantation
0.0475808102	an anterior
0.0475682384	the anterior
0.0475594198	performed after
0.0475500608	not possible
0.0475500362	in 23 patients
0.0475267429	not affected by
0.0474950303	acceleration of
0.0474900192	possible cause
0.0474762198	the removal of
0.0474664580	the pulmonary
0.0474382937	way to
0.0474306298	due to sick sinus syndrome
0.0474299912	the maximum
0.0474211330	0.3 ¬†
0.0474039073	an urgent
0.0474014970	complaints of
0.0473920678	the long term follow up
0.0473819318	an electronic
0.0473574035	followed at
0.0473544056	a role
0.0473413633	a 3 year
0.0473382787	3 mm
0.0473377689	this novel
0.0473272736	in patients with unexplained
0.0473194545	an algorithm
0.0473191009	particularly for
0.0473079424	patients with avb
0.0473050389	under control
0.0472900520	lp group
0.0472553603	to make
0.0472522650	an abdominal
0.0472257015	significantly higher with
0.0472080844	rare complication of
0.0472038210	weight at
0.0471938394	this trial
0.0471913624	no signs
0.0471905977	this setting
0.0471703087	the basal
0.0471638439	a structured
0.0471621150	the difficulty
0.0471550870	a more
0.0471391047	the long term results
0.0471371657	n = 50
0.0471195773	after 3 months
0.0471041629	not previously
0.0470964182	logistic euroscore of
0.0470957973	to determine risk factors
0.0470688367	the mean age of patients
0.0470564900	28 ¬†
0.0470507104	the quality of life of patients
0.0470295889	major cause
0.0470170959	the classic
0.0470161930	the tavi group
0.0469970808	of 44
0.0469862073	3 times
0.0469808759	not affected
0.0469695351	in 11 patients
0.0469558591	in patients with bicuspid
0.0469491762	analysis of randomized
0.0469454625	significantly decreased in
0.0469353011	this large
0.0469315891	an early
0.0469297294	occur during
0.0469294126	suggested as
0.0469118092	significantly different from
0.0469099594	twenty four patients
0.0468747813	a secondary
0.0468459141	used to investigate
0.0468360013	all cause mortality after
0.0468342003	6.3 ¬±
0.0468222065	the risk of complications
0.0468085858	requirement after
0.0468037975	the average age
0.0467893030	in 75
0.0467878925	no prior
0.0467784406	the risk of mortality
0.0467743268	in 7 patients
0.0467709387	kinetics of
0.0467670808	and 45
0.0467470244	implanted before
0.0467365290	an active
0.0467354119	to show
0.0467111150	with dextrocardia
0.0467108394	important role in
0.0467086730	than 90
0.0467042325	1 ¬†
0.0467010056	and mid term outcomes
0.0466988792	the vicinity of
0.0466843368	the ablation group
0.0466570358	leadless pacemaker in
0.0466350995	conducted in
0.0466281473	the pericardium
0.0466147838	1.0 ¬†
0.0466096242	manipulation of
0.0466029842	large right
0.0465864847	the elderly
0.0465818263	the procedural
0.0465734890	and 2 patients
0.0465541057	20 patients
0.0465539440	more than 10
0.0465493430	ivabradine on
0.0465406658	assessment of cardiac
0.0465312622	95 ci 1.0
0.0465219206	a selective
0.0465169068	33 patients
0.0465166357	the primary endpoint of
0.0465157369	21 patients
0.0465019293	12 years
0.0464989561	and need for permanent
0.0464964257	or palpitations
0.0464888148	the future
0.0464887609	low morbidity and
0.0464877351	high level of
0.0464833182	third of
0.0464427923	no significant change in
0.0464369713	a pacemaker or implantable cardioverter defibrillator
0.0464362777	to help
0.0464280729	infection occurred in
0.0464070426	15 year
0.0464044663	4.7 ¬†
0.0463933552	52 ¬±
0.0463914344	valve replacement in patients with
0.0463699591	an intrinsic
0.0463660419	110 patients
0.0463591709	in 25 patients
0.0463564296	in 12 patients
0.0463454846	the tumor
0.0463392638	within normal
0.0463377932	2 min
0.0463244073	but one
0.0462829016	respect to
0.0462790654	patients included in
0.0462550553	9 year
0.0462501866	a risk factor
0.0462438815	a period of
0.0462275152	model system
0.0462243895	6.7 years
0.0462242442	65 patients
0.0462232537	in patients with chronic
0.0462219272	in comparison with
0.0462182518	the food
0.0462108501	the italian
0.0462104786	4.5 vs
0.0461927627	the generation of
0.0461924727	those patients with
0.0461797980	a full
0.0461764632	this process
0.0461623619	2 ¬† years
0.0461504093	undergone pacemaker
0.0461479119	particularly in
0.0461421150	the core
0.0461224609	this model
0.0461167307	dual chamber pacemaker in
0.0461114086	no correlation
0.0461048985	estimated using
0.0460832311	66 ¬±
0.0460807830	a temporary
0.0460554117	procedures in patients
0.0460541905	programmed to
0.0460499843	cases with
0.0460492647	identified in
0.0460481992	65 ¬†
0.0460386777	in 45
0.0460214264	without contrast
0.0460067698	intestinal pacemaker
0.0459987783	heart failure patients with
0.0459777825	to synchronize
0.0459755842	pacing in patients with
0.0459716569	more than 1
0.0459617172	the firing rate
0.0459045661	3 ¬† days
0.0458944769	especially in patients with
0.0458727994	the great
0.0458642252	different types of
0.0458602968	the apex
0.0458513853	an s icd
0.0458510603	the autonomic
0.0458494850	the skin
0.0458481147	boy with
0.0458457249	not well
0.0458423923	not find
0.0458346338	to capture
0.0458337253	the risk factors for
0.0458314168	10 days
0.0458258650	transcatheter heart valve in
0.0458236605	an artificial
0.0458221918	5 vs
0.0458023830	underwent tavr between
0.0457993503	the rastelli
0.0457980048	performed via
0.0457905173	in sweden
0.0457905173	in denmark
0.0457670808	and 35
0.0457369076	2.6 ¬±
0.0457304283	the need for pacemaker implantation
0.0457282373	30 day follow up
0.0457239363	129 patients
0.0457160767	an old
0.0457030418	exception of
0.0456872046	than patients with
0.0456744608	risk population
0.0456688878	group than
0.0456578634	of patients required
0.0456543790	the incidence of postoperative
0.0456459024	than 40
0.0456434892	14 patients
0.0456400324	within 1 ¬†
0.0456331299	regurgitation in patients
0.0456307138	the covid 19
0.0456238068	these channels
0.0456217240	a physiological
0.0456119595	this algorithm
0.0455868072	use in patients
0.0455737711	after pm implantation
0.0455676661	cohort of
0.0455586787	in 17 patients
0.0455471362	this method
0.0455292984	from mice
0.0455050225	12 vs
0.0455031199	this registry
0.0455016006	a cohort study
0.0455009250	a repeat
0.0454888148	the survey
0.0454821810	not considered
0.0454818589	recommendations for
0.0454649973	hospitalizations for
0.0454590753	guidelines for
0.0454570946	an alternative to surgical
0.0454353123	in patients with paroxysmal
0.0454311015	not available
0.0454281081	8.3 ¬±
0.0454085501	need for pacemaker
0.0454060624	39 patients
0.0453972798	inactivation of
0.0453960177	associated with higher risk of
0.0453898233	17 ¬†
0.0453828278	a challenge
0.0453741135	a dose
0.0453731869	after 30
0.0453723093	new technique
0.0453513027	separation of
0.0453396846	often used
0.0453285758	a dose dependent
0.0453283393	the incidence of pacemaker
0.0453228366	significantly increased in
0.0453209244	calculated as
0.0453147191	for such patients
0.0452950880	and 33
0.0452859963	an implant
0.0452474800	an upgrade
0.0452467828	the gut
0.0452465060	three days
0.0452413503	9 years
0.0452332397	observed for
0.0452146468	the bladder
0.0452044886	these mice
0.0451966636	107 patients
0.0451961424	neurons in
0.0451877402	an isolated
0.0451866906	an intra
0.0451857895	a strong predictor of
0.0451753301	the overall incidence of
0.0451657267	considered in patients with
0.0451626484	septal myectomy in
0.0451520953	2 cm
0.0451519086	a computational model
0.0451497148	performed in patients with
0.0451450624	compared to other
0.0451326448	an elective
0.0451231755	during sleep
0.0451095768	in patients presenting
0.0451051644	first case report
0.0450999883	different cell
0.0450846153	range of
0.0450804141	and 0.5
0.0450790349	even in
0.0450767002	a self expanding
0.0450631547	14 vs
0.0450629114	a 10 year
0.0450346430	in 2003
0.0450320261	the myocardium
0.0450310430	electrical stimulation of
0.0450262909	accumulation of
0.0450261433	as expected
0.0450001771	17 vs
0.0449985445	in group b
0.0449969347	18 patients
0.0449941819	months before
0.0449815600	any stroke
0.0449471112	the etiology
0.0449097589	at 0.5
0.0448934716	patterns of
0.0448919540	for predicting
0.0448847139	no signs of
0.0448829498	other cases
0.0448774951	the contralateral
0.0448726362	a hybrid
0.0448705127	years of
0.0448670067	performed during
0.0448473495	mm ¬†
0.0448448830	a better understanding of
0.0448419542	back to
0.0448407196	option for patients
0.0448292510	and need for pacemaker
0.0448084333	modality for
0.0448038323	during transcatheter aortic
0.0447961001	levels in
0.0447890689	74 patients
0.0447887465	postoperative aortic
0.0447860098	a recent
0.0447750175	at long term follow up
0.0447715519	on in hospital
0.0447703524	84 patients
0.0447608823	2017 to
0.0447584469	episode of
0.0447526755	retrospective study of
0.0447387273	a frequent
0.0447309822	patients older than
0.0447239063	0.4 vs
0.0447155293	a new generation
0.0447111007	a survey
0.0447105999	the morning
0.0447023624	this research
0.0446997543	underwent tavr from
0.0446972845	the extent to
0.0446953250	44 patients
0.0446936753	of note
0.0446840783	report on
0.0446658462	59 ¬±
0.0446611424	used in patients with
0.0446536771	the 1 year follow up
0.0446521849	the gastrointestinal
0.0446459024	than 50
0.0446220798	severe conduction
0.0446136149	to produce
0.0446128330	before surgery
0.0446091707	15 ¬†
0.0445962738	associated with higher rates of
0.0445804141	of 45
0.0445736979	common in patients
0.0445710952	or ‚ÄØ = ‚ÄØ
0.0445664911	after 6 months
0.0445513758	23 ¬†
0.0445419170	at 5 year
0.0445367071	in europe
0.0445249078	a new onset
0.0445243689	adjust for
0.0445133765	a suitable
0.0445114500	positive predictive value of
0.0445071763	the treatment of severe
0.0444848883	hospital due to
0.0444846950	current study
0.0444806141	calcification on
0.0444320276	associated with adverse
0.0444217846	6 year
0.0444191732	in young patients
0.0443952415	2.9 vs
0.0443888199	of 19
0.0443879845	the indications for
0.0443768856	rise in
0.0443665165	and 2.7
0.0443236472	especially for
0.0443234789	described as
0.0443156968	seen in patients
0.0442995952	25 patients
0.0442953327	predictors of long
0.0442950880	and 68
0.0442943840	permanent pacemaker implantation in patients with
0.0442905855	on exercise
0.0442838214	c +
0.0442782814	diagnosis and treatment of
0.0442723100	20 ¬†
0.0442719464	by comparing
0.0442704093	complex cardiac
0.0442406728	in nonagenarians
0.0442293122	the clinical features
0.0442292806	8 vs
0.0442223190	by regulating
0.0442214462	into four
0.0442037888	blinded to
0.0441927627	the onset of
0.0441911160	the nationwide inpatient
0.0441884915	in pacemaker recipients
0.0441830378	and procedural data
0.0441792076	in patients with cardiovascular
0.0441648420	mortality at 1 year
0.0441631506	the natural
0.0441616957	effective than
0.0441449167	low risk of
0.0441324096	with 10
0.0441174578	surgical treatment for
0.0441147063	all subjects
0.0441003092	mean length of
0.0440951250	the canadian
0.0440854672	an intervention
0.0440630033	data on patients
0.0440619038	the incidence rate
0.0440617659	the management of patients
0.0440462171	a cut off
0.0440419564	reduction of
0.0440387465	ventricular block
0.0440179507	the properties of
0.0440160989	as defined
0.0440132579	a short
0.0440100012	rate of complete
0.0440080150	characteristics between
0.0440002434	no late
0.0439902178	few years
0.0439856702	the left anterior
0.0439793760	suppression of
0.0439756042	not by
0.0439651334	queried for
0.0439614648	for 6 months
0.0439485267	not candidates for
0.0439466666	quality of
0.0439460827	60 ¬†
0.0439362849	the ongoing
0.0438899041	or absence
0.0438786972	in 1 case
0.0438679845	the placement of
0.0438569972	in two groups
0.0438549500	surgery for
0.0438108531	useful in
0.0437902672	improved to
0.0437893030	of 28
0.0437831733	of cardiac electronic devices
0.0437829847	the world
0.0437742869	the exception of
0.0437669901	second case
0.0437629019	age at
0.0437544663	0.4 ¬†
0.0437522546	due to complete heart block
0.0437515846	¬† 0.3
0.0437444920	pacemaker neurons in
0.0437332756	patients with bicuspid as
0.0437248685	the secondary outcomes
0.0437136328	to evaluate whether
0.0436929441	the mean transvalvular
0.0436812107	between january 2013 and
0.0436761870	various cardiac
0.0436719612	due to complete
0.0436462147	even after
0.0436362959	the use of cardiac implantable
0.0436342821	followed for
0.0436140289	a child
0.0436128293	of patients with implanted
0.0436073886	useful to
0.0435599756	of interest
0.0435571393	to assess whether
0.0435522622	the outcomes of patients
0.0435454062	paced from
0.0435414725	56 ¬±
0.0435251751	found between
0.0434938879	a global
0.0434882936	lead failure in
0.0434823168	27 ¬†
0.0434478057	the primary composite
0.0434431520	these complications
0.0434427627	the site of
0.0434359435	patients at risk of
0.0434337626	the ipsilateral
0.0434319917	14 year
0.0434306802	a dog
0.0434301843	in 29 patients
0.0434274328	to match
0.0434262348	10 vs
0.0434227669	42 ¬†
0.0434227669	34 ¬†
0.0434046724	shortening of
0.0434043493	the first to
0.0433995240	14 years
0.0433933552	1.7 ¬±
0.0433740339	cardiac involvement in
0.0433728939	to affect
0.0433615322	and december
0.0433579581	more often in
0.0433573821	following implantation
0.0433502486	in 96
0.0433478601	considered to
0.0433423056	severe aortic stenosis in
0.0433372657	also showed
0.0433281831	a prospective cohort
0.0433239726	60 patients
0.0433195678	of patients with severe
0.0433177405	a case report and review of
0.0433158295	3 s
0.0433094880	for patients with severe aortic stenosis
0.0433054044	the most recent
0.0432977953	a cohort of patients
0.0432885019	using whole
0.0432868589	most common indication for
0.0432705580	a questionnaire
0.0432662662	higher than in
0.0432654286	35 ¬†
0.0432554575	injection of
0.0432541471	feasible in
0.0432491549	the need for permanent pacemaker
0.0432491518	no difference in 30 day
0.0432406705	with 40
0.0432402843	a new permanent
0.0432323823	previously reported in
0.0432315417	the preferred
0.0432225697	a key
0.0432223690	to occur
0.0432151764	a rare presentation of
0.0432007131	a comparative
0.0431961321	median time
0.0431908830	model for
0.0431816741	the af group
0.0431671174	a biventricular
0.0431612329	enrolled between
0.0431592802	and short term outcomes
0.0431475449	safe in patients with
0.0431459727	lower in patients
0.0431211561	in patients without
0.0431133217	mean duration
0.0431048095	af before
0.0430950624	compared to non
0.0430761325	also demonstrated
0.0430342695	right ventricular pacemaker
0.0430285118	mean ¬±
0.0430214728	changes on
0.0430150220	or greater
0.0429927490	a higher prevalence of
0.0429904465	the inclusion
0.0429793760	consideration of
0.0429735379	the number of leads
0.0429723494	in patients with moderate
0.0429712401	the correlation
0.0429607085	to do
0.0429505598	sources of
0.0429481171	2.8 ¬±
0.0429414574	of 20 patients
0.0429336875	16 years
0.0429323898	associated with longer
0.0429248260	assessed for
0.0429115154	these conditions
0.0429066895	analyzed by
0.0429004968	reply to
0.0428761325	5 cases
0.0428690966	a linear
0.0428610746	non coronary
0.0428567646	after propensity score
0.0428527014	performed in patients
0.0428527014	observed in patients
0.0428494974	the mid term
0.0428471884	a propensity
0.0428426352	transvenous right
0.0428393030	of 78
0.0428383151	in parallel with
0.0428329573	a risk score
0.0428243916	results show
0.0428149727	the fourth
0.0428041485	56 patients
0.0427837135	january 2000 and
0.0427537926	in patients with permanent pacemakers
0.0427447393	two hundred and
0.0427444258	tested by
0.0427329175	n ¬† = ¬† 4
0.0427284034	of people with
0.0427169076	3.5 ¬†
0.0427158007	in patients with refractory
0.0427086241	a 15 year
0.0427082189	the retina
0.0427014134	no changes
0.0426985206	in asymptomatic patients
0.0426944477	a cardiac resynchronization
0.0426922611	to regulate
0.0426898456	no other
0.0426609956	in france
0.0426497433	the response of
0.0426263670	a pilot
0.0426240890	large number of
0.0426230403	confirmed in
0.0426146382	assessments of
0.0426056993	the united network
0.0426044801	detected on
0.0426003827	a higher prevalence
0.0425991446	in people with
0.0425916256	to inform
0.0425902433	the inferior
0.0425887431	patients indicated for
0.0425868072	system in patients
0.0425749124	and hence
0.0425738797	the correct
0.0425737150	a decrease in
0.0425492549	and 24 hours
0.0425477206	made in
0.0425404587	no in hospital
0.0425327459	recommended for
0.0425317213	for patients with severe
0.0425252580	case of pacemaker
0.0425193030	of 43
0.0425173767	45 year
0.0425126797	an mr
0.0425062399	of 150
0.0425016635	vicinity of
0.0424929014	50 vs
0.0424850205	prevention of
0.0424673007	improved from
0.0424622793	the percentage of
0.0424502434	per group
0.0424187161	the safety profile
0.0424065608	feasibility of
0.0424043493	as well as to
0.0423812976	32 patients
0.0423741135	a biological
0.0423698657	but without
0.0423686674	the generation
0.0423544536	no paravalvular
0.0423448333	a routine
0.0423392906	cardiac causes
0.0423130199	the extraction of
0.0423067118	40 years
0.0423041485	71 patients
0.0423038712	state of
0.0423037434	patients eligible for
0.0422905474	not significant
0.0422828015	an adequate
0.0422827459	difficult to
0.0422816169	a self expanding valve
0.0422654286	26 ¬±
0.0422620154	to record pacemaker
0.0422564191	the propensity
0.0422379920	for bleeding
0.0422354570	the whole cell
0.0422351478	parameters of
0.0422327371	the respective
0.0422327371	the beginning
0.0422296432	a considerable
0.0422278205	better understanding of
0.0422126864	end of
0.0422087188	and need for permanent pacemaker
0.0422054306	3 ¬† years
0.0422038533	no serious
0.0422016838	patients with known
0.0421905889	centre between
0.0421887249	experience of
0.0421735559	of 62
0.0421638841	all cause mortality in
0.0421582363	significantly longer in
0.0421452290	= 18
0.0421150760	to enable
0.0421082643	the stylet
0.0421068496	70 year
0.0420795159	necessary for
0.0420760772	compared with patients with
0.0420461732	older patients with
0.0420402433	the modified
0.0420393030	in 71
0.0420282313	a typical
0.0420215364	to allow for
0.0419967982	distribution of
0.0419511150	16 vs
0.0419387597	point of
0.0419309560	an adult
0.0419297561	the ability of
0.0419178653	2008 and
0.0418965825	the right coronary artery
0.0418875000	important to
0.0418874787	11 vs
0.0418710051	most effective
0.0418615344	in patients with cardiovascular implantable
0.0418434844	no recurrence
0.0418330679	for pacemaker patients
0.0418313815	the first case of
0.0418294143	a marker of
0.0418226777	mean heart rate
0.0418066180	cardiac defibrillators
0.0417724062	indicated in patients with
0.0417693510	proportion of patients with
0.0417492363	and 1 year outcomes
0.0417428932	observed on
0.0417385920	institute for
0.0417322005	to allow
0.0417316363	by performing
0.0417188148	the septum
0.0417139228	savr vs
0.0417038392	of pacemakers and implantable cardioverter defibrillators
0.0417030598	a dual chamber pacemaker with
0.0416938565	access for
0.0416818431	a young
0.0416721242	awareness of
0.0416590394	with preserved
0.0416497134	the characteristics of
0.0416476400	a reliable
0.0416472659	also provide
0.0416430146	variations in
0.0416425437	and lack of
0.0416335643	a traditional
0.0416309139	implantation of epicardial
0.0416142876	low complication
0.0416121015	at high risk of
0.0416076277	the insertion of
0.0415930146	optimization of
0.0415830377	120 ¬†
0.0415652835	an overall
0.0415652031	the prespecified
0.0415628454	in 16 patients
0.0415511638	an electrophysiology
0.0415357474	these two
0.0415344314	of cardiac implantable electronic
0.0415193030	of 90
0.0415170808	and 36
0.0415111703	permanent pacemaker implantation due to
0.0414997641	49 patients
0.0414941038	also observed
0.0414835435	this problem
0.0414823855	still not
0.0414592384	from baseline
0.0414562327	the overall survival
0.0414562198	the change in
0.0414558770	the potential of
0.0414540701	age of
0.0414211330	0.9 ¬†
0.0414095861	an electrocardiogram
0.0413941054	20 patients with
0.0413883076	devices such as
0.0413749262	performed for
0.0413731311	1996 and
0.0413682281	a high rate of
0.0413592007	2007 to
0.0413488558	the shoulder
0.0413375105	the second generation
0.0413356736	extraction in patients
0.0413313407	no procedural
0.0413204810	500 patients
0.0413154939	in adults with congenital heart disease
0.0413108053	the incidence of permanent pacemaker
0.0412913462	28 patients
0.0412830538	1.01 to
0.0412803590	the original
0.0412621849	associated with increased risk for
0.0412465466	20 year
0.0412396257	this pilot
0.0412296062	no cases of
0.0412250400	for avnrt
0.0412173272	a v
0.0412173179	higher rates
0.0412084175	most commonly used
0.0412047793	the expression of
0.0411961432	observed at
0.0411755392	the ed
0.0411736134	patients admitted to
0.0411718190	after surgical aortic
0.0411666032	drop in
0.0411661707	a third
0.0411649685	pacemaker use
0.0411634866	phosphorylation of
0.0411634050	or older
0.0411452290	= 50
0.0411285782	four patients with
0.0411276277	the recurrence of
0.0411201388	prolongation of
0.0411149790	activity in
0.0411120729	energy from
0.0411114471	95 ¬†
0.0411087065	analysis found
0.0411043728	some patients with
0.0410919166	a bridge
0.0410895502	rates of new
0.0410875275	an indication
0.0410738004	= 30
0.0410715517	positive for
0.0410281992	48 ¬†
0.0410264426	all cause mortality at 1 year
0.0410096862	occurred during
0.0410028351	the clinical outcome
0.0410002111	the benefits
0.0409917795	in patients with symptomatic
0.0409869927	the zebrafish
0.0409822402	in accordance
0.0409796108	and new permanent pacemaker
0.0409552584	mean follow up period
0.0409515035	12 days
0.0409507495	the rest
0.0409459727	pacing in patients
0.0409311931	connected with
0.0409285535	also evaluated
0.0409212549	in adults
0.0409073234	but potentially
0.0409055505	a systematic
0.0408999787	help to
0.0408811848	sign of
0.0408579301	50 year old
0.0408393103	45 ¬±
0.0408346229	a systematic review and
0.0408315563	an increasingly
0.0408268268	this rare
0.0408232837	of older patients
0.0408220149	1.09 to
0.0408182417	associated with lower risk of
0.0408104069	different time
0.0408098204	the physician
0.0408067111	occurred in two
0.0408044011	and outcomes of patients
0.0408024246	an extended
0.0407904894	source of
0.0407652104	significantly reduced in
0.0407531848	aortic valve system
0.0407505173	in two cases
0.0407445466	for in hospital mortality
0.0406949761	associated with in hospital
0.0406812107	a contraindication for
0.0406752580	2.5 ¬†
0.0406729166	of patients aged
0.0406687133	operations for
0.0406265665	time after
0.0406151619	year old boy with
0.0406119773	analyzed for
0.0406108093	and two patients
0.0406012644	for medicare
0.0405963038	avr using
0.0405618263	the coronary
0.0405598549	cardiac surgery for
0.0405485097	a small number of
0.0405484166	to record
0.0405436302	secondary prevention of
0.0405433811	the method
0.0405314274	by at least
0.0405236743	degradation of
0.0405219206	a distinct
0.0404983221	a significant reduction
0.0404851510	likely due to
0.0404808284	the vertebrate
0.0404765466	7 year
0.0404758770	and mortality in
0.0404673744	an appropriate
0.0404551248	risk stratification of
0.0404465444	second valve
0.0404379655	1.1 to
0.0404377386	the drosophila circadian
0.0404241922	this area
0.0404196770	a treatment
0.0404143422	‚ÄØ =
0.0404006811	increasingly used in
0.0403943638	a regular
0.0403785583	95 ci =
0.0403644343	no new
0.0403640382	option in patients with
0.0403389232	or equal
0.0403373260	strategy of
0.0403258125	decreased by
0.0403254628	right ventricular pacing in patients
0.0403199352	the atria
0.0403108750	clinical presentation of
0.0403013758	21 years
0.0403002156	a differential diagnosis
0.0402936074	in patients implanted
0.0402777298	after implant
0.0402761608	the result
0.0402724656	women with
0.0402553892	an inappropriate
0.0402341791	crt system
0.0402255490	not observed
0.0402243806	the mean duration
0.0401955594	modifications of
0.0401952580	42 ¬±
0.0401942683	in eight
0.0401874107	high percentage of
0.0401839756	10 cases
0.0401819924	continued to
0.0401792076	in patients with heart
0.0401724335	a multicenter study
0.0401713632	the phantom
0.0401682329	in 3 cases
0.0401463511	a fundamental
0.0401424160	composition of
0.0401399181	in china
0.0401384225	associated with better
0.0401350870	up of
0.0401281981	a follow up
0.0401109474	the master pacemaker
0.0401075472	in patients with cardiac devices
0.0401022246	to evaluate safety
0.0400848402	study aims
0.0400634386	90 ¬†
0.0400572354	on telemetry
0.0400428792	the coronavirus disease
0.0400379560	removed from
0.0400329096	2002 and
0.0400298249	compression of
0.0400281181	the time course
0.0400221553	the rate of postoperative
0.0400170808	in 57
0.0400158796	a relatively
0.0400028159	other complications
0.0399968954	without further
0.0399903728	and degree of
0.0399875831	hospitalization for
0.0399711239	months following
0.0399608069	7 vs
0.0399474981	for patients with cardiac
0.0399403187	minority of
0.0399374785	system disease
0.0399223193	17 patients
0.0399158475	a pacemaker dependent
0.0399107653	morbidity and mortality in
0.0398814169	differences in mortality
0.0398809606	38 patients
0.0398787723	29 patients
0.0398776111	28 vs
0.0398728967	particularly in patients
0.0398650911	the next generation
0.0398490188	a stable
0.0398348450	signals from
0.0398337253	the comparison of
0.0398292327	using cox
0.0398164100	the field of
0.0398118446	the safety and effectiveness of
0.0397935489	primary prevention of
0.0397931695	rate than
0.0397902886	the beating rate
0.0397894674	all three
0.0397844895	the level of
0.0397811859	diagnosed at
0.0397802063	circadian pacemaker in
0.0397621631	other types of
0.0397591958	compliance with
0.0397448933	observed in patients with
0.0397448222	shown by
0.0397379338	the mean follow up
0.0397316969	98 patients
0.0397264753	to find
0.0397258198	with less than
0.0397063269	the ventricles
0.0396869567	the measurement
0.0396854083	the validity
0.0396757015	identified using
0.0396742390	and consequently
0.0396608344	pacemaker implantation due to
0.0396566311	from january 2014
0.0396564237	fluctuations in
0.0396555492	within 30 days after
0.0396545742	year old patient with
0.0396364843	but does not
0.0396309136	a dynamic
0.0396201306	drugs on
0.0396150585	complications following
0.0395842238	this series
0.0395825471	the incidence rate of
0.0395758213	a higher percentage of
0.0395713313	the assessment of
0.0395676661	function of
0.0395610709	mechanism for
0.0395597561	2 definitions
0.0395573056	group =
0.0395538797	the endogenous
0.0395527961	of patients without
0.0395497565	cause of mortality
0.0395445338	dose during
0.0395435208	expense of
0.0395056317	the requirement
0.0395024657	13 ¬†
0.0394999365	charts of
0.0394980511	with cieds
0.0394978513	agreement with
0.0394935514	and 2017
0.0394808284	the fetus
0.0394611380	this practice
0.0394568620	the feasibility and safety of
0.0394448164	3 year
0.0394446657	in place
0.0394259917	2002 to
0.0394259917	2004 to
0.0394244663	3.4 ¬†
0.0394170563	11 years
0.0393971226	a persistent
0.0393933836	3 transcatheter heart valve
0.0393835949	a pacemaker with
0.0393779447	at presentation
0.0393733599	obtained at
0.0393675334	developed new
0.0393661001	recorded in
0.0393635471	increase in mortality
0.0393625597	new atrial fibrillation
0.0393568834	a clear
0.0393533134	a self expandable
0.0393441977	complications after
0.0393395896	the qrs complex
0.0393391245	the result of
0.0393330199	and timing of
0.0393230903	enriched in
0.0393224632	after alcohol
0.0393168705	in 28 patients
0.0393156049	eleven patients
0.0393085865	without increasing
0.0392971387	a lower risk of
0.0392710785	the department of
0.0392677816	40 ¬†
0.0392566998	the first report of
0.0392534567	in 27 patients
0.0392500802	38 vs
0.0392458244	0.72 to
0.0392401846	literature on
0.0392378214	induced changes
0.0392336538	data from patients
0.0392276018	all procedures
0.0392272620	in patients with dual chamber
0.0392213253	a maximum
0.0392069085	death from
0.0392039588	after 30 days
0.0391978749	and palpitations
0.0391849053	the prognostic significance
0.0391727679	a high prevalence
0.0391660643	a rare clinical
0.0391536095	the potential risks
0.0391417058	65 vs
0.0391101559	a family
0.0391093737	and 2018
0.0391049054	the process
0.0390907316	and 2020
0.0390811575	comparison with
0.0390640208	deactivation of
0.0390625220	in one third
0.0390474656	of valsalva
0.0390443643	of patients treated
0.0390346288	obtained for
0.0390218112	a young patient with
0.0390159316	also known
0.0390156163	institution from
0.0389991809	by fluoroscopy
0.0389966885	an indicator
0.0389838961	for severe as
0.0389702037	the conduction system
0.0389671426	offered to
0.0389654286	31 ¬†
0.0389654286	16 ¬†
0.0389521498	adjusted or
0.0389482323	infective endocarditis with
0.0389457422	cause of death in
0.0389347770	24 ¬†
0.0389342711	two case
0.0389266823	of in hospital death
0.0389223193	23 patients
0.0389178653	2009 and
0.0389146323	conducted using
0.0389124246	0.1 to
0.0389024749	associated with adverse outcomes
0.0389016005	consequences of
0.0388994890	undergoing tavr with
0.0388686190	the subcutaneous
0.0388587777	pacemaker function of
0.0388550574	a challenging
0.0388474962	prognosis after
0.0388356736	monitoring in patients
0.0388353354	satisfaction with
0.0388217815	characteristics of
0.0388178120	and 14 patients
0.0388170808	of 2.5
0.0388130199	the recovery of
0.0388123214	people with
0.0388115269	and 1 month
0.0387907153	70 ¬†
0.0387823460	the mid
0.0387761521	therapy for
0.0387549171	of 101
0.0387405237	altered by
0.0387358201	undergoing tavi with
0.0387286976	a sensitivity of
0.0387270219	performed from
0.0387263269	the preceding
0.0387234596	from 2001
0.0387171220	on outcomes after transcatheter
0.0387148659	65 ¬±
0.0387095398	at least 3
0.0386821421	durations of
0.0386622949	treatment option in
0.0386584517	and possibly
0.0386560872	and new pacemaker
0.0386549234	need of permanent pacemaker
0.0386506593	design of
0.0386496922	n ¬† = 1
0.0386448287	as well
0.0386416768	22 patients
0.0386255229	of fallot
0.0386098531	the 34 mm
0.0386076277	the symptoms of
0.0386034751	a critical role
0.0385946678	of 23
0.0385893103	reported case of
0.0385819405	the magnet
0.0385756158	53 patients
0.0385669068	a double
0.0385428803	clinical data of
0.0385375106	parameters such as
0.0385338862	and outcomes in patients
0.0385337192	to check
0.0385336572	concentrations of
0.0385314198	the cumulative
0.0385296936	no surgical
0.0385200170	at 3 month
0.0385104188	mechanisms of
0.0385100168	an inferior
0.0385024657	11 ¬†
0.0384648021	the sinoatrial
0.0384508523	the most common complications
0.0384458367	the back
0.0384427070	of 2.9
0.0384416040	to place
0.0384265252	a 1 year
0.0384252822	mortality occurred in
0.0384205640	undergoing implantation of
0.0384155322	valve failure
0.0384033793	41 patients
0.0384003448	the independent
0.0383894433	other groups
0.0383775761	1.02 to
0.0383758247	by providing
0.0383461847	aiming to
0.0383434008	2000 and
0.0383004747	mortality between
0.0382998499	and 1.1
0.0382973805	and three dimensional
0.0382971196	value =
0.0382901092	with new generation
0.0382690654	4 year
0.0382604864	the sk4
0.0382559592	time of implantation
0.0382352894	bradycardia due to
0.0382266155	heating of
0.0382192077	also assessed
0.0382170562	a less invasive
0.0382113122	2005 to
0.0382009720	the sts
0.0381885197	these results show
0.0381857082	all patients with
0.0381733007	allow for
0.0381686656	occurred in one
0.0381665153	implantation after
0.0381577555	no cases
0.0381558008	effectiveness and safety of
0.0381492554	into three
0.0381397361	in 22 patients
0.0381288502	104 patients
0.0381234950	a poor
0.0380773361	heart failure due to
0.0380660136	the diaphragm
0.0380602953	presented as
0.0380543725	interest in
0.0380451354	all groups
0.0380361142	in part
0.0380294564	administration of
0.0380068437	the most commonly
0.0380052758	overall population
0.0379993469	the resultant
0.0379851478	presented in
0.0379802434	50 ¬†
0.0379745249	done in
0.0379720868	the inward
0.0379579452	systematic review and meta analysis of
0.0379495001	after operation
0.0379439600	a first line
0.0379340828	the initiation
0.0379064593	identified from
0.0379056526	a progressive
0.0379006389	a simplified
0.0378915031	for implantation of
0.0378873689	to more
0.0378857630	a 70 year
0.0378843684	compared among
0.0378812325	a minority of
0.0378776216	the very elderly
0.0378734528	most common cause
0.0378672624	expression in
0.0378630270	but significantly
0.0378623665	in younger patients
0.0378484596	from 2006
0.0378424217	models for
0.0378388030	placed at
0.0378164907	an effect
0.0378105211	limited to
0.0378000499	mean age at
0.0377945088	complication of
0.0377919153	8 months
0.0377809292	orientation of
0.0377797798	bursts of
0.0377759828	the differences between
0.0377610853	a network of
0.0377327016	30 day clinical outcomes
0.0377187345	admissions for
0.0377153854	considered in
0.0377096602	the base
0.0377096602	the actual
0.0377078803	an electrophysiological
0.0377020219	the outcome of
0.0376796082	a change
0.0376749239	of 67
0.0376618409	a serious
0.0376616229	the axillary
0.0376608351	activity rhythms in
0.0376523244	use of remote
0.0376506870	in octogenarians
0.0376432278	rate control in
0.0376372836	as per
0.0376270296	the primary pacemaker of
0.0376101383	performance of
0.0376021594	the rates of
0.0375947931	with self expandable
0.0375924835	not detected
0.0375898900	on pacemaker potentials
0.0375792328	the need for ppm
0.0375699558	statement on
0.0375675059	2012 to
0.0375572130	the middle
0.0375546730	a potent
0.0375530591	different between groups
0.0375515556	on electrocardiography
0.0375394108	patients referred to
0.0375379560	recordings from
0.0375373260	area of
0.0375093832	also performed
0.0375060782	electrical device
0.0374931057	in 62
0.0374871950	¬† months after
0.0374836890	140 patients
0.0374831819	implantation at
0.0374705689	implanted for
0.0374558144	an area
0.0374376305	the emergence
0.0374354832	treatments for
0.0374155322	severe heart
0.0374077276	the risk of major
0.0374041448	and 6 month
0.0373952415	1.6 vs
0.0373920859	86 patients
0.0373910609	need for permanent
0.0373887465	present case
0.0373839194	1.5 years
0.0373520743	associated with significantly lower
0.0373382505	expansion of
0.0373346298	72 patients
0.0373277615	a significant reduction of
0.0373208742	in spain
0.0373053591	low rates
0.0373000019	defined device
0.0372995678	and 5 ¬†
0.0372987287	three year
0.0372931407	on dialysis
0.0372604787	the nasal
0.0372582573	of 2.2
0.0372560839	good results
0.0372449326	+ neurons
0.0372446986	median follow up time of
0.0372308222	but lower
0.0372206377	also similar
0.0372056104	a benign
0.0371824524	the edwards sapien 3
0.0371813353	r ¬† =
0.0371724973	upgrade to
0.0371721962	an association between
0.0371595836	mostly in
0.0371579185	the relationship of
0.0371393607	an index
0.0371260872	many patients
0.0371143642	hospital between
0.0371139444	a high percentage
0.0370857995	a well known
0.0370758837	and long term outcomes of
0.0370726379	limited by
0.0370718015	used in clinical
0.0370684005	all p ¬†
0.0370389437	a shift
0.0370263594	8 year
0.0370261256	the only independent predictor of
0.0370179507	the diagnosis and
0.0370098173	the parasympathetic
0.0370088673	for patients with cieds
0.0370075885	twenty one patients
0.0370052447	a next generation
0.0369951596	the effects
0.0369943111	effectiveness of
0.0369779941	no previous
0.0369681702	most cases
0.0369549308	12 year
0.0369549308	30 year
0.0369521498	algorithms for
0.0369478685	frequency of
0.0369435934	a sutureless
0.0369399308	a diagnosis of
0.0369342436	at 6 month follow up
0.0369254090	the most widely
0.0369053242	pacemaker located in
0.0368977260	aortic valve replacement in patients with
0.0368970351	50 year
0.0368648816	an increasing number of
0.0368642450	syncope in patients
0.0368499310	factors for
0.0368433593	survival of
0.0368220559	from mouse
0.0368168429	recorded by
0.0368148364	those observed
0.0368127312	at six
0.0368115501	d vs
0.0368113829	the opposite
0.0367933593	introduction of
0.0367739222	thoracotomy for
0.0367695580	many years
0.0367607662	a tendency
0.0367576016	the causes
0.0367524297	a 45 year
0.0367519008	¬† t
0.0367478209	rates between
0.0367429302	tavi system
0.0367277538	a particular
0.0367264871	the wound
0.0367227501	first year
0.0367111601	the manufacturer
0.0367077626	dependent patient with
0.0366745522	2009 to
0.0366706593	longer in
0.0366656578	no case
0.0366602914	mean duration of
0.0366580949	via right
0.0366529369	and complications associated with
0.0366458462	82 ¬±
0.0366458462	58 ¬±
0.0366458462	0.6 ¬±
0.0366380657	calculated for
0.0366338253	a shorter
0.0366319281	ablation of
0.0366287267	experiences of
0.0366272643	a subgroup of
0.0366252656	arrhythmias such as
0.0366162849	the spatial
0.0366149958	13 year
0.0366035186	guidelines on
0.0366011222	only significant
0.0365905907	all cases of
0.0365859804	recorded at
0.0365824144	1 vs
0.0365815431	on 1 year
0.0365772682	old patient with
0.0365767876	management devices
0.0365647586	80 ¬†
0.0365607621	new left
0.0365583473	the 3 month
0.0365566018	year following
0.0365518483	in patients with known
0.0365382505	induction of
0.0365356110	a favorable
0.0365220708	survival in patients with
0.0365175096	at increased risk of
0.0365140214	this observational
0.0365088796	48 patients
0.0364999365	epidemiology of
0.0364892830	implanted at
0.0364881581	treatment in patients
0.0364836286	visualization of
0.0364794464	a significant impact on
0.0364761577	the incidence of ppi
0.0364728462	day mortality
0.0364601010	considered for
0.0364482043	plsvc with
0.0364420247	the envelope
0.0364267170	the central nervous
0.0364258753	to differentiate into
0.0364111648	2006 to
0.0364002434	with ivabradine
0.0363921726	protocols for
0.0363889655	concern for
0.0363772643	a contraindication to
0.0363759071	of 30 patients
0.0363382554	of action
0.0363373260	setting of
0.0363232126	all other
0.0363101451	complications associated with
0.0363047619	regions of
0.0363033523	the non coronary
0.0362860841	several years
0.0362832218	died from
0.0362632212	the primary outcome of
0.0362612087	entrainment of
0.0362574825	the degree
0.0362562133	results indicated
0.0362180988	old woman with
0.0361919015	in 24 patients
0.0361891323	19 ¬†
0.0361867402	adjustment for
0.0361841393	the only significant
0.0361689874	no history of
0.0361688087	direction of
0.0361641023	occurred after
0.0361638794	10 year period
0.0361571215	2005 and
0.0361505641	perception of
0.0361392731	a rare complication of
0.0361128232	due to complete atrioventricular block
0.0360649680	conducted for
0.0360587179	a broad
0.0360542727	the complexity
0.0360465397	60 ¬±
0.0360459828	and feasibility of
0.0360265271	follow up duration of
0.0360244324	an apical
0.0360160136	the causal
0.0360022299	ablation in patients with
0.0359917943	and type of
0.0359889591	development of new
0.0359869906	infusion of
0.0359698482	the s
0.0359667190	the incremental
0.0359587766	for patients with atrial fibrillation
0.0359466303	of more than mild
0.0359420247	the heartbeat
0.0359399308	a reduction in
0.0359384946	common in
0.0359317147	lower than in
0.0359210052	screening for
0.0359137124	symptoms such as
0.0359048018	the surrounding
0.0359045859	an advanced
0.0358943736	outcome of patients with
0.0358919006	treated using
0.0358812976	37 patients
0.0358785860	for risk stratification
0.0358724380	early clinical and
0.0358686664	in comparison
0.0358549432	requirements for
0.0358220705	sensitive to
0.0358199535	purpose of
0.0358191723	13 years
0.0358181490	observed after
0.0358180266	analysis of risk
0.0358170789	in terms of mortality
0.0357996005	and mortality in patients
0.0357992647	allows for
0.0357956126	a number of
0.0357956050	widely used in
0.0357719487	for in hospital
0.0357286976	two cases of
0.0357239277	mean aortic valve
0.0357234088	in 35
0.0357169344	a high incidence
0.0357129647	the standard of care
0.0357091833	clinical outcome of
0.0356999369	variants in
0.0356832093	yet to
0.0356644428	the magnitude of
0.0356373518	only in patients
0.0356293733	a trend
0.0356249976	function as
0.0356078267	the medial
0.0356049054	the change
0.0356004878	reported as
0.0355999668	the effects on
0.0355998134	af at
0.0355839386	total number of
0.0355774355	the heating
0.0355737922	a robust
0.0355607721	five patients with
0.0355574714	to discharge
0.0355571256	a reference
0.0355546730	in infancy
0.0355478667	a permanent pacemaker for
0.0355408836	case series of
0.0355345836	mm vs
0.0355247002	a rare complication after
0.0355098193	to support
0.0354987396	obtained during
0.0354973787	challenging due to
0.0354641713	surgical ablation for
0.0354410918	and outcome of
0.0354318431	the composite
0.0354282005	the subjective
0.0354237160	102 patients
0.0354170713	of falls
0.0354133018	also significantly
0.0354069195	the 12 month
0.0354027654	62 patients
0.0354012961	in group 1 and
0.0353987411	the operator
0.0353949334	40 patients with
0.0353904610	the number of cardiac
0.0353743320	the diagnosis of cardiac
0.0353647586	29 ¬±
0.0353475687	outside of
0.0353317505	27 patients
0.0353290414	array of
0.0353173109	of respondents
0.0352969059	indicated for
0.0352912975	conducted at
0.0352860897	a contemporary
0.0352821525	at 12 month
0.0352736291	study aimed to
0.0352611982	worsening of
0.0352500802	2.5 vs
0.0352500439	to light
0.0352439976	seen at
0.0352429292	not significantly
0.0352281858	the resting
0.0352250508	or defibrillator implantation
0.0352086565	both types of
0.0352048698	the membranous
0.0352048683	in mind
0.0351966502	no evidence
0.0351936248	no differences between
0.0351897697	adjusted for
0.0351870229	the clinical impact
0.0351864220	2010 to
0.0351747265	the in hospital mortality
0.0351625802	a brief
0.0351577519	a report of
0.0351573757	80 years old
0.0351353895	a physician
0.0351170337	examined using
0.0351117604	regurgitation following
0.0351058857	a pacemaker or defibrillator
0.0350975168	an echocardiogram
0.0350868295	limitations of
0.0350822496	clinical course of
0.0350813815	the severity of
0.0350799668	the decrease in
0.0350783309	outcome in
0.0350770334	a rare but
0.0350760811	of 105
0.0350482517	symptoms of
0.0350470646	the geriatric
0.0350384103	point for
0.0350308293	reported to
0.0350263962	a rare cause
0.0350142099	the earliest
0.0350032837	deficits in
0.0350028546	different devices
0.0349984449	cost of
0.0349977260	cardiac resynchronization therapy in patients with
0.0349956811	the contrary
0.0349884946	site of
0.0349884946	effective in
0.0349839580	mechanism by
0.0349833299	activated by
0.0349829408	prognosis in patients with
0.0349719902	the advantages
0.0349687018	improvement of
0.0349625457	no association between
0.0349624768	term outcomes in
0.0349507084	a standardized
0.0349451484	the best of
0.0349273393	as possible
0.0349210918	the identification of
0.0349210371	use of cardiac implantable electronic devices
0.0349198233	75 ¬±
0.0348945513	of patients after
0.0348891514	incidence rate of
0.0348746487	the ventral
0.0348624725	lead extraction for
0.0348589702	other clinical
0.0348546334	2 criteria
0.0348504146	the gold standard for
0.0348469484	taken to
0.0348433593	decreased in
0.0348418529	mortality rate of
0.0348314350	decreases in
0.0348300370	fraction of
0.0348167807	studies on
0.0347973664	the transition
0.0347954084	by cox
0.0347646947	frequently associated with
0.0347367966	a mouse model of
0.0347325215	a marked
0.0347008054	a lower risk
0.0346986590	designed for
0.0346955594	lengthening of
0.0346936858	registry of patients
0.0346908793	after admission
0.0346811732	pacemaker therapy in
0.0346811732	cardiac events in
0.0346787743	on electrocardiogram
0.0346678816	in patients with obstructive
0.0346655322	center study
0.0346551613	sensitivity of
0.0346467691	an adjusted
0.0346344215	implantation due to
0.0346284530	patients treated by
0.0346225747	limitation of
0.0346077585	the safety and efficacy
0.0346014507	cells into
0.0345925291	functionality of
0.0345807275	an uncommon but
0.0345798099	a novel self
0.0345763815	cardiovascular events in
0.0345679509	cause mortality
0.0345526553	the relation between
0.0345496706	oscillations in
0.0345471199	of propofol
0.0345389437	a heterogeneous
0.0345344085	dogs with
0.0345334519	the primary pacemaker
0.0345296899	for identifying
0.0345244414	a semi
0.0345220708	implantation in patients with
0.0344939702	a dominant
0.0344920591	no association
0.0344905734	h after
0.0344857420	position of
0.0344711475	six patients with
0.0344510324	low mortality and
0.0344491653	median age of
0.0344472530	from baseline to
0.0344287771	surgical ablation of
0.0344280707	not found
0.0344248833	three months after
0.0344167905	safe and effective in
0.0343884851	for diagnosing
0.0343829197	to document
0.0343768081	follow up period of
0.0343531443	25 years
0.0343485841	also analyzed
0.0343414460	as compared with
0.0343295303	a 12 lead ecg
0.0343280092	markers of
0.0343157473	42 patients
0.0343083894	high rates
0.0343063638	2006 and
0.0342889720	obtained in
0.0342811557	the risk of permanent
0.0342694085	valve replacement in
0.0342690753	delivery of
0.0342612152	the pacemaker potentials of
0.0342453030	perforation by
0.0342449958	implications of
0.0342385920	connection to
0.0342338449	layer of
0.0342337736	the comparison
0.0342331945	median follow up of
0.0342323939	a bridge to
0.0342309732	a key role in
0.0342149087	onset of
0.0341991710	treatment for patients
0.0341918837	51 patients
0.0341889271	those treated
0.0341828833	1.3 ¬±
0.0341808023	and 58
0.0341792076	than patients
0.0341719962	to correct
0.0341662216	the thorax
0.0341621647	all four
0.0341603381	¬† +
0.0341555771	and 24 h
0.0341529467	findings on
0.0341423982	the rabbit
0.0341226909	with severe symptomatic
0.0341031122	forty patients
0.0341004636	1000 patients
0.0340939550	particularly in patients with
0.0340768077	correction of
0.0340691873	the left axillary
0.0340647586	all adult
0.0340477270	n ¬† = 2
0.0340429720	target for
0.0340265397	14 ¬†
0.0340197369	the relationship
0.0340131252	syncope due to
0.0340091403	such cases
0.0340091403	those reported
0.0339984449	burden of
0.0339984449	amplitude of
0.0339973135	after surgery for
0.0339930131	7 days after
0.0339762909	migration of
0.0339708499	6 ¬† months after
0.0339651959	2 groups
0.0339627898	recurrence of
0.0339599302	but higher
0.0339478685	increases in
0.0339359886	the predictive value of
0.0339272069	events following
0.0339183123	remains to
0.0339162849	the environment
0.0339028510	an option
0.0339023278	the estimation
0.0338994747	commonly associated with
0.0338971029	the neck
0.0338890314	atrial arrhythmias in
0.0338770626	arrhythmias during
0.0338742737	aortic stenosis at
0.0338642450	valve in patients
0.0338508339	patient died of
0.0338474689	and 49
0.0338251811	atrial fibrillation in patients with
0.0338182842	this type of
0.0338172295	a basis for
0.0338170375	patients with or without
0.0338124201	the three groups
0.0338102876	following implantation of
0.0338080056	the phase of
0.0338048018	the hypothalamic
0.0338045171	surgery in patients with
0.0337966369	a significant predictor
0.0337913090	overall rate
0.0337760404	and 65
0.0337746849	individuals with
0.0337716074	30 days following
0.0337586359	this subgroup
0.0337516414	a magnet
0.0337273006	modification of
0.0337167737	lead extraction in patients with
0.0337133724	pacemaker because of
0.0336931209	the action
0.0336918148	under different
0.0336897656	retrieval of
0.0336862172	associated with shorter
0.0336651016	the pandemic
0.0336434716	features of
0.0336349217	died of
0.0336336689	monitoring during
0.0336291111	patients affected by
0.0336187184	incidence of ppm
0.0336089362	sustained at
0.0336063196	mean aortic
0.0336057880	availability of
0.0336048230	the percentage of patients
0.0336020466	radiotherapy for
0.0336020340	more common in
0.0335799668	and resolution of
0.0335780562	as independent predictors
0.0335697069	operation for
0.0335685696	factors such as
0.0335647586	as measured
0.0335381581	procedure in patients
0.0335268692	the random effects
0.0335244988	the identification
0.0335224536	variability in
0.0335183547	treatment in patients with
0.0335124338	undergoing tavr at
0.0335111645	¬† 5
0.0335093648	clusters of
0.0335064034	mortality compared to
0.0334947037	and characterization of
0.0334935514	and 2016
0.0334892266	median follow up period of
0.0334880209	not necessary
0.0334787866	centers between
0.0334676495	the circadian pacemaker in
0.0334676495	the operation of
0.0334610673	and less than
0.0334542698	pacing via
0.0334503275	reported in patients with
0.0334474320	from january 2015
0.0334367097	an elevated
0.0334347954	indicated in
0.0334233833	transients in
0.0334199596	the benefits of
0.0334169621	to demonstrate
0.0333986909	presented for
0.0333924536	despite higher
0.0333895896	the propensity score
0.0333757472	lead implantation in
0.0333748818	in patients after
0.0333684349	the danish
0.0333574432	a very rare
0.0333452593	the shape
0.0333210396	reduced from
0.0332735325	a woman
0.0332695918	at 6 month
0.0332686745	to become
0.0332640767	proposed to
0.0332482797	cases per
0.0332448222	directly on
0.0332433688	subjects with
0.0332212690	the decrease
0.0332066706	deemed to
0.0332038254	2 ¬†
0.0332023967	or trace
0.0331872720	using self
0.0331803448	the type
0.0331680768	decreased to
0.0331657029	than 5
0.0331582351	and more than
0.0331544852	a muscarinic
0.0331490601	impact of different
0.0331411355	values for
0.0331395272	the first reported
0.0331343324	the morphological
0.0331083511	the cost effectiveness of
0.0331020599	paced for
0.0330935423	hundred and
0.0330868295	measurement of
0.0330829743	the mechanism of
0.0330712394	incidence of device
0.0330572214	a minority
0.0330354066	as determined by
0.0330214861	to contribute
0.0330110059	a true
0.0330048435	this strategy
0.0329923415	centers in
0.0329737545	not effective
0.0329726349	frequencies of
0.0329443227	prospective study of
0.0329376467	76 patients
0.0329233204	the nature
0.0329192782	effective for
0.0329056341	events during
0.0329023278	the composition
0.0329016448	this purpose
0.0328945513	a pacemaker at
0.0328692890	the evolution
0.0328523842	the transcatheter valve
0.0328469991	cardiac arrest due to
0.0328402672	died in
0.0328288364	a change in
0.0328275663	of 18 patients
0.0328173120	to december 2013
0.0328037030	recurred in
0.0328002627	the addition of
0.0327972460	value in
0.0327901468	5 months
0.0327610853	the rest of
0.0327403947	the basic
0.0327303909	6 months after
0.0327287267	marker of
0.0327265432	resynchronization therapy in patients with
0.0327176932	no significant changes
0.0327149292	the 17
0.0327020219	the degree of
0.0327015615	a low rate of
0.0326987396	occur after
0.0326867106	to require
0.0326818395	such as pacemakers
0.0326669982	a retrospective cohort study of
0.0326591188	processing of
0.0326580958	mechanism of
0.0326546023	the field
0.0326463664	with more than
0.0326457218	databases for
0.0326259917	2001 to
0.0326200024	one patient with
0.0326152708	the pacemaker function
0.0326057449	the effectiveness and safety of
0.0325999668	and improvement in
0.0325791604	cause death
0.0325771443	a series
0.0325721179	the transcription
0.0325653022	burden after
0.0325410251	infection due to
0.0325240858	each study
0.0325041485	94 patients
0.0325010674	complications during
0.0324937222	with ccavb
0.0324918347	on whether
0.0324664831	the kinetics
0.0324664831	the definition
0.0324632822	angle of
0.0324590090	years after
0.0324587964	an intermediate
0.0324549938	treatment of patients
0.0324521498	synchronized with
0.0324469085	resection of
0.0324425040	good clinical
0.0324334644	procedures during
0.0324312392	the first line
0.0324311645	¬† 10
0.0324278389	for evaluation of
0.0324033553	11 months
0.0324003757	risks of
0.0323966142	vs 10
0.0323913071	difference in
0.0323879479	major cause of
0.0323712828	no recurrence of
0.0323601816	the pacemaker cells of
0.0323346042	a low incidence
0.0323247579	information from
0.0323113829	the 2nd
0.0322892788	disease in patients with
0.0322742671	into two
0.0322625635	of at af
0.0322572382	to reveal
0.0322363305	after pacemaker implantation in
0.0322251532	a pacemaker system
0.0322045092	in patients at
0.0321961101	non significant
0.0321942699	the ideal
0.0321881126	the performance of
0.0321864831	with new generation devices
0.0321803448	the duration
0.0321777811	99 patients
0.0321666648	the efficacy and safety of
0.0321660841	risk of ppm
0.0321641368	with higher risk
0.0321407532	with changes in
0.0321331572	available to
0.0321221591	approaches for
0.0321168327	significance of
0.0321097875	a pediatric
0.0321002614	feature of
0.0320872505	a useful
0.0320700748	knowledge on
0.0320584010	the pacemaker activity
0.0320564473	the heart rhythm
0.0320485310	medical history of
0.0320284390	in patients implanted with
0.0320137425	all cause mortality at 1
0.0319916310	the last follow up
0.0319797215	to december 2017
0.0319687018	efficacy of
0.0319547793	the duration of
0.0319467691	on surface
0.0319408756	measured in
0.0319378425	¬† years after
0.0318869257	a mixed
0.0318326241	1998 to
0.0318263718	parallel to
0.0318154467	information for
0.0318128244	not related to
0.0318095219	the utility of
0.0317879494	an upgrade to
0.0317687133	survivors with
0.0317660446	the medical records
0.0317630583	occurred at
0.0317571715	characteristics associated with
0.0317473135	the method of
0.0317311859	detected at
0.0317233204	the start
0.0317058711	adults with
0.0316954430	in cases of
0.0316843114	in patients with severe symptomatic
0.0316737311	the incidence of pocket
0.0316670911	no evidence for
0.0316626323	primary outcome of
0.0316603667	the density of
0.0316579185	the mechanisms by
0.0316457218	accuracy for
0.0316434356	an incidence
0.0316421093	the intended
0.0316269085	differentiation of
0.0316116868	as defined by
0.0315992054	but only
0.0315941476	choice for
0.0315824209	the differentiation
0.0315773682	a 6 month
0.0315710328	150 patients
0.0315663543	30 days after
0.0315640866	widely used for
0.0315464302	of alcohol septal
0.0315440487	not require
0.0315377466	extraction of pacemaker and
0.0315330043	replacement with
0.0315313587	one death
0.0315169405	greater in
0.0315057320	concentration of
0.0314777720	in 97
0.0314729547	review of
0.0314712518	the success of
0.0314674302	for patients with heart
0.0314651312	both devices
0.0314554924	stability of
0.0314490557	an option for
0.0314385659	a 12 lead
0.0314314911	outcome in patients with
0.0314213318	generated from
0.0314119325	timing of
0.0314115521	2003 and
0.0314061898	the cost effectiveness
0.0314012961	the experience of
0.0313906644	1 av
0.0313894005	route for
0.0313878685	the choice of
0.0313825065	a subset
0.0313801816	a low risk of
0.0313636511	a result
0.0313538102	or even
0.0313519081	of 89
0.0313512840	and improvement of
0.0313512840	the pattern of
0.0313339372	the concept of
0.0313295968	first to
0.0313239908	proven to
0.0313210771	the incidence of new
0.0313043391	postoperative period of
0.0313005116	positioned in
0.0312804795	a 1.5
0.0312754026	to design
0.0312521522	within one
0.0312363305	the inhibition of
0.0312326803	the 1st
0.0312271256	more severe
0.0312251047	the medulla
0.0312239277	a low rate
0.0312208460	time related
0.0311940865	an endocardial
0.0311934290	a prophylactic
0.0311893200	validation of
0.0311867402	source for
0.0311851019	return of
0.0311790180	1 month follow up
0.0311781747	to drive
0.0311764259	av block due to
0.0311740627	the potential to
0.0311733132	a safe and
0.0311724578	a specificity of
0.0311691323	22 ¬†
0.0311614911	block in patients with
0.0311605403	assessed at
0.0311483863	mutations in
0.0311471278	the potential for
0.0311388360	characteristics of patients with
0.0311336689	database from
0.0311273960	an analysis of
0.0311202256	the central nervous system
0.0311191153	and 2 years
0.0311113225	88 patients
0.0311079397	follow up time of
0.0311016658	frequent after
0.0310836186	case report of
0.0310825022	in 46 patients
0.0310696339	formation of
0.0310666263	the formation of
0.0310511293	center from
0.0310260404	in 73
0.0310214794	of transcatheter versus
0.0310045849	collected on
0.0309898254	also similar between
0.0309789421	noted to
0.0309710051	no statistically
0.0309554156	cardiac function in
0.0309475787	a review of
0.0309354832	binding to
0.0309118403	generation of
0.0309081415	three years
0.0309029971	and function of
0.0308864063	reoperation for
0.0308800935	for patients with symptomatic
0.0308702412	a cardiac implantable
0.0308597875	and older
0.0308393030	the 34
0.0308194005	segments of
0.0308068106	search for
0.0307986764	the multivariate
0.0307968931	mortality than
0.0307958377	as shown
0.0307956126	the detection of
0.0307812856	not significantly associated with
0.0307717557	a 12 lead electrocardiogram
0.0307570614	the neuropeptide
0.0307521224	known complication of
0.0307396719	the necessity of
0.0307015290	with high mortality
0.0306980649	basis for
0.0306943698	the dog
0.0306915834	the dominant
0.0306899490	dependent patients with
0.0306658624	revealed by
0.0306643204	outcomes between
0.0306577837	to reach
0.0306546023	the pericardial
0.0306502477	30 day mortality in
0.0306445970	a smaller
0.0306429957	a safe and feasible
0.0306417089	and outcomes of transcatheter aortic
0.0306302879	predictive value of
0.0306292003	of pacemaker recipients
0.0306226201	not prevent
0.0306198734	mutation in
0.0306090251	web of
0.0305999493	discharge to
0.0305972362	conducted on
0.0305901306	burden on
0.0305864996	an association
0.0305829197	101 patients
0.0305598326	to december 2018
0.0305535781	a porcine
0.0305532717	the decision
0.0305381581	af in patients
0.0305122060	the reduction of
0.0305020708	af in patients with
0.0304905087	the extent
0.0304898181	for transcatheter aortic
0.0304857252	correlation with
0.0304844191	clocks in
0.0304534892	a minimally
0.0304469085	interpretation of
0.0304427070	and 43
0.0304340679	side effects of
0.0304212051	the 6 month
0.0303965089	rate in patients
0.0303601816	a heart rate of
0.0303056029	interference from
0.0303010327	referred to as
0.0302926692	amplitudes of
0.0302890495	no statistically significant difference in
0.0302877302	factor associated with
0.0302802627	the contribution of
0.0302783826	a paucity of
0.0302687018	knowledge of
0.0302669620	origin of
0.0302575687	associated with significantly higher
0.0302411976	a leadless pacemaker in
0.0302151673	participating in
0.0302045092	during implantation of
0.0302003448	the success
0.0301803448	the increase
0.0301786594	marker for
0.0301660423	extraction using
0.0301558425	a predictor
0.0301482248	allowed for
0.0301427106	the impact of different
0.0301333972	in patients treated with
0.0301331572	the later
0.0301228932	reported by
0.0301185002	and december 2016
0.0301041485	a murine
0.0301032792	the widespread
0.0301015185	the mean age at
0.0300928600	all cause death or
0.0300923608	mean follow up of
0.0300885185	to form
0.0300846618	first year of
0.0300737913	to improve patient
0.0300647586	100 ¬†
0.0300600055	as measured by
0.0300583154	an experienced
0.0300572354	to inhibit
0.0300534102	at risk for
0.0300515384	the discovery
0.0300417701	the noncoronary
0.0300206801	the mean duration of
0.0299996054	recurrence after
0.0299982593	in low risk patients with
0.0299866537	the beating
0.0299779897	the rate of pacemaker
0.0299657002	to influence
0.0299475787	a lack of
0.0299188087	blockade of
0.0299167861	consumption of
0.0299134644	received by
0.0299085799	pacemaker potentials of
0.0298933754	significant risk of
0.0298918398	presented at
0.0298764720	achieved with
0.0298708169	ablation during
0.0298609786	a very low
0.0298519186	need for ppm
0.0298512840	of cases with
0.0298334054	with increased morbidity
0.0298088393	explantation of
0.0298088364	the mechanisms of
0.0298002995	doses of
0.0297956126	in case of
0.0297947853	successful in
0.0297823198	research on
0.0297809631	30 ¬†
0.0297688165	coupled to
0.0297681716	in contrast to
0.0297641356	of 96
0.0297552348	association of
0.0297445828	many patients with
0.0297192890	the predominant
0.0297149292	of 74
0.0297096673	the observation
0.0297086689	benefit of
0.0296975568	a complete atrioventricular
0.0296949000	eight patients with
0.0296627769	decreased after
0.0296614911	death in patients with
0.0296614911	function in patients with
0.0296471278	the benefit of
0.0296440767	extracted with
0.0296392689	savr in patients with
0.0296359386	overall in hospital
0.0296327371	the usual
0.0296313839	the pineal
0.0296259899	an adverse
0.0296150506	indications for pacemaker
0.0295996786	complication following
0.0295852322	3 groups
0.0295692088	safe and effective for
0.0295488368	the 30 day mortality rate
0.0295477816	7 ¬†
0.0295466403	time period
0.0295169645	the left subclavian
0.0294973233	coupled with
0.0294795374	the presence or absence of
0.0294779032	as predictors of
0.0294737702	the mean society of thoracic surgeons
0.0294693429	localized in
0.0294676858	two months
0.0294427070	and 72
0.0294369031	the most common indication
0.0294183114	this complex
0.0294163304	the timing and
0.0294062097	for prevention
0.0293963100	pattern of
0.0293956564	neonates with
0.0293946850	used to identify patients
0.0293878685	an average of
0.0293877302	burden in patients with
0.0293803421	performed before and
0.0293768900	further analysis
0.0293705538	made by
0.0293645065	pacemaker function in
0.0293530860	observational study of
0.0293428364	in patients at low
0.0293251857	from 8
0.0293224477	4 months
0.0292956126	the lack of
0.0292882773	hospital from
0.0292825665	for management of
0.0292762544	and safety of
0.0292688165	synchronized to
0.0292667299	an attempt to
0.0292592373	demonstrated by
0.0292586359	on multivariable
0.0292532796	the independent predictors of
0.0292191115	the safety and
0.0292096029	on pacemaker activity
0.0291795879	pronounced in
0.0291667113	a well established
0.0291517686	enhancement of
0.0291487114	the 30 day follow up
0.0291443832	periods of
0.0291411701	an invasive
0.0291393684	dysfunction due to
0.0291308120	patients with history of
0.0291182393	with 95 confidence intervals
0.0291146827	hospitalized with
0.0291044191	severity of
0.0291011089	no impact on
0.0290984449	set of
0.0290773415	versus right
0.0290661275	the median follow up
0.0290601875	costs associated with
0.0290596899	option in
0.0290510251	utilization of
0.0290456346	a minimum
0.0290260404	of 59
0.0290081087	morphology of
0.0290024983	one case of
0.0289998577	the vast
0.0289992717	the accessory
0.0289899775	undertaken to
0.0289866537	the tip
0.0289812939	the usage
0.0289753394	and stroke rates
0.0289631356	0.2 to
0.0289464436	a follow up of
0.0289444478	a definitive
0.0289354832	registered with
0.0289047130	a subcutaneous
0.0289033298	repositioning of
0.0288948852	at 0.4
0.0288878685	in adults with
0.0288766315	key role in
0.0288485118	a decrease
0.0288464656	the clinical significance
0.0288363305	and cost of
0.0288330210	1 month after
0.0288097941	46 patients
0.0288028854	evaluated for
0.0287895219	the accuracy of
0.0287841271	recovery after
0.0287795309	to december 2015
0.0287689295	a wireless
0.0287508680	24 hours after
0.0287228045	measured at
0.0287169607	after administration of
0.0287151673	slowing of
0.0287149292	of 68
0.0287137874	manifestations of
0.0287067391	first follow up
0.0287023967	to suppress
0.0287006852	at risk of
0.0286904743	for treatment of
0.0286781231	and in hospital outcomes of
0.0286756652	risks for
0.0286653022	width of
0.0286645015	the function of
0.0286421726	presents with
0.0286421726	guidance for
0.0286393015	heterogeneity in
0.0286060807	movement of
0.0285859449	needed for
0.0285551036	the start of
0.0285525665	to result in
0.0285276719	algorithm for
0.0285262544	the feasibility and
0.0285063613	the real
0.0285001311	male with
0.0284982487	the nationwide
0.0284958769	a master
0.0284851918	selected for
0.0284688819	performed between
0.0284656103	the long term outcomes of
0.0284577322	the incidence and
0.0284491115	the risk for
0.0284190058	of af in patients
0.0284165153	replacement for
0.0284087038	occur in
0.0283870556	protocol for
0.0283825956	any significant
0.0283818340	slope of
0.0283810195	of choice
0.0283782447	improved after
0.0283532239	a high incidence of
0.0283493664	controlling for
0.0283409349	the course
0.0283330741	compared between patients with
0.0283274308	in children with
0.0283268218	recipients with
0.0283196036	in patients with heart failure and
0.0283150583	a simulation
0.0282961209	in chinese patients
0.0282930420	infant with
0.0282912180	of patients at
0.0282882773	required after
0.0282874056	of choice for
0.0282585785	in three cases
0.0282554215	the emergency department with
0.0282520036	into two groups according to
0.0282477450	exist on
0.0282357816	atrioventricular block during
0.0282217702	3 months after
0.0282163305	in children and
0.0282071100	recorded on
0.0281898544	repair with
0.0281819897	4.8 ¬†
0.0281808516	of pacemaker related
0.0281691323	25 ¬†
0.0281682221	of people
0.0281582318	durability of
0.0281529369	3 months of
0.0281527811	for evaluating
0.0281520352	noted in
0.0281443832	closure of
0.0281437339	complexity of
0.0281337262	of 500
0.0281321249	the correlation between
0.0281303505	year outcomes in
0.0281221591	synchronization of
0.0281216708	using data from
0.0281128645	pairs with
0.0281097875	a balloon
0.0281033468	length of
0.0280965943	indices of
0.0280844483	acquisition of
0.0280633841	the absence
0.0280623715	to highlight
0.0280505116	issue of
0.0280459145	a range of
0.0280459145	the prognosis of
0.0280409485	treated at
0.0280291552	of 2 years
0.0280235270	the rate of permanent pacemaker
0.0280170849	composite of
0.0280080150	channels by
0.0279875831	reviewed for
0.0279842129	and 24 months
0.0279669548	strategies for
0.0279408756	feasible and
0.0279139102	diagnosed in
0.0278898776	patients diagnosed with
0.0278597875	the sensitivity
0.0278532068	dynamics of
0.0278393907	relevant to
0.0278311846	degeneration of
0.0278270077	theory of
0.0278246260	at higher risk of
0.0278231872	an improvement in
0.0278003457	the american college of
0.0277959473	2001 and
0.0277937945	the location of
0.0277846773	with increased mortality
0.0277784661	a candidate
0.0277427786	the pathophysiology of
0.0277400500	beneficial in
0.0277363907	in pediatric patients with
0.0277358132	the range of
0.0277268131	parameters associated with
0.0276974796	a strategy of
0.0276931209	the pediatric
0.0276913484	complication after
0.0276899111	the aorta
0.0276728901	the vagus
0.0276715915	the regulation of
0.0276573657	contraindicated in
0.0276537372	version of
0.0276501488	in infants
0.0276421726	delivered to
0.0276381852	the records of
0.0276209487	quality of life of
0.0275867782	mv at
0.0275759946	required to
0.0275756198	an improvement
0.0275653022	curve for
0.0275599738	extracted by
0.0275589005	use of mechanical
0.0275505116	profiles of
0.0275453435	endpoint of
0.0275197369	the importance
0.0275157542	the beat
0.0274969973	thresholds at
0.0274801164	hearts with
0.0274777963	pacemaker implantation because of
0.0274744753	on outcomes of
0.0274612001	a loss of
0.0274455249	accuracy of
0.0274432860	of individuals with
0.0274346820	at 1 ¬†
0.0274324448	in patients with and without
0.0274307484	replacement due to
0.0273925296	a comparison of
0.0273849054	outcomes according to
0.0273840547	a model of
0.0273839871	pacemaker implant in
0.0273770626	conducted from
0.0273740412	and further
0.0273645725	prediction of
0.0273575961	the myenteric
0.0273557231	a specialized
0.0273519107	heart rate by
0.0273433238	a flexible
0.0273396474	discharged to
0.0273331738	new permanent
0.0273226543	also present
0.0273197801	records of
0.0273025665	and amplitude of
0.0272948454	the evening
0.0272606993	kept in
0.0272562544	the activity of
0.0272363907	the safety and feasibility of
0.0272319062	the choice
0.0272258010	also found
0.0271991115	the period of
0.0271883777	clinical characteristics of
0.0271760281	cardiomyocytes from
0.0271544614	in individuals
0.0271401115	minutes after
0.0271233389	the speed of
0.0271200024	and validation of
0.0271192337	the impact
0.0270705907	the cost of
0.0270689082	pacemaker system in
0.0270436509	valve replacement with
0.0270415396	not observed in
0.0270277088	examined for
0.0270260404	of 73
0.0270158112	the establishment of
0.0270158112	the relevance of
0.0270075129	the number of patients with
0.0269863635	3 ‚ÄØ
0.0269755407	to modulate
0.0269679942	in zebrafish
0.0269521498	comparisons of
0.0269263060	the overall incidence
0.0269240627	the amplitude of
0.0269196638	an effective and
0.0269161276	at baseline to
0.0268993884	analyzed from
0.0268978667	with development of
0.0268885281	set at
0.0268725296	the progression of
0.0268606340	propagation of
0.0268573570	evidence on
0.0268365527	the circadian clock in
0.0268331173	a third degree
0.0268314339	11.8 ¬±
0.0268088364	the position of
0.0267722626	a meta
0.0267688165	recurrences of
0.0267673391	a family history of
0.0267645797	in cases with
0.0267641998	available on
0.0267569208	icd system
0.0267548450	reconstruction of
0.0267230403	interaction of
0.0267162410	during follow
0.0267151225	an edwards
0.0267033793	a concern
0.0266883375	a function of
0.0266724027	documented in
0.0266712961	the utilization of
0.0266232914	choice of
0.0266220559	a marker
0.0266115424	due to complete atrioventricular
0.0266113225	for preventing
0.0266057989	genes in
0.0265894453	defibrillator pacemaker
0.0265880074	improved by
0.0265867556	with increased risk of
0.0265802372	common after
0.0265659474	the mouse small
0.0265605403	recurrences in
0.0265548858	center experience with
0.0265412367	the necessity
0.0265364900	an ischemic
0.0265262544	the prevalence and
0.0265245132	2 cases of
0.0265119323	late after
0.0264631265	in patients with as
0.0264468498	tested for
0.0264329708	the indication for
0.0264290414	correlated to
0.0264170124	the european society of
0.0264152936	2000 to
0.0264033204	the funny
0.0264032182	at 30 ¬†
0.0263992085	failure due to
0.0263965089	imaging of patients
0.0263792478	the selection of
0.0263694869	the control of
0.0263543443	whereas in
0.0263519145	no further
0.0263453260	changed to
0.0263214998	not different
0.0263137945	a reduction of
0.0263095117	in childhood
0.0262992195	obstruction after
0.0262937945	the combination of
0.0262739222	gain of
0.0262703239	variations of
0.0262571248	regulated in
0.0262557320	rhythmicity in
0.0262457218	start of
0.0262319438	after 12 months
0.0262272069	employed to
0.0262249207	the treatment of patients with
0.0262236981	site for
0.0262163305	the response to
0.0262111494	used in patients
0.0261940627	the ratio of
0.0261762181	block during
0.0261580865	tested in
0.0261325528	capture during
0.0261158118	reports of
0.0260977950	the incidence and predictors
0.0260927206	at increased risk
0.0260479891	the median age of
0.0260349715	location of
0.0260260404	of 54
0.0260049508	the decision to
0.0260049508	in view of
0.0260047719	thrombus in
0.0259824775	in at least
0.0259763909	at admission
0.0259434012	a statistically
0.0259400702	in patients over
0.0259358270	tool to
0.0259348034	and prognosis of
0.0259163304	the majority of patients with
0.0259016560	a significant difference in
0.0258534068	integration of
0.0258517686	exclusion of
0.0258209012	quality of life after
0.0258124097	elements of
0.0258041922	of children with
0.0257937880	treated for
0.0257934842	or 30 day
0.0257863578	of 120
0.0257862274	a cohort
0.0257775738	mortality in patients with
0.0257759438	in europe and
0.0257426022	arrhythmias in patients with
0.0257398425	the requirement for
0.0257382774	10 months
0.0257363907	a high risk of
0.0257217702	to account for
0.0257114783	hospitals in
0.0257111355	specificity of
0.0257109757	the amount
0.0256683144	a multivariate
0.0256254753	complication during
0.0256123315	105 patients
0.0256095599	arrhythmias after
0.0256085527	the standard of
0.0255867556	for development of
0.0255830730	applied in
0.0255741482	the newer
0.0255716417	also observed in
0.0255665856	and echocardiographic outcomes
0.0255449173	with antibiotics
0.0255381626	heart block as
0.0255352432	any patient
0.0254944689	waves in
0.0254848034	the composite of
0.0254711602	the rate of new
0.0254679942	the subgroup
0.0254545857	the co
0.0254521498	maintenance of
0.0253939673	comprised of
0.0253833972	and clinical outcomes of
0.0253715886	difficulties in
0.0253701050	a mutation
0.0253685031	valve replacement for
0.0253631572	the self
0.0253621982	a crucial
0.0253561190	250 patients
0.0253478828	the accuracy
0.0253384072	implantation via
0.0253337413	the formation
0.0253229747	the indications and
0.0252986764	the prevention
0.0252977021	occurring in
0.0252937945	the ability to
0.0252905087	the cephalic
0.0252878355	a canine
0.0252845884	classes of
0.0252812055	the pacemaker activity of
0.0252691603	selection for
0.0252471256	the roles
0.0252163305	the tricuspid valve and
0.0252122445	a role in
0.0251807236	mean time
0.0251666130	the left atrium and
0.0251304457	on computed
0.0251037772	death due to
0.0250986613	and 2013
0.0250978828	the investigation
0.0250963701	basis of
0.0250778230	the length of
0.0250483035	cases without
0.0250444689	inhibitor of
0.0250320655	as assessed by
0.0250212408	up time
0.0250159258	mild to
0.0250078803	to play
0.0249978513	phases of
0.0249883184	shorter in
0.0249841546	comparison to
0.0249726349	strength of
0.0249632860	the procedural and
0.0249581110	the surface of
0.0249452464	a majority
0.0249044178	burden in
0.0248868286	opportunity to
0.0248715117	occurs in
0.0248485010	pacemaker placement for
0.0248475334	aims to investigate
0.0248467171	sixty patients
0.0248314339	7.1 ¬±
0.0248113225	a cardiologist
0.0247764542	the burden
0.0247469085	impairment of
0.0247358862	attempt to
0.0247310093	not undergo
0.0247060672	sufficient for
0.0246896889	seizures with
0.0246591651	the maze
0.0246369596	the nervous
0.0246319393	to select
0.0246292756	means of
0.0246125419	patients with ie
0.0246000024	the surgical treatment of
0.0245925971	the circadian period
0.0245660535	a worse
0.0245551036	a child with
0.0245411133	lower in patients with
0.0245211148	discharge from
0.0245176307	of children
0.0245098524	with greater
0.0245062544	the difference in
0.0244967978	syncope after
0.0244459024	between 2012
0.0244442032	month after
0.0243838492	subunit of
0.0243635706	parameters between
0.0243633972	the clinical outcomes of
0.0243319423	from 2009
0.0243319423	from 2008
0.0243158118	profile of
0.0243146892	a closed
0.0243095877	the success rate of
0.0243045658	the lead to
0.0242896474	discharged with
0.0242645797	the involvement of
0.0242452609	a set of
0.0242445797	the investigation of
0.0242378991	with evidence of
0.0242039815	consequences for
0.0241996392	expansion in
0.0241965546	of patients implanted with
0.0241731209	the balloon
0.0241496638	of patients treated with
0.0241496638	the patients at
0.0241399978	no change in
0.0241174318	to exhibit
0.0240873180	a consequence of
0.0240868752	critical to
0.0240596412	the design of
0.0240512055	in patients presenting with
0.0240486764	a mouse
0.0240347221	intensity of
0.0240339705	a reduction
0.0240272069	myectomy for
0.0239805037	two groups based on
0.0239673208	the proportion
0.0239612001	the device in
0.0239359094	result of
0.0239349658	the management of patients with
0.0239311682	the application of
0.0238816560	the safety and performance of
0.0238692195	episodes during
0.0238391366	in hospital mortality of
0.0238171783	longevity of
0.0238083567	with moderate to
0.0237738637	1 propensity
0.0237646064	this study provides
0.0237151219	and mortality in patients with
0.0237086689	importance of
0.0236915148	factor for
0.0236908462	the significance of
0.0236842326	to follow
0.0236806852	the sensitivity of
0.0236806852	a complication of
0.0236731209	the cost
0.0236575325	a subgroup
0.0236458501	a difference in
0.0236457218	solution for
0.0236430800	warranted to
0.0236365247	outcomes among
0.0236101909	30 days of
0.0236046794	center between
0.0236017226	the clinical impact of
0.0235931407	a multidisciplinary
0.0235913452	techniques for
0.0235663305	the acute and
0.0235551635	pacemaker implanted in
0.0235445132	the basis for
0.0235291245	key to
0.0235245132	the apex of
0.0235005728	the feasibility and safety
0.0234905955	the independent predictors
0.0234895877	the burden of
0.0234885135	clinic for
0.0234865198	no data
0.0234771528	severe as and
0.0234768971	applied for
0.0234718468	inferior to
0.0234632860	the dynamics of
0.0234551801	tools for
0.0234517562	for inclusion
0.0234459024	between 2013
0.0234403954	of hcn channels in
0.0234192195	switch to
0.0234165984	from 2011
0.0233833656	for severe aortic stenosis in
0.0233456975	no effect
0.0233241991	to open
0.0233240536	artifacts in
0.0233137413	the origin
0.0233078753	dynamics in
0.0233042886	the likelihood
0.0233009785	necessity of
0.0232338345	the most common cause
0.0232267389	the proportion of patients with
0.0232200735	usage of
0.0232109800	neurons from
0.0232022130	a minimum of
0.0232018961	first case of
0.0231729547	involvement of
0.0231726644	a population of
0.0231687375	devices in patients with
0.0231529369	the nature of
0.0231496638	in patients with pacemakers and
0.0231417488	from 2013
0.0231085527	and clinical outcomes in
0.0231028479	the functioning of
0.0230989466	a concentration
0.0230750816	the area
0.0230602090	the median follow up of
0.0230557176	to report on
0.0230482626	of 76
0.0230329725	yield of
0.0230262544	the prevention of
0.0230139705	the end
0.0229624948	the subgroup of
0.0229549658	in elderly patients with
0.0229521498	stages of
0.0229205793	in patients referred for
0.0229049220	evident in
0.0228841313	of transcatheter aortic valve implantation in
0.0228736771	the risks of
0.0228597470	positioning of
0.0228446702	primary pacemaker of
0.0228443832	measure of
0.0228443832	investigation of
0.0228311038	to december
0.0228259832	the incidences of
0.0228157692	the left and right
0.0228132592	the receiver
0.0228102090	the median follow up time
0.0227875863	activation by
0.0227825665	the disruption of
0.0227601909	between groups in
0.0227595514	lower after
0.0227512551	modes of
0.0227463364	the difference between
0.0226973053	attempted to
0.0226733132	the form of
0.0226637417	simulations of
0.0226475618	investigated by
0.0226457218	workup of
0.0226308145	technology for
0.0226050910	goal of
0.0225805164	a lower rate
0.0225686005	the median length of
0.0225652769	a femoral
0.0225609417	therapies for
0.0225231746	with complete atrioventricular block and
0.0224900013	attempts to
0.0224719012	the brachiocephalic
0.0224349085	encountered in
0.0224198734	release of
0.0224173945	function during
0.0223355831	order to
0.0222965074	the pathophysiology
0.0222915191	the prediction
0.0222757543	etiology of
0.0222578991	one patient in
0.0222277131	registered in
0.0222135538	infants with
0.0221996392	hospitalized in
0.0221887375	monitoring in patients with
0.0221806852	the results show
0.0221620503	the advantages of
0.0221562181	dysfunction after
0.0221496638	the reduction in
0.0221406325	capacity for
0.0221317886	with severe as
0.0221258501	for detection of
0.0221179914	a pregnant
0.0221142306	the treatment of patients
0.0221116653	pacing leads in
0.0221007620	department with
0.0220715157	in vivo and in
0.0220632212	and frequency of
0.0220488080	and quality of
0.0220429002	of consciousness
0.0220252194	and effectiveness of
0.0220246895	the determinants of
0.0220122060	the administration of
0.0219733132	in association with
0.0219432212	the median time to
0.0219328190	syncope during
0.0219099907	the sum of
0.0219040547	the initiation of
0.0218721601	valve surgery for
0.0218673518	and 12 months after
0.0218420422	the existence
0.0218097131	a case series of
0.0217957548	safe and feasible in
0.0217868226	the suprachiasmatic
0.0217764542	the benefit
0.0217739847	the era of
0.0217681528	after propensity
0.0217569799	a meta analysis of
0.0216956010	activity during
0.0216512226	collected at
0.0216268576	and outcomes after
0.0216204954	a past
0.0215885527	of arrhythmias in
0.0215654188	correction for
0.0215631819	block with
0.0215611896	collected for
0.0215459145	the etiology of
0.0215414421	interference with
0.0215245132	for prevention of
0.0215213543	the covid
0.0215188165	exist in
0.0215078803	87 patients
0.0215060605	planned to
0.0215051747	a number
0.0214577222	the interaction of
0.0214540849	cm from
0.0214430803	interaction with
0.0214405335	utilized in
0.0214370085	more frequent in
0.0214349085	attempted in
0.0214339293	the relation
0.0214333609	mechanisms by
0.0214233132	in subjects with
0.0214102599	a mean follow up
0.0213873940	5 years after
0.0213846434	lower mean
0.0213837479	trend for
0.0213718468	heterogeneity of
0.0213146750	trends of
0.0213083748	12 months after
0.0213012055	the incidence and predictors of
0.0213004850	an incidence of
0.0212878355	a means
0.0212772301	day follow up
0.0212752194	the sutureless and
0.0212699380	a narrow
0.0212671256	a transesophageal
0.0212654823	the prognostic value of
0.0212632212	12 months of
0.0212527705	a composite
0.0212294439	shift in
0.0212039719	with lower risk of
0.0211629220	the distance between
0.0211629220	the left side
0.0211496638	of pacemakers and
0.0211478828	the progression
0.0211192337	a review
0.0211192337	the onset
0.0210885527	the sensitivity and
0.0210833275	of 102
0.0210690147	of transvenous lead extraction in
0.0210376410	era of
0.0210333807	transfer to
0.0210188165	administered to
0.0210152539	the process of
0.0210095877	and specificity of
0.0210062544	the distribution of
0.0209786614	in patients with severe as
0.0209753280	the risk factors of
0.0209743026	a literature
0.0209631589	the prognostic significance of
0.0209519206	2 years after
0.0209496167	a focus
0.0209461035	in neonates
0.0209358982	three cases of
0.0209157366	with severe as and
0.0209122093	a rise
0.0208823278	the direction
0.0208652294	the differential diagnosis of
0.0208324144	with either
0.0208259832	the advantage of
0.0208241001	the combination
0.0207914518	in high risk patients with
0.0207789226	the prognostic value
0.0207654971	to respond
0.0207620887	the persistence of
0.0207277222	a role for
0.0207161577	collected by
0.0207154747	with symptoms of
0.0207102859	challenge for
0.0207091389	for patients at
0.0206827217	cardiomyopathy with
0.0206824448	the probability of
0.0206806852	the quality of
0.0206776493	essential to
0.0206720559	a multivariable
0.0206258501	of death in
0.0206217577	pairs of
0.0206215185	and maintenance of
0.0206192122	the clinical course
0.0205848557	than half of
0.0205836209	electronic devices in
0.0205768024	the characteristics and
0.0205721352	delays in
0.0205445334	of cases of
0.0205163364	in individuals with
0.0205102584	the maintenance of
0.0204972626	of transcatheter aortic valve replacement in
0.0204744508	view of
0.0204626913	the perioperative management of
0.0204521498	efficiency of
0.0203880263	activities of
0.0203718468	adaptation of
0.0203533367	and extent of
0.0203478230	and severity of
0.0203135298	evaluated at
0.0203077842	pms with
0.0203029747	the short and
0.0202945230	aim to
0.0202765397	92 patients
0.0202682418	sequence of
0.0202595514	survival at
0.0202527705	a combination
0.0202456105	the clinical significance of
0.0202445797	the source of
0.0202225677	implantation because of
0.0202051717	of cieds in
0.0201806852	the state of
0.0201496638	of pacemaker activity in
0.0201050910	magnitude of
0.0201014360	a temporary transvenous
0.0200414546	advantages of
0.0200071462	in selected patients with
0.0200046895	the induction of
0.0199822660	between 2015
0.0199788648	of cajal
0.0199016560	the patient presented with
0.0198863635	deviation of
0.0198774446	the diagnostic accuracy of
0.0198755287	the percentage
0.0198622093	a bicuspid
0.0198603306	threshold at
0.0198564110	introduced to
0.0198387995	the roles of
0.0198333690	a community
0.0198148590	homeostasis in
0.0198087418	the interaction between
0.0198058005	evolution of
0.0197958281	a majority of
0.0197762181	intervention for
0.0197739222	trace in
0.0197739222	pathogenesis of
0.0197277339	the appearance of
0.0196923490	more frequently in
0.0196631261	the retina and
0.0196412856	production of
0.0196083063	of syncope in
0.0195854979	for permanent pacemaker implantation in
0.0195823579	of care for
0.0195662746	possibility of
0.0195526158	within 30 days of
0.0195287094	of moderate to
0.0195167978	lower for
0.0194962554	the origin of
0.0194725598	the complexity of
0.0194723157	an alternative for
0.0194696167	the magnitude
0.0194192500	the strength of
0.0194029672	benefits of
0.0193976466	admission for
0.0193867716	a half
0.0193580300	30 day outcomes of
0.0193573657	dependence of
0.0193434547	with lower rates of
0.0193370886	age of patients
0.0193213129	a matter
0.0193110672	the stability of
0.0192878355	a cut
0.0192682418	implemented in
0.0192358270	indicator of
0.0192347167	the area under
0.0192236744	a course
0.0191608783	the pathogenesis
0.0191575264	first report of
0.0191095877	a retrospective study of
0.0191015185	the area of
0.0190663305	and risk factors of
0.0190515157	of cardiac pacing in
0.0190470205	presenting to
0.0190007067	institution for
0.0189620307	force on
0.0189438795	with transposition
0.0189317886	the utilization and
0.0189076357	finding of
0.0188816560	the diagnosis and treatment of
0.0188685294	smaller in
0.0188610421	recordings of
0.0188574446	the natural history of
0.0188411433	and performance of
0.0188368521	with high risk of
0.0188347913	the intuity
0.0188182188	selection of
0.0187389824	to treat patients with
0.0187044499	the prognostic impact of
0.0186951219	with syncope and
0.0186944128	challenge to
0.0186407516	status after
0.0185890950	pathophysiology of
0.0185747595	ability of
0.0185667556	for pacemaker implantation in
0.0185667556	this group of
0.0185661300	relevance of
0.0185190200	potential to
0.0185071462	the depth of
0.0184962554	the integration of
0.0184466989	for pacemakers and
0.0183434578	the period from
0.0182910672	the synchronization of
0.0182221906	combination with
0.0182051557	mean age of patients
0.0181973053	phenotypes of
0.0181899072	1 year outcomes of
0.0181892245	speed of
0.0181683375	the evolution of
0.0181582351	the two groups in
0.0181421253	extent of
0.0181376410	progress of
0.0181046311	with transposition of
0.0180095877	the prediction of
0.0180093676	the distribution
0.0179980073	the medical records of
0.0179387375	complications in patients with
0.0179324448	the differentiation of
0.0179272069	scheduled to
0.0178680627	with absent right
0.0178004171	a less
0.0177309800	parameters at
0.0177024383	classification of
0.0176936639	utilized to
0.0176548192	validated in
0.0176494633	child with
0.0176412856	embolization of
0.0175982760	the international classification of
0.0175973053	prevalent in
0.0175887995	in dogs with
0.0175842202	number of patients with
0.0175680500	the implementation of
0.0175515157	the effectiveness and
0.0175449770	the cumulative incidence of
0.0175295633	in young patients with
0.0175162554	the efficiency of
0.0175073657	reached in
0.0174997410	a decline in
0.0174843221	year mortality in
0.0174768971	search of
0.0174564110	concept of
0.0174392500	the emergence of
0.0174238448	an 82
0.0173743584	imaging in patients with
0.0173168521	the efficacy and
0.0173049197	by implantation of
0.0172945132	a protocol for
0.0172776466	minutes for
0.0172752194	with pacemakers and
0.0172552194	and design of
0.0171718831	for prediction of
0.0171395514	potentials in
0.0171230924	a c
0.0170605305	an impact on
0.0170374836	abnormalities on
0.0170264133	error of
0.0169903325	the amplitude and
0.0169892245	predicted to
0.0169627737	maintained in
0.0169610672	within 30 ¬† days of
0.0169314108	= ¬†
0.0169117736	¬† year
0.0168289999	the likelihood of
0.0167969973	shape of
0.0167965714	the reasons for
0.0167827077	a significant improvement in
0.0167454220	2 weeks of
0.0167309800	suggested to
0.0166973034	following tavr with
0.0166591651	the relevance
0.0166494633	crucial to
0.0166264133	set to
0.0165801050	a systematic review of
0.0165800322	a feasible and
0.0165264253	more prevalent in
0.0164285056	enrolled from
0.0163166942	capacity in
0.0162937293	subgroup of
0.0162878355	a differential
0.0162660550	care for
0.0162552854	inserted in
0.0162062181	prognosis of
0.0161342547	syncope in patients with
0.0161276466	timing for
0.0161086644	prognosis in
0.0160957366	and management of patients with
0.0159996823	the advantage
0.0159279497	anomalies in
0.0158691688	a random
0.0158471817	the usefulness of
0.0158098474	year old female patient with
0.0157620887	the availability of
0.0156946163	remodeling in
0.0156743510	a gain of
0.0156167394	a mathematical
0.0155889824	of death or
0.0155648590	functioning of
0.0154271152	line with
0.0154072729	2 years of
0.0151772729	and length of
0.0148486355	persisted in
0.0148326182	introduced in
0.0147875863	depth of
0.0147537765	the usefulness
0.0147123558	matter of
0.0146973034	the inability to
0.0146837192	serious complication of
0.0145898206	of death from
0.0145435243	and mortality after
0.0145117736	significantly between
0.0145014852	the italian association of
0.0144581502	the contribution
0.0144072729	of pacemaker implantation in
0.0140787554	the adoption of
0.0140506516	on outcomes after
0.0139176733	after removal of
0.0138657366	to identify patients with
0.0137323888	with patients without
0.0135991406	context of
0.0135426802	30 ¬† days after
0.0133134263	worse in
0.0132272729	of life in
0.0130973053	density of
0.0129743026	a loss
0.0129520804	of genes
0.0124999342	recommended to
0.0120679558	a common complication of
0.0120457312	to peak
0.0120104734	in neonates and
0.0119987524	between patients with and
0.0119542547	stenosis in patients with
0.0119401413	of clock genes in
0.0118206241	to contribute to
0.0115660550	confirmed to
0.0114205494	and hospitalization for
0.0109675881	extraction in patients with
0.0099277775	overall incidence of
